[
  {
    "id": 10,
    "user_query": "Name synonym of Acrokeratosis paraneoplastica.",
    "llama-2-13b-chat-hf_response": "Acrokeratosis paraneoplastica is also known as:\nA. Pemphigus.\nB. Bullous pemphigoid.\nC. Chronic benign intraepithelial lesion.\nD. Mucous membrane pemphigoid.\nCorrect answer: A. Pemphigus.\nRationale: Acrokeratosis paraneoplastica is a type of pemphigus, a group of autoimmune blistering diseases that affect the skin and mucous membranes. Pemphigus is a broader term that encompasses several subtypes, including acrokeratosis paraneoplastica. The other options are not synonyms of acrokeratosis paraneoplastica.",
    "llama-2-13b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-13b-chat-hf_fact": [],
    "llama-2-13b-chat-hf_judge": []
  },
  {
    "id": 47,
    "user_query": "Is Weaver syndrome similar to Sotos?",
    "llama-2-13b-chat-hf_response": "Weaver syndrome and Sotos syndrome are both rare genetic disorders that can cause intellectual disability, developmental delays, and physical abnormalities. However, they are distinct conditions with different causes and clinical features.\nWeaver syndrome, also known as 22q11.2 deletion syndrome, is caused by a deletion of a small portion of chromosome 22. This condition is relatively rare, affecting about 1 in 50,000 to 1 in 100,000 individuals. People with Weaver syndrome may have intellectual disability, speech and language delays, and a higher risk of developing certain medical conditions, such as heart defects, cleft palate, and immune system problems.\nSotos syndrome, also known as mega-cortical dysplasia, is caused by a mutation in the NSD1 gene. This condition is even rarer than Weaver syndrome, affecting about 1 in 15,000 to 1 in 20,000 individuals. People with Sotos syndrome may have intellectual disability, seizures, and a distinctive facial appearance, including a broad forehead, prominent eyes, and a wide mouth. They may also have physical abnormalities, such as a large head, short stature, and joint deformities.\nWhile both Weaver syndrome and Sotos syndrome can cause intellectual disability and developmental delays, there are some key differences between the two conditions. Weaver syndrome is more common and typically has a milder clinical presentation, while Sotos syndrome is rarer and often has a more severe clinical course. Additionally, Sotos syndrome is often associated with a distinctive facial appearance and a higher risk of seizures, while Weaver syndrome is not.\nIn summary, while Weaver syndrome and Sotos syndrome share some similarities, they are distinct conditions with different causes and clinical features. A thorough diagnostic evaluation, including genetic testing and a physical examination, is necessary to determine the specific diagnosis and appropriate management for an individual with these conditions.",
    "llama-2-13b-chat-hf_fact_raw": "1. Weaver syndrome is a rare genetic disorder that affects about 1 in 50,000 to 1 in 100,000 individuals.\n2. The cause of Weaver syndrome is a deletion of a small portion of chromosome 22.\n3. Sotos syndrome is a genetic disorder that affects about 1 in 15,000 to 1 in 20,000 individuals.\n4. The cause of Sotos syndrome is a mutation in the NSD1 gene.\n5. Both Weaver syndrome and Sotos syndrome can cause intellectual disability and developmental delays, but they have different clinical features and severity.",
    "llama-2-13b-chat-hf_fact": [
      "Weaver syndrome is a rare genetic disorder that affects about 1 in 50,000 to 1 in 100,000 individuals.",
      "The cause of Weaver syndrome is a deletion of a small portion of chromosome 22.",
      "Sotos syndrome is a genetic disorder that affects about 1 in 15,000 to 1 in 20,000 individuals.",
      "The cause of Sotos syndrome is a mutation in the NSD1 gene.",
      "Both Weaver syndrome and Sotos syndrome can cause intellectual disability and developmental delays, but they have different clinical features and severity."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: The cause of Weaver syndrome is typically a mutation in the EZH2 gene, not a deletion on chromosome 22.\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 81,
    "user_query": "List the releases of JASPAR database",
    "llama-2-13b-chat-hf_response": "=====================================\nJASPAR (Japanese Arabidopsis Specialized Plant Protein Resource) is a comprehensive database of protein families and functional assignments for Arabidopsis thaliana. Here are the releases of JASPAR database:\n1. JASPAR2010: This was the first release of JASPAR, which included protein families and functional assignments for 12,423 Arabidopsis proteins.\n2. JASPAR2011: This release included an updated set of protein families and functional assignments for 13,370 Arabidopsis proteins.\n3. JASPAR2012: This release included an updated set of protein families and functional assignments for 14,312 Arabidopsis proteins, as well as a new feature for predicting protein-protein interactions.\n4. JASPAR2013: This release included an updated set of protein families and functional assignments for 15,372 Arabidopsis proteins, as well as new features for predicting protein-protein interactions and identifying functional modules.\n5. JASPAR2014: This release included an updated set of protein families and functional assignments for 16,432 Arabidopsis proteins, as well as new features for predicting protein-protein interactions and identifying functional modules.\n6. JASPAR2015: This release included an updated set of protein families and functional assignments for 17,492 Arabidopsis proteins, as well as new features for predicting protein-protein interactions and identifying functional modules.\n7. JASPAR2016: This release included an updated set of protein families and functional assignments for 18,562 Arabidopsis proteins, as well as new features for predicting protein-protein interactions and identifying functional modules.\n8. JASPAR2017: This release included an updated set of protein families and functional assignments for 19,632 Arabidopsis proteins, as well as new features for predicting protein-protein interactions and identifying functional modules.\n9. JASPAR2018: This release included an updated set of protein families and functional assignments for 20,702 Arabidopsis proteins,",
    "llama-2-13b-chat-hf_fact_raw": "1. The JASPAR database is a comprehensive database of protein families and functional assignments for Arabidopsis thaliana.\n2. JASPAR2010 was the first release of the JASPAR database.\n3. JASPAR2012 introduced a new feature for predicting protein-protein interactions.\n4. Each release of JASPAR included an updated set of protein families and functional assignments for Arabidopsis proteins with increasing numbers each year.\n5. JASPAR2017 included an updated set of protein families and functional assignments for 19,632 Arabidopsis proteins.",
    "llama-2-13b-chat-hf_fact": [
      "The JASPAR database is a comprehensive database of protein families and functional assignments for Arabidopsis thaliana.",
      "JASPAR2010 was the first release of the JASPAR database.",
      "JASPAR2012 introduced a new feature for predicting protein-protein interactions.",
      "Each release of JASPAR included an updated set of protein families and functional assignments for Arabidopsis proteins with increasing numbers each year.",
      "JASPAR2017 included an updated set of protein families and functional assignments for 19,632 Arabidopsis proteins."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: The JASPAR database is a comprehensive database of transcription factor binding profiles for various species, not specifically for Arabidopsis thaliana protein families and functional assignments.\n2. FALSE [correction]: JASPAR was first released before 2010, with earlier versions such as JASPAR CORE dating back to at least 2004.\n3. FALSE [correction]: JASPAR is primarily known for providing transcription factor binding profiles, not for predicting protein-protein interactions.\n4. TRUE: Each release of JASPAR typically includes an updated set of transcription factor binding profiles, which could be considered \"protein families,\" and new data on their DNA-binding preferences, which relates to functional assignments.\n5. FALSE [correction]: JASPAR2017 did not specifically include an updated set of protein families and functional assignments for 19,632 Arabidopsis proteins. JASPAR focuses on transcription factor binding profiles and the number provided is not specific to Arabidopsis nor aligned with JASPAR's primary data content.",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 99,
    "user_query": "What is the function of the viral KP4 protein?",
    "llama-2-13b-chat-hf_response": "The KP4 protein is a viral protein that is encoded by the human papillomavirus (HPV) and is involved in the regulation of viral gene expression and the replication of the virus. The KP4 protein is a zinc finger protein that contains a conserved DNA binding domain and is thought to play a role in the regulation of transcription of the HPV genome.\nThe KP4 protein is a viral protein that is encoded by the human papillomavirus (HPV) and is involved in the regulation of viral gene expression and the replication of the virus. The KP4 protein is a zinc finger protein that contains a conserved DNA binding domain and is thought to play a role in the regulation of transcription of the HPV genome.\nThe KP4 protein is a viral protein that is encoded by the human papillomavirus (HPV) and is involved in the regulation of viral gene expression and the replication of the virus. The KP4 protein is a zinc finger protein that contains a conserved DNA binding domain and is thought to play a role in the regulation of transcription of the HPV genome.\nThe KP4 protein is a viral protein that is encoded by the human papillomavirus (HPV) and is involved in the regulation of viral gene expression and the replication of the virus. The KP4 protein is a zinc finger protein that contains a conserved DNA binding domain and is thought to play a role in the regulation of transcription of the HPV genome.\nThe KP4 protein is a viral protein that is encoded by the human papillomavirus (HPV) and is involved in the regulation of viral gene expression and the replication of the virus. The KP4 protein is a zinc finger protein that contains a conserved DNA binding domain and is thought to play a role in the regulation of transcription of the HPV genome.",
    "llama-2-13b-chat-hf_fact_raw": "1. The KP4 protein is encoded by the human papillomavirus (HPV).\n2. The KP4 protein is involved in the regulation of viral gene expression.\n3. The KP4 protein plays a role in the replication of the virus.\n4. The KP4 protein is a zinc finger protein.\n5. The KP4 protein has a conserved DNA binding domain.",
    "llama-2-13b-chat-hf_fact": [
      "The KP4 protein is encoded by the human papillomavirus (HPV).",
      "The KP4 protein is involved in the regulation of viral gene expression.",
      "The KP4 protein plays a role in the replication of the virus.",
      "The KP4 protein is a zinc finger protein.",
      "The KP4 protein has a conserved DNA binding domain."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: The KP4 protein is not encoded by human papillomavirus (HPV); it is a fungal protein produced by the virus Ustilago maydis, also known as corn smut fungus.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nNote: The KP4 protein is actually a virotoxin from Ustilago maydis and isn't directly related to HPV nor its gene expression, replication, or specific structural characteristics such as being a zinc finger protein or possessing a conserved DNA binding domain. The information about KP4 in relation to HPV is incorrect; therefore, the rest of the statements' truthfulness cannot be evaluated without the correct context or additional information.",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 124,
    "user_query": "Is DITPA a thyroid hormone analog utilized in experimental and clinical studies",
    "llama-2-13b-chat-hf_response": "?\nYes, DITPA (3,5-diiodothyropropionic acid) is a synthetic thyroid hormone analog that has been utilized in both experimental and clinical studies. DITPA is a potent and selective agonist of the thyroid hormone receptor (TR), and it has been used to study the effects of thyroid hormone on various tissues and organs, as well as to treat hypothyroidism and other thyroid-related disorders.\nIn experimental studies, DITPA has been used to investigate the role of thyroid hormone in regulating metabolism, growth, and development in various tissues, including the brain, liver, and skeletal muscle. DITPA has also been used to study the effects of thyroid hormone on gene expression and to identify genes that are regulated by thyroid hormone.\nIn clinical studies, DITPA has been used to treat hypothyroidism, a condition characterized by low levels of thyroid hormones. DITPA has been shown to be effective in raising thyroid hormone levels and improving symptoms such as fatigue, weight gain, and cold intolerance. DITPA has also been used to treat other thyroid-related disorders, such as thyroid eye disease and thyroid nodules.\nOverall, DITPA is a valuable tool for studying the effects of thyroid hormone and for treating thyroid-related disorders. However, it is important to note that DITPA is a synthetic compound and may have different effects and side effects compared to natural thyroid hormones. Therefore, DITPA should only be used under the guidance of a healthcare professional.",
    "llama-2-13b-chat-hf_fact_raw": "1. DITPA is a synthetic thyroid hormone analog.\n2. DITPA is a potent and selective agonist of the thyroid hormone receptor (TR).\n3. DITPA has been used in experimental studies to study thyroid hormone effects on metabolism, growth, and development.\n4. DITPA has been utilized in clinical studies to treat hypothyroidism and other thyroid-related disorders.\n5. DITPA can raise thyroid hormone levels and improve symptoms of hypothyroidism.",
    "llama-2-13b-chat-hf_fact": [
      "DITPA is a synthetic thyroid hormone analog.",
      "DITPA is a potent and selective agonist of the thyroid hormone receptor (TR).",
      "DITPA has been used in experimental studies to study thyroid hormone effects on metabolism, growth, and development.",
      "DITPA has been utilized in clinical studies to treat hypothyroidism and other thyroid-related disorders.",
      "DITPA can raise thyroid hormone levels and improve symptoms of hypothyroidism."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: DITPA is not a potent and selective agonist of the thyroid hormone receptor (TR). It acts on the thyroid hormone pathway but is considered less potent than natural thyroid hormones.\n3. TRUE\n4. FALSE [correction]: DITPA has been utilized in clinical studies, but primarily for conditions such as heart failure and not widely for treating hypothyroidism or other thyroid-related disorders.\n5. UNKNOWN",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 144,
    "user_query": "What is the COUGER tool?",
    "llama-2-13b-chat-hf_response": "The COUGER tool is a web-based tool that helps healthcare providers and public health officials identify and manage potential cases of COVID-19. It was developed by the Centers for Disease Control and Prevention (CDC) and is designed to assist in the early detection and containment of COVID-19 outbreaks.\nThe COUGER tool is an acronym for \"COVID-19 Outbreak Understanding and Generating Epidemiologic Reports.\" It is a comprehensive tool that includes a series of questions and prompts to help healthcare providers and public health officials gather information about potential COVID-19 cases, including symptoms, travel history, and exposure to others. The tool also provides guidance on how to collect and submit specimens for testing, as well as how to report and manage cases and outbreaks.\nThe COUGER tool is designed to be user-friendly and accessible, and it can be used by healthcare providers and public health officials in a variety of settings, including hospitals, clinics, and long-term care facilities. It is an important resource for healthcare providers and public health officials as they work to prevent and control the spread of COVID-19.",
    "llama-2-13b-chat-hf_fact_raw": "1. The COUGER tool is a web-based tool developed by the Centers for Disease Control and Prevention (CDC).\n2. It is designed to help healthcare providers and public health officials identify and manage potential cases of COVID-19.\n3. COUGER stands for \"COVID-19 Outbreak Understanding and Generating Epidemiologic Reports.\"\n4. The tool includes questions and prompts to gather information about potential COVID-19 cases, such as symptoms and travel history.\n5. The COUGER tool provides guidance on collecting and submitting specimens for testing and reporting and managing cases and outbreaks.",
    "llama-2-13b-chat-hf_fact": [
      "The COUGER tool is a web-based tool developed by the Centers for Disease Control and Prevention (CDC).",
      "It is designed to help healthcare providers and public health officials identify and manage potential cases of COVID-19.",
      "COUGER stands for \"COVID-19 Outbreak Understanding and Generating Epidemiologic Reports.\"",
      "The tool includes questions and prompts to gather information about potential COVID-19 cases, such as symptoms and travel history.",
      "The COUGER tool provides guidance on collecting and submitting specimens for testing and reporting and managing cases and outbreaks."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. FALSE [correction]: COUGER stands for \"COronavirus GUideline for ER,\" not \"COVID-19 Outbreak Understanding and Generating Epidemiologic Reports.\"\n4. TRUE\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 145,
    "user_query": "Are there drugs for Tick-borne Encephalitis?",
    "llama-2-13b-chat-hf_response": "There are several drugs that have been used to treat tick-borne encephalitis, including:\n1. Antiviral medications: These drugs can help reduce the severity and duration of the infection. Examples include ribavirin, lamivudine, and acyclovir.\n2. Corticosteroids: These medications can help reduce inflammation in the brain and improve symptoms such as headache, fever, and muscle weakness. Examples include prednisone and dexamethasone.\n3. Supportive care medications: These drugs can help manage symptoms such as fever, headache, and muscle pain. Examples include acetaminophen (Tylenol) and ibuprofen (Advil).\n4. Antibiotics: These drugs can help prevent or treat secondary bacterial infections that can occur as a complication of tick-borne encephalitis. Examples include doxycycline and ciprofloxacin.\nIt's important to note that the most effective treatment for tick-borne encephalitis is early diagnosis and supportive care, including hospitalization and intensive care as needed. In severe cases, the infection can be fatal, and the best outcome is often achieved with prompt and appropriate treatment.\nIt's also important to note that there is no specific treatment for tick-borne encephalitis, and the best treatment approach will depend on the severity and location of the infection, as well as the patient's overall health and medical history. In some cases, a combination of antiviral and corticosteroid medications may be used, and in severe cases, hospitalization and intensive care may be necessary.\nIt's important to seek medical attention immediately if you suspect you or someone you know has been infected with tick-borne encephalitis, as early diagnosis and treatment are critical to preventing complications and improving outcomes.",
    "llama-2-13b-chat-hf_fact_raw": "1. Antiviral medications are used to treat tick-borne encephalitis and can reduce the severity and duration of the infection.\n2. Corticosteroids are used to reduce inflammation in the brain and improve symptoms of tick-borne encephalitis.\n3. Supportive care medications help manage symptoms of tick-borne encephalitis such as fever, headache, and muscle pain.\n4. Antibiotics can prevent or treat secondary bacterial infections that may complicate tick-borne encephalitis.\n5. Early diagnosis and supportive care, including hospitalization and intensive care, are critical for treating severe cases of tick-borne encephalitis.",
    "llama-2-13b-chat-hf_fact": [
      "Antiviral medications are used to treat tick-borne encephalitis and can reduce the severity and duration of the infection.",
      "Corticosteroids are used to reduce inflammation in the brain and improve symptoms of tick-borne encephalitis.",
      "Supportive care medications help manage symptoms of tick-borne encephalitis such as fever, headache, and muscle pain.",
      "Antibiotics can prevent or treat secondary bacterial infections that may complicate tick-borne encephalitis.",
      "Early diagnosis and supportive care, including hospitalization and intensive care, are critical for treating severe cases of tick-borne encephalitis."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: There are no specific antiviral medications approved for the treatment of tick-borne encephalitis. Treatment mainly focuses on supportive care to alleviate symptoms.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 151,
    "user_query": "Which genome browser database for DNA shape annotations is available?",
    "llama-2-13b-chat-hf_response": "There are several genome browser databases available for DNA shape annotations, including:\n1. Ensembl: Ensembl is a comprehensive and integrated genomic resource that provides DNA shape annotations for a wide range of organisms, including humans, mice, and other model organisms. Ensembl's DNA shape annotations include information on gene structure, exon-intron boundaries, and other features that can affect gene expression and regulation.\n2. UCSC Genome Browser: The University of California, Santa Cruz (UCSC) Genome Browser is a widely used resource that provides DNA shape annotations for a variety of organisms, including humans, mice, and other model organisms. The UCSC Genome Browser includes information on gene structure, exon-intron boundaries, and other features that can affect gene expression and regulation.\n3. NCBI Genome Browser: The National Center for Biotechnology Information (NCBI) Genome Browser is a comprehensive genomic resource that provides DNA shape annotations for a wide range of organisms, including humans, mice, and other model organisms. The NCBI Genome Browser includes information on gene structure, exon-intron boundaries, and other features that can affect gene expression and regulation.\n4. GRCh38: The Genome Reference Consortium (GRC) Human Genome Assembly (GRCh38) is a comprehensive genomic resource that provides DNA shape annotations for the human genome. GRCh38 includes information on gene structure, exon-intron boundaries, and other features that can affect gene expression and regulation.\n5. Mouse Genome Browser: The Mouse Genome Browser is a comprehensive genomic resource that provides DNA shape annotations for the mouse genome. The Mouse Genome Browser includes information on gene structure, exon-intron boundaries, and other features that can affect gene expression and regulation.\n6. Zebrafish Genome Browser: The Zebrafish Genome Browser is a comprehensive genomic resource that provides DNA shape annotations for the zebrafish genome. The Zebrafish Genome Browser includes information on gene structure, exon-intron boundaries, and other features that can affect gene expression and regulation.\n7. WormBase: WormBase is a comprehensive genomic resource that provides DNA shape annotations for the nematode worm Caen",
    "llama-2-13b-chat-hf_fact_raw": "1. Ensembl provides DNA shape annotations for organisms including humans, mice, and other model organisms.\n2. The UCSC Genome Browser is used for DNA shape annotations and includes a variety of organisms.\n3. NCBI Genome Browser offers DNA shape annotations for a wide range of organisms, including humans and mice.\n4. GRCh38 provides DNA shape annotations for the human genome.\n5. The Mouse Genome Browser offers DNA shape annotations for the mouse genome.",
    "llama-2-13b-chat-hf_fact": [
      "Ensembl provides DNA shape annotations for organisms including humans, mice, and other model organisms.",
      "The UCSC Genome Browser is used for DNA shape annotations and includes a variety of organisms.",
      "NCBI Genome Browser offers DNA shape annotations for a wide range of organisms, including humans and mice.",
      "GRCh38 provides DNA shape annotations for the human genome.",
      "The Mouse Genome Browser offers DNA shape annotations for the mouse genome."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: Ensembl provides genomic data and annotations, but it does not specialize in DNA shape annotations.\n2. UNKNOWN: While the UCSC Genome Browser provides a platform for a wide array of genomic data, it’s unclear from the given statement whether it specifically provides DNA shape annotations.\n3. FALSE [correction]: NCBI Genome Browser offers a range of genomic data, but it does not specifically provide DNA shape annotations.\n4. FALSE [correction]: GRCh38 is a human genome assembly provided by the Genome Reference Consortium and does not inherently provide DNA shape annotations, which are specialized data.\n5. UNKNOWN: There isn't enough information provided about the ‘Mouse Genome Browser’ and whether it offers DNA shape annotations for the mouse genome. It could be a reference to a specific tool or database, but more context is needed to determine its offerings.",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 174,
    "user_query": "Which syndromes are associated with mutations in the EZH2 gene?",
    "llama-2-13b-chat-hf_response": "The EZH2 gene provides instructions for making a protein called enzyme histone methyltransferase 2 (EZH2). This protein is involved in regulating gene expression by adding a chemical tag called a methyl group to specific proteins. Mutations in the EZH2 gene have been associated with several syndromes, including:\n1. Ring chromosome 20 syndrome: This syndrome is caused by a mutation in one copy of the EZH2 gene on a ring chromosome 20. People with this condition have a range of developmental delays and health problems, including intellectual disability, growth delays, and congenital anomalies.\n2. MLL (KMT2A) mixed-lineage leukemia: This is a rare blood disorder that is caused by a mutation in one copy of the EZH2 gene. It is characterized by the overproduction of immature white blood cells, which can lead to a variety of health problems.\n3. B-cell acute lymphoblastic leukemia (ALL): Mutations in the EZH2 gene have been found in some cases of B-cell ALL, a type of cancer that affects the blood and bone marrow.\n4. Clonal hematopoiesis: This is a condition in which a single mutated stem cell gives rise to a population of abnormal blood cells. Mutations in the EZH2 gene have been found in some cases of clonal hematopoiesis.\n5. Myelodysplastic syndrome (MDS): This is a group of blood disorders characterized by the abnormal growth of immature blood cells in the bone marrow. Mutations in the EZH2 gene have been found in some cases of MDS.\n6. Chronic myelomonocytic leukemia (CMML): This is a rare blood disorder that is characterized by the overproduction of immature white blood cells. Mutations in the EZH2 gene have been found in some cases of CMML.\nIt's important to note that not all mutations in the EZH2 gene are associated with these syndromes, and some people with these conditions may not have any mutations in the EZH2 gene. Additionally, the specific sympt",
    "llama-2-13b-chat-hf_fact_raw": "1. Mutations in the EZH2 gene have been associated with Ring chromosome 20 syndrome.\n2. MLL mixed-lineage leukemia is caused by a mutation in the EZH2 gene.\n3. B-cell acute lymphoblastic leukemia has been linked to mutations in the EZH2 gene.\n4. Mutations in the EZH2 gene have been found in some cases of clonal hematopoiesis.\n5. The EZH2 gene mutations have been identified in some cases of myelodysplastic syndrome and chronic myelomonocytic leukemia.",
    "llama-2-13b-chat-hf_fact": [
      "Mutations in the EZH2 gene have been associated with Ring chromosome 20 syndrome.",
      "MLL mixed-lineage leukemia is caused by a mutation in the EZH2 gene.",
      "B-cell acute lymphoblastic leukemia has been linked to mutations in the EZH2 gene.",
      "Mutations in the EZH2 gene have been found in some cases of clonal hematopoiesis.",
      "The EZH2 gene mutations have been identified in some cases of myelodysplastic syndrome and chronic myelomonocytic leukemia."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: Mutations in the EZH2 gene have been associated with Weaver syndrome, not Ring chromosome 20 syndrome.\n2. FALSE [correction]: MLL (mixed-lineage leukemia) is usually associated with translocations involving the MLL gene on chromosome 11q23, not mutations in the EZH2 gene.\n3. TRUE: B-cell acute lymphoblastic leukemia has been linked to mutations in the EZH2 gene.\n4. TRUE: Mutations in the EZH2 gene have been found in some cases of clonal hematopoiesis, which is a preleukemic condition.\n5. TRUE: The EZH2 gene mutations have been identified in some cases of myelodysplastic syndrome and chronic myelomonocytic leukemia.",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 193,
    "user_query": "List human proteins that are subject to a dimer-to-tetramer transition.",
    "llama-2-13b-chat-hf_response": "There are several human proteins that are known to undergo a dimer-to-tetramer transition. Here are some examples:\n1. Hemoglobin: Hemoglobin is a dimer of two subunits, each of which contains a heme group that binds oxygen. Under certain conditions, such as changes in pH or temperature, the dimer can convert to a tetramer, which is thought to be more stable and resistant to denaturation.\n2. Myoglobin: Myoglobin is a dimer of two subunits, each of which contains a heme group that binds oxygen. Like hemoglobin, myoglobin can undergo a dimer-to-tetramer transition under certain conditions.\n3. Cytochrome c: Cytochrome c is a small protein that plays a crucial role in the electron transport chain in mitochondria. It exists as a dimer in its reduced form, but can convert to a tetramer under certain conditions.\n4. Ferritin: Ferritin is a protein that stores and releases iron ions in cells. It exists as a homodimer, but can undergo a dimer-to-tetramer transition under certain conditions.\n5. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH): GAPDH is a protein that plays a role in glycolysis and is found in many tissues, including muscle, liver, and brain. It exists as a dimer, but can convert to a tetramer under certain conditions.\n6. Enolase: Enolase is an enzyme that catalyzes the conversion of enolpyruvate to pyruvate in the glycolytic pathway. It exists as a dimer, but can undergo a dimer-to-tetramer transition under certain conditions.\n7. Malate dehydrogenase: Malate dehydrogenase is an enzyme that catalyzes the conversion of malate to oxaloacetate in the citric acid cycle. It exists as a dimer, but can undergo a dimer-to-tetramer transition under certain conditions.\nThese are just a few examples of human prote",
    "llama-2-13b-chat-hf_fact_raw": "1. Hemoglobin can convert from a dimer to a tetramer under certain conditions.\n2. Myoglobin can undergo a dimer-to-tetramer transition under certain conditions.\n3. Cytochrome c exists as a dimer in its reduced form but can convert to a tetramer.\n4. Ferritin undergoes a dimer-to-tetramer transition under certain conditions.\n5. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) exists as a dimer but can convert to a tetramer under certain conditions.",
    "llama-2-13b-chat-hf_fact": [
      "Hemoglobin can convert from a dimer to a tetramer under certain conditions.",
      "Myoglobin can undergo a dimer-to-tetramer transition under certain conditions.",
      "Cytochrome c exists as a dimer in its reduced form but can convert to a tetramer.",
      "Ferritin undergoes a dimer-to-tetramer transition under certain conditions.",
      "Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) exists as a dimer but can convert to a tetramer under certain conditions."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: Hemoglobin exists as a tetramer (two alpha and two beta subunits) and does not convert from a dimer to a tetramer.\n2. FALSE [correction]: Myoglobin functions as a monomer and does not form dimers or tetramers.\n3. FALSE [correction]: Cytochrome c is generally found as a monomeric protein and does not switch between dimeric and tetrameric forms.\n4. UNKNOWN: Ferritin naturally assembles into a large multi-subunit complex, commonly a hollow sphere composed of 24 subunits, but whether it transitions specifically between dimer and tetramer under certain conditions is not well-established without additional context.\n5. TRUE: Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) can exist as both a dimer and a tetramer, and the oligomeric state can shift under certain conditions.",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 210,
    "user_query": "Which protein has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein?",
    "llama-2-13b-chat-hf_response": "A) Bcl-2\nB) Bcl-xL\nC) Mcl-1\nD) Apoptosis-related protein 1 (ARC1)\nCorrect answer: B) Bcl-xL\nRationale: Phospholamban (PLN) is a protein that regulates calcium signaling in the heart and has been implicated in cardiac hypertrophy and heart failure. Bcl-xL is an anti-apoptotic protein that has been shown to interact with PLN and protect against apoptosis. Mcl-1 and Apoptosis-related protein 1 (ARC1) are also anti-apoptotic proteins, but there is no evidence to suggest that they interact with PLN.",
    "llama-2-13b-chat-hf_fact_raw": "1. Phospholamban (PLN) regulates calcium signaling in the heart.\n2. PLN has been implicated in cardiac hypertrophy and heart failure.\n3. Bcl-xL is an anti-apoptotic protein.\n4. Bcl-xL has been shown to interact with PLN.\n5. Mcl-1 and Apoptosis-related protein 1 (ARC1) have not been shown to interact with PLN.",
    "llama-2-13b-chat-hf_fact": [
      "Phospholamban (PLN) regulates calcium signaling in the heart.",
      "PLN has been implicated in cardiac hypertrophy and heart failure.",
      "Bcl-xL is an anti-apoptotic protein.",
      "Bcl-xL has been shown to interact with PLN.",
      "Mcl-1 and Apoptosis-related protein 1 (ARC1) have not been shown to interact with PLN."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. FALSE [correction]: Without context, it is not possible to confidently assert if Mcl-1 and ARC1 have or have not been shown to interact with PLN. The statement is definitive, yet without supporting evidence or specific studies, we cannot determine its accuracy. Therefore, it is safest to consider this statement unknown.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 218,
    "user_query": "Has vitamin D has been shown to reduce incidence of falls in older people in clinical trials?",
    "llama-2-13b-chat-hf_response": "Yes, there is evidence from clinical trials that vitamin D supplementation can reduce the incidence of falls in older people.\nA 2010 meta-analysis of 13 randomized controlled trials found that vitamin D supplementation was associated with a significant reduction in the risk of falls in older adults. The meta-analysis, which was published in the Journal of Bone and Mineral Research, found that vitamin D supplementation reduced the risk of falls by 16% (95% CI, 10-23%).\nA more recent Cochrane review of 20 randomized controlled trials found that vitamin D supplementation was associated with a 17% reduction in the risk of falls (95% CI, 11-24%) in older adults. The review, which was published in 2018, also found that the effect of vitamin D supplementation on fall risk was most pronounced in trials that included participants with low baseline levels of vitamin D.\nThe mechanisms by which vitamin D may reduce the risk of falls are not fully understood, but it is thought that vitamin D may play a role in maintaining muscle strength and flexibility, as well as regulating bone metabolism. Additionally, vitamin D may have anti-inflammatory effects, which could also contribute to its potential benefits for fall prevention.\nIt's important to note that while the evidence suggests that vitamin D supplementation may be effective in reducing the risk of falls in older adults, more research is needed to confirm these findings and to determine the optimal dosage and duration of supplementation. Additionally, it's important to consult with a healthcare provider before starting any new supplement regimen.",
    "llama-2-13b-chat-hf_fact_raw": "1. A 2010 meta-analysis of 13 randomized controlled trials found a 16% reduction in the risk of falls with vitamin D supplementation in older adults.\n2. The 2010 meta-analysis was published in the Journal of Bone and Mineral Research.\n3. A Cochrane review in 2018 of 20 randomized controlled trials found a 17% reduction in the risk of falls with vitamin D supplementation in older adults.\n4. The Cochrane review found that the effect of vitamin D on fall risk was most significant in participants with low baseline levels of vitamin D.\n5. Vitamin D may reduce the risk of falls by maintaining muscle strength and flexibility, regulating bone metabolism, and having anti-inflammatory effects.",
    "llama-2-13b-chat-hf_fact": [
      "A 2010 meta-analysis of 13 randomized controlled trials found a 16% reduction in the risk of falls with vitamin D supplementation in older adults.",
      "The 2010 meta-analysis was published in the Journal of Bone and Mineral Research.",
      "A Cochrane review in 2018 of 20 randomized controlled trials found a 17% reduction in the risk of falls with vitamin D supplementation in older adults.",
      "The Cochrane review found that the effect of vitamin D on fall risk was most significant in participants with low baseline levels of vitamin D.",
      "Vitamin D may reduce the risk of falls by maintaining muscle strength and flexibility, regulating bone metabolism, and having anti-inflammatory effects."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 222,
    "user_query": "Is there any association between Jarid2 and miR-155 in Th17 cells?",
    "llama-2-13b-chat-hf_response": "Jarid2 is a histone-modifying enzyme that has been shown to be involved in the regulation of Th17 cell differentiation. miR-155 is a microRNA that has been shown to be involved in the regulation of Th17 cell differentiation and function.\nThere is evidence to suggest that Jarid2 and miR-155 may be associated in the regulation of Th17 cells. For example, one study found that Jarid2 is a target of miR-155 in Th17 cells, and that miR-155 regulates the expression of Jarid2 (1). Another study found that Jarid2 is required for the expression of miR-155 in Th17 cells, and that miR-155 regulates the expression of Jarid2 (2).\nFurthermore, both Jarid2 and miR-155 have been shown to be involved in the regulation of Th17 cell differentiation and function. For example, Jarid2 has been shown to be required for the differentiation of Th17 cells, and miR-155 has been shown to be involved in the regulation of Th17 cell proliferation and cytokine production (3, 4).\nOverall, there is evidence to suggest that Jarid2 and miR-155 may be associated in the regulation of Th17 cells, and that they may both be involved in the regulation of Th17 cell differentiation and function.\nReferences:\n1. Wang et al. (2013). Jarid2 is a target of miR-155 in T helper 17 cells. Journal of Biological Chemistry, 288(22), 16132-16140.\n2. Li et al. (2015). Jarid2 is required for the expression of miR-155 in T helper 17 cells. Immunology, 155(2), 234-244.\n3. Zhang et al. (2013). Jarid2 is essential for the differentiation of T helper 17 cells. Journal of Experimental Medicine, 210(11), 223",
    "llama-2-13b-chat-hf_fact_raw": "1. Jarid2 is a histone-modifying enzyme that plays a role in the regulation of Th17 cell differentiation.\n2. miR-155 is a microRNA that is involved in the regulation of Th17 cell differentiation and function.\n3. A study found that Jarid2 is a target of miR-155 in Th17 cells.\n4. Another study discovered that Jarid2 is required for the expression of miR-155 in Th17 cells.\n5. Jarid2 and miR-155 have been shown to influence Th17 cell proliferation and cytokine production.",
    "llama-2-13b-chat-hf_fact": [
      "Jarid2 is a histone-modifying enzyme that plays a role in the regulation of Th17 cell differentiation.",
      "miR-155 is a microRNA that is involved in the regulation of Th17 cell differentiation and function.",
      "A study found that Jarid2 is a target of miR-155 in Th17 cells.",
      "Another study discovered that Jarid2 is required for the expression of miR-155 in Th17 cells.",
      "Jarid2 and miR-155 have been shown to influence Th17 cell proliferation and cytokine production."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: Jarid2 is not a histone-modifying enzyme itself; rather, it is a component of the Polycomb repressive complex 2 (PRC2) that plays a role in regulating gene expression, including possibly influencing Th17 cell differentiation.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: To the best of my knowledge as of March 2023, Jarid2 is not required for the expression of miR-155 in Th17 cells; instead, Jarid2 is a target of miR-155 in Th17 cells according to the provided statement. This particular relationship usually indicates that miR-155 regulates the expression of Jarid2, not the other way around.\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 224,
    "user_query": "How many genes does the human hoxD cluster contain?",
    "llama-2-13b-chat-hf_response": "The human hoxD cluster contains 4 genes.",
    "llama-2-13b-chat-hf_fact_raw": "1. The human hoxD cluster contains 4 genes.",
    "llama-2-13b-chat-hf_fact": [
      "The human hoxD cluster contains 4 genes."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: The human HOXD cluster contains 9 genes.",
    "llama-2-13b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 268,
    "user_query": "List phosphorylation consensus motifs for Casein Kinase 1 (CK1)?",
    "llama-2-13b-chat-hf_response": "Casein Kinase 1 (CK1) is a serine/threonine kinase that is involved in various cellular processes, including cell signaling, metabolism, and protein synthesis. CK1 has multiple isoforms, and each isoform has its own specific phosphorylation consensus motifs. Here are some of the known phosphorylation consensus motifs for CK1:\n1. Serine 21/22/23 in the C-terminal domain of casein kinase 1α (CK1α): This motif is phosphorylated by CK1α and is important for the regulation of protein synthesis and cell proliferation.\n2. Threonine 14/15 in the N-terminal domain of CK1α: This motif is phosphorylated by CK1α and is involved in the regulation of cell signaling and protein synthesis.\n3. Serine 32/33 in the C-terminal domain of CK1β: This motif is phosphorylated by CK1β and is involved in the regulation of protein synthesis and cell proliferation.\n4. Threonine 28 in the N-terminal domain of CK1β: This motif is phosphorylated by CK1β and is involved in the regulation of cell signaling and protein synthesis.\n5. Serine 45/46 in the C-terminal domain of CK1ε: This motif is phosphorylated by CK1ε and is involved in the regulation of protein synthesis and cell proliferation.\n6. Threonine 22 in the N-terminal domain of CK1ε: This motif is phosphorylated by CK1ε and is involved in the regulation of cell signaling and protein synthesis.\nIt's worth noting that these consensus motifs are not the only phosphorylation sites for CK1, and other sites may also be phosphorylated under different conditions or by different isoforms of the enzyme. Additionally, the specific phosphorylation sites and their downstream effects may vary depending on the cell type and the specific signal",
    "llama-2-13b-chat-hf_fact_raw": "1. Casein Kinase 1 (CK1) is a serine/threonine kinase that is involved in various cellular processes.\n2. CK1 has multiple isoforms, each with its own specific phosphorylation consensus motifs.\n3. Serine 21/22/23 in the C-terminal domain of casein kinase 1α (CK1α) is a known phosphorylation consensus motif for CK1α.\n4. Threonine 14/15 in the N-terminal domain of CK1α is a known phosphorylation consensus motif for CK1α.\n5. Serine 32/33 in the C-terminal domain of CK1β is a known phosphorylation consensus motif for CK1β.",
    "llama-2-13b-chat-hf_fact": [
      "Casein Kinase 1 (CK1) is a serine/threonine kinase that is involved in various cellular processes.",
      "CK1 has multiple isoforms, each with its own specific phosphorylation consensus motifs.",
      "Serine 21/22/23 in the C-terminal domain of casein kinase 1α (CK1α) is a known phosphorylation consensus motif for CK1α.",
      "Threonine 14/15 in the N-terminal domain of CK1α is a known phosphorylation consensus motif for CK1α.",
      "Serine 32/33 in the C-terminal domain of CK1β is a known phosphorylation consensus motif for CK1β."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The specific serine residues in the C-terminal domain of CK1α that are phosphorylation sites have not been provided. Therefore, without specific literature or data verifying Serine 21/22/23 as phosphorylation sites for CK1α, this statement cannot be confirmed.\n4. UNKNOWN: Without specific literature or data verifying Threonine 14/15 as phosphorylation sites for CK1α, the statement's accuracy cannot be determined.\n5. UNKNOWN: There is no commonly referred to isoform known as CK1β, and without specific data or literature, it's unclear whether Serine 32/33 is a phosphorylation motif in any existing isoform of CK1.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 305,
    "user_query": "Which are the different proteins/isoforms encoded but the ASPH (aspartate beta-hydroxylase) gene in humans?",
    "llama-2-13b-chat-hf_response": "The ASPH (aspartate beta-hydroxylase) gene in humans encodes for multiple proteins/isoforms, including:\n1. ASPH: This is the full-length form of the protein, which is primarily localized to the mitochondria and catalyzes the conversion of aspartate to oxoglutarate.\n2. ASPH-short: This is a shorter form of the protein that is produced through alternative splicing and is primarily localized to the cytosol.\n3. ASPH-C: This is a carboxyl-terminal truncated form of the protein that is produced through alternative splicing and is primarily localized to the mitochondria.\n4. ASPH-N: This is a nucleolar form of the protein that is produced through alternative splicing and is primarily localized to the nucleolus.\n5. ASPH-S: This is a soluble form of the protein that is produced through alternative splicing and is primarily localized to the cytoplasm.\n6. ASPH-L: This is a longer form of the protein that is produced through alternative splicing and is primarily localized to the mitochondria.\nEach of these isoforms has a distinct function and is involved in different cellular processes, such as protein synthesis, mitochondrial function, and regulation of gene expression. The specific functions of each isoform are not well understood and are the subject of ongoing research.",
    "llama-2-13b-chat-hf_fact_raw": "1. The ASPH gene in humans encodes for multiple proteins/isoforms.\n2. The full-length form of the ASPH protein is primarily localized to the mitochondria.\n3. The ASPH-short is a shorter form of the protein produced through alternative splicing and localized to the cytosol.\n4. The ASPH-C is a carboxyl-terminal truncated form of the protein localized to the mitochondria.\n5. The ASPH-N is a nucleolar form of the protein localized to the nucleolus.",
    "llama-2-13b-chat-hf_fact": [
      "The ASPH gene in humans encodes for multiple proteins/isoforms.",
      "The full-length form of the ASPH protein is primarily localized to the mitochondria.",
      "The ASPH-short is a shorter form of the protein produced through alternative splicing and localized to the cytosol.",
      "The ASPH-C is a carboxyl-terminal truncated form of the protein localized to the mitochondria.",
      "The ASPH-N is a nucleolar form of the protein localized to the nucleolus."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The full-length form of the ASPH protein is primarily localized to the endoplasmic reticulum.\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nNote: Without specific or technical references, it is challenging to confirm or refute the details provided in statements 3, 4, and 5, as they require specialized knowledge about the ASPH gene and its protein isoforms that might not be common knowledge or readily accessible. Therefore, these statements are marked as UNKNOWN.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 330,
    "user_query": "When was empagliflozin FDA approved?",
    "llama-2-13b-chat-hf_response": "Empagliflozin was FDA approved on 08/18/2014.\nWhat is the brand name for empagliflozin?\nThe brand name for empagliflozin is Jardiance.\nWhat is the drug class of empagliflozin?\nEmpagliflozin is classified as a sodium-glucose cotransporter 2 (SGLT2) inhibitor.\nWhat are the indications for empagliflozin?\nEmpagliflozin is indicated for the treatment of type 2 diabetes mellitus (T2DM) in adults.\nWhat are the dosage forms of empagliflozin?\nEmpagliflozin is available in the following dosage forms:\n* Tablets (10 mg, 25 mg)\n* Oral solution (2.5 mg/mL)\nWhat is the recommended starting dose of empagliflozin?\nThe recommended starting dose of empagliflozin is 10 mg once daily, and the maximum recommended dose is 25 mg once daily.\nWhat is the mechanism of action of empagliflozin?\nEmpagliflozin works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubules, thereby reducing the reabsorption of glucose back into the bloodstream and increasing urinary glucose excretion.\nWhat are the adverse effects of empagliflozin?\nCommon adverse effects of empagliflozin include:\n* Urinary tract infections\n* Increased urination\n* Increased thirst\n* Headache\n* Nausea\n* Vomiting\n* Diarrhea\n* Abdominal pain\nWhat are the contraindications for empagliflozin?\nEmpagliflozin is contraindicated in patients with:\n* Severe renal impairment (estimated glomerular filtration rate [eGFR] <30 mL/min/1.73 m2)\n* End-stage renal disease (ESRD)\n* Hypersensitivity",
    "llama-2-13b-chat-hf_fact_raw": "1. Empagliflozin was FDA approved on August 18, 2014.\n2. The brand name for empagliflozin is Jardiance.\n3. Empagliflozin is classified as a sodium-glucose cotransporter 2 (SGLT2) inhibitor.\n4. Empagliflozin is indicated for the treatment of type 2 diabetes mellitus (T2DM) in adults.\n5. The recommended starting dose of empagliflozin is 10 mg once daily, and the maximum recommended dose is 25 mg once daily.",
    "llama-2-13b-chat-hf_fact": [
      "Empagliflozin was FDA approved on August 18, 2014.",
      "The brand name for empagliflozin is Jardiance.",
      "Empagliflozin is classified as a sodium-glucose cotransporter 2 (SGLT2) inhibitor.",
      "Empagliflozin is indicated for the treatment of type 2 diabetes mellitus (T2DM) in adults.",
      "The recommended starting dose of empagliflozin is 10 mg once daily, and the maximum recommended dose is 25 mg once daily."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 350,
    "user_query": "What are the results of loss of the protein Lon1 in the plant Arabidopsis?",
    "llama-2-13b-chat-hf_response": "Loss of the protein Lon1 in the plant Arabidopsis results in several developmental and physiological abnormalities. Here are some of the main results:\n1. Delayed flowering: Lon1-deficient plants have a delayed flowering phenotype, which means that they take longer to produce flowers and set seed.\n2. Dwarfism: Lon1-deficient plants are shorter and have smaller rosettes than wild-type plants.\n3. Thicker stems: The stems of Lon1-deficient plants are thicker and more fleshy than wild-type plants.\n4. Yellowing of leaves: The leaves of Lon1-deficient plants are often yellowish or chlorotic, indicating a defect in chlorophyll biosynthesis.\n5. Increased sensitivity to abiotic stress: Lon1-deficient plants are more sensitive to abiotic stressors such as high salinity, drought, and extreme temperatures.\n6. Reduced root growth: Lon1-deficient plants have reduced root growth and biomass compared to wild-type plants.\n7. Increased susceptibility to pathogens: Lon1-deficient plants are more susceptible to pathogens such as bacteria and fungi.\n8. Reduced seed germination and viability: Lon1-deficient seeds have reduced germination and viability compared to wild-type seeds.\nOverall, the loss of the protein Lon1 in Arabidopsis leads to a range of developmental and physiological abnormalities that can affect the plant's growth, reproduction, and stress tolerance.",
    "llama-2-13b-chat-hf_fact_raw": "1. Lon1-deficient Arabidopsis plants have a delayed flowering phenotype.\n2. Dwarfism is observed in Lon1-deficient Arabidopsis plants, as they are shorter with smaller rosettes than wild-type plants.\n3. The stems of Lon1-deficient Arabidopsis plants are thicker and more fleshy than those of wild-type plants.\n4. Leaves of Lon1-deficient Arabidopsis plants often appear yellowish or chlorotic.\n5. Lon1-deficient Arabidopsis plants have an increased sensitivity to abiotic stress such as high salinity, drought, and extreme temperatures.",
    "llama-2-13b-chat-hf_fact": [
      "Lon1-deficient Arabidopsis plants have a delayed flowering phenotype.",
      "Dwarfism is observed in Lon1-deficient Arabidopsis plants, as they are shorter with smaller rosettes than wild-type plants.",
      "The stems of Lon1-deficient Arabidopsis plants are thicker and more fleshy than those of wild-type plants.",
      "Leaves of Lon1-deficient Arabidopsis plants often appear yellowish or chlorotic.",
      "Lon1-deficient Arabidopsis plants have an increased sensitivity to abiotic stress such as high salinity, drought, and extreme temperatures."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The stems of Lon1-deficient Arabidopsis plants are not typically described as thicker and more fleshy; it is common for mutant plants to have a variety of growth defects, but without specific context, it is not possible to assert that thick, fleshy stems are a characteristic of Lon1-deficient plants.\n4. UNKNOWN: Without specific context or information from a study, it is not possible to determine whether the leaves of Lon1-deficient Arabidopsis plants often appear yellowish or chlorotic.\n5. UNKNOWN: Although mutant plants can exhibit increased sensitivity to abiotic stress, the effects of Lon1 deficiency on sensitivity to abiotic stresses like high salinity, drought, and extreme temperatures would need to be confirmed by experimental data.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 409,
    "user_query": "Does a linker histone exist in the yeast genome?",
    "llama-2-13b-chat-hf_response": "In yeast, the linker histone H1 is not present in the genome. Instead, the yeast genome contains a histone H3-like protein called Spt3, which plays a role in the regulation of chromatin structure and gene expression. Spt3 is a member of the histone H3 family and is highly conserved across different species of yeast. It is involved in the formation of higher-order chromatin structures and is required for proper gene expression and cell growth.\nIn contrast, the linker histone H1 is present in the genomes of animals and humans, where it plays a role in the formation of higher-order chromatin structures and the regulation of gene expression. The linker histone H1 is not present in the yeast genome, and instead, the yeast genome contains the histone H3-like protein Spt3.\nTherefore, the answer to the question \"\" is no, there is no linker histone H1 in the yeast genome, but there is a histone H3-like protein called Spt3 that plays a similar role in regulating chromatin structure and gene expression.",
    "llama-2-13b-chat-hf_fact_raw": "1. The linker histone H1 is not present in the yeast genome.\n2. The yeast genome contains a histone H3-like protein called Spt3.\n3. Spt3 is involved in the regulation of chromatin structure and gene expression.\n4. Histone H3 is highly conserved across different species of yeast.\n5. The linker histone H1 performs functions in animals and humans, including the formation of higher-order chromatin structures and the regulation of gene expression.",
    "llama-2-13b-chat-hf_fact": [
      "The linker histone H1 is not present in the yeast genome.",
      "The yeast genome contains a histone H3-like protein called Spt3.",
      "Spt3 is involved in the regulation of chromatin structure and gene expression.",
      "Histone H3 is highly conserved across different species of yeast.",
      "The linker histone H1 performs functions in animals and humans, including the formation of higher-order chromatin structures and the regulation of gene expression."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The yeast genome contains a histone H3-like protein called Hht1 or Hht2 (depending on the specific yeast species), not Spt3. Spt3 is a different protein that is part of the SAGA complex involved in transcriptional regulation.\n3. FALSE [correction]: As the previous statement about Spt3 being a histone H3-like protein was incorrect, this statement is also false. Spt3, being part of the SAGA complex, does play a role in the regulation of chromatin structure and gene expression, but it is not a histone H3-like protein.\n4. TRUE\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 418,
    "user_query": "Is there evidence that tomato juice lowers cholesterol levels?",
    "llama-2-13b-chat-hf_response": "Tomato juice has been suggested as a potential way to lower cholesterol levels, but the evidence for this claim is mixed. Some studies have found that tomato juice may help lower cholesterol levels, while others have found no effect.\nOne study published in the Journal of Agricultural and Food Chemistry found that mice fed a diet supplemented with tomato juice had lower levels of cholesterol and triglycerides than mice not given the supplement. Another study published in the Journal of Lipid Research found that human subjects who drank 2 cups of tomato juice per day for 6 weeks had lower levels of LDL (bad) cholesterol and higher levels of HDL (good) cholesterol than those who did not drink the tomato juice.\nHowever, other studies have found no effect of tomato juice on cholesterol levels. A review of 17 clinical trials published in the Journal of Clinical Lipidology found that tomato juice had no significant effect on cholesterol levels. Another study published in the Journal of Nutrition found that drinking 2 cups of tomato juice per day for 8 weeks had no effect on cholesterol levels in healthy adults.\nOverall, the evidence for the claim that tomato juice lowers cholesterol levels is mixed and more research is needed to fully understand the potential effects of tomato juice on cholesterol levels. It is important to note that while some studies have suggested that tomato juice may have potential health benefits, it is not a substitute for a healthy diet and lifestyle.",
    "llama-2-13b-chat-hf_fact_raw": "1. A study published in the Journal of Agricultural and Food Chemistry showed that mice fed with tomato juice had lower levels of cholesterol and triglycerides.\n2. A study in the Journal of Lipid Research observed lower levels of LDL cholesterol and higher levels of HDL cholesterol in human subjects who drank 2 cups of tomato juice per day for 6 weeks.\n3. The Journal of Clinical Lipidology published a review of 17 clinical trials indicating that tomato juice had no significant effect on cholesterol levels.\n4. A study in the Journal of Nutrition found that drinking 2 cups of tomato juice per day for 8 weeks had no effect on cholesterol levels in healthy adults.",
    "llama-2-13b-chat-hf_fact": [
      "A study published in the Journal of Agricultural and Food Chemistry showed that mice fed with tomato juice had lower levels of cholesterol and triglycerides.",
      "A study in the Journal of Lipid Research observed lower levels of LDL cholesterol and higher levels of HDL cholesterol in human subjects who drank 2 cups of tomato juice per day for 6 weeks.",
      "The Journal of Clinical Lipidology published a review of 17 clinical trials indicating that tomato juice had no significant effect on cholesterol levels.",
      "A study in the Journal of Nutrition found that drinking 2 cups of tomato juice per day for 8 weeks had no effect on cholesterol levels in healthy adults."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n\nWithout access to the specific studies from these journals, I cannot determine the truthfulness of these statements. The statements seem plausible and they reference reputable journals, but without the actual articles or summaries, I cannot confirm their accuracy.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 472,
    "user_query": "How do Hsp70 and Hsp110 affect mRNA stability?",
    "llama-2-13b-chat-hf_response": "Heat shock proteins (Hsps) are upregulated in response to cellular stress and play a crucial role in maintaining protein homeostasis. In addition to their chaperone functions, Hsps have been shown to regulate mRNA stability. Hsp70 and Hsp110 are two of the most well-studied Hsps in this context. Here, we will discuss how Hsp70 and Hsp110 affect mRNA stability.\nHsp70 and Hsp110 are both involved in the regulation of mRNA stability through their interactions with the RNA-binding protein, RNA-binding protein 1 (RBP1). RBP1 is a key regulator of mRNA stability and is involved in the degradation of mRNAs with aberrant splicing or polyadenylation. Hsp70 and Hsp110 interact with RBP1 and prevent its degradation of mRNAs, leading to increased mRNA stability.\nHsp70 and Hsp110 also regulate mRNA stability by modulating the activity of the RNA exosome, a complex of proteins that degrade mRNAs. The RNA exosome is composed of several subunits, including the RNA-binding proteins Rrp1 and Rrp2, and the catalytic subunits Rnt1 and Rnt2. Hsp70 and Hsp110 interact with the RNA exosome and prevent its degradation of mRNAs, leading to increased mRNA stability.\nIn addition, Hsp70 and Hsp110 have been shown to regulate the translation of mRNAs. Hsp70 and Hsp110 can bind to the 3' untranslated region (UTR) of mRNAs and prevent the degradation of these mRNAs by the RNA exosome. This leads to an increase in the translation of these mRNAs and a decrease in their degradation.\nIn conclusion, Hsp70 and Hsp110 play a crucial role in regulating mRNA stability by interacting with RBP1 and the RNA exosome, and by modulating the translation of",
    "llama-2-13b-chat-hf_fact_raw": "1. Heat shock proteins (Hsps) such as Hsp70 and Hsp110 are upregulated in response to cellular stress and help maintain protein homeostasis.\n2. Hsp70 and Hsp110 are involved in regulating mRNA stability by interacting with RNA-binding protein 1 (RBP1).\n3. Hsp70 and Hsp110 prevent the degradation of mRNAs by RBP1, which is involved in the degradation of mRNAs with aberrant splicing or polyadenylation.\n4. Hsp70 and Hsp110 modulate the activity of the RNA exosome, which is responsible for degrading mRNAs.\n5. Hsp70 and Hsp110 can bind to the 3' untranslated region of mRNAs and prevent their degradation by the RNA exosome, which leads to an increase in the translation of these mRNAs.",
    "llama-2-13b-chat-hf_fact": [
      "Heat shock proteins (Hsps) such as Hsp70 and Hsp110 are upregulated in response to cellular stress and help maintain protein homeostasis.",
      "Hsp70 and Hsp110 are involved in regulating mRNA stability by interacting with RNA-binding protein 1 (RBP1).",
      "Hsp70 and Hsp110 prevent the degradation of mRNAs by RBP1, which is involved in the degradation of mRNAs with aberrant splicing or polyadenylation.",
      "Hsp70 and Hsp110 modulate the activity of the RNA exosome, which is responsible for degrading mRNAs.",
      "Hsp70 and Hsp110 can bind to the 3' untranslated region of mRNAs and prevent their degradation by the RNA exosome, which leads to an increase in the translation of these mRNAs."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE - Heat shock proteins (Hsps), such as Hsp70 and Hsp110, are indeed upregulated in response to cellular stress and are known to play a crucial role in maintaining protein homeostasis by helping proteins to fold and prevent aggregation.\n2. UNKNOWN - While Hsp70 is known to be involved in several cellular processes, including the regulation of mRNA, the specific interaction with RNA-binding protein 1 (RBP1) and the involvement of Hsp110 in this process is not standard knowledge and would require specific literature to confirm or deny.\n3. UNKNOWN - The specific role of Hsp70 and Hsp110 in protecting mRNAs from degradation by RBP1, particularly in the context of aberrant splicing or polyadenylation, is not general knowledge and requires specific referencing to confirm or refute.\n4. UNKNOWN - Although Hsp70 and other heat shock proteins have been implicated in various aspects of RNA metabolism, the modulation of RNA exosome activity by Hsp70 and Hsp110 would require specific scientific evidence to validate.\n5. UNKNOWN - The mechanism by which Hsp70 and Hsp110 might bind to the 3' untranslated region of mRNAs and influence their stability or translation involves specific interactions that are not widely recognized without detailed scientific research to support such claims.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 481,
    "user_query": "Which deiodinases are present in skeletal  muscle?",
    "llama-2-13b-chat-hf_response": "There are three isoforms of deiodinases present in skeletal muscle:\n1. D1 (type 1 deiodinase): This enzyme is primarily involved in the activation of T4 to T3 in skeletal muscle.\n2. D2 (type 2 deiodinase): This enzyme is primarily involved in the inactivation of T3 to reverse T3 (rT3) in skeletal muscle.\n3. D3 (type 3 deiodinase): This enzyme is primarily involved in the activation of T4 to T3 in skeletal muscle, but it also has a minor role in the inactivation of T3 to rT3.\nSo, in summary, there are three deiodinases present in skeletal muscle: D1, D2, and D3.",
    "llama-2-13b-chat-hf_fact_raw": "1. There are three isoforms of deiodinases present in skeletal muscle: D1, D2, and D3.\n2. Type 1 deiodinase (D1) is involved in the activation of T4 to T3 in skeletal muscle.\n3. Type 2 deiodinase (D2) is primarily involved in the inactivation of T3 to reverse T3 (rT3) in skeletal muscle.\n4. Type 3 deiodinase (D3) is involved in the activation of T4 to T3 in skeletal muscle and has a minor role in the inactivation of T3 to rT3.",
    "llama-2-13b-chat-hf_fact": [
      "There are three isoforms of deiodinases present in skeletal muscle: D1, D2, and D3.",
      "Type 1 deiodinase (D1) is involved in the activation of T4 to T3 in skeletal muscle.",
      "Type 2 deiodinase (D2) is primarily involved in the inactivation of T3 to reverse T3 (rT3) in skeletal muscle.",
      "Type 3 deiodinase (D3) is involved in the activation of T4 to T3 in skeletal muscle and has a minor role in the inactivation of T3 to rT3."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Type 2 deiodinase (D2) is primarily involved in the conversion of T4 to T3, not the inactivation of T3 to reverse T3 (rT3) in skeletal muscle.\n4. FALSE [correction]: Type 3 deiodinase (D3) is involved in the inactivation of T4 to reverse T3 (rT3) and the conversion of T3 to diiodothyronine (T2), not the activation of T4 to T3.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 534,
    "user_query": "List inflammatory caspase proteins?",
    "llama-2-13b-chat-hf_response": "After reviewing my previous response, I noticed that I missed one important inflammatory caspase protein, which is caspase-7 (MAVS). Therefore, I correct my previous response as follows:\nThere are several inflammatory caspase proteins that have been identified and studied. Here are some examples:\n1. Caspase-1 (IL-1β): Caspase-1 is a key enzyme involved in the processing and activation of the pro-inflammatory cytokines interleukin-1β (IL-1β) and interleukin-18 (IL-18). Activation of caspase-1 leads to the production of these cytokines, which play a role in the inflammatory response.\n2. Caspase-3 (CPP32): Caspase-3 is a cysteine protease that is involved in the execution of apoptosis, or programmed cell death. Activation of caspase-3 leads to the breakdown of cellular components and the release of pro-inflammatory cytokines, which can contribute to the inflammatory response.\n3. Caspase-4 (MCH2): Caspase-4 is a member of the caspase family that is primarily involved in the regulation of inflammation. Activation of caspase-4 leads to the production of pro-inflammatory cytokines, such as TNF-α and IL-1β, which can exacerbate inflammation.\n4. Caspase-5 (cIAP1): Caspase-5 is a cysteine protease that is involved in the regulation of inflammation and the immune response. Activation of caspase-5 leads to the production of pro-inflammatory cytokines, such as TNF-α and IL-1β, which can contribute to the inflammatory response.\n5. Caspase-7 (MAVS): Caspase-7 is a cysteine protease that is involved in the regulation of inflammation and the immune response. Activation of caspase-7 leads to the production of pro-inflammatory cytokines, such as TNF-α and IL-1β,",
    "llama-2-13b-chat-hf_fact_raw": "1. Caspase-1 is involved in the processing and activation of interleukin-1β (IL-1β) and interleukin-18 (IL-18).\n2. Caspase-3 is a cysteine protease involved in the execution of apoptosis.\n3. Caspase-4 is primarily involved in the regulation of inflammation and activation leads to the production of pro-inflammatory cytokines.\n4. Caspase-5 is involved in the regulation of inflammation and the immune response, and its activation leads to the production of cytokines like TNF-α and IL-1β.\n5. Caspase-7 is involved in the regulation of inflammation and the immune response, and its activation also leads to the production of pro-inflammatory cytokines.",
    "llama-2-13b-chat-hf_fact": [
      "Caspase-1 is involved in the processing and activation of interleukin-1β (IL-1β) and interleukin-18 (IL-18).",
      "Caspase-3 is a cysteine protease involved in the execution of apoptosis.",
      "Caspase-4 is primarily involved in the regulation of inflammation and activation leads to the production of pro-inflammatory cytokines.",
      "Caspase-5 is involved in the regulation of inflammation and the immune response, and its activation leads to the production of cytokines like TNF-α and IL-1β.",
      "Caspase-7 is involved in the regulation of inflammation and the immune response, and its activation also leads to the production of pro-inflammatory cytokines."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Caspase-5 is involved in the regulation of inflammation and the immune response, and its activation leads to the processing and activation of IL-1β, but not typically TNF-α.\n5. FALSE [correction]: Caspase-7 is similar to caspase-3 and is involved in the execution phase of apoptosis, but it is not primarily known for regulating inflammation or leading to the production of pro-inflammatory cytokines.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 579,
    "user_query": "Is there any link between the aurora B kinase and the polycomb protein ring1B?",
    "llama-2-13b-chat-hf_response": "The aurora B kinase and the polycomb protein Ring1B have been shown to interact and cooperate in regulating various cellular processes, including cell proliferation, differentiation, and survival. Here are some examples of their potential linkages:\n1. Regulation of gene expression: Aurora B kinase has been shown to phosphorylate and activate Ring1B, which in turn regulates the expression of target genes involved in cell cycle progression and apoptosis.\n2. Chromatin remodeling: Ring1B is a component of the polycomb repressive complex 1 (PRC1), which is involved in chromatin remodeling and gene silencing. Aurora B kinase has been shown to phosphorylate and activate PRC1, leading to the repression of target genes.\n3. Cell cycle regulation: Aurora B kinase and Ring1B have been shown to cooperate in regulating the G1/S checkpoint and progression through the cell cycle.\n4. Tumorigenesis: Overexpression of Aurora B kinase and Ring1B has been implicated in tumorigenesis, and their cooperation has been suggested to contribute to the development of cancer.\nIn summary, there is evidence to suggest that Aurora B kinase and Ring1B interact and cooperate in regulating various cellular processes, including gene expression, chromatin remodeling, cell cycle progression, and tumorigenesis.",
    "llama-2-13b-chat-hf_fact_raw": "1. Aurora B kinase has been shown to phosphorylate and activate Ring1B.\n2. Ring1B is a component of the polycomb repressive complex 1 (PRC1), which is involved in chromatin remodeling and gene silencing.\n3. Aurora B kinase has been shown to interact with PRC1 and is implicated in the repression of target genes.\n4. Aurora B kinase and Ring1B are involved in regulating the G1/S checkpoint in the cell cycle.\n5. Overexpression of Aurora B kinase and Ring1B has been implicated in tumorigenesis.",
    "llama-2-13b-chat-hf_fact": [
      "Aurora B kinase has been shown to phosphorylate and activate Ring1B.",
      "Ring1B is a component of the polycomb repressive complex 1 (PRC1), which is involved in chromatin remodeling and gene silencing.",
      "Aurora B kinase has been shown to interact with PRC1 and is implicated in the repression of target genes.",
      "Aurora B kinase and Ring1B are involved in regulating the G1/S checkpoint in the cell cycle.",
      "Overexpression of Aurora B kinase and Ring1B has been implicated in tumorigenesis."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE \n\nExplanation:\n1. The specific biochemical function of Aurora B kinase phosphorylating and activating Ring1B is not commonly known information and would require a specific scientific reference to confirm its validity.\n2. Ring1B is indeed a component of the polycomb repressive complex 1 (PRC1), which is known to be involved in chromatin remodeling and gene silencing, making this statement true.\n3. The interaction between Aurora B kinase and PRC1 and its implications in the repression of target genes would require specific scientific literature for confirmation.\n4. The role of Aurora B kinase and Ring1B in regulating the G1/S checkpoint is a very specialized piece of information and would need a specific reference to confirm whether this statement is true or false.\n5. Overexpression of Aurora B kinase has been implicated in tumorigenesis, and Ring1B, as part of a polycomb repressive complex, is involved in gene expression regulation which can be linked to cancer when dysregulated, therefore this statement is considered to be true.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 597,
    "user_query": "What are the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates?",
    "llama-2-13b-chat-hf_response": "In vertebrates, the most frequent non-canonical sequence motifs at the donor and acceptor splice sites are:\nDonor splice site motifs:\n1. GT-AG: This is the most common donor splice site motif in vertebrates, with a frequency of approximately 70%.\n2. GA-AG: This motif is the second most common donor splice site motif in vertebrates, with a frequency of approximately 20%.\n3. GC-AG: This motif is less common, with a frequency of approximately 5%.\nAcceptor splice site motifs:\n1. AG-GT: This is the most common acceptor splice site motif in vertebrates, with a frequency of approximately 70%.\n2. AG-GA: This motif is the second most common acceptor splice site motif in vertebrates, with a frequency of approximately 20%.\n3. GC-AG: This motif is less common, with a frequency of approximately 5%.\nIt's worth noting that these frequencies can vary depending on the specific species and the context of the splice site. Additionally, some studies have reported different frequencies for these motifs in different vertebrate species.",
    "llama-2-13b-chat-hf_fact_raw": "1. GT-AG is the most common donor splice site motif in vertebrates, with a frequency of approximately 70%.\n2. GA-AG is the second most common donor splice site motif in vertebrates, with a frequency of approximately 20%.\n3. GC-AG has a frequency of approximately 5% at the donor splice site in vertebrates.\n4. AG-GT is the most common acceptor splice site motif in vertebrates, with a frequency of approximately 70%.\n5. AG-GA is the second most common acceptor splice site motif in vertebrates, with a frequency of approximately 20%.",
    "llama-2-13b-chat-hf_fact": [
      "GT-AG is the most common donor splice site motif in vertebrates, with a frequency of approximately 70%.",
      "GA-AG is the second most common donor splice site motif in vertebrates, with a frequency of approximately 20%.",
      "GC-AG has a frequency of approximately 5% at the donor splice site in vertebrates.",
      "AG-GT is the most common acceptor splice site motif in vertebrates, with a frequency of approximately 70%.",
      "AG-GA is the second most common acceptor splice site motif in vertebrates, with a frequency of approximately 20%."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The second most common donor splice site motif is not GA-AG; instead, the consensus sequence for the second most common donor splice site motif can vary and it isn't typically summarized as having a frequency such as 20%.\n3. UNKNOWN: Specific frequency figures for less common splice site motifs like GC-AG can vary depending on the source, and without the specific context or reference, the exact frequency is difficult to confirm.\n4. FALSE [correction]: The most common acceptor splice site motif in vertebrates is not AG-GT; the consensus sequence is typically AG at the acceptor site, with the most common sequence being YAG (where Y is a pyrimidine base).\n5. FALSE [correction]: AG-GA is not the second most common acceptor splice site motif in vertebrates; acceptor splice site motifs do not typically follow this notation and the ranking of their commonality is not usually expressed in such a way.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "false",
      "false"
    ]
  },
  {
    "id": 629,
    "user_query": "Which event results in the acetylation of S6K1?",
    "llama-2-13b-chat-hf_response": "A) Insulin signaling\nB) Growth factor signaling\nC) Glucocorticoid signaling\nD) Nutrient deprivation\nCorrect answer: A) Insulin signaling\nExplanation: Insulin signaling activates the protein kinase B (PKB) pathway, which phosphorylates and activates S6K1. This leads to the acetylation of S6K1, which promotes protein synthesis and cell growth. Growth factor signaling, glucocorticoid signaling, and nutrient deprivation can also affect S6K1 activity, but they do not result in its acetylation.",
    "llama-2-13b-chat-hf_fact_raw": "1. Acetylation of S6K1 is a result of insulin signaling.\n2. Insulin signaling activates the protein kinase B (PKB) pathway.\n3. Activation of the PKB pathway leads to the phosphorylation and activation of S6K1.\n4. The acetylation of S6K1 promotes protein synthesis and cell growth.\n5. Growth factor signaling, glucocorticoid signaling, and nutrient deprivation do not result in the acetylation of S6K1.",
    "llama-2-13b-chat-hf_fact": [
      "Acetylation of S6K1 is a result of insulin signaling.",
      "Insulin signaling activates the protein kinase B (PKB) pathway.",
      "Activation of the PKB pathway leads to the phosphorylation and activation of S6K1.",
      "The acetylation of S6K1 promotes protein synthesis and cell growth.",
      "Growth factor signaling, glucocorticoid signaling, and nutrient deprivation do not result in the acetylation of S6K1."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Growth factor signaling can lead to the acetylation of S6K1. Glucocorticoid signaling and nutrient deprivation are less directly linked to S6K1 acetylation, so without more context, it's difficult to confirm the absolute nature of the statement, but at least for growth factors, they can result in acetylation events within the cell.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 632,
    "user_query": "What is the cause of episodic ataxia type 6?",
    "llama-2-13b-chat-hf_response": "Episodic ataxia type 6 (EA6) is a rare genetic disorder caused by mutations in the GluR2 gene. This gene encodes a subunit of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor, a type of glutamate receptor that plays a critical role in regulating synaptic plasticity and neuronal excitability.\nMutations in the GluR2 gene lead to an imbalance in the function of the AMPA receptor, causing an increase in the activity of the receptor and leading to episodes of ataxia, myokymia, and seizures. The exact mechanism by which these mutations lead to the symptoms of EA6 is not fully understood, but it is thought to involve changes in the regulation of synaptic transmission and the balance of excitation and inhibition in the brain.\nIn addition to mutations in the GluR2 gene, other genetic and environmental factors may also contribute to the development of EA6. For example, some studies have suggested that mutations in other genes that are involved in the regulation of synaptic transmission, such as the GAD65 gene, may also contribute to the development of EA6. Additionally, exposure to certain toxins or infections may trigger the onset of EA6 in some individuals.\nOverall, the exact cause of EA6 is complex and likely involves a combination of genetic and environmental factors. Further research is needed to fully understand the underlying mechanisms of this disorder and to develop effective treatments for those affected.",
    "llama-2-13b-chat-hf_fact_raw": "1. Episodic ataxia type 6 (EA6) is caused by mutations in the GluR2 gene.\n2. The GluR2 gene encodes a subunit of the AMPA receptor, which is involved in synaptic plasticity and neuronal excitability.\n3. Mutations in the GluR2 gene can lead to an increase in the activity of the AMPA receptor.\n4. Symptoms of EA6 include episodes of ataxia, myokymia, and seizures.\n5. The development of EA6 may involve a combination of genetic and environmental factors.",
    "llama-2-13b-chat-hf_fact": [
      "Episodic ataxia type 6 (EA6) is caused by mutations in the GluR2 gene.",
      "The GluR2 gene encodes a subunit of the AMPA receptor, which is involved in synaptic plasticity and neuronal excitability.",
      "Mutations in the GluR2 gene can lead to an increase in the activity of the AMPA receptor.",
      "Symptoms of EA6 include episodes of ataxia, myokymia, and seizures.",
      "The development of EA6 may involve a combination of genetic and environmental factors."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: Episodic ataxia type 6 (EA6) is not associated with mutations in the GluR2 gene. It is associated with mutations in the SLC1A3 gene.\n2. TRUE\n3. TRUE: While the statement is generally correct that mutations in the GluR2 gene can lead to an increase in the activity of the AMPA receptor, without specific context on whether one is discussing an actual disease or condition linked to the GluR2 gene, the implication might not necessarily be correct for EA6.\n4. UNKNOWN: Without specific information on EA6 symptoms from the passage, this cannot be determined. However, episodic ataxia disorders typically involve episodes of ataxia, but other symptoms may vary.\n5. TRUE: Though specific to EA6 is not provided, in general, the development of genetic disorders such as episodic ataxias may involve both genetic and potential environmental factors.",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 646,
    "user_query": "Are chromomethylases present in animal genomes?",
    "llama-2-13b-chat-hf_response": "One study published in the journal Nature Communications in 2019 found that chromomethylases are present in the genomes of animals, including humans. The study used a technique called RNA interference to knock down the expression of the chromomethylase gene in human cells and found that this led to changes in the structure of chromatin and the expression of nearby genes.\nNo other errors were found in my previous response.",
    "llama-2-13b-chat-hf_fact_raw": "1. A study published in Nature Communications in 2019 reported the presence of chromomethylases in animal genomes.\n2. The study used RNA interference to knock down chromomethylase gene expression in human cells.\n3. The knockdown of chromomethylase gene expression led to changes in chromatin structure.\n4. The knockdown of chromomethylase gene expression affected the expression of nearby genes.",
    "llama-2-13b-chat-hf_fact": [
      "A study published in Nature Communications in 2019 reported the presence of chromomethylases in animal genomes.",
      "The study used RNA interference to knock down chromomethylase gene expression in human cells.",
      "The knockdown of chromomethylase gene expression led to changes in chromatin structure.",
      "The knockdown of chromomethylase gene expression affected the expression of nearby genes."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n\nWithout specific details regarding the precise findings of the study, such as methodology and results concerning the knockdown of chromomethylase gene expression and the ensuing effects on chromatin structure and gene expression, the veracity of statements 2, 3, and 4 cannot be determined from the information provided.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 650,
    "user_query": "List packages for transcription factor binding sites' (TFBS) analysis available in R/Bioconductor",
    "llama-2-13b-chat-hf_response": "There are several packages available in R/Bioconductor for the analysis of transcription factor binding sites (TFBS). Here are some of the most popular ones:\n1. TFBS: This package provides a set of functions for the detection of TFBS in DNA sequences. It uses a combination of position weight matrices (PWMs) and hidden Markov models (HMMs) to identify putative TFBS.\n2. RSAT: This package provides a set of functions for the analysis of TFBS, including the detection of PWMs and the prediction of TFBS in DNA sequences. It also includes tools for the analysis of ChIP-seq data.\n3. HMMER: This package provides a set of functions for the detection of TFBS using HMMs. It includes a range of pre-defined PWMs for different transcription factors, as well as tools for creating custom PWMs.\n4. TRANSFAC: This package provides a set of functions for the analysis of TFBS using PWMs. It includes a range of pre-defined PWMs for different transcription factors, as well as tools for creating custom PWMs.\n5. GenomicAlign: This package provides a set of functions for the analysis of TFBS in genomic context. It includes tools for the alignment of DNA sequences to a reference genome, as well as functions for the identification of putative TFBS.\n6. DeepTF: This package provides a set of functions for the analysis of TFBS using deep learning methods. It includes tools for the prediction of TFBS in DNA sequences, as well as functions for the analysis of ChIP-seq data.\n7. TFBS-predict: This package provides a set of functions for the prediction of TFBS in DNA sequences. It uses a combination of machine learning algorithms and PWMs to identify putative TFBS.\n8. TF-finder: This package provides a set of functions for the detection of TFBS using a combination of PWMs and HMMs. It includes tools for the analysis of ChIP-seq data, as well as functions for the prediction of TFBS in DNA sequences.\nThese packages can be installed and loaded into R using the standard package installation procedures. Once installed, they can be used to perform a range of analyses, including",
    "llama-2-13b-chat-hf_fact_raw": "1. The TFBS package in R/Bioconductor provides functions for detecting TFBS using position weight matrices and hidden Markov models.\n2. The RSAT package in R/Bioconductor offers tools for detecting PWMs and predicting TFBS, as well as analyzing ChIP-seq data.\n3. The HMMER package in R/Bioconductor includes functions for TFBS detection with HMMs and pre-defined PWMs for various transcription factors.\n4. The TRANSFAC package in R/Bioconductor allows for TFBS analysis using PWMs and includes pre-defined PWMs for transcription factors.\n5. The GenomicAlign package in R/Bioconductor provides functions for analyzing TFBS in a genomic context and tools for aligning DNA sequences to a reference genome.",
    "llama-2-13b-chat-hf_fact": [
      "The TFBS package in R/Bioconductor provides functions for detecting TFBS using position weight matrices and hidden Markov models.",
      "The RSAT package in R/Bioconductor offers tools for detecting PWMs and predicting TFBS, as well as analyzing ChIP-seq data.",
      "The HMMER package in R/Bioconductor includes functions for TFBS detection with HMMs and pre-defined PWMs for various transcription factors.",
      "The TRANSFAC package in R/Bioconductor allows for TFBS analysis using PWMs and includes pre-defined PWMs for transcription factors.",
      "The GenomicAlign package in R/Bioconductor provides functions for analyzing TFBS in a genomic context and tools for aligning DNA sequences to a reference genome."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: HMMER is not a package specifically in R/Bioconductor for TFBS detection with HMMs. It is a suite of programs for protein sequence similarity searches using HMMs and is typically used for protein domain identification, not directly for transcription factor binding site (TFBS) prediction.\n4. FALSE [correction]: TRANSFAC is not a package in R/Bioconductor. It is actually a database of eukaryotic transcription factors, their genomic binding sites, and DNA-binding profiles. However, there may be R/Bioconductor packages that interface with the TRANSFAC database or use its data.\n5. FALSE [correction]: The GenomicAlign package does not exist. For analyzing transcription factor binding sites (TFBS) in a genomic context, one might actually use packages such as GenomicRanges or Biostrings in R/Bioconductor; these allow for alignment and analysis of DNA sequences, but not specifically for TFBS analysis. For aligning DNA sequences to a reference genome, the Bioconductor package 'GenomicAlignments' might be used.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 721,
    "user_query": "List clinical trials for prevention of sarcopenia",
    "llama-2-13b-chat-hf_response": "Here are some clinical trials related to the prevention of sarcopenia:\n1. \"Effects of Resistance Training and Protein Supplementation on Muscle Mass and Function in Older Adults: A Randomized Controlled Trial\" (2018)\nThis study, published in the Journal of the American Geriatrics Society, investigated the effects of resistance training and protein supplementation on muscle mass and function in older adults. The study included 100 older adults (ages 65-75) who were randomly assigned to either a resistance training and protein supplementation group or a control group. The results showed that the resistance training and protein supplementation group had greater gains in muscle mass and strength compared to the control group.\n2. \"A Randomized Controlled Trial of the Effects of Exercise and Protein Supplementation on Body Composition and Functional Ability in Older Adults\" (2017)\nThis study, published in the Journal of Gerontology: Medical Sciences, investigated the effects of exercise and protein supplementation on body composition and functional ability in older adults. The study included 120 older adults (ages 65-75) who were randomly assigned to either an exercise and protein supplementation group or a control group. The results showed that the exercise and protein supplementation group had greater improvements in body composition and functional ability compared to the control group.\n3. \"The Effects of Progressive Resistance Training on Muscle Mass, Strength, and Functional Ability in Older Adults: A Systematic Review and Meta-Analysis\" (2019)\nThis systematic review and meta-analysis, published in the Journal of Aging and Physical Activity, investigated the effects of progressive resistance training on muscle mass, strength, and functional ability in older adults. The review included 22 studies and found that progressive resistance training was effective in improving muscle mass, strength, and functional ability in older adults.\n4. \"The Effects of Aerobic Exercise and Resistance Training on Body Composition and Functional Ability in Older Adults: A Randomized Controlled Trial\" (2018)\nThis study, published in the Journal",
    "llama-2-13b-chat-hf_fact_raw": "1. A study titled \"Effects of Resistance Training and Protein Supplementation on Muscle Mass and Function in Older Adults: A Randomized Controlled Trial\" was published in the Journal of the American Geriatrics Society in 2018.\n2. The study mentioned above included 100 older adults aged 65-75 who were randomly assigned to two groups.\n3. Another study called \"A Randomized Controlled Trial of the Effects of Exercise and Protein Supplementation on Body Composition and Functional Ability in Older Adults\" was published in the Journal of Gerontology: Medical Sciences in 2017.\n4. The latter study involved 120 older adults aged 65-75 who were randomly assigned to either an intervention group or a control group.\n5. A systematic review and meta-analysis published in the Journal of Aging and Physical Activity in 2019 included 22 studies on the effects of progressive resistance training on older adults.",
    "llama-2-13b-chat-hf_fact": [
      "A study titled \"Effects of Resistance Training and Protein Supplementation on Muscle Mass and Function in Older Adults: A Randomized Controlled Trial\" was published in the Journal of the American Geriatrics Society in 2018.",
      "The study mentioned above included 100 older adults aged 65-75 who were randomly assigned to two groups.",
      "Another study called \"A Randomized Controlled Trial of the Effects of Exercise and Protein Supplementation on Body Composition and Functional Ability in Older Adults\" was published in the Journal of Gerontology: Medical Sciences in 2017.",
      "The latter study involved 120 older adults aged 65-75 who were randomly assigned to either an intervention group or a control group.",
      "A systematic review and meta-analysis published in the Journal of Aging and Physical Activity in 2019 included 22 studies on the effects of progressive resistance training on older adults."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nExplanation:\nWithout specific access to the journals or database entries that detail the publication history of the named studies, I cannot verify the accuracy of the statements regarding their titles, publication years, study designs, or participant details. Therefore, all responses are UNKNOWN. Verification would require a literature search in relevant databases or direct access to the journals mentioned.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 722,
    "user_query": "Which is the database of molecular recognition features in membrane proteins?",
    "llama-2-13b-chat-hf_response": "There are several databases of molecular recognition features in membrane proteins, including:\n1. Membrane Protein Data Bank (MPDB): This database contains a collection of membrane protein structures and their associated recognition features, such as binding sites and interfaces.\n2. Protein Data Bank (PDB): This database contains a wide range of protein structures, including membrane proteins, and includes information on their molecular recognition features.\n3. Membrane Protein Structural Database (MPSD): This database contains a collection of membrane protein structures, including their three-dimensional structures and molecular recognition features.\n4. Membrane Protein Functional Database (MPFD): This database contains information on the functional sites and molecular recognition features of membrane proteins.\n5. Membrane Protein-Ligand Database (MPLD): This database contains information on the interactions between membrane proteins and their ligands, including the molecular recognition features of the binding sites.\n6. PDB-TM: This database contains a collection of membrane protein structures and their associated molecular recognition features, including binding sites and interfaces.\n7. Membrane Protein Recognition Database (MPRD): This database contains a collection of membrane protein structures and their associated molecular recognition features, including binding sites and interfaces.\n8. Membrane Protein-Ligand Interaction Database (MPLID): This database contains information on the interactions between membrane proteins and their ligands, including the molecular recognition features of the binding sites.\nThese databases can be accessed online and provide a wealth of information on the molecular recognition features of membrane proteins.",
    "llama-2-13b-chat-hf_fact_raw": "1. The Membrane Protein Data Bank (MPDB) is a database that contains a collection of membrane protein structures and their recognition features.\n2. The Protein Data Bank (PDB) includes information on a wide range of protein structures, including membrane proteins, along with their molecular recognition features.\n3. The Membrane Protein Structural Database (MPSD) provides a collection of membrane protein structures including their three-dimensional structures and molecular recognition features.\n4. The Membrane Protein Functional Database (MPFD) offers information on the functional sites and molecular recognition features of membrane proteins.\n5. The Membrane Protein-Ligand Database (MPLD) contains information on the interactions between membrane proteins and their ligands, including molecular recognition features of the binding sites.",
    "llama-2-13b-chat-hf_fact": [
      "The Membrane Protein Data Bank (MPDB) is a database that contains a collection of membrane protein structures and their recognition features.",
      "The Protein Data Bank (PDB) includes information on a wide range of protein structures, including membrane proteins, along with their molecular recognition features.",
      "The Membrane Protein Structural Database (MPSD) provides a collection of membrane protein structures including their three-dimensional structures and molecular recognition features.",
      "The Membrane Protein Functional Database (MPFD) offers information on the functional sites and molecular recognition features of membrane proteins.",
      "The Membrane Protein-Ligand Database (MPLD) contains information on the interactions between membrane proteins and their ligands, including molecular recognition features of the binding sites."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: The correct name is the Membrane Proteins of Known 3D Structure database (MPSTRUC), which is a curated collection of membrane protein structures with an emphasis on their structural categorization and classification.\n2. TRUE\n3. UNKNOWN: There's no widely recognized database specifically named the \"Membrane Protein Structural Database (MPSD)\". It might be a confusion with MPSTRUC or a specialized database not well-known or possibly outdated.\n4. UNKNOWN: Similarly, there is no well-known database specifically named the \"Membrane Protein Functional Database (MPFD)\". The function of membrane proteins is commonly studied through various databases, including the Protein Data Bank (PDB), but \"MPFD\" does not correspond to a well-known resource.\n5. UNKNOWN: While databases exist that contain information on protein-ligand interactions, the specific name \"Membrane Protein-Ligand Database (MPLD)\" does not correspond to any well-known database. It is possible that this is a specialized or less commonly referenced database or it may not exist at all.",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 745,
    "user_query": "Is rivaroxaban metabolized in kidneys?",
    "llama-2-13b-chat-hf_response": "Rivaroxaban is metabolized in the liver by cytochrome P450 (CYP) enzymes, principally CYP3A4, and to a lesser extent by CYP2C9 and CYP2C19. The major metabolic pathway is hydrolysis of the ester bond, resulting in formation of the active metabolite, SR-BAT. The kidneys play a minor role in the metabolism of rivaroxaban, as they do not contain significant amounts of CYP enzymes. However, the kidneys do contribute to the elimination of rivaroxaban and its metabolites, primarily through glomerular filtration and tubular secretion.\nTherefore, while the liver is the primary site of metabolism for rivaroxaban, the kidneys do play a role in its elimination.",
    "llama-2-13b-chat-hf_fact_raw": "1. Rivaroxaban is metabolized in the liver.\n2. The primary enzymes involved in the metabolism of rivaroxaban are cytochrome P450 (CYP) enzymes, mainly CYP3A4.\n3. The kidneys play a minor role in the metabolism of rivaroxaban due to the low presence of CYP enzymes.\n4. The elimination of rivaroxaban and its metabolites involves the kidneys, primarily through glomerular filtration and tubular secretion.\n5. Hydrolysis of the ester bond is the major metabolic pathway for rivaroxaban, resulting in the formation of the active metabolite SR-BAT.",
    "llama-2-13b-chat-hf_fact": [
      "Rivaroxaban is metabolized in the liver.",
      "The primary enzymes involved in the metabolism of rivaroxaban are cytochrome P450 (CYP) enzymes, mainly CYP3A4.",
      "The kidneys play a minor role in the metabolism of rivaroxaban due to the low presence of CYP enzymes.",
      "The elimination of rivaroxaban and its metabolites involves the kidneys, primarily through glomerular filtration and tubular secretion.",
      "Hydrolysis of the ester bond is the major metabolic pathway for rivaroxaban, resulting in the formation of the active metabolite SR-BAT."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The kidneys play a significant role in the elimination of rivaroxaban, but not in its metabolism. The role of the kidneys involves the excretion of the drug and its metabolites, rather than metabolism.\n4. TRUE\n5. FALSE [correction]: Hydrolysis does contribute to the metabolism of rivaroxaban, but the primary metabolic pathways involve oxidation by CYP enzymes, not hydrolysis of the ester bond. Furthermore, there is no evidence to suggest that SR-BAT is an active metabolite of rivaroxaban.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 763,
    "user_query": "Which genes are regulated by TRalpha2  in the heart?",
    "llama-2-13b-chat-hf_response": "In the heart, TRalpha2 has been shown to regulate a variety of genes involved in cardiac function and development. Some of the key genes regulated by TRalpha2 in the heart include:\n1. Cardiac troponin: TRalpha2 regulates the expression of cardiac troponin, a protein that plays a critical role in the regulation of muscle contraction.\n2. Myosin heavy chain: TRalpha2 regulates the expression of myosin heavy chain, a protein that is essential for muscle contraction.\n3. Myocardin: TRalpha2 regulates the expression of myocardin, a transcription factor that regulates the expression of genes involved in cardiac muscle contraction and development.\n4. N-cadherin: TRalpha2 regulates the expression of N-cadherin, a protein that is involved in cell adhesion and the maintenance of tissue structure.\n5. beta-myosin heavy chain: TRalpha2 regulates the expression of beta-myosin heavy chain, a protein that is involved in the regulation of muscle contraction.\n6. cardiac-specific tropomyosin: TRalpha2 regulates the expression of cardiac-specific tropomyosin, a protein that is involved in the regulation of muscle contraction.\n7. Calcium handling proteins: TRalpha2 regulates the expression of calcium handling proteins such as calcium channels, calcium pumps and calcium buffers, which are essential for proper calcium signaling and muscle contraction.\n8. Cell cycle regulators: TRalpha2 regulates the expression of cell cycle regulators such as cyclin-dependent kinases (CDKs) and cyclins, which are involved in the regulation of cell proliferation and differentiation.\n9. Anti-apoptotic proteins: TRalpha2 regulates the expression of anti-apoptotic proteins such as Bcl-2 and Bcl-xL, which are involved in the regulation of programmed cell death (apoptosis).\n10. Inflammatory response genes: TRalpha2 regulates the expression of inflammatory response genes such as NF-κB, STAT3, and COX-2, which are involved in the regulation of inflammation",
    "llama-2-13b-chat-hf_fact_raw": "1. TRalpha2 regulates the expression of cardiac troponin in the heart.\n2. TRalpha2 regulates the expression of myosin heavy chain in the heart.\n3. TRalpha2 regulates the expression of myocardin in the heart.\n4. TRalpha2 regulates the expression of N-cadherin in the heart.\n5. TRalpha2 regulates the expression of beta-myosin heavy chain in the heart.",
    "llama-2-13b-chat-hf_fact": [
      "TRalpha2 regulates the expression of cardiac troponin in the heart.",
      "TRalpha2 regulates the expression of myosin heavy chain in the heart.",
      "TRalpha2 regulates the expression of myocardin in the heart.",
      "TRalpha2 regulates the expression of N-cadherin in the heart.",
      "TRalpha2 regulates the expression of beta-myosin heavy chain in the heart."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN: The role of TRalpha2 in the regulation of cardiac troponin expression is not clearly stated, and specific scientific knowledge is required to confirm this.\n2. UNKNOWN: Similarly, the role of TRalpha2 in the regulation of myosin heavy chain expression is not specified here, and detailed scientific understanding would be necessary to verify this claim.\n3. UNKNOWN: The effect of TRalpha2 on the expression of myocardin is not provided, and without additional context or research, the truth of this statement cannot be determined.\n4. UNKNOWN: The involvement of TRalpha2 in regulating N-cadherin expression in the heart cannot be validated without more specific information or scientific expertise.\n5. UNKNOWN: Without knowing more about the specific role of TRalpha2 in cardiac physiology, it is not possible to accurately determine the veracity of the statement regarding the regulation of beta-myosin heavy chain expression. \n\nNote: TRalpha2 is a thyroid hormone receptor isoform, and its role in regulating the expression of various cardiac genes could be quite complex and specific to each gene, requiring detailed knowledge from the latest scientific research.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 786,
    "user_query": "List available biomedical question answering systems.",
    "llama-2-13b-chat-hf_response": "There are several biomedical question answering systems available, including:\n1. PubMed QA: This system answers questions about biomedical literature using PubMed, a database of biomedical articles.\n2. BioASQ: This system answers questions about biomedical literature, including questions about gene and protein information, disease and treatment information, and biomedical ontologies.\n3. MedQA: This system answers questions about clinical decision support, including questions about diagnosis, treatment, and patient care.\n4. Biocreative: This system answers questions about biomedical text, including questions about gene and protein information, disease and treatment information, and biomedical ontologies.\n5. BM-QuestionAnswering: This system answers questions about biomedical literature, including questions about gene and protein information, disease and treatment information, and biomedical ontologies.\n6. Biomedical Question Answering System (BM-QA): This system answers questions about biomedical literature, including questions about gene and protein information, disease and treatment information, and biomedical ontologies.\n7. Medical Information Extraction and Question Answering System (MIEQAS): This system answers questions about medical information, including questions about diagnosis, treatment, and patient care.\n8. Biomedical Text Mining and Question Answering System (BMT-QA): This system answers questions about biomedical text, including questions about gene and protein information, disease and treatment information, and biomedical ontologies.\n9. Biomedical Question Answering System using Natural Language Processing (BM-QA-NLP): This system answers questions about biomedical literature, including questions about gene and protein information, disease and treatment information, and biomedical ontologies.\n10. Biomedical Question Answering System using Machine Learning (BM-QA-ML): This system answers questions about biomedical literature, including questions about gene and protein information, disease and treatment information, and biomedical ontologies.\nThese are just a few examples of the many biomedical question answering systems available. Each system has its own strengths and limitations, and the choice of which system to use will depend on the specific needs of the user.",
    "llama-2-13b-chat-hf_fact_raw": "1. PubMed QA is a biomedical question answering system that uses the PubMed database to provide answers about biomedical literature.\n2. BioASQ is a biomedical question answering system that provides information on gene and protein information, disease and treatment information, and biomedical ontologies.\n3. MedQA is a biomedical question answering system that supports clinical decision-making with answers about diagnosis, treatment, and patient care.\n4. Biocreative is a system that answers questions about biomedical text, including gene and protein information, disease and treatment information, and biomedical ontologies.\n5. The Medical Information Extraction and Question Answering System (MIEQAS) answers questions related to medical information such as diagnosis, treatment, and patient care.",
    "llama-2-13b-chat-hf_fact": [
      "PubMed QA is a biomedical question answering system that uses the PubMed database to provide answers about biomedical literature.",
      "BioASQ is a biomedical question answering system that provides information on gene and protein information, disease and treatment information, and biomedical ontologies.",
      "MedQA is a biomedical question answering system that supports clinical decision-making with answers about diagnosis, treatment, and patient care.",
      "Biocreative is a system that answers questions about biomedical text, including gene and protein information, disease and treatment information, and biomedical ontologies.",
      "The Medical Information Extraction and Question Answering System (MIEQAS) answers questions related to medical information such as diagnosis, treatment, and patient care."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. FALSE [correction]: Biocreative is not a question answering system; it is a series of challenges that aim to evaluate text mining and information extraction systems applied to the biomedical domain.\n5. UNKNOWN",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 794,
    "user_query": "Which trancription factor activates the betalain pathway?",
    "llama-2-13b-chat-hf_response": "The betalain pathway is activated by the transcription factor Cytc1 (cytochrome c1). Cytc1 is a transcription factor that regulates the expression of genes involved in the betalain biosynthesis pathway. It is a key regulator of the betalain pathway and is required for the production of betalains in plants.\nThe betalain pathway is a complex process that involves the coordinated expression of multiple genes. The pathway starts with the synthesis of the amino acid precursors of betalains, which are then converted into the final pigments through a series of enzyme-catalyzed reactions. The expression of the genes involved in the betalain pathway is regulated by a variety of transcription factors, including Cytc1.\nCytc1 is a transcription factor that is localized to the chloroplasts of plant cells. It is a key regulator of chloroplast gene expression and is involved in the regulation of a variety of chloroplast functions, including photosynthesis and pigment biosynthesis. Cytc1 is a transcriptional activator that binds to specific DNA sequences in the promoter regions of target genes and recruits other transcription factors to activate their transcription.\nIn the betalain pathway, Cytc1 activates the expression of several genes involved in the biosynthesis of betalains, including the genes encoding the enzymes involved in the synthesis of the precursor molecules. Cytc1 also regulates the expression of genes involved in the transport of betalains from the chloroplasts to the vacuoles, where they are stored and accumulated.\nOverall, the activation of the betalain pathway by Cytc1 is a critical step in the regulation of betalain biosynthesis in plants. The precise regulation of the betalain pathway by Cytc1 allows plants to fine-tune the production of betalains in response to changing environmental conditions, such as light intensity and temperature.",
    "llama-2-13b-chat-hf_fact_raw": "1. The transcription factor Cytc1 (cytochrome c1) activates the betalain pathway.\n2. Cytc1 regulates the expression of genes involved in betalain biosynthesis.\n3. The betalain pathway involves the synthesis of amino acid precursors which are converted into pigments.\n4. Cytc1 is localized to the chloroplasts of plant cells and regulates chloroplast gene expression.\n5. Cytc1 activates the expression of genes involved in the biosynthesis of betalains and their transport to vacuoles.",
    "llama-2-13b-chat-hf_fact": [
      "The transcription factor Cytc1 (cytochrome c1) activates the betalain pathway.",
      "Cytc1 regulates the expression of genes involved in betalain biosynthesis.",
      "The betalain pathway involves the synthesis of amino acid precursors which are converted into pigments.",
      "Cytc1 is localized to the chloroplasts of plant cells and regulates chloroplast gene expression.",
      "Cytc1 activates the expression of genes involved in the biosynthesis of betalains and their transport to vacuoles."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: It is the transcription factor BvMYB1 that activates the betalain pathway, not Cytc1 (cytochrome c1).\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Cytc1 (cytochrome c1) is a component of the electron transport chain in mitochondria, not localized to the chloroplasts.\n5. UNKNOWN\n\nNote: Statement 5 might be true if BvMYB1 or a like-functioning transcription factor were referred to instead of Cytc1, but without specific information about Cytc1’s role in the biosynthesis of betalains and their transport to vacuoles, a conclusion cannot be drawn.",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 883,
    "user_query": "Global quantitative phosphoproteomic analyses are emerging. List the preferred technologies for the enrichment for phosphorylated peptides?",
    "llama-2-13b-chat-hf_response": "There are several preferred technologies for the enrichment of phosphorylated peptides in global quantitative phosphoproteomic analyses. These include:\n1. Immunoprecipitation (IP) with phospho-specific antibodies: This method uses antibodies specific to phosphorylated residues to enrich for phosphorylated peptides.\n2. Phosphopeptide enrichment using metal oxide beads: This method uses metal oxide beads that are specific to phosphorylated residues to enrich for phosphorylated peptides.\n3. Phosphopeptide enrichment using graphene oxide: This method uses graphene oxide to enrich for phosphorylated peptides.\n4. Phosphopeptide enrichment using hydrophobic interaction chromatography (HIC): This method uses HIC to enrich for phosphorylated peptides based on their hydrophobic properties.\n5. Phosphopeptide enrichment using titanium dioxide (TiO2): This method uses TiO2 to enrich for phosphorylated peptides.\n6. Phosphopeptide enrichment using magnetic nanoparticles: This method uses magnetic nanoparticles to enrich for phosphorylated peptides.\n7. Phosphopeptide enrichment using microfluidics: This method uses microfluidics to enrich for phosphorylated peptides based on their size and charge.\n8. Phosphopeptide enrichment using solid-phase enrichment (SPE): This method uses SPE to enrich for phosphorylated peptides based on their hydrophobic properties.\nEach of these methods has its own advantages and disadvantages, and the choice of method will depend on the specific research question and experimental design.",
    "llama-2-13b-chat-hf_fact_raw": "1. Immunoprecipitation with phospho-specific antibodies is used to enrich for phosphorylated peptides in global quantitative phosphoproteomic analyses.\n2. Metal oxide beads are used for phosphopeptide enrichment based on their specificity to phosphorylated residues.\n3. Graphene oxide can be utilized to enrich for phosphorylated peptides in phosphoproteomic analyses.\n4. Hydrophobic interaction chromatography is a method used to enrich for phosphorylated peptides based on their hydrophobic properties.\n5. Titanium dioxide is employed for phosphopeptide enrichment in global quantitative phosphoproteomic analyses.",
    "llama-2-13b-chat-hf_fact": [
      "Immunoprecipitation with phospho-specific antibodies is used to enrich for phosphorylated peptides in global quantitative phosphoproteomic analyses.",
      "Metal oxide beads are used for phosphopeptide enrichment based on their specificity to phosphorylated residues.",
      "Graphene oxide can be utilized to enrich for phosphorylated peptides in phosphoproteomic analyses.",
      "Hydrophobic interaction chromatography is a method used to enrich for phosphorylated peptides based on their hydrophobic properties.",
      "Titanium dioxide is employed for phosphopeptide enrichment in global quantitative phosphoproteomic analyses."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Hydrophobic interaction chromatography is a method used to separate peptides based on their hydrophobic properties, not specifically for enriching phosphorylated peptides.\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 901,
    "user_query": "Which disorder is rated by Palmini classification?",
    "llama-2-13b-chat-hf_response": "Palmini classification is a system used to rate the severity of intellectual disability, which is a neurodevelopmental disorder characterized by below-average intelligence and difficulty with daily living skills. The Palmini classification system was developed by Dr. Joseph Palmini and is widely used in clinical settings.\nThe Palmini classification system rates intellectual disability on a scale of mild, moderate, severe, and profound. The classification is based on the individual's level of cognitive functioning, adaptive behaviors, and social and communication skills.\nHere is a brief overview of the Palmini classification system:\n* Mild Intellectual Disability: Individuals with mild intellectual disability have cognitive functioning that is only slightly below average. They may have some difficulty with academic tasks, but are generally able to function in a regular classroom setting.\n* Moderate Intellectual Disability: Individuals with moderate intellectual disability have cognitive functioning that is below average, but not as severe as those with severe intellectual disability. They may require some support in academic and daily living skills.\n* Severe Intellectual Disability: Individuals with severe intellectual disability have significant cognitive impairments and require extensive support in all areas of functioning. They may have difficulty with communication, social interactions, and daily living skills.\n* Profound Intellectual Disability: Individuals with profound intellectual disability have the most severe cognitive impairments and require extensive support in all areas of functioning. They may have little or no ability to communicate or perform daily living skills.\nIt's important to note that the Palmini classification system is not a diagnosis in itself, but rather a way of rating the severity of intellectual disability. A diagnosis of intellectual disability is made based on a combination of cognitive and adaptive behavior assessments.",
    "llama-2-13b-chat-hf_fact_raw": "1. The Palmini classification is a system that rates the severity of intellectual disability.\n2. Dr. Joseph Palmini developed the Palmini classification system.\n3. The Palmini classification system includes four levels of intellectual disability: mild, moderate, severe, and profound.\n4. The classification rates intellectual disability based on cognitive functioning, adaptive behaviors, and social and communication skills.\n5. The Palmini classification is used in a clinical setting to assess individuals with intellectual disability.",
    "llama-2-13b-chat-hf_fact": [
      "The Palmini classification is a system that rates the severity of intellectual disability.",
      "Dr. Joseph Palmini developed the Palmini classification system.",
      "The Palmini classification system includes four levels of intellectual disability: mild, moderate, severe, and profound.",
      "The classification rates intellectual disability based on cognitive functioning, adaptive behaviors, and social and communication skills.",
      "The Palmini classification is used in a clinical setting to assess individuals with intellectual disability."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: The Palmini classification is not a recognized system for rating the severity of intellectual disability. The American Association on Intellectual and Developmental Disabilities (AAIDD) and the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) provide widely accepted systems for classification.\n2. FALSE [correction]: Since the Palmini classification system does not exist for intellectual disability rating, there is no Dr. Joseph Palmini known to have developed such a classification system.\n3. UNKNOWN: Because the Palmini classification does not exist, it's unclear what levels it would include if it were a valid system. However, the four levels of intellectual disability mentioned are consistent with recognized systems like AAIDD and DSM-5.\n4. UNKNOWN: While the criteria mentioned are used in established systems to rate intellectual disability, it is not known what the Palmini classification would use since it is not a recognized system.\n5. FALSE [correction]: The Palmini classification, not being a recognized system, is not used in a clinical setting to assess individuals with intellectual disability. Accepted systems such as those provided by AAIDD and DSM-5 are used for clinical assessment.",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 905,
    "user_query": "Are viruses involved in the etiology of human subacute thyroiditis?",
    "llama-2-13b-chat-hf_response": "Yes, viruses have been implicated in the etiology of human subacute thyroiditis (SAT). Several studies have suggested that SAT may be caused by a viral infection, and several viruses have been identified as potential culprits.\nOne of the most well-known viruses associated with SAT is the thyroiditis-associated virus (TV), which was first identified in the 1990s. TV is a member of the picornavirus family and has been found to be present in the thyroid glands of patients with SAT. Studies have shown that TV can infect thyroid cells and trigger an immune response, leading to inflammation and thyroid dysfunction.\nOther viruses that have been linked to SAT include:\n1. Adenovirus: Adenovirus has been detected in the thyroid glands of some patients with SAT, and it is thought to play a role in the development of the disease.\n2. Enterovirus: Enterovirus is a common virus that can cause a range of illnesses, including SAT. Some studies have found that enterovirus is present in the thyroid glands of patients with SAT.\n3. Herpesvirus: Herpesvirus is a virus that can cause a range of illnesses, including SAT. Some studies have found that herpesvirus is present in the thyroid glands of patients with SAT.\n4. Epstein-Barr virus (EBV): EBV is a common virus that can cause infectious mononucleosis, and it has also been linked to SAT. Some studies have found that EBV is present in the thyroid glands of patients with SAT.\nIt's worth noting that not all patients with SAT have evidence of a viral infection, and the exact mechanisms by which viruses contribute to the development of the disease are not fully understood. However, the evidence suggests that viruses play a role in the etiology of SAT, and further research is needed to fully understand the relationship between viruses and this condition.",
    "llama-2-13b-chat-hf_fact_raw": "1. Viruses have been implicated in the etiology of human subacute thyroiditis (SAT).\n2. The thyroiditis-associated virus (TV), which is a member of the picornavirus family, has been found in the thyroid glands of patients with SAT.\n3. Adenovirus has been detected in the thyroid glands of some patients with SAT.\n4. Enterovirus has been found in the thyroid glands of patients with SAT in some studies.\n5. Epstein-Barr virus (EBV) has been linked to SAT and detected in the thyroid glands of patients with this condition.",
    "llama-2-13b-chat-hf_fact": [
      "Viruses have been implicated in the etiology of human subacute thyroiditis (SAT).",
      "The thyroiditis-associated virus (TV), which is a member of the picornavirus family, has been found in the thyroid glands of patients with SAT.",
      "Adenovirus has been detected in the thyroid glands of some patients with SAT.",
      "Enterovirus has been found in the thyroid glands of patients with SAT in some studies.",
      "Epstein-Barr virus (EBV) has been linked to SAT and detected in the thyroid glands of patients with this condition."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: There is no specific entity known as \"thyroiditis-associated virus (TV)\" that is recognized as part of the picornavirus family linked to SAT. Picornaviruses, in general, have been studied for their potential association with various forms of thyroiditis, but the term TV is not standard.\n3. TRUE\n4. TRUE\n5. UNKNOWN (While Epstein-Barr virus (EBV) has been associated with various autoimmune diseases and conditions such as infectious mononucleosis, its direct link to SAT specifically is not conclusively established and may vary according to different studies.)",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 963,
    "user_query": "Is STAT3 involved in EIF2AK2-dependent suppression of autophagy?",
    "llama-2-13b-chat-hf_response": "In the paper \"EIF2AK2-mediated phosphorylation of STAT3 regulates its activity and promotes tumorigenesis\" by Zhang et al. (2019), the authors found that EIF2AK2-mediated phosphorylation of STAT3 regulates its activity and promotes tumorigenesis. They also found that EIF2AK2-mediated phosphorylation of STAT3 inhibits autophagy by suppressing the activity of ATG1.\nHere are some potential mechanisms by which STAT3 may be involved in EIF2AK2-dependent suppression of autophagy:\n1. Phosphorylation of STAT3 by EIF2AK2: EIF2AK2 phosphorylates STAT3 on specific serine residues, leading to its activation and nuclear translocation. Activated STAT3 can then suppress the activity of ATG1 and other autophagy-related genes, leading to inhibition of autophagy.\n2. Inhibition of ATG1 by STAT3: Activated STAT3 can bind to the ATG1 promoter and suppress its transcription, leading to reduced ATG1 protein levels and impaired autophagy.\n3. Inhibition of autophagy-related genes by STAT3: Activated STAT3 can also suppress the expression of other autophagy-related genes, such as LC3B and ATG5, leading to impaired autophagy.\n4. Inhibition of the PI3K/Akt/mTOR pathway by STAT3: Activated STAT3 can also inhibit the PI3K/Akt/mTOR pathway, which is a key regulator of autophagy. Inhibition of this pathway can lead to impaired autophagy.\nOverall, the data suggest that EIF2AK2-mediated phosphorylation of STAT3 plays a critical role in regulating autophagy and promoting tumorigenesis. Inhibition of STAT3 or the EIF2AK2-STAT3 pathway may be a potential therapeutic strategy for cancer treatment.",
    "llama-2-13b-chat-hf_fact_raw": "1. EIF2AK2-mediated phosphorylation of STAT3 regulates its activity and promotes tumorigenesis according to the paper by Zhang et al. (2019).\n2. EIF2AK2-mediated phosphorylation of STAT3 inhibits autophagy by suppressing the activity of ATG1.\n3. Phosphorylation of STAT3 by EIF2AK2 leads to its activation and nuclear translocation.\n4. Activated STAT3 can suppress the transcription of the ATG1 promoter, leading to reduced ATG1 protein levels.\n5. Activated STAT3 can inhibit the PI3K/Akt/mTOR pathway, which is a key regulator of autophagy.",
    "llama-2-13b-chat-hf_fact": [
      "EIF2AK2-mediated phosphorylation of STAT3 regulates its activity and promotes tumorigenesis according to the paper by Zhang et al. (2019).",
      "EIF2AK2-mediated phosphorylation of STAT3 inhibits autophagy by suppressing the activity of ATG1.",
      "Phosphorylation of STAT3 by EIF2AK2 leads to its activation and nuclear translocation.",
      "Activated STAT3 can suppress the transcription of the ATG1 promoter, leading to reduced ATG1 protein levels.",
      "Activated STAT3 can inhibit the PI3K/Akt/mTOR pathway, which is a key regulator of autophagy."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided are very specific and pertain to scientific research findings. Without access to the paper by Zhang et al. (2019) or additional information on EIF2AK2, STAT3, and their interplay with autophagy and the PI3K/Akt/mTOR pathway, I cannot verify the accuracy of these statements. These specific details would require validation through the actual scientific literature referenced.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 973,
    "user_query": "Describe what is the usage of the Theatre software tool for genomic analysis.",
    "llama-2-13b-chat-hf_response": "The Theatre software tool is a genomic analysis software tool that is used to analyze and visualize genomic data. It is designed to be user-friendly and accessible to researchers who may not have a background in bioinformatics or computer programming.\nTheatre offers a range of features and functionalities that make it a powerful tool for genomic analysis. Some of the key features of Theatre include:\n1. Data import and export: Theatre can import and export a wide range of genomic data formats, including BAM, FASTQ, and VCF.\n2. Visualization: Theatre offers a range of visualization tools that allow researchers to visualize their data in a variety of ways, including as a scatter plot, a bar chart, or a heatmap.\n3. Genomic annotation: Theatre can annotate genomic data with information about gene expression, regulatory elements, and other features.\n4. Variant analysis: Theatre can identify and analyze genetic variants, including single nucleotide polymorphisms (SNPs) and insertions/deletions.\n5. Genome assembly: Theatre can assemble genomic DNA sequences from high-throughput sequencing data.\n6. Transcriptome analysis: Theatre can analyze RNA-seq data to identify differentially expressed genes and to understand the transcriptome of a particular sample.\n7. Epigenetics analysis: Theatre can analyze DNA methylation and histone modification data to understand the epigenetic landscape of a particular sample.\n8. Genome-wide association studies (GWAS): Theatre can perform GWAS to identify genetic variants associated with a particular disease or trait.\n9. Machine learning: Theatre can use machine learning algorithms to identify patterns and relationships in genomic data.\nTheatre is a powerful tool for genomic analysis that can be used for a wide range of applications, including basic research, drug discovery, and clinical diagnostics. Its user-friendly interface and accessible features make it a valuable resource for researchers who are new to genomic analysis.",
    "llama-2-13b-chat-hf_fact_raw": "1. The Theatre software tool is used to analyze and visualize genomic data.\n2. Theatre can import and export various genomic data formats, such as BAM, FASTQ, and VCF.\n3. Theatre offers visualization tools like scatter plots, bar charts, and heatmaps.\n4. Theatre can perform genomic annotation, variant analysis, and genome assembly.\n5. Theatre is utilized for applications such as basic research, drug discovery, and clinical diagnostics.",
    "llama-2-13b-chat-hf_fact": [
      "The Theatre software tool is used to analyze and visualize genomic data.",
      "Theatre can import and export various genomic data formats, such as BAM, FASTQ, and VCF.",
      "Theatre offers visualization tools like scatter plots, bar charts, and heatmaps.",
      "Theatre can perform genomic annotation, variant analysis, and genome assembly.",
      "Theatre is utilized for applications such as basic research, drug discovery, and clinical diagnostics."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information about a software tool named \"Theatre\" related to genomic data analysis, it's impossible to determine the veracity of these statements. The term \"Theatre\" doesn't correspond to a well-known tool in the genomics field as of my last update, so the statements could refer to a fictional or less-known software, or they could be made-up features attributed to a correctly named but unrelated software. If \"Theatre\" is indeed a software tool for genomic data but under a less common name or newly developed, the knowledge about its features and applications would not be available without more context or up-to-date information.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 997,
    "user_query": "Which  is the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences",
    "llama-2-13b-chat-hf_response": "of length $n$ and $m$ respectively?\nI know that the time complexity of the Smith-Waterman algorithm is $O(n^2m)$ in the worst case, but I am not sure how to prove it.\nI have tried to use the recurrence relation for the algorithm, but I am not sure how to use it to prove the time complexity.\nCan someone please help me with this?\nThank you!\nAnswer: The Smith-Waterman algorithm has a time complexity of $O(n^2m)$ in the worst case, and this can be proven using the recurrence relation for the algorithm.\nThe recurrence relation for the Smith-Waterman algorithm is as follows:\n$$T(n,m) = T(n-1,m) + T(n,m-1) + \\min\\limits_{i=1}^{n-1} \\left\\{ T(n-i,m-i) + \\frac{m}{i} \\right\\}$$\nwhere $T(n,m)$ is the time complexity of the algorithm for two sequences of length $n$ and $m$ respectively.\nTo prove the time complexity, we can use the master theorem, which states that the time complexity of a recurrence relation of the form:\n$$T(n) = aT(n-1) + bT(n-2) + \\cdots + cT(1) + d$$\nwhere $a, b, \\ldots, d$ are constants, can be determined as follows:\n$$T(n) = O\\left( \\max\\limits_{1 \\leq i \\leq n} \\left\\{ a^i \\right\\} \\right)$$\nIn this case, we have:\n$$T(n,m) = aT(n-1,m) + bT(n,m-1) + \\min\\limits_{i=1}^{n-1} \\left\\{ T(n-i,m-i) + \\frac{m}{i} \\right\\}$$\nwhere $a = 1$ and $b = 1$.\nUsing the master theorem, we can see that the time complexity of the Smith-Waterman algorithm is:\n$$T(n,m) = O\\left( \\max\\",
    "llama-2-13b-chat-hf_fact_raw": "1. The Smith-Waterman algorithm has a time complexity of $O(n^2m)$ in the worst case.\n2. The time complexity can be proven using the recurrence relation for the algorithm.\n3. The recurrence relation for the Smith-Waterman algorithm is $T(n,m) = T(n-1,m) + T(n,m-1) + \\min\\limits_{i=1}^{n-1} \\left\\{ T(n-i,m-i) + \\frac{m}{i} \\right\\}$.\n4. The master theorem can be used to determine the time complexity of a recurrence relation.",
    "llama-2-13b-chat-hf_fact": [
      "The Smith-Waterman algorithm has a time complexity of $O(n^2m)$ in the worst case.",
      "The time complexity can be proven using the recurrence relation for the algorithm.",
      "The recurrence relation for the Smith-Waterman algorithm is $T(n,m) = T(n-1,m) + T(n,m-1) + \\min\\limits_{i=1}^{n-1} \\left\\{ T(n-i,m-i) + \\frac{m}{i} \\right\\}$.",
      "The master theorem can be used to determine the time complexity of a recurrence relation."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: The Smith-Waterman algorithm typically has a time complexity of $O(nm)$ in the worst case, where $n$ and $m$ are the lengths of the sequences being aligned.\n2. TRUE: Time complexity of dynamic programming algorithms like the Smith-Waterman can often be proven using their recurrence relation.\n3. FALSE [correction]: The recurrence relation for the Smith-Waterman algorithm is not the one stated in the statement. The actual recurrence involves considering the scores of aligning the current character in one sequence with the other sequence, aligning them with a gap, or not aligning them at all – which is not accurately described by the given relation.\n4. TRUE: The master theorem provides a method for determining the time complexity of divide-and-conquer algorithms that follow certain types of recurrence relations. However, it is important to note that the Smith-Waterman algorithm does not typically fall into this category since it uses dynamic programming rather than divide-and-conquer.",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1004,
    "user_query": "Which SLC family is FLVCR1 a member of?",
    "llama-2-13b-chat-hf_response": "There is an error in my previous response. FLVCR1 is a member of the SLC14A family of solute carriers, not the SLC14 family. Here is the corrected response: FLVCR1 is a member of the SLC14A family of solute carriers. No.",
    "llama-2-13b-chat-hf_fact_raw": "1. FLVCR1 is a member of the SLC14A family of solute carriers.",
    "llama-2-13b-chat-hf_fact": [
      "FLVCR1 is a member of the SLC14A family of solute carriers."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: FLVCR1 is not a member of the SLC14A family of solute carriers. FLVCR1 belongs to the Major Facilitator Superfamily (MFS). The SLC14A family includes urea transporters, which are different from the heme transport function of FLVCR1.",
    "llama-2-13b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 1047,
    "user_query": "List GATA-1 interacting partners as discovered with the help of the biotinylation tagging approach.",
    "llama-2-13b-chat-hf_response": "After reviewing my previous response, I noticed that I missed one of the GATA-1 interacting partners. Here is the complete list of GATA-1 interacting partners:\n1. Hemoglobin subunit alpha (HBA)\n2. Erythropoietin (EPO)\n3. Transferrin (TF)\n4. Ferritin (FER)\n5. Vitamin D receptor (VDR)\n6. Retinoblastoma protein (RBP)\n7. E2F transcription factor (E2F)\n8. P53 tumor suppressor (TP53)\n9. Myc proto-oncogene (MYC)\n10. GATA-binding protein 1 (GATA1)\nI apologize for the oversight and hope this complete list is helpful.",
    "llama-2-13b-chat-hf_fact_raw": "1. Hemoglobin subunit alpha (HBA) is a GATA-1 interacting partner.\n2. Erythropoietin (EPO) is a GATA-1 interacting partner.\n3. Transferrin (TF) is a GATA-1 interacting partner.\n4. Ferritin (FER) is a GATA-1 interacting partner.\n5. Vitamin D receptor (VDR) is a GATA-1 interacting partner.",
    "llama-2-13b-chat-hf_fact": [
      "Hemoglobin subunit alpha (HBA) is a GATA-1 interacting partner.",
      "Erythropoietin (EPO) is a GATA-1 interacting partner.",
      "Transferrin (TF) is a GATA-1 interacting partner.",
      "Ferritin (FER) is a GATA-1 interacting partner.",
      "Vitamin D receptor (VDR) is a GATA-1 interacting partner."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN: The statement regarding the interaction between Hemoglobin subunit alpha (HBA) and GATA-1 is not straightforward as GATA-1 is a transcription factor involved in the regulation of erythropoiesis. Direct interaction would be unusual as HBA is a protein produced as a result of gene expression, not a typical interacting partner of transcription factors.\n2. FALSE [correction]: Erythropoietin (EPO) is a hormone produced by the kidneys to stimulate red blood cell production and GATA-1 regulates genes involved in erythropoiesis, but EPO itself is not a direct GATA-1 interacting partner.\n3. FALSE [correction]: Transferrin (TF) is involved in iron transport; however, it is not typically described as a direct GATA-1 interacting partner.\n4. UNKNOWN: Ferritin (FER) is involved in iron storage within cells and GATA-1 is associated with erythropoiesis where iron homeostasis is important. However, whether ferritin directly interacts with GATA-1 as a partner in a molecular sense is not well-established and would require specific biochemical evidence.\n5. FALSE [correction]: The Vitamin D receptor (VDR) is a member of the nuclear receptor family of transcription factors and is not typically associated with direct interactions with GATA-1, which primarily functions in hematopoietic cells.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "false",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 1072,
    "user_query": "What is the outcome of TAF10 interacting with the GATA1 transcription factor?",
    "llama-2-13b-chat-hf_response": "TAF10 is a histone acetyltransferase that is involved in regulating gene expression by acetylating histones and other proteins. GATA1 is a transcription factor that is involved in the regulation of gene expression in hematopoietic cells.\nResearch has shown that TAF10 interacts with GATA1 and regulates its transcriptional activity. TAF10 acetylates GATA1 on specific lysine residues, leading to increased stability and transcriptional activity of GATA1. This interaction is important for the regulation of gene expression in hematopoietic cells, particularly during erythropoiesis and megakaryocyte development.\nIn addition, TAF10 has been shown to regulate the expression of genes involved in cell cycle progression and apoptosis, and is required for the proper differentiation of hematopoietic cells.\nOverall, the interaction between TAF10 and GATA1 is an important regulator of gene expression in hematopoietic cells, and plays a critical role in the development and function of the hematopoietic system.",
    "llama-2-13b-chat-hf_fact_raw": "1. TAF10 is a histone acetyltransferase involved in regulating gene expression.\n2. GATA1 is a transcription factor involved in regulating gene expression in hematopoietic cells.\n3. TAF10 interacts with GATA1 and regulates its transcriptional activity by acetylating it on specific lysine residues.\n4. The interaction between TAF10 and GATA1 plays a role in the regulation of gene expression during erythropoiesis and megakaryocyte development.\n5. TAF10 is required for the proper differentiation of hematopoietic cells.",
    "llama-2-13b-chat-hf_fact": [
      "TAF10 is a histone acetyltransferase involved in regulating gene expression.",
      "GATA1 is a transcription factor involved in regulating gene expression in hematopoietic cells.",
      "TAF10 interacts with GATA1 and regulates its transcriptional activity by acetylating it on specific lysine residues.",
      "The interaction between TAF10 and GATA1 plays a role in the regulation of gene expression during erythropoiesis and megakaryocyte development.",
      "TAF10 is required for the proper differentiation of hematopoietic cells."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: TAF10 is a subunit of the multi-protein TFIID complex involved in the initiation of the transcription by RNA polymerase II; it is not a histone acetyltransferase.\n2. TRUE\n3. UNKNOWN\n4. TRUE: While the direct interaction regarding acetylation might be unknown, TAF10's involvement in the transcription complex important for erythropoiesis implicitly suggests it plays a role in such processes, often interconnected with GATA1 function.\n5. TRUE: TAF10, as part of the transcription initiation complex, is implicated in the regulation of gene expression which is necessary for the proper differentiation of various cell types, including hematopoietic cells.",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1082,
    "user_query": "Are there any Decision support systems for chronic pain management ?",
    "llama-2-13b-chat-hf_response": "Yes, there are several decision support systems (DSS) for chronic pain management that can help healthcare providers make more informed decisions about patient care. These systems use a combination of clinical guidelines, patient-specific data, and artificial intelligence to provide personalized recommendations for pain management. Some examples of DSS for chronic pain management include:\n1. The Pain Management Decision Support System (PMDSS): This system was developed by the American Pain Society and is designed to provide healthcare providers with evidence-based recommendations for pain management. The system takes into account patient-specific factors such as age, gender, and medical history, as well as the severity and location of the pain.\n2. The Chronic Pain Management System (CPMS): This system was developed by the University of California, Los Angeles (UCLA) and is designed to provide healthcare providers with personalized recommendations for chronic pain management. The system uses a combination of clinical guidelines and patient-specific data to provide recommendations for medication, physical therapy, and other interventions.\n3. The Pain Management Optimization System (PMOS): This system was developed by the University of Utah and is designed to provide healthcare providers with personalized recommendations for pain management. The system uses a combination of clinical guidelines and patient-specific data to provide recommendations for medication, physical therapy, and other interventions.\n4. The Chronic Pain Care Management System (CPCMS): This system was developed by the University of Washington and is designed to provide healthcare providers with personalized recommendations for chronic pain management. The system uses a combination of clinical guidelines and patient-specific data to provide recommendations for medication, physical therapy, and other interventions.\n5. The Pain Management Decision Support System (PMDSS) for Opioid Prescribing: This system was developed by the Centers for Disease Control and Prevention (CDC) and is designed to provide healthcare providers with evidence-based recommendations for opioid prescribing. The system takes into account patient-specific factors such as age, gender, and medical history, as well as the severity and location of the pain.\nThese are just a few examples of the many decision support systems available for chronic pain",
    "llama-2-13b-chat-hf_fact_raw": "1. The Pain Management Decision Support System (PMDSS) was developed by the American Pain Society.\n2. The Chronic Pain Management System (CPMS) was developed by the University of California, Los Angeles (UCLA).\n3. The Pain Management Optimization System (PMOS) was developed by the University of Utah.\n4. The Chronic Pain Care Management System (CPCMS) was developed by the University of Washington.\n5. The Pain Management Decision Support System (PMDSS) for Opioid Prescribing was developed by the Centers for Disease Control and Prevention (CDC).",
    "llama-2-13b-chat-hf_fact": [
      "The Pain Management Decision Support System (PMDSS) was developed by the American Pain Society.",
      "The Chronic Pain Management System (CPMS) was developed by the University of California, Los Angeles (UCLA).",
      "The Pain Management Optimization System (PMOS) was developed by the University of Utah.",
      "The Chronic Pain Care Management System (CPCMS) was developed by the University of Washington.",
      "The Pain Management Decision Support System (PMDSS) for Opioid Prescribing was developed by the Centers for Disease Control and Prevention (CDC)."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. FALSE [correction]: The CDC developed the CDC Guideline for Prescribing Opioids for Chronic Pain, not the Pain Management Decision Support System (PMDSS).",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 1149,
    "user_query": "Which is the subcellular localization of the protein angiogenin?",
    "llama-2-13b-chat-hf_response": "A) Nucleus\nB) Cytoplasm\nC) Mitochondria\nD) Endoplasmic reticulum\nAngiogenin is a protein that is involved in the formation of new blood vessels, and it is produced by cells in response to hypoxia. It is a secreted protein, meaning that it is produced in the cell and then released into the extracellular space. Therefore, the correct answer is B) Cytoplasm.",
    "llama-2-13b-chat-hf_fact_raw": "1. Angiogenin is a protein involved in the formation of new blood vessels.\n2. Angiogenin is produced by cells in response to hypoxia.\n3. Angiogenin is a secreted protein.\n4. The correct subcellular localization of angiogenin is the cytoplasm.",
    "llama-2-13b-chat-hf_fact": [
      "Angiogenin is a protein involved in the formation of new blood vessels.",
      "Angiogenin is produced by cells in response to hypoxia.",
      "Angiogenin is a secreted protein.",
      "The correct subcellular localization of angiogenin is the cytoplasm."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: While angiogenin can be found in the cytoplasm, it is also secreted outside of cells. Thus, its correct subcellular localization is not limited to just the cytoplasm; it should also include its extracellular presence.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1161,
    "user_query": "How does ranolazine affect kinase signaling activation in the heart?",
    "llama-2-13b-chat-hf_response": "Ranolazine is a medication that is used to treat chronic angina, a condition characterized by chest pain or discomfort due to reduced blood flow to the heart muscle. It works by inhibiting the activity of an enzyme called diacylglycerol acyltransferase (DGAT) and increasing the activity of an enzyme called nitric oxide synthase (NOS). This leads to increased production of nitric oxide (NO), a molecule that causes blood vessels to relax and widen, allowing more blood to flow to the heart muscle.\nIn addition to its effects on blood flow, ranolazine has been shown to affect kinase signaling pathways in the heart. Kinases are enzymes that add phosphate groups to other proteins, which can activate or inhibit various cellular signaling pathways. Ranolazine has been shown to activate certain kinases, such as protein kinase G (PKG) and extracellular signal-regulated kinase (ERK), which can lead to changes in the expression of genes involved in cardiac function and metabolism.\nOne study published in the journal Circulation Research found that ranolazine activated PKG in cardiac cells, leading to increased phosphorylation of the protein kinase C (PKC) alpha subunit. This activation of PKC alpha led to increased phosphorylation of the contractile protein myosin light chain, which can increase cardiac contractility and improve cardiac function.\nAnother study published in the journal American Journal of Physiology-Heart and Circulatory Physiology found that ranolazine activated ERK in cardiac cells, leading to increased phosphorylation of the transcription factor Elk-1. This activation of Elk-1 led to increased expression of genes involved in cardiac function and metabolism, such as the gene for the contractile protein myosin heavy chain.\nOverall, the effects of ranolazine on kinase signaling pathways in the heart may contribute to its therapeutic effects in chronic angina. By activating certain kinases, such as PKG and ERK, ranolazine can improve cardiac contractility and increase the expression of genes involved in cardiac function and metabolism.",
    "llama-2-13b-chat-hf_fact_raw": "1. Ranolazine is used to treat chronic angina by inhibiting the activity of DGAT and increasing the activity of NOS.\n2. Ranolazine increases the production of nitric oxide, which causes blood vessels to relax and widen.\n3. Ranolazine has been shown to activate protein kinase G (PKG) and extracellular signal-regulated kinase (ERK) in the heart.\n4. A study in Circulation Research found that ranolazine activated PKG, leading to increased phosphorylation of the PKC alpha subunit and myosin light chain in cardiac cells.\n5. A study in the American Journal of Physiology-Heart and Circulatory Physiology found that ranolazine activated ERK, leading to increased phosphorylation of the transcription factor Elk-1 and the expression of genes involved in cardiac function and metabolism.",
    "llama-2-13b-chat-hf_fact": [
      "Ranolazine is used to treat chronic angina by inhibiting the activity of DGAT and increasing the activity of NOS.",
      "Ranolazine increases the production of nitric oxide, which causes blood vessels to relax and widen.",
      "Ranolazine has been shown to activate protein kinase G (PKG) and extracellular signal-regulated kinase (ERK) in the heart.",
      "A study in Circulation Research found that ranolazine activated PKG, leading to increased phosphorylation of the PKC alpha subunit and myosin light chain in cardiac cells.",
      "A study in the American Journal of Physiology-Heart and Circulatory Physiology found that ranolazine activated ERK, leading to increased phosphorylation of the transcription factor Elk-1 and the expression of genes involved in cardiac function and metabolism."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: Ranolazine is used to treat chronic angina by inhibiting the late phase of the inward sodium current (INa) during cardiac repolarization and has not been shown to inhibit DGAT (diacylglycerol O-acyltransferase). There is no substantial evidence that it increases the activity of NOS (nitric oxide synthase) as its primary mechanism of action.\n2. TRUE\n3. UNKNOWN: Without access to specific research studies or established pharmacological data, it's not possible to confirm whether ranolazine activates protein kinase G (PKG) and extracellular signal-regulated kinase (ERK) in the heart.\n4. UNKNOWN: This statement provides specific information about a study and its findings, but without access to the study details from \"Circulation Research,\" the truth of the statement cannot be confirmed.\n5. UNKNOWN: Similar to the previous statement, this statement cites a specific study and findings, but without access to the detailed study from the \"American Journal of Physiology-Heart and Circulatory Physiology,\" the accuracy of the statement cannot be verified.",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1225,
    "user_query": "Is the regulation of Vsr endonuclease independent of the growth phase of bacteria?",
    "llama-2-13b-chat-hf_response": "Vsr endonuclease is a site-specific recombinase that is involved in the regulation of gene expression in bacteria. The regulation of Vsr endonuclease is thought to be independent of the growth phase of bacteria, meaning that it is not affected by the cell cycle or the availability of nutrients. This is because Vsr endonuclease is a constitutively expressed enzyme that is present in all cells, regardless of their growth phase.\nOne study published in the journal Nature Microbiology found that the expression of Vsr endonuclease is not affected by the growth phase of Escherichia coli (E. coli) bacteria. The researchers used a combination of molecular biology techniques, including quantitative real-time polymerase chain reaction (qRT-PCR) and Western blotting, to measure the expression of Vsr endonuclease in E. coli cells grown under different conditions. They found that the expression of Vsr endonuclease was constant across all growth phases, indicating that it is not regulated by the cell cycle or the availability of nutrients.\nAnother study published in the journal PLOS ONE also found that the regulation of Vsr endonuclease is independent of the growth phase of bacteria. The researchers used a similar approach to the previous study, using qRT-PCR and Western blotting to measure the expression of Vsr endonuclease in E. coli cells grown under different conditions. They found that the expression of Vsr endonuclease was constant across all growth phases, suggesting that it is not regulated by the cell cycle or the availability of nutrients.\nOverall, these studies suggest that the regulation of Vsr endonuclease is independent of the growth phase of bacteria, meaning that it is not affected by the cell cycle or the availability of nutrients. This is an important finding, as it suggests that Vsr endonuclease can be used as a tool for the precise regulation of gene expression in bacteria, regardless of the growth phase.",
    "llama-2-13b-chat-hf_fact_raw": "1. Vsr endonuclease is a site-specific recombinase involved in regulating gene expression in bacteria.\n2. Vsr endonuclease is constitutively expressed and present in all cells, regardless of their growth phase.\n3. A study published in Nature Microbiology reported that the expression of Vsr endonuclease in E. coli bacteria is not affected by the growth phase.\n4. The same study used quantitative real-time polymerase chain reaction (qRT-PCR) and Western blotting to measure the expression of Vsr endonuclease.\n5. Another study in the journal PLOS ONE also found that the regulation of Vsr endonuclease is independent of the growth phase of bacteria.",
    "llama-2-13b-chat-hf_fact": [
      "Vsr endonuclease is a site-specific recombinase involved in regulating gene expression in bacteria.",
      "Vsr endonuclease is constitutively expressed and present in all cells, regardless of their growth phase.",
      "A study published in Nature Microbiology reported that the expression of Vsr endonuclease in E. coli bacteria is not affected by the growth phase.",
      "The same study used quantitative real-time polymerase chain reaction (qRT-PCR) and Western blotting to measure the expression of Vsr endonuclease.",
      "Another study in the journal PLOS ONE also found that the regulation of Vsr endonuclease is independent of the growth phase of bacteria."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: Vsr endonuclease is actually a DNA repair enzyme, not a recombinase, involved with very short patch repair (VSP repair) for mismatched bases arising from deamination of methylcytosines in bacteria.\n2. UNKNOWN: Unless specific literature is provided for Vsr endonuclease expression levels across all growth phases, the statement is too general to confirm as true or false.\n3. UNKNOWN: Without access to the specific study from Nature Microbiology, the veracity of this statement cannot be ascertained.\n4. UNKNOWN: Again, without the specific study to confirm the methods used, we cannot definitively say whether the statement is true or false.\n5. UNKNOWN: Without seeing the PLOS ONE study, we cannot determine the truthfulness of the statement about the regulation of Vsr endonuclease.",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1233,
    "user_query": "What are the computational tools for the prediction of beta-barrel transmembrane proteins?",
    "llama-2-13b-chat-hf_response": "There are several computational tools available for the prediction of beta-barrel transmembrane proteins. Some of the commonly used tools include:\n1. TMHMM: This tool uses a hidden Markov model to predict the transmembrane regions of a protein. It can also predict the orientation of the transmembrane helices.\n2. PHD: This tool uses a probabilistic approach to predict the transmembrane regions of a protein. It can also predict the orientation of the transmembrane helices.\n3. BT-Pred: This tool uses a support vector machine (SVM) to predict the transmembrane regions of a protein. It can also predict the orientation of the transmembrane helices.\n4. TMB-Pred: This tool uses a combination of sequence and structural features to predict the transmembrane regions of a protein. It can also predict the orientation of the transmembrane helices.\n5. Beta-Barrel Predictor: This tool uses a combination of sequence and structural features to predict the transmembrane regions of a protein. It can also predict the orientation of the transmembrane helices.\n6. Transmembrane Protein Predictor (TPP): This tool uses a combination of sequence and structural features to predict the transmembrane regions of a protein. It can also predict the orientation of the transmembrane helices.\n7. MemProt: This tool uses a combination of sequence and structural features to predict the transmembrane regions of a protein. It can also predict the orientation of the transmembrane helices.\n8. Prosmemb: This tool uses a combination of sequence and structural features to predict the transmembrane regions of a protein. It can also predict the orientation of the transmembrane helices.\nThese tools have been developed based on the analysis of known transmembrane protein structures and sequences, and they use various machine learning algorithms to predict the transmembrane regions of a protein. They can be useful for predicting the transmembrane regions of a protein when the structure is not available or when the protein is not well-studied. However, it is important to note that the accuracy of these tools can vary depending on the quality of the input data and the method used. Therefore, it is recommended to use multiple tools and compare their predictions to increase the accuracy of the results.",
    "llama-2-13b-chat-hf_fact_raw": "1. TMHMM is a tool that uses a hidden Markov model to predict transmembrane regions of a protein.\n2. PHD is a tool that uses a probabilistic approach to predict transmembrane regions of a protein.\n3. BT-Pred is a tool that uses a support vector machine (SVM) to predict transmembrane regions of a protein.\n4. TMB-Pred uses a combination of sequence and structural features to predict transmembrane regions of a protein.\n5. The prediction accuracy of these tools can vary based on input data quality and prediction method used.",
    "llama-2-13b-chat-hf_fact": [
      "TMHMM is a tool that uses a hidden Markov model to predict transmembrane regions of a protein.",
      "PHD is a tool that uses a probabilistic approach to predict transmembrane regions of a protein.",
      "BT-Pred is a tool that uses a support vector machine (SVM) to predict transmembrane regions of a protein.",
      "TMB-Pred uses a combination of sequence and structural features to predict transmembrane regions of a protein.",
      "The prediction accuracy of these tools can vary based on input data quality and prediction method used."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: PHD is a tool used for predicting secondary structures of proteins, not specifically for transmembrane regions.\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1251,
    "user_query": "Galassi classification is used for which disorder?",
    "llama-2-13b-chat-hf_response": "Galassi classification is used for the classification of intellectual disability. It is a systematic approach to the assessment and diagnosis of intellectual disability, which was developed by Dr. Joseph Galassi. The Galassi classification system categorizes individuals with intellectual disability into one of six categories based on their cognitive and adaptive abilities. The six categories are:\n1. Mild Intellectual Disability: Individuals with mild intellectual disability have cognitive and adaptive abilities that are only slightly below average.\n2. Moderate Intellectual Disability: Individuals with moderate intellectual disability have cognitive and adaptive abilities that are significantly below average.\n3. Severe Intellectual Disability: Individuals with severe intellectual disability have cognitive and adaptive abilities that are very significantly below average.\n4. Profound Intellectual Disability: Individuals with profound intellectual disability have cognitive and adaptive abilities that are extremely below average.\n5. Autism Spectrum Disorder: Individuals with autism spectrum disorder have cognitive and adaptive abilities that are below average, and they also exhibit symptoms of autism, such as difficulty with social interaction and communication.\n6. Other Developmental Disorders: Individuals with other developmental disorders, such as Down syndrome or Fragile X syndrome, may also be classified using the Galassi system if they have significant cognitive and adaptive impairments.\nThe Galassi classification system is widely used by professionals in the field of intellectual disability to help identify the specific needs of individuals with intellectual disability and to guide the development of appropriate interventions and support.",
    "llama-2-13b-chat-hf_fact_raw": "1. Galassi classification is used for the classification of intellectual disability.\n2. The Galassi classification system was developed by Dr. Joseph Galassi.\n3. The system categorizes individuals with intellectual disability into one of six categories based on cognitive and adaptive abilities.\n4. The six categories include mild, moderate, severe, profound intellectual disability, autism spectrum disorder, and other developmental disorders.\n5. The system is widely used by professionals in the field of intellectual disability for identification and intervention purposes.",
    "llama-2-13b-chat-hf_fact": [
      "Galassi classification is used for the classification of intellectual disability.",
      "The Galassi classification system was developed by Dr. Joseph Galassi.",
      "The system categorizes individuals with intellectual disability into one of six categories based on cognitive and adaptive abilities.",
      "The six categories include mild, moderate, severe, profound intellectual disability, autism spectrum disorder, and other developmental disorders.",
      "The system is widely used by professionals in the field of intellectual disability for identification and intervention purposes."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: The Galassi classification is not used for the classification of intellectual disability; instead, it refers to a classification system for femoroacetabular impingement, a condition related to the hip joint.\n2. UNKNOWN\n3. FALSE [correction]: Given that the Galassi classification does not pertain to intellectual disability, it does not categorize individuals with intellectual disability into categories based on cognitive and adaptive abilities.\n4. FALSE [correction]: Since the Galassi classification system is not related to intellectual disability, it does not include these six categories for intellectual disability, autism spectrum disorder, and other developmental disorders.\n5. FALSE [correction]: As the Galassi classification is not associated with intellectual disability, it is not used by professionals in the field for identification and intervention purposes regarding intellectual disability.",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 1304,
    "user_query": "List common features of Shapiro syndrome",
    "llama-2-13b-chat-hf_response": "Shapiro syndrome is a rare genetic disorder that affects the development of the brain and nervous system. Here are some common features of Shapiro syndrome:\n1. Intellectual disability: Children with Shapiro syndrome often have significant intellectual disability and may have difficulty with speech, language, and other cognitive skills.\n2. Seizures: Seizures are a common feature of Shapiro syndrome, and they can be difficult to control.\n3. Autism spectrum disorder: Many children with Shapiro syndrome have autism spectrum disorder (ASD), which can affect their social and communication skills.\n4. Developmental delays: Children with Shapiro syndrome may experience delays in reaching developmental milestones, such as sitting, standing, and walking.\n5. Vision and hearing problems: Shapiro syndrome can cause vision and hearing problems, including cataracts, glaucoma, and hearing loss.\n6. Sleep disturbances: Children with Shapiro syndrome may experience sleep disturbances, such as insomnia and restlessness.\n7. Behavioral problems: Shapiro syndrome can cause behavioral problems, such as anxiety, aggression, and hyperactivity.\n8. Congenital anomalies: Some children with Shapiro syndrome may have congenital anomalies, such as heart defects or cleft palate.\n9. Short stature: Children with Shapiro syndrome may be shorter than their peers, due to growth hormone deficiency or other hormonal imbalances.\n10. Increased risk of infections: Shapiro syndrome can increase the risk of infections, particularly respiratory infections.\nIt's important to note that every child with Shapiro syndrome is unique and may experience a different combination of these features. If you suspect that your child may have Shapiro syndrome, it's important to consult with a healthcare professional for an accurate diagnosis and appropriate treatment.",
    "llama-2-13b-chat-hf_fact_raw": "1. Shapiro syndrome is a genetic disorder that affects the development of the brain and nervous system.\n2. A common feature of Shapiro syndrome is intellectual disability, which can include difficulties with speech, language, and cognitive skills.\n3. Seizures are a frequent occurrence in individuals with Shapiro syndrome.\n4. Developmental delays, such as delays in sitting, standing, and walking, are typical in children with Shapiro syndrome.\n5. Vision and hearing problems, including conditions like cataracts and glaucoma, can be associated with Shapiro syndrome.",
    "llama-2-13b-chat-hf_fact": [
      "Shapiro syndrome is a genetic disorder that affects the development of the brain and nervous system.",
      "A common feature of Shapiro syndrome is intellectual disability, which can include difficulties with speech, language, and cognitive skills.",
      "Seizures are a frequent occurrence in individuals with Shapiro syndrome.",
      "Developmental delays, such as delays in sitting, standing, and walking, are typical in children with Shapiro syndrome.",
      "Vision and hearing problems, including conditions like cataracts and glaucoma, can be associated with Shapiro syndrome."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: Shapiro syndrome is not primarily a genetic disorder; it is a rare neurologic condition characterized by recurrent episodes of hypothermia, hyperhidrosis, and agenesis of the corpus callosum.\n2. UNKNOWN\n3. TRUE\n4. UNKNOWN\n5. FALSE [correction]: Vision and hearing problems such as cataracts and glaucoma are not commonly associated with Shapiro syndrome. It typically involves episodes of hypothermia and sweating and may include various neurological symptoms, but vision and hearing problems are not characteristic features of the syndrome.",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "unknown",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 1320,
    "user_query": "Which disease is linked to mutations within BRAG1?",
    "llama-2-13b-chat-hf_response": "BRAG1 is a gene that is linked to the following disease:\nA) Colorectal cancer\nB) Ovarian cancer\nC) Prostate cancer\nD) Breast cancer\nCorrect answer: A) Colorectal cancer\nMutations within the BRAG1 gene have been found to be associated with an increased risk of colorectal cancer. The BRAG1 gene is a tumor suppressor gene that plays a critical role in regulating cell growth and differentiation. Mutations within the BRAG1 gene can lead to the loss of its tumor suppressor function, contributing to the development and progression of colorectal cancer.",
    "llama-2-13b-chat-hf_fact_raw": "1. Mutations within the BRAG1 gene are associated with an increased risk of colorectal cancer.\n2. The BRAG1 gene is a tumor suppressor gene.\n3. The BRAG1 gene plays a role in regulating cell growth and differentiation.\n4. Loss of tumor suppressor function in the BRAG1 gene can contribute to the development and progression of colorectal cancer.",
    "llama-2-13b-chat-hf_fact": [
      "Mutations within the BRAG1 gene are associated with an increased risk of colorectal cancer.",
      "The BRAG1 gene is a tumor suppressor gene.",
      "The BRAG1 gene plays a role in regulating cell growth and differentiation.",
      "Loss of tumor suppressor function in the BRAG1 gene can contribute to the development and progression of colorectal cancer."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: Mutations within the APC gene, not BRAG1, are associated with an increased risk of colorectal cancer.\n2. UNKNOWN\n3. UNKNOWN\n4. FALSE [correction]: Loss of tumor suppressor function in the APC gene, not BRAG1, can contribute to the development and progression of colorectal cancer.",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 1362,
    "user_query": "Which protein is the main inhibitor of protein phosphatase 1 (PP1)?",
    "llama-2-13b-chat-hf_response": "PP1 is a serine/threonine protein phosphatase that is involved in regulating various cellular processes, including cell signaling, metabolism, and gene expression. There are several proteins that can inhibit PP1, but the main inhibitor is likely to be a protein called tuberous sclerosis complex 1 (TSC1).\nTSC1 is a tumor suppressor protein that is encoded by the TSC1 gene. It is a large protein that contains multiple functional domains, including an N-terminal domain that binds to PP1 and inhibits its activity. TSC1 also interacts with other proteins, such as the mTOR (mechanistic target of rapamycin) protein, to regulate cell growth and metabolism.\nOther proteins that can inhibit PP1 include the protein kinase A (PKA) regulatory subunit, which can phosphorylate and inhibit PP1, and the protein phosphatase 2A (PP2A) regulatory subunit, which can also inhibit PP1. However, TSC1 is the main inhibitor of PP1 and plays a critical role in regulating cell growth and metabolism.",
    "llama-2-13b-chat-hf_fact_raw": "1. Protein phosphatase 1 (PP1) is involved in regulating cell signaling, metabolism, and gene expression.\n2. Tuberous sclerosis complex 1 (TSC1) is considered to be the main inhibitor of protein phosphatase 1 (PP1).\n3. The TSC1 gene encodes the tumor suppressor protein TSC1.\n4. TSC1 contains an N-terminal domain that binds to PP1 and inhibits its activity.\n5. TSC1 interacts with the mechanistic target of rapamycin (mTOR) protein to regulate cell growth and metabolism.",
    "llama-2-13b-chat-hf_fact": [
      "Protein phosphatase 1 (PP1) is involved in regulating cell signaling, metabolism, and gene expression.",
      "Tuberous sclerosis complex 1 (TSC1) is considered to be the main inhibitor of protein phosphatase 1 (PP1).",
      "The TSC1 gene encodes the tumor suppressor protein TSC1.",
      "TSC1 contains an N-terminal domain that binds to PP1 and inhibits its activity.",
      "TSC1 interacts with the mechanistic target of rapamycin (mTOR) protein to regulate cell growth and metabolism."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Tuberous sclerosis complex 1 (TSC1) is not considered to be the main inhibitor of protein phosphatase 1 (PP1). TSC1 is part of a complex that inhibits the mechanistic target of rapamycin (mTOR) pathway.\n3. TRUE\n4. FALSE [correction]: TSC1 does not contain an N-terminal domain that binds to PP1. Instead, TSC1 forms a complex with TSC2, and this complex inhibits mTOR.\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1374,
    "user_query": "Which mechanisms underlie adaptive mutagenesis (stationary-phase mutagenesis) in Bacillus subtilis?",
    "llama-2-13b-chat-hf_response": "Several mechanisms have been proposed to underlie adaptive mutagenesis in Bacillus subtilis, including:\n1. Error-prone DNA repair: During stationary phase, the DNA repair machinery is less active, leading to an accumulation of DNA damage, which can introduce mutations into the genome.\n2. Mutator proteins: B. subtilis has several mutator proteins, such as PolE and PolZ, that can introduce mutations into the genome during DNA replication. These proteins can be upregulated during stationary phase, leading to an increase in the frequency of mutations.\n3. DNA damage and repair: B. subtilis has a variety of DNA damage and repair pathways, including nucleotide excision repair, base excision repair, and homologous recombination. These pathways can introduce mutations into the genome, potentially leading to the emergence of adaptive mutants.\n4. Epigenetic modifications: Epigenetic modifications, such as DNA methylation and histone modification, can also play a role in adaptive mutagenesis. These modifications can affect gene expression and potentially lead to the emergence of adaptive mutants.\n5. Selection pressure: Selection pressure, such as antibiotic exposure or nutrient limitation, can drive the evolution of adaptive mutants. During stationary phase, the selective pressure may be higher due to the limited availability of nutrients and the accumulation of DNA damage.\n6. Genome instability: B. subtilis has a high frequency of genome instability, which can lead to the emergence of adaptive mutants. This instability can be caused by a variety of factors, including errors during DNA replication and repair, and the presence of mobile genetic elements.\nNo, there are no other errors in my response.",
    "llama-2-13b-chat-hf_fact_raw": "1. During the stationary phase, the DNA repair machinery in Bacillus subtilis is less active, which can lead to an accumulation of mutations.\n2. Bacillus subtilis has mutator proteins such as PolE and PolZ that can introduce mutations during DNA replication.\n3. Bacillus subtilis is capable of using DNA damage and repair pathways like nucleotide excision repair, base excision repair, and homologous recombination that can introduce mutations.\n4. Epigenetic modifications in Bacillus subtilis, including DNA methylation and histone modification, may affect gene expression related to adaptive mutagenesis.\n5. Selection pressures such as antibiotic exposure or nutrient limitation can drive the evolution of adaptive mutants in Bacillus subtilis during the stationary phase.",
    "llama-2-13b-chat-hf_fact": [
      "During the stationary phase, the DNA repair machinery in Bacillus subtilis is less active, which can lead to an accumulation of mutations.",
      "Bacillus subtilis has mutator proteins such as PolE and PolZ that can introduce mutations during DNA replication.",
      "Bacillus subtilis is capable of using DNA damage and repair pathways like nucleotide excision repair, base excision repair, and homologous recombination that can introduce mutations.",
      "Epigenetic modifications in Bacillus subtilis, including DNA methylation and histone modification, may affect gene expression related to adaptive mutagenesis.",
      "Selection pressures such as antibiotic exposure or nutrient limitation can drive the evolution of adaptive mutants in Bacillus subtilis during the stationary phase."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: During the stationary phase, the DNA repair machinery in Bacillus subtilis is typically more active to prevent the accumulation of mutations.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Bacillus subtilis does not have histones to modify, so it cannot perform histone modification. However, DNA methylation may affect gene expression related to adaptive mutagenesis.\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1399,
    "user_query": "What causes erucism?",
    "llama-2-13b-chat-hf_response": "Erucism is a rare condition that is caused by a combination of genetic and environmental factors. The exact cause of erucism is not fully understood, but it is thought to be related to the following:\n1. Genetics: Erucism is often inherited in an autosomal dominant pattern, which means that a single copy of the mutated gene is enough to cause the condition.\n2. Abnormalities in the structure of the skin: Erucism is characterized by abnormalities in the structure of the skin, including the presence of keratinocytes, which are cells that produce keratin, a protein that gives skin its strength and flexibility.\n3. Hormonal imbalances: Hormonal imbalances, such as an excess of androgens (male hormones) or a deficiency of estrogens (female hormones), can contribute to the development of erucism.\n4. Environmental factors: Exposure to certain chemicals, such as pesticides or heavy metals, has been linked to the development of erucism.\n5. Nutritional deficiencies: Poor nutrition, particularly a lack of vitamin A and zinc, can contribute to the development of erucism.\n6. Infections: Certain infections, such as herpes simplex virus, can cause erucism.\n7. Autoimmune disorders: Autoimmune disorders, such as psoriasis or lupus, can cause erucism.\n8. Cancer: In rare cases, erucism can be a symptom of certain types of cancer, such as basal cell carcinoma or squamous cell carcinoma.\nIt's important to note that erucism is a rare condition, and the exact cause may not be the same for every individual. A healthcare professional can help determine the underlying cause of erucism and develop an appropriate treatment plan.",
    "llama-2-13b-chat-hf_fact_raw": "1. Erucism is thought to be inherited in an autosomal dominant pattern.\n2. The condition is characterized by abnormalities in the structure of the skin, including the presence of keratinocytes.\n3. Hormonal imbalances, such as an excess of androgens or a deficiency of estrogens, can be factors contributing to erucism.\n4. Exposure to certain chemicals like pesticides or heavy metals has been linked to the development of erucism.\n5. Nutritional deficiencies, especially a lack of vitamin A and zinc, can contribute to the development of erucism.",
    "llama-2-13b-chat-hf_fact": [
      "Erucism is thought to be inherited in an autosomal dominant pattern.",
      "The condition is characterized by abnormalities in the structure of the skin, including the presence of keratinocytes.",
      "Hormonal imbalances, such as an excess of androgens or a deficiency of estrogens, can be factors contributing to erucism.",
      "Exposure to certain chemicals like pesticides or heavy metals has been linked to the development of erucism.",
      "Nutritional deficiencies, especially a lack of vitamin A and zinc, can contribute to the development of erucism."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN: Erucism is not a commonly recognized medical condition or term. It might be confused with a genetic condition that affects skin or hair, but without a specific medical context or clear definition, it's not possible to determine the inheritance pattern.\n\n2. UNKNOWN: Since erucism is not a recognized medical condition, it's uncertain what is meant by \"abnormalities in the structure of the skin, including the presence of keratinocytes.\" Keratinocytes are normal cells found in the epidermis of the skin, so their presence itself is not an abnormality.\n\n3. UNKNOWN: Because erucism is not clearly defined, it is unknown whether hormonal imbalances contribute to the condition.\n\n4. UNKNOWN: Without a clear definition of erucism, it is not possible to confirm whether exposure to chemicals like pesticides or heavy metals is linked to its development.\n\n5. UNKNOWN: Similarly, without a proper medical context or definition for erucism, it is not possible to determine if nutritional deficiencies such as a lack of vitamin A and zinc play a role in its development.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1413,
    "user_query": "What are the indications for hydrochlorothiazide?",
    "llama-2-13b-chat-hf_response": "Hydrochlorothiazide is a diuretic medication that is used to treat a variety of conditions, including:\n1. Hypertension (high blood pressure): Hydrochlorothiazide is used to lower blood pressure in patients with hypertension. It works by increasing urine production, which helps to reduce the amount of fluid in the body and lower blood pressure.\n2. Heart failure: Hydrochlorothiazide is used to treat heart failure by reducing the amount of fluid in the body and improving blood flow to the heart.\n3. Kidney disease: Hydrochlorothiazide is used to treat kidney disease by reducing the amount of fluid in the body and helping to remove excess fluid and waste products from the kidneys.\n4. Edema (swelling): Hydrochlorothiazide is used to treat edema (swelling) in the legs, ankles, and feet. It works by reducing the amount of fluid in the body and improving blood flow to the affected area.\n5. Hyperlipidemia (high cholesterol): Hydrochlorothiazide is used to treat high cholesterol by reducing the amount of cholesterol in the blood.\n6. Migraines: Hydrochlorothiazide is sometimes used to treat migraines by reducing the amount of fluid in the body and improving blood flow to the brain.\n7. Meniere's disease: Hydrochlorothiazide is sometimes used to treat Meniere's disease, a condition that affects the inner ear and can cause vertigo, tinnitus, and hearing loss.\n8. Diabetes insipidus: Hydrochlorothiazide is sometimes used to treat diabetes insipidus, a condition that causes the body to produce too much urine.\nIt's important to note that hydrochlorothiazide should only be used to treat these conditions under the guidance of a healthcare professional. It's important to follow the recommended dosage and to monitor your condition regularly to ensure that the medication is working effectively and safely.",
    "llama-2-13b-chat-hf_fact_raw": "1. Hydrochlorothiazide is used to treat hypertension by increasing urine production to reduce fluid in the body.\n2. Hydrochlorothiazide is used to treat heart failure by reducing fluid in the body and improving blood flow to the heart.\n3. Hydrochlorothiazide is used in the treatment of kidney disease by helping to remove excess fluid and waste products from the kidneys.\n4. Hydrochlorothiazide is used to treat edema in the legs, ankles, and feet by reducing fluid in the body.\n5. Hydrochlorothiazide is sometimes used to treat Meniere's disease, which affects the inner ear and can cause symptoms like vertigo and hearing loss.",
    "llama-2-13b-chat-hf_fact": [
      "Hydrochlorothiazide is used to treat hypertension by increasing urine production to reduce fluid in the body.",
      "Hydrochlorothiazide is used to treat heart failure by reducing fluid in the body and improving blood flow to the heart.",
      "Hydrochlorothiazide is used in the treatment of kidney disease by helping to remove excess fluid and waste products from the kidneys.",
      "Hydrochlorothiazide is used to treat edema in the legs, ankles, and feet by reducing fluid in the body.",
      "Hydrochlorothiazide is sometimes used to treat Meniere's disease, which affects the inner ear and can cause symptoms like vertigo and hearing loss."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Hydrochlorothiazide can be used in the treatment of kidney disease to help control high blood pressure and prevent fluid overload, but its role is not primarily in removing waste products from the kidneys.\n4. TRUE\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1447,
    "user_query": "Has silicon been used in treatment of  incontinence ?",
    "llama-2-13b-chat-hf_response": "Yes, silicon has been used in the treatment of incontinence. Silicon-based materials have been used in the development of various medical devices and implants that are designed to treat urinary incontinence. These devices and implants are typically made of a silicon-based polymer, such as silicone, and are designed to be inserted into the body to support the bladder and urethra.\nSome examples of silicon-based devices and implants that have been used to treat incontinence include:\n1. Urinary incontinence slings: These are mesh-like devices made of silicone that are inserted under the urethra and pelvic floor muscles to support the bladder and urethra. They are used to treat stress urinary incontinence, which is the most common type of incontinence.\n2. Bladder support devices: These are devices that are inserted into the bladder to provide support and help prevent urine leakage. They can be made of silicone or other materials and are typically used to treat urge incontinence.\n3. Incontinence implants: These are small, silicone-based devices that are implanted in the body to support the bladder and urethra. They can be used to treat a variety of incontinence types, including stress and urge incontinence.\n4. Pelvic floor reconstruction devices: These are devices that are used to repair or reconstruct the pelvic floor muscles and tissues that have been damaged or weakened due to childbirth, surgery, or other conditions. They can be made of silicone or other materials and are typically used to treat stress urinary incontinence.\nSilicon-based devices and implants have several advantages over other materials. They are biocompatible, meaning they can be safely inserted into the body, and they are also flexible and durable, which makes them well-suited for use in the body. Additionally, silicon-based devices and implants can be customized to fit the individual needs of each patient, which can improve their effectiveness and reduce the risk of complications.\nIt's important to note that while silicon-based devices and implants can be effective in treating incontinence, they are not suitable",
    "llama-2-13b-chat-hf_fact_raw": "1. Silicon-based materials are used in the development of medical devices and implants to treat urinary incontinence.\n2. Urinary incontinence slings, made of silicone, are mesh-like devices that support the bladder and urethra to treat stress urinary incontinence.\n3. Bladder support devices made of silicone are inserted into the bladder to help prevent urine leakage and treat urge incontinence.\n4. Incontinence implants are silicone-based devices implanted in the body to support the bladder and urethra and can treat stress and urge incontinence.\n5. Pelvic floor reconstruction devices, which can be made of silicone, are used to repair or reconstruct weakened pelvic floor muscles and tissues.",
    "llama-2-13b-chat-hf_fact": [
      "Silicon-based materials are used in the development of medical devices and implants to treat urinary incontinence.",
      "Urinary incontinence slings, made of silicone, are mesh-like devices that support the bladder and urethra to treat stress urinary incontinence.",
      "Bladder support devices made of silicone are inserted into the bladder to help prevent urine leakage and treat urge incontinence.",
      "Incontinence implants are silicone-based devices implanted in the body to support the bladder and urethra and can treat stress and urge incontinence.",
      "Pelvic floor reconstruction devices, which can be made of silicone, are used to repair or reconstruct weakened pelvic floor muscles and tissues."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Bladder support devices made of silicone are not inserted into the bladder. They are generally inserted through the vagina and placed under the urethra or bladder neck to help prevent urine leakage, but they do not treat urge incontinence specifically.\n4. TRUE\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1454,
    "user_query": "What is the association between moon cycle and rupture risk of intracranial aneurysms?",
    "llama-2-13b-chat-hf_response": "There is some evidence to suggest that the moon cycle may be associated with an increased risk of rupture of intracranial aneurysms. One study published in the journal \"Stroke\" in 2013 found that the risk of aneurysm rupture was higher during the full moon and lower during the new moon. The study analyzed data from 626 patients with intracranial aneurysms who were treated at a single center over a 12-year period. The researchers found that the risk of rupture was significantly higher during the full moon than during other phases of the moon cycle.\nAnother study published in the journal \"Neurology\" in 2017 found similar results. The study analyzed data from 1,376 patients with intracranial aneurysms who were treated at a single center over a 10-year period. The researchers found that the risk of rupture was higher during the full moon and lower during the new moon.\nIt is thought that the association between the moon cycle and aneurysm rupture risk may be due to changes in blood pressure and blood vessel diameter that occur during the menstrual cycle. Some studies have suggested that the hormonal changes that occur during the menstrual cycle may affect blood pressure and blood vessel diameter, which could increase the risk of aneurysm rupture.\nIt is important to note that these studies were small and had limited sample sizes, so more research is needed to confirm these findings and establish a definitive link between the moon cycle and aneurysm rupture risk. Additionally, the exact mechanisms by which the moon cycle may affect aneurysm rupture risk are not well understood and require further investigation.",
    "llama-2-13b-chat-hf_fact_raw": "1. A study published in the journal \"Stroke\" in 2013 suggested a higher risk of aneurysm rupture during the full moon compared to other phases.\n2. The \"Stroke\" study spanned 12 years and included 626 patients with intracranial aneurysms from a single center.\n3. A study published in the journal \"Neurology\" in 2017 found that the risk of rupture was higher during the full moon and lower during the new moon.\n4. The \"Neurology\" study involved 1,376 patients with intracranial aneurysms over a 10-year period at a single center.\n5. Changes in blood pressure and blood vessel diameter during the menstrual cycle are proposed as possible factors linking the moon cycle to aneurysm rupture risk.",
    "llama-2-13b-chat-hf_fact": [
      "A study published in the journal \"Stroke\" in 2013 suggested a higher risk of aneurysm rupture during the full moon compared to other phases.",
      "The \"Stroke\" study spanned 12 years and included 626 patients with intracranial aneurysms from a single center.",
      "A study published in the journal \"Neurology\" in 2017 found that the risk of rupture was higher during the full moon and lower during the new moon.",
      "The \"Neurology\" study involved 1,376 patients with intracranial aneurysms over a 10-year period at a single center.",
      "Changes in blood pressure and blood vessel diameter during the menstrual cycle are proposed as possible factors linking the moon cycle to aneurysm rupture risk."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nMy response is based on the fact that while specific studies are referenced, without the actual content of the studies or evidence from reputable sources, it is not possible to verify the truthfulness of these statements. Therefore, the veracity of these statements remains UNKNOWN.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1477,
    "user_query": "Does HuR protein regulate the splicing process?",
    "llama-2-13b-chat-hf_response": "HuR is a protein that plays a crucial role in the regulation of mRNA stability and translation. However, there is evidence to suggest that HuR may also be involved in the regulation of pre-mRNA splicing.\nOne study found that HuR binds to the intron of the gene encoding the protein TNF-alpha and enhances the inclusion of a specific exon in the mature mRNA (1). Another study found that HuR regulates the alternative splicing of the gene encoding the protein CD45, which is involved in the immune response (2).\nAdditionally, HuR has been shown to interact with the splicing factor SF2/ASF, which is involved in the splicing of pre-mRNA (3). This interaction suggests that HuR may play a role in the regulation of splicing.\nOverall, while the exact mechanisms by which HuR regulates splicing are not fully understood, there is evidence to suggest that it may play a role in this process.\nReferences:\n1. Li et al. (2010). HuR regulates the inclusion of a specific exon in the mature mRNA of the TNF-alpha gene. Nucleic Acids Research, 38(10), 3318-3328.\n2. Zhang et al. (2012). HuR regulates the alternative splicing of the CD45 gene in T cells. Journal of Immunology, 188(12), 5388-5396.\n3. Wang et al. (2013). HuR interacts with SF2/ASF and regulates the splicing of pre-mRNA. RNA, 19(12), 1613-1624.\nNo errors were found in the response.",
    "llama-2-13b-chat-hf_fact_raw": "1. HuR protein is involved in the regulation of mRNA stability and translation.\n2. HuR may be involved in the regulation of pre-mRNA splicing according to evidence.\n3. HuR has been found to bind to the intron of the gene encoding TNF-alpha, enhancing exon inclusion in the mRNA.\n4. The alternative splicing of the gene encoding the protein CD45 is regulated by HuR, as per a study.\n5. HuR is shown to interact with the splicing factor SF2/ASF, which is involved in splicing pre-mRNA.",
    "llama-2-13b-chat-hf_fact": [
      "HuR protein is involved in the regulation of mRNA stability and translation.",
      "HuR may be involved in the regulation of pre-mRNA splicing according to evidence.",
      "HuR has been found to bind to the intron of the gene encoding TNF-alpha, enhancing exon inclusion in the mRNA.",
      "The alternative splicing of the gene encoding the protein CD45 is regulated by HuR, as per a study.",
      "HuR is shown to interact with the splicing factor SF2/ASF, which is involved in splicing pre-mRNA."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: HuR has been found to bind to the 3' UTR of the gene encoding TNF-alpha, influencing its stability and translation, not specifically enhancing exon inclusion during splicing.\n4. FALSE [correction]: The regulation of alternative splicing of the gene encoding the protein CD45 has been associated with other proteins, but there is no direct evidence that HuR regulates this process.\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 1492,
    "user_query": "Describe the known functions for the prothymosin alpha c-terminal peptide?",
    "llama-2-13b-chat-hf_response": "Prothymosin alpha (Proα) is a protein that is expressed in the cytoplasm of immature T cells and is important for their development and survival. The c-terminal peptide of Proα (Proα-CT) has been shown to have a number of known functions, including:\n1. Inhibition of T cell activation: Proα-CT has been shown to inhibit the activation of T cells by blocking the interaction between the T cell receptor (TCR) and the CD3 complex.\n2. Inhibition of T cell proliferation: Proα-CT has been shown to inhibit the proliferation of T cells by blocking the activation of the T cell cycle.\n3. Induction of T cell apoptosis: Proα-CT has been shown to induce the apoptosis of T cells by activating the mitochondrial pathway.\n4. Modulation of cytokine production: Proα-CT has been shown to modulate the production of cytokines by T cells, such as interleukin-2 (IL-2) and interferon-gamma (IFN-γ).\n5. Inhibition of T cell migration: Proα-CT has been shown to inhibit the migration of T cells to the sites of inflammation.\n6. Inhibition of T cell adhesion: Proα-CT has been shown to inhibit the adhesion of T cells to the extracellular matrix.\n7. Anti-inflammatory effects: Proα-CT has been shown to have anti-inflammatory effects by inhibiting the production of pro-inflammatory cytokines.\n8. Anti-tumor effects: Proα-CT has been shown to have anti-tumor effects by inhibiting the growth of tumor cells.\nOverall, the c-terminal peptide of Proα has been shown to have a number of important functions in the regulation of T cell development and function, and may have potential as a therapeutic agent for the treatment of immune-related diseases.",
    "llama-2-13b-chat-hf_fact_raw": "1. The c-terminal peptide of Prothymosin alpha (Proα-CT) inhibits T cell activation by blocking the T cell receptor (TCR) interaction with the CD3 complex.\n2. Proα-CT inhibits T cell proliferation by blocking the activation of the T cell cycle.\n3. Proα-CT induces T cell apoptosis by activating the mitochondrial pathway.\n4. Proα-CT modulates the production of cytokines by T cells, including interleukin-2 (IL-2) and interferon-gamma (IFN-γ).\n5. Proα-CT has been shown to have anti-tumor effects by inhibiting the growth of tumor cells.",
    "llama-2-13b-chat-hf_fact": [
      "The c-terminal peptide of Prothymosin alpha (Proα-CT) inhibits T cell activation by blocking the T cell receptor (TCR) interaction with the CD3 complex.",
      "Proα-CT inhibits T cell proliferation by blocking the activation of the T cell cycle.",
      "Proα-CT induces T cell apoptosis by activating the mitochondrial pathway.",
      "Proα-CT modulates the production of cytokines by T cells, including interleukin-2 (IL-2) and interferon-gamma (IFN-γ).",
      "Proα-CT has been shown to have anti-tumor effects by inhibiting the growth of tumor cells."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE\n\nRational for UNKNOWN response: The detailed molecular mechanism of how Proα-CT might induce T cell apoptosis, including whether it specifically activates the mitochondrial pathway, requires citing specific scientific evidence or literature which has not been provided in the given context. Without such evidence, the statement remains ambiguous.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 1516,
    "user_query": "Which peptide plays a pivotal role in human cystatin C fibrillization?",
    "llama-2-13b-chat-hf_response": "Cystatin C is a cysteine proteinase inhibitor that is involved in regulating the activity of proteolytic enzymes in the body. It is also a major component of the extracellular matrix and is implicated in various diseases, including cancer and neurodegenerative disorders. One of the key features of cystatin C is its ability to form fibrils, which are long, linear structures composed of protein monomers. The formation of these fibrils is thought to play a role in the regulation of cystatin C's biological functions, as well as its involvement in disease processes.\nRecently, researchers have identified a specific peptide sequence within cystatin C that is responsible for its fibrillization. This peptide, known as the \"fibrillization-promoting peptide\" (FPP), is located in the N-terminal region of the protein and contains a sequence of amino acids that is responsible for its ability to induce fibrillization. The FPP has been shown to be the primary driver of cystatin C fibrillization, and its presence is necessary for the formation of stable fibrils.\nThe FPP is a short peptide sequence that consists of approximately 20 amino acids. It is flanked by two longer stretches of amino acids, which are involved in the formation of the fibrillar structure. The FPP is highly conserved across different species, indicating its importance in the regulation of cystatin C's biological functions.\nThe discovery of the FPP has provided new insights into the mechanisms of cystatin C fibrillization and has opened up new avenues for the study of this protein's biological functions. It has also raised the possibility of using cystatin C fibrillization as a therapeutic target for the treatment of diseases such as cancer and neurodegenerative disorders, where cystatin C is implicated.\nIn summary, the peptide that plays a pivotal role in human cystatin C fibrillization is the fibrillization-promoting peptide (FPP), which is located in the N-terminal region of the protein and is responsible for its ability to induce fibrill",
    "llama-2-13b-chat-hf_fact_raw": "1. Cystatin C is a cysteine proteinase inhibitor involved in regulating proteolytic enzymes in the body.\n2. Cystatin C is a component of the extracellular matrix and implicated in various diseases, including cancer and neurodegenerative disorders.\n3. Researchers have identified a specific peptide sequence within cystatin C, known as the \"fibrillization-promoting peptide\" (FPP), responsible for its fibrillization.\n4. The FPP is located in the N-terminal region of cystatin C and contains approximately 20 amino acids.\n5. The FPP is highly conserved across different species.",
    "llama-2-13b-chat-hf_fact": [
      "Cystatin C is a cysteine proteinase inhibitor involved in regulating proteolytic enzymes in the body.",
      "Cystatin C is a component of the extracellular matrix and implicated in various diseases, including cancer and neurodegenerative disorders.",
      "Researchers have identified a specific peptide sequence within cystatin C, known as the \"fibrillization-promoting peptide\" (FPP), responsible for its fibrillization.",
      "The FPP is located in the N-terminal region of cystatin C and contains approximately 20 amino acids.",
      "The FPP is highly conserved across different species."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. FALSE [correction]: The fibrillization-promoting region of cystatin C is not located in the N-terminal region but rather is believed to be in its midsection, in the region consisting of amino acids 51-57, which is a shorter stretch than approximately 20 amino acids.\n5. UNKNOWN",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1574,
    "user_query": "Does the concentration of protein HIF-1α increase after the administration of the cytoprotective prodrug\"amifostine\" (ethyol) ?",
    "llama-2-13b-chat-hf_response": "The cytoprotective prodrug amifostine (ethyol) is used to protect normal tissues from the toxic effects of radiation and chemotherapy. Amifostine is converted to the active compound, amifostine phosphate, which is a potent inhibitor of hypoxia-inducible factor-1 (HIF-1) activity. HIF-1 is a transcription factor that plays a critical role in response to hypoxia.\nTherefore, it is likely that the concentration of HIF-1α, a key subunit of HIF-1, would decrease after the administration of amifostine, as the active compound inhibits the activity of HIF-1. This decrease in HIF-1α concentration could potentially reduce the expression of genes involved in the response to hypoxia, such as genes involved in angiogenesis, glucose metabolism, and cell survival.\nHowever, it is important to note that the exact effects of amifostine on HIF-1α concentration and activity have not been well-studied, and further research is needed to fully understand the mechanisms by which amifostine affects HIF-1α and its downstream targets.",
    "llama-2-13b-chat-hf_fact_raw": "1. Amifostine is used to protect normal tissues from the toxic effects of radiation and chemotherapy.\n2. Amifostine is converted to the active compound, amifostine phosphate.\n3. Amifostine phosphate is a potent inhibitor of hypoxia-inducible factor-1 (HIF-1) activity.\n4. HIF-1 is a transcription factor that plays a critical role in response to hypoxia.\n5. The exact effects of amifostine on HIF-1α concentration and activity have not been well-studied.",
    "llama-2-13b-chat-hf_fact": [
      "Amifostine is used to protect normal tissues from the toxic effects of radiation and chemotherapy.",
      "Amifostine is converted to the active compound, amifostine phosphate.",
      "Amifostine phosphate is a potent inhibitor of hypoxia-inducible factor-1 (HIF-1) activity.",
      "HIF-1 is a transcription factor that plays a critical role in response to hypoxia.",
      "The exact effects of amifostine on HIF-1α concentration and activity have not been well-studied."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Amifostine is converted to the active compound, WR-1065.\n3. UNKNOWN\n4. TRUE\n5. UNKNOWN",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1588,
    "user_query": "Which histone marks are deposited by Set7?",
    "llama-2-13b-chat-hf_response": "Set7 is a histone H3 lysine 4 (H3K4) methyltransferase that is involved in the regulation of various cellular processes, including transcriptional elongation, gene expression, and chromatin remodeling. Set7 is known to deposit histone H3 lysine 4 trimethylation (H3K4me3) and histone H3 lysine 27 trimethylation (H3K27me3) marks.\nH3K4me3 is a repressive mark that is involved in the regulation of transcriptional elongation and is often associated with gene silencing. H3K27me3 is also a repressive mark that is involved in the regulation of gene expression and is often associated with the maintenance of cellular identity and the suppression of gene expression during cell differentiation.\nIn addition to these repressive marks, Set7 has also been shown to deposit other histone marks, including histone H3 lysine 9 (H3K9) dimethylation and histone H3 lysine 23 (H3K23) trimethylation. These marks are involved in various cellular processes, including transcriptional activation, chromatin remodeling, and DNA repair.\nOverall, Set7 is a multifunctional histone methyltransferase that plays a complex role in the regulation of chromatin structure and gene expression, and its dysregulation has been implicated in various diseases, including cancer and neurological disorders.",
    "llama-2-13b-chat-hf_fact_raw": "1. Set7 is a histone H3 lysine 4 (H3K4) methyltransferase.\n2. Set7 deposits histone H3 lysine 4 trimethylation (H3K4me3) marks.\n3. Set7 deposits histone H3 lysine 27 trimethylation (H3K27me3) marks.\n4. Set7 also deposits histone H3 lysine 9 (H3K9) dimethylation marks.\n5. Set7 deposits histone H3 lysine 23 (H3K23) trimethylation marks.",
    "llama-2-13b-chat-hf_fact": [
      "Set7 is a histone H3 lysine 4 (H3K4) methyltransferase.",
      "Set7 deposits histone H3 lysine 4 trimethylation (H3K4me3) marks.",
      "Set7 deposits histone H3 lysine 27 trimethylation (H3K27me3) marks.",
      "Set7 also deposits histone H3 lysine 9 (H3K9) dimethylation marks.",
      "Set7 deposits histone H3 lysine 23 (H3K23) trimethylation marks."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Set7 specifically deposits histone H3 lysine 4 monomethylation (H3K4me1) marks, not trimethylation.\n3. FALSE [correction]: Set7 does not deposit histone H3 lysine 27 trimethylation (H3K27me3) marks; this modification is associated with other methyltransferases like EZH2.\n4. FALSE [correction]: Set7 specifically deposits monomethylation marks at lysine 4 on histone H3 (H3K4me1) and is not known for depositing dimethylation marks at lysine 9 on histone H3 (H3K9me2).\n5. UNKNOWN",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1620,
    "user_query": "How many disulfide bridges has the protein hepcidin got?",
    "llama-2-13b-chat-hf_response": "Hepcidin is a protein that is composed of 253 amino acids and contains 4 disulfide bridges.",
    "llama-2-13b-chat-hf_fact_raw": "1. Hepcidin is composed of 253 amino acids.\n2. Hepcidin contains 4 disulfide bridges.",
    "llama-2-13b-chat-hf_fact": [
      "Hepcidin is composed of 253 amino acids.",
      "Hepcidin contains 4 disulfide bridges."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: Hepcidin is composed of 25 amino acids.\n2. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "true"
    ]
  },
  {
    "id": 1643,
    "user_query": "What is the localization of the protein encoded by the gene DNAJC11?",
    "llama-2-13b-chat-hf_response": "The protein encoded by the gene DNAJC11 is localized to the cytoplasm and nucleus.",
    "llama-2-13b-chat-hf_fact_raw": "1. The protein encoded by the gene DNAJC11 is localized to the cytoplasm.\n2. The protein encoded by the gene DNAJC11 is also localized to the nucleus.",
    "llama-2-13b-chat-hf_fact": [
      "The protein encoded by the gene DNAJC11 is localized to the cytoplasm.",
      "The protein encoded by the gene DNAJC11 is also localized to the nucleus."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n\nGiven that these statements pertain to the localization of a protein encoded by a specific gene (DNAJC11), without specific scientific literature or data to confirm or refute the cellular localization of this protein, it's not possible to assess the veracity of the statements. Localization of proteins can be complex and may include multiple cellular compartments. Therefore, information from a reliable scientific source would be required to determine the truthfulness of these statements.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1655,
    "user_query": "Are ultraconserved elements depleted among copy number variants (CNVs)?",
    "llama-2-13b-chat-hf_response": "Background:\nUltraconserved elements (UCEs) are short sequences that are highly conserved across species. They are thought to be important for the regulation of gene expression and other cellular processes. Copy number variants (CNVs) are regions of the genome that are duplicated or deleted, and they are associated with a variety of diseases and traits.\nQuestion: Are UCEs depleted among CNVs?\nMethods:\n1. Identify CNVs in a sample of individuals using a high-resolution array or sequencing data.\n2. Identify UCEs in the genome using a computational method such as the UCE discovery pipeline.\n3. Compare the frequency of UCEs in CNVs to the frequency of UCEs in non-CNV regions of the genome.\nExpected results:\nBased on previous studies, we expect that UCEs will be depleted among CNVs. This is because CNVs are often the result of genetic mutations, and UCEs are highly conserved and therefore less likely to be affected by these mutations. Additionally, UCEs are thought to be important for the regulation of gene expression, and the disruption of UCEs in CNVs may interfere with this regulation.\nConclusion:\nThe depletion of UCEs among CNVs would support the idea that UCEs play an important role in the regulation of gene expression and other cellular processes. Additionally, the identification of UCEs in CNVs could provide insight into the mechanisms underlying the development of diseases and traits associated with CNVs.",
    "llama-2-13b-chat-hf_fact_raw": "1. Ultraconserved elements (UCEs) are highly conserved across species.\n2. UCEs are thought to be important for the regulation of gene expression and other cellular processes.\n3. Copy number variants (CNVs) are regions of the genome that are duplicated or deleted and associated with various diseases and traits.\n4. Previous studies expect that UCEs will be depleted among CNVs due to their high conservation and importance in gene expression regulation.\n5. The identification of UCEs in CNVs could provide insight into the mechanisms underlying the development of diseases and traits associated with CNVs.",
    "llama-2-13b-chat-hf_fact": [
      "Ultraconserved elements (UCEs) are highly conserved across species.",
      "UCEs are thought to be important for the regulation of gene expression and other cellular processes.",
      "Copy number variants (CNVs) are regions of the genome that are duplicated or deleted and associated with various diseases and traits.",
      "Previous studies expect that UCEs will be depleted among CNVs due to their high conservation and importance in gene expression regulation.",
      "The identification of UCEs in CNVs could provide insight into the mechanisms underlying the development of diseases and traits associated with CNVs."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe statements provided are consistent with scientific understanding related to ultraconserved elements (UCEs) and copy number variants (CNVs). UCEs are indeed highly conserved sequences that are believed to play crucial roles in gene expression and regulation, making it likely for past studies to predict their depletion in CNVs. The identification of UCEs in CNVs can indeed offer insights into the genetic basis of diseases and traits associated with CNVs.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1665,
    "user_query": "Which is the substrate of the haspin kinase during mitosis?",
    "llama-2-13b-chat-hf_response": "A) Microtubules\nB) Microfilaments\nC) Nucleoskeleton\nD) Plasma membrane\nCorrect answer: A) Microtubules\nExplanation:\nThe haspin kinase is a protein that plays a crucial role in regulating the progression of mitosis. During mitosis, the haspin kinase is activated and phosphorylates various substrates, including the microtubule-associated protein tau. The phosphorylation of tau by haspin kinase leads to the stabilization of microtubules, which are essential for the proper separation of chromosomes during cell division. Therefore, the correct answer is A) Microtubules.",
    "llama-2-13b-chat-hf_fact_raw": "1. The substrate of the haspin kinase during mitosis is microtubules.\n2. The haspin kinase phosphorylates the microtubule-associated protein tau.\n3. The phosphorylation of tau by haspin kinase stabilizes microtubules.\n4. Microtubules are essential for the proper separation of chromosomes during cell division.",
    "llama-2-13b-chat-hf_fact": [
      "The substrate of the haspin kinase during mitosis is microtubules.",
      "The haspin kinase phosphorylates the microtubule-associated protein tau.",
      "The phosphorylation of tau by haspin kinase stabilizes microtubules.",
      "Microtubules are essential for the proper separation of chromosomes during cell division."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: The substrate of the haspin kinase during mitosis is histone H3, not microtubules.\n2. FALSE [correction]: Haspin kinase phosphorylates histone H3 at threonine 3 (Thr3) during mitosis, not the microtubule-associated protein tau.\n3. FALSE [correction]: The phosphorylation of histone H3 by haspin kinase helps to regulate chromosome behavior during mitosis, not the stabilization of microtubules.\n4. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 1696,
    "user_query": "What is the mechanism of viroid replication?",
    "llama-2-13b-chat-hf_response": "Viroids are small, single-stranded RNA molecules that replicate inside plant cells. They do not encode for any proteins and do not have a genome, yet they are able to replicate and spread within the host plant. The mechanism of viroid replication is not fully understood, but it is thought to involve the host plant's RNA-dependent RNA polymerase (RdRp) enzyme.\nHere is a possible mechanism of viroid replication:\n1. The viroid RNA molecule is recognized by the host plant's RdRp enzyme, which binds to the RNA and initiates its replication.\n2. The RdRp enzyme reads the viroid RNA template and synthesizes a complementary RNA strand.\n3. The newly synthesized RNA strand is then used as a template for the synthesis of additional RNA strands.\n4. The process of RNA synthesis is repeated multiple times, leading to the amplification of the viroid RNA population within the host plant.\n5. The amplified viroid RNA molecules can then be transported to other parts of the plant, allowing the viroid to spread and infect other cells.\nIt is worth noting that the exact mechanism of viroid replication is still a subject of research and there may be other factors involved in the replication process that are not yet fully understood.",
    "llama-2-13b-chat-hf_fact_raw": "1. Viroids are single-stranded RNA molecules that replicate inside plant cells.\n2. Viroids do not encode for proteins and do not have a genome.\n3. Viroid replication is thought to involve the host plant's RNA-dependent RNA polymerase (RdRp) enzyme.\n4. The RdRp enzyme synthesizes a complementary RNA strand using the viroid RNA template.\n5. Amplified viroid RNA molecules can spread and infect other parts of the host plant.",
    "llama-2-13b-chat-hf_fact": [
      "Viroids are single-stranded RNA molecules that replicate inside plant cells.",
      "Viroids do not encode for proteins and do not have a genome.",
      "Viroid replication is thought to involve the host plant's RNA-dependent RNA polymerase (RdRp) enzyme.",
      "The RdRp enzyme synthesizes a complementary RNA strand using the viroid RNA template.",
      "Amplified viroid RNA molecules can spread and infect other parts of the host plant."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Viroids do not encode for proteins, but they do have a genome, which is composed of a short strand of circular RNA.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1723,
    "user_query": "Does fibronectin constitute a serum biomarker for Duchenne muscular dystrophy?",
    "llama-2-13b-chat-hf_response": "Background: Duchenne muscular dystrophy (DMD) is a severe and debilitating genetic disorder characterized by progressive muscle weakness and wasting. There is currently no cure for DMD, and the diagnosis is based on a combination of clinical, genetic, and laboratory tests.\nAim: To investigate whether fibronectin, a protein that plays a crucial role in muscle development and maintenance, constitutes a serum biomarker for DMD.\nMethods: We measured fibronectin levels in serum samples from 25 DMD patients and 25 healthy controls using a commercial enzyme-linked immunosorbent assay (ELISA) kit. We also evaluated the correlation between fibronectin levels and clinical and laboratory parameters, such as creatine kinase (CK) and muscle strength, in DMD patients.\nResults: We found that fibronectin levels were significantly higher in DMD patients than in healthy controls (p < 0.001). Moreover, we observed a positive correlation between fibronectin levels and CK levels (r = 0.63, p < 0.001) and a negative correlation between fibronectin levels and muscle strength (r = -0.53, p < 0.001) in DMD patients.\nConclusion: Our findings suggest that fibronectin may constitute a useful serum biomarker for DMD. The elevated levels of fibronectin in DMD patients may reflect the muscle damage and degeneration that occurs in this disease. The positive correlation between fibronectin levels and CK levels, as well as the negative correlation between fibronectin levels and muscle strength, support the potential clinical utility of fibronectin as a biomarker for DMD. Further studies are needed to validate these findings and to determine the sensitivity and specificity of fibronectin as a diagnostic marker for DMD.",
    "llama-2-13b-chat-hf_fact_raw": "1. Duchenne muscular dystrophy is a severe genetic disorder characterized by progressive muscle weakness and wasting.\n2. Fibronectin plays a crucial role in muscle development and maintenance.\n3. Serum fibronectin levels were higher in DMD patients compared to healthy controls with statistical significance (p < 0.001).\n4. There is a positive correlation between serum fibronectin levels and creatine kinase levels in DMD patients (r = 0.63, p < 0.001).\n5. There is a negative correlation between serum fibronectin levels and muscle strength in DMD patients (r = -0.53, p < 0.001).",
    "llama-2-13b-chat-hf_fact": [
      "Duchenne muscular dystrophy is a severe genetic disorder characterized by progressive muscle weakness and wasting.",
      "Fibronectin plays a crucial role in muscle development and maintenance.",
      "Serum fibronectin levels were higher in DMD patients compared to healthy controls with statistical significance (p < 0.001).",
      "There is a positive correlation between serum fibronectin levels and creatine kinase levels in DMD patients (r = 0.63, p < 0.001).",
      "There is a negative correlation between serum fibronectin levels and muscle strength in DMD patients (r = -0.53, p < 0.001)."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe true/false validation of statements 3, 4, and 5 requires specific data or results from scientific studies that are not provided. Without access to such data or results, it is impossible to confirm the accuracy of these statements.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1763,
    "user_query": "Data from which major epigenome projects are contained in the DeepBlue epigenomic data server?",
    "llama-2-13b-chat-hf_response": "The DeepBlue epigenomic data server contains data from several major epigenome projects, including:\n1. ENCODE (Encyclopedia of DNA Elements): A collaborative effort between the US National Human Genome Research Institute (NHGRI) and the National Institute of Mental Health (NIMH) that aims to map all the functional elements in the human genome.\n2. Roadmap Epigenomics: A project funded by the National Institutes of Health (NIH) to generate high-resolution epigenetic maps for a variety of human tissues and cell types.\n3. GTEx (Genotype-Tissue Expression): A project funded by the NIH to generate RNA-seq data for a wide range of human tissues and cell types.\n4. HipSci (Human Intestinal Single Cell Consortium): A project funded by the Wellcome Trust and the Medical Research Council (MRC) to generate single-cell RNA-seq data for the human intestinal tract.\n5. Human Brain Project: A large-scale effort to map the neural circuits of the human brain and their role in behavior and disease.\n6. Cancer Genome Atlas (TCGA): A collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI) to generate comprehensive genomic and epigenomic data for a wide range of human cancers.\n7. Epigenome Roadmap: A project funded by the NIH to generate high-resolution epigenetic maps for a variety of human tissues and cell types.\n8. Methylation Array Consortium: A project funded by the NIH to generate methylation array data for a wide range of human tissues and cell types.\n9. Single Cell Epigenomics Consortium: A project funded by the NIH to generate single-cell epigenetic data for a variety of human tissues and cell types.\nThese projects have generated a vast amount of data, including DNA methylation profiles, histone modification profiles, and gene expression profiles, for a wide range of human tissues and cell types. The DeepBlue epigenomic data server provides a centralized resource for accessing and analyzing these data.",
    "llama-2-13b-chat-hf_fact_raw": "1. The DeepBlue epigenomic data server contains data from the ENCODE project, a collaborative effort between the NHGRI and NIMH.\n2. The Roadmap Epigenomics project, funded by the NIH, is one of the major epigenome projects data contained in the DeepBlue server.\n3. GTEx, funded by the NIH, aims to generate RNA-seq data for a range of human tissues and cell types, and its data is included in the DeepBlue server.\n4. The Cancer Genome Atlas is a collaborative project between the NCI and NHGRI, and its genomic and epigenomic data is available on the DeepBlue server.\n5. The Epigenome Roadmap project, funded by the NIH, has generated epigenetic maps for various human tissues and cell types, with its data stored in the DeepBlue server.",
    "llama-2-13b-chat-hf_fact": [
      "The DeepBlue epigenomic data server contains data from the ENCODE project, a collaborative effort between the NHGRI and NIMH.",
      "The Roadmap Epigenomics project, funded by the NIH, is one of the major epigenome projects data contained in the DeepBlue server.",
      "GTEx, funded by the NIH, aims to generate RNA-seq data for a range of human tissues and cell types, and its data is included in the DeepBlue server.",
      "The Cancer Genome Atlas is a collaborative project between the NCI and NHGRI, and its genomic and epigenomic data is available on the DeepBlue server.",
      "The Epigenome Roadmap project, funded by the NIH, has generated epigenetic maps for various human tissues and cell types, with its data stored in the DeepBlue server."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: The DeepBlue epigenomic data server contains data predominantly from the BLUEPRINT project, which is a collaborative effort between several organizations. The ENCODE project has its own data server.\n2. TRUE\n3. UNKNOWN: While GTEx, funded by the NIH, aims to generate RNA-seq data for a range of human tissues and cell types, it is not explicitly clear whether its data is integrated into the DeepBlue server without access to the server's current data catalog or a supporting reference.\n4. UNKNOWN: The Cancer Genome Atlas is a collaborative project between the NCI and NHGRI, known for its genomic data. Whether its genomic and epigenomic data are available on the DeepBlue server would need to be confirmed with the server's data catalog or a related reference.\n5. FALSE [correction]: The NIH-funded Roadmap Epigenomics Project did generate epigenetic maps for various human tissues and cell types, but saying \"the Epigenome Roadmap project\" instead of \"the Roadmap Epigenomics Project\" may be deemed inaccurate if one strictly adheres to the project's official title. However, whether its data is stored in the DeepBlue server specifically would need to be confirmed with current data listings or external validation.",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 1792,
    "user_query": "Which tool employs self organizing maps for analyzing synonymous codon usage?",
    "llama-2-13b-chat-hf_response": "One tool that provides a comprehensive analysis of synonymous codon usage is \"CodonCode\" (http://www.codoncode.com). It uses a codon usage matrix (CUM) to visualize the usage of synonymous codons and to identify clusters of codons with similar usage patterns.\nI apologize for any inconvenience caused by my previous mistake. Please let me know if you have any further questions.\nNo.",
    "llama-2-13b-chat-hf_fact_raw": "1. \"CodonCode\" is a tool that analyzes synonymous codon usage.\n2. \"CodonCode\" employs a codon usage matrix (CUM) for visualization purposes.\n3. The tool identifies clusters of codons with similar usage patterns.",
    "llama-2-13b-chat-hf_fact": [
      "\"CodonCode\" is a tool that analyzes synonymous codon usage.",
      "\"CodonCode\" employs a codon usage matrix (CUM) for visualization purposes.",
      "The tool identifies clusters of codons with similar usage patterns."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN [clarification]: Without specific information about a tool named \"CodonCode,\" it is unclear whether it employs a codon usage matrix for visualization. Codon analysis tools often use various methods for visualization, and a codon usage matrix could be one such method. However, without confirmation regarding the features of \"CodonCode,\" the truth of this statement cannot be ascertained.\n3. UNKNOWN [clarification]: Similar to the previous statement, without specific information about the features of \"CodonCode,\" it is not possible to confirm whether the tool identifies clusters of codons with similar usage patterns. This is a reasonable function for a codon analysis tool, but without concrete details on \"CodonCode,\" the validity of this statement cannot be determined.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1793,
    "user_query": "What is MINDY-1?",
    "llama-2-13b-chat-hf_response": "MINDY-1 (Molecular Inhibitor of Neuronal Death in Yolk-1) is a protein that is produced in the brain and has been shown to play a role in the regulation of neuronal survival and death. It is a member of the Bcl-2 family of proteins, which are involved in the regulation of programmed cell death (apoptosis).\nMINDY-1 was first identified in the early 2000s as a protein that was expressed in the brain and was found to be involved in the regulation of neuronal survival. Since then, it has been the subject of extensive research, and it has been shown to have a number of different functions in the brain.\nOne of the key functions of MINDY-1 is to inhibit the activity of pro-apoptotic proteins, such as Bax and Bak, which are involved in the induction of apoptosis. By inhibiting the activity of these proteins, MINDY-1 helps to protect neurons from death and promote their survival.\nIn addition to its role in regulating neuronal survival, MINDY-1 has also been shown to be involved in the regulation of synaptic plasticity and learning and memory. It has been shown to play a role in the regulation of the strength of synaptic connections between neurons, and it has been implicated in the formation and retrieval of memories.\nOverall, MINDY-1 is a protein that plays a critical role in the regulation of neuronal survival and death, and it has important functions in the brain that are involved in learning and memory.",
    "llama-2-13b-chat-hf_fact_raw": "1. MINDY-1 is a protein produced in the brain that regulates neuronal survival and death.\n2. It is a member of the Bcl-2 family of proteins that are involved in programmed cell death (apoptosis).\n3. MINDY-1 was first identified in the early 2000s.\n4. MINDY-1 inhibits the activity of pro-apoptotic proteins, such as Bax and Bak.\n5. MINDY-1 is involved in the regulation of synaptic plasticity and learning and memory.",
    "llama-2-13b-chat-hf_fact": [
      "MINDY-1 is a protein produced in the brain that regulates neuronal survival and death.",
      "It is a member of the Bcl-2 family of proteins that are involved in programmed cell death (apoptosis).",
      "MINDY-1 was first identified in the early 2000s.",
      "MINDY-1 inhibits the activity of pro-apoptotic proteins, such as Bax and Bak.",
      "MINDY-1 is involved in the regulation of synaptic plasticity and learning and memory."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe context of MINDY-1 and its characteristics and functions in the brain or in relation to apoptosis is unclear from the provided statements without a reliable source or scientific literature to verify the information. As a result, it's difficult to determine the truthfulness of the statements without additional context.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1810,
    "user_query": "Which software package is available for the analysis of conserved genomic loci?",
    "llama-2-13b-chat-hf_response": "There are several software packages available for the analysis of conserved genomic loci, including:\n1. BLAST (Basic Local Alignment Search Tool): This is a widely used tool for comparing biological sequences (DNA, RNA, or protein) to identify similarities and infer evolutionary relationships. BLAST can be used to identify conserved regions between different species or strains.\n2. ClustalW: This is a multiple sequence alignment tool that can be used to identify conserved regions in a set of sequences. ClustalW can also be used to identify gaps and insertions/deletions in the sequences.\n3. MUSCLE (Multiple Sequence Comparison by Log-Expectation): This is another multiple sequence alignment tool that can be used to identify conserved regions in a set of sequences. MUSCLE is based on the progressive method and is known for its high accuracy and speed.\n4. MAFFT (Multiple Alignment Using Fast Fourier Transform): This is a multiple sequence alignment tool that uses the Fast Fourier Transform (FFT) to quickly align multiple sequences. MAFFT can be used to identify conserved regions in a set of sequences and can also be used to infer evolutionary relationships.\n5. Phyre2: This is a web-based tool that can be used to identify conserved regions in a set of sequences. Phyre2 uses a combination of multiple sequence alignment and phylogenetic analysis to identify conserved regions and infer evolutionary relationships.\n6. Consensus-Deep: This is a tool that can be used to identify conserved regions in a set of sequences using a consensus-decomposition approach. Consensus-Deep can be used to identify conserved regions in both coding and non-coding regions of the genome.\n7. GERP (Genomic Evolutionary Rate Profiling): This is a tool that can be used to identify conserved regions in a set of sequences and to infer evolutionary rates in different parts of the genome. GERP can be used to identify functional elements such as promoters, enhancers, and gene bodies.\n8. HISAT2 (Hierarchical Indexing for Spliced Transcript Alignment): This is a tool that can be used to align RNA-seq reads to a reference genome and to identify",
    "llama-2-13b-chat-hf_fact_raw": "1. BLAST is a tool for comparing biological sequences to identify similarities and infer evolutionary relationships.\n2. ClustalW is a multiple sequence alignment tool used to identify conserved regions and gaps or insertions/deletions in sequences.\n3. MUSCLE is a multiple sequence alignment tool known for its accuracy and speed.\n4. MAFFT uses Fast Fourier Transform for quickly aligning multiple sequences.\n5. GERP is used to identify conserved regions and infer evolutionary rates in different parts of the genome.",
    "llama-2-13b-chat-hf_fact": [
      "BLAST is a tool for comparing biological sequences to identify similarities and infer evolutionary relationships.",
      "ClustalW is a multiple sequence alignment tool used to identify conserved regions and gaps or insertions/deletions in sequences.",
      "MUSCLE is a multiple sequence alignment tool known for its accuracy and speed.",
      "MAFFT uses Fast Fourier Transform for quickly aligning multiple sequences.",
      "GERP is used to identify conserved regions and infer evolutionary rates in different parts of the genome."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1860,
    "user_query": "Please list 3 diseases associated with the PIEZO2 gene.",
    "llama-2-13b-chat-hf_response": "Here are three diseases associated with the PIEZO2 gene:\n1. Hypertension: The PIEZO2 gene has been associated with hypertension, as mutations in the gene can lead to increased blood pressure.\n2. Atrial fibrillation: PIEZO2 mutations have also been linked to an increased risk of atrial fibrillation, a common heart rhythm disorder.\n3. Pulmonary arterial hypertension: The PIEZO2 gene has been implicated in the development of pulmonary arterial hypertension, a condition characterized by high blood pressure in the lungs.",
    "llama-2-13b-chat-hf_fact_raw": "1. Mutations in the PIEZO2 gene can lead to hypertension.\n2. PIEZO2 gene mutations are linked to an increased risk of atrial fibrillation.\n3. The PIEZO2 gene is implicated in the development of pulmonary arterial hypertension.",
    "llama-2-13b-chat-hf_fact": [
      "Mutations in the PIEZO2 gene can lead to hypertension.",
      "PIEZO2 gene mutations are linked to an increased risk of atrial fibrillation.",
      "The PIEZO2 gene is implicated in the development of pulmonary arterial hypertension."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: The PIEZO2 gene is not typically associated with hypertension. It is more commonly associated with the body's sense of touch and proprioception.\n2. UNKNOWN: There isn't a commonly established link between PIEZO2 gene mutations and atrial fibrillation, as the latter is most often associated with other risk factors and genes.\n3. TRUE: Mutations in the PIEZO2 gene have been implicated in the development of certain forms of hereditary pulmonary arterial hypertension.",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1867,
    "user_query": "What is promoted by ERAP1-ERAP2 dimerization?",
    "llama-2-13b-chat-hf_response": "ERAP1-ERAP2 dimerization promotes the degradation of misfolded proteins.\nERAP1-ERAP2 dimerization inhibits the degradation of misfolded proteins.\nERAP1-ERAP2 dimerization activates the degradation of misfolded proteins.\nERAP1-ERAP2 dimerization regulates the localization of misfolded proteins.\nCorrect answer: ERAP1-ERAP2 dimerization activates the degradation of misfolded proteins.\nERAP1 and ERAP2 are ubiquitin E1 ligases that play a crucial role in the ubiquitin-proteasome pathway, which is responsible for the degradation of misfolded proteins. The dimerization of ERAP1 and ERAP2 has been shown to promote the degradation of misfolded proteins. The dimerization of these two proteins leads to the activation of the ubiquitin-proteasome pathway, which results in the degradation of misfolded proteins. Therefore, the correct answer is option A: ERAP1-ERAP2 dimerization activates the degradation of misfolded proteins.",
    "llama-2-13b-chat-hf_fact_raw": "1. ERAP1-ERAP2 dimerization activates the degradation of misfolded proteins.\n2. ERAP1 and ERAP2 are ubiquitin E1 ligases.\n3. The ubiquitin-proteasome pathway is responsible for the degradation of misfolded proteins.\n4. Dimerization of ERAP1 and ERAP2 promotes the degradation of misfolded proteins.\n5. The activation of the ubiquitin-proteasome pathway leads to the degradation of misfolded proteins.",
    "llama-2-13b-chat-hf_fact": [
      "ERAP1-ERAP2 dimerization activates the degradation of misfolded proteins.",
      "ERAP1 and ERAP2 are ubiquitin E1 ligases.",
      "The ubiquitin-proteasome pathway is responsible for the degradation of misfolded proteins.",
      "Dimerization of ERAP1 and ERAP2 promotes the degradation of misfolded proteins.",
      "The activation of the ubiquitin-proteasome pathway leads to the degradation of misfolded proteins."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: ERAP1 and ERAP2 are aminopeptidases that trim peptides for presentation by MHC class I molecules; they do not dimerize to activate the degradation of misfolded proteins.\n2. FALSE [correction]: ERAP1 and ERAP2 are not ubiquitin E1 ligases; they are aminopeptidases involved in the processing of antigenic peptides.\n3. TRUE: The ubiquitin-proteasome pathway is indeed responsible for the degradation of misfolded proteins among many other functions in the cell.\n4. FALSE [correction]: While ERAP1 and ERAP2 do form heterodimers, this dimerization is relevant to their role in trimming peptides for MHC class I presentation, not directly for the degradation of misfolded proteins.\n5. TRUE: Activation of the ubiquitin-proteasome pathway does lead to the degradation of misfolded proteins.",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1890,
    "user_query": "What is the function of R-spondin 1 and noggin in non-damaged gallbladders?",
    "llama-2-13b-chat-hf_response": "R-spondin 1 and noggin are two proteins that are expressed in the non-damaged gallbladder and have been shown to play a role in the regulation of gallbladder function.\nR-spondin 1 is a ligand for the TGF-beta superfamily of growth factors, and it has been shown to regulate the expression of genes involved in cell growth, differentiation, and tissue repair. In the gallbladder, R-spondin 1 is expressed in the epithelial cells and is thought to play a role in maintaining the integrity of the epithelial lining and regulating the proliferation of epithelial cells.\nNoggin is a protein that inhibits the activity of BMP (bone morphogenetic protein) signaling, which is involved in the regulation of cell growth and differentiation. In the gallbladder, noggin is expressed in the smooth muscle cells and is thought to regulate the contraction and relaxation of the smooth muscle cells, which is important for the proper functioning of the gallbladder.\nIn non-damaged gallbladders, R-spondin 1 and noggin are important for maintaining the normal functioning of the gallbladder. R-spondin 1 helps to regulate the proliferation and differentiation of epithelial cells, while noggin helps to regulate the contraction and relaxation of smooth muscle cells.\nIn addition, R-spondin 1 and noggin may also play a role in the regulation of gallbladder emptying and the release of bile into the small intestine. For example, R-spondin 1 has been shown to regulate the expression of genes involved in the regulation of gallbladder emptying, and noggin has been shown to regulate the contraction of the smooth muscle cells in the gallbladder neck, which is important for the release of bile into the small intestine.\nOverall, R-spondin 1 and noggin are important for maintaining the normal functioning of the non-damaged gallbladder, and their dysregulation may contribute to the development of gallbladder disease.",
    "llama-2-13b-chat-hf_fact_raw": "1. R-spondin 1 is a ligand for the TGF-beta superfamily of growth factors and regulates gene expression involved in cell growth, differentiation, and tissue repair.\n2. In the non-damaged gallbladder, R-spondin 1 is expressed in epithelial cells and plays a role in maintaining the integrity of the epithelial lining.\n3. Noggin is a protein that inhibits BMP signaling, which is involved in the regulation of cell growth and differentiation.\n4. In the non-damaged gallbladder, noggin is expressed in smooth muscle cells and helps regulate their contraction and relaxation.\n5. R-spondin 1 and noggin play a role in the regulation of gallbladder emptying and the release of bile into the small intestine.",
    "llama-2-13b-chat-hf_fact": [
      "R-spondin 1 is a ligand for the TGF-beta superfamily of growth factors and regulates gene expression involved in cell growth, differentiation, and tissue repair.",
      "In the non-damaged gallbladder, R-spondin 1 is expressed in epithelial cells and plays a role in maintaining the integrity of the epithelial lining.",
      "Noggin is a protein that inhibits BMP signaling, which is involved in the regulation of cell growth and differentiation.",
      "In the non-damaged gallbladder, noggin is expressed in smooth muscle cells and helps regulate their contraction and relaxation.",
      "R-spondin 1 and noggin play a role in the regulation of gallbladder emptying and the release of bile into the small intestine."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: R-spondin 1 is not a ligand for the TGF-beta superfamily but rather acts as a ligand for the LGR4/5/6 receptors, and it is involved in the Wnt signaling pathway, which regulates cell proliferation, differentiation, and stem cell renewal.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: While noggin is indeed a protein that inhibits BMP (bone morphogenetic protein) signaling, its specific expression in the non-damaged gallbladder, particularly in smooth muscle cells, and its role in regulating their contraction and relaxation is not well-established and would require specific biological context to confirm.\n5. FALSE [correction]: The roles of R-spondin 1 and noggin in regulating gallbladder emptying and the release of bile into the small intestine are not directly established. These processes are primarily coordinated by complex physiological mechanisms involving hormones and neural control rather than by these specific proteins alone.",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 1937,
    "user_query": "Does NADPH oxidase 5 require any subunit for function?",
    "llama-2-13b-chat-hf_response": "NADPH oxidase 5 (NOX5) is a member of the NOX family of enzymes that catalyze the transfer of electrons from NADPH to oxygen, leading to the formation of superoxide anions. While the other NOX isoforms require specific subunits for their function, the requirement for subunits in NOX5 is less clear.\nSome studies suggest that NOX5 may function as a homodimer, with two identical subunits (p22phox and p47phox) forming a stable complex that is required for enzymatic activity. Other studies have suggested that NOX5 may function as a monomer, with the p22phox subunit being sufficient for enzymatic activity.\nIt is worth noting that the crystal structure of NOX5 has not been resolved, making it difficult to determine the exact subunit requirements for the enzyme. Additionally, the specific subunits required for NOX5 function may vary depending on the cellular context and the specific redox signaling pathway being activated.\nIn summary, while the exact subunit requirements for NOX5 are not fully understood, it is likely that the enzyme functions as a heterodimer or homodimer, with the p22phox and p47phox subunits playing a critical role in its activity. However, the specific subunit requirements for NOX5 may vary depending on the cellular context and the specific redox signaling pathway being activated.",
    "llama-2-13b-chat-hf_fact_raw": "1. NADPH oxidase 5 (NOX5) is a member of the NOX family of enzymes.\n2. NOX5 catalyzes the transfer of electrons from NADPH to oxygen to form superoxide anions.\n3. Other NOX isoforms require specific subunits for their function.\n4. There is a suggestion that NOX5 may function as a homodimer with p22phox and p47phox subunits.\n5. The crystal structure of NOX5 has not been resolved.",
    "llama-2-13b-chat-hf_fact": [
      "NADPH oxidase 5 (NOX5) is a member of the NOX family of enzymes.",
      "NOX5 catalyzes the transfer of electrons from NADPH to oxygen to form superoxide anions.",
      "Other NOX isoforms require specific subunits for their function.",
      "There is a suggestion that NOX5 may function as a homodimer with p22phox and p47phox subunits.",
      "The crystal structure of NOX5 has not been resolved."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: NOX5 is unique among NOX enzymes as it does not require p22phox or any other cytosolic subunits such as p47phox for its function; it can function independently.\n5. UNKNOWN",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1944,
    "user_query": "What is the connection between furin and hepcidin?",
    "llama-2-13b-chat-hf_response": "Furin and hepcidin are two proteins that play important roles in regulating iron metabolism in the body. While they have distinct functions, they are connected through a negative feedback loop that helps maintain iron homeostasis. Here's a brief overview of their connections:\n1. Hepcidin regulates furin expression: Hepcidin, a hormone produced by the liver in response to iron overload, inhibits the expression of furin. When hepcidin levels are high, furin production is reduced, leading to decreased iron absorption in the gut and decreased iron release from storage sites.\n2. Furin regulates hepcidin degradation: Furin is involved in the degradation of hepcidin. When furin is active, it can cleave hepcidin into smaller peptides that are more easily excreted by the kidneys, leading to a decrease in hepcidin levels.\n3. Hepcidin-Furin axis and iron homeostasis: The balance between hepcidin and furin is critical for maintaining iron homeostasis in the body. When iron levels are high, hepcidin levels increase, inhibiting furin expression and promoting iron storage. Conversely, when iron levels are low, hepcidin levels decrease, allowing furin expression to increase and promoting iron release from storage sites.\n4. Regulation of erythropoiesis: The hepcidin-furin axis also plays a role in regulating erythropoiesis, the production of red blood cells. Hepcidin inhibits erythropoiesis when iron levels are high, while furin promotes erythropoiesis when iron levels are low.\nIn summary, the connection between furin and hepcidin is a negative feedback loop that regulates iron metabolism and maintains iron homeostasis in the body. Hepcidin inhibits furin expression, while furin regulates hepcidin degradation, and together they modulate iron absorption, storage, and release, as well as erythropoiesis.",
    "llama-2-13b-chat-hf_fact_raw": "1. Hepcidin is a hormone produced by the liver in response to iron overload.\n2. High levels of hepcidin inhibit the expression of furin.\n3. Furin is involved in the degradation of hepcidin.\n4. The balance between hepcidin and furin maintains iron homeostasis in the body.\n5. The hepcidin-furin axis plays a role in regulating erythropoiesis.",
    "llama-2-13b-chat-hf_fact": [
      "Hepcidin is a hormone produced by the liver in response to iron overload.",
      "High levels of hepcidin inhibit the expression of furin.",
      "Furin is involved in the degradation of hepcidin.",
      "The balance between hepcidin and furin maintains iron homeostasis in the body.",
      "The hepcidin-furin axis plays a role in regulating erythropoiesis."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: High levels of hepcidin inhibit the expression of ferroportin, not furin.\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1956,
    "user_query": "Which is the largest metabolic gene cluster in yeast?",
    "llama-2-13b-chat-hf_response": "The largest metabolic gene cluster in yeast is the ADH (alcohol dehydrogenase) gene cluster. This cluster contains 27 genes that are involved in the metabolism of sugars and the production of alcohol. The ADH gene cluster is located on chromosome 5 in Saccharomyces cerevisiae, the baker's yeast, and is one of the largest known gene clusters in yeast. The genes in this cluster are organized in a specific order and are regulated by a single promoter, which allows for coordinated expression of the genes. The ADH gene cluster is important for the production of ethanol during fermentation, and mutations in this cluster can affect the efficiency and yield of ethanol production.",
    "llama-2-13b-chat-hf_fact_raw": "1. The largest metabolic gene cluster in yeast is the ADH gene cluster.\n2. The ADH gene cluster contains 27 genes involved in sugar metabolism and alcohol production.\n3. This gene cluster is located on chromosome 5 in Saccharomyces cerevisiae.\n4. Saccharomyces cerevisiae is commonly known as baker's yeast.\n5. Mutations in the ADH gene cluster can affect the efficiency and yield of ethanol production.",
    "llama-2-13b-chat-hf_fact": [
      "The largest metabolic gene cluster in yeast is the ADH gene cluster.",
      "The ADH gene cluster contains 27 genes involved in sugar metabolism and alcohol production.",
      "This gene cluster is located on chromosome 5 in Saccharomyces cerevisiae.",
      "Saccharomyces cerevisiae is commonly known as baker's yeast.",
      "Mutations in the ADH gene cluster can affect the efficiency and yield of ethanol production."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. TRUE\n\nThe statements regarding the ADH gene cluster (statements 1, 2, and 3) require specific genetic knowledge that has not been provided, and it may vary depending on the most current research. Therefore, without additional context or current research data, we cannot determine the truth value of statements 1, 2, and 3. Statements 4 and 5 are generally understood to be true, with Saccharomyces cerevisiae commonly known as baker's yeast, and mutations in metabolic gene clusters such as ADH affecting ethanol production efficiency and yield.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 1967,
    "user_query": "What is the role of LIMT lncRNA?",
    "llama-2-13b-chat-hf_response": "LIMT (Loss of Imprinting in Mammary Tumors) is a long non-coding RNA (lncRNA) that has been implicated in the development and progression of various types of cancer, including breast cancer. The exact role of LIMT in cancer is still not fully understood, but it is thought to play a role in regulating gene expression, particularly in the context of epigenetic silencing.\nLIMT is known to be overexpressed in many types of cancer, including breast cancer, and this overexpression is thought to contribute to the development and progression of cancer by disrupting normal cellular processes. For example, LIMT has been shown to inhibit the expression of tumor suppressor genes, such as PTEN, and to promote the expression of oncogenes, such as MYC.\nIn addition to its role in cancer, LIMT has also been implicated in the development of certain developmental disorders, such as Beckwith-Wiedemann syndrome, which is characterized by overgrowth and developmental delays.\nOverall, the role of LIMT in cancer and development is complex and multifaceted, and further research is needed to fully understand its mechanisms of action and its potential as a therapeutic target for cancer treatment.",
    "llama-2-13b-chat-hf_fact_raw": "1. LIMT (Loss of Imprinting in Mammary Tumors) is a long non-coding RNA (lncRNA).\n2. LIMT has been implicated in the development and progression of various types of cancer, including breast cancer.\n3. LIMT is thought to play a role in regulating gene expression through epigenetic silencing.\n4. LIMT is known to be overexpressed in many types of cancer.\n5. LIMT has been implicated in the development of certain developmental disorders, such as Beckwith-Wiedemann syndrome.",
    "llama-2-13b-chat-hf_fact": [
      "LIMT (Loss of Imprinting in Mammary Tumors) is a long non-coding RNA (lncRNA).",
      "LIMT has been implicated in the development and progression of various types of cancer, including breast cancer.",
      "LIMT is thought to play a role in regulating gene expression through epigenetic silencing.",
      "LIMT is known to be overexpressed in many types of cancer.",
      "LIMT has been implicated in the development of certain developmental disorders, such as Beckwith-Wiedemann syndrome."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN (There is no consensus in open scientific literature or databases confirming LIMT as a widely recognized long non-coding RNA associated with cancer; LIMT might be specific to this context but not known broadly.)\n2. UNKNOWN (Assuming LIMT is a long non-coding RNA as specified in statement 1, it's possible it has been implicated in various cancers, but without specific literature or studies, it's impossible to confirm.)\n3. UNKNOWN (While many lncRNAs are indeed involved in gene regulation through epigenetic mechanisms, this statement's accuracy specifically about LIMT cannot be verified without additional context or sources.)\n4. UNKNOWN (The statement presupposes that LIMT is a recognized long non-coding RNA involved in cancer. Without supporting evidence, this cannot be confirmed.)\n5. UNKNOWN (While Beckwith-Wiedemann syndrome is a developmental disorder known to involve genetic and epigenetic changes, there's no direct information provided or widely recognized correlation between LIMT and Beckwith-Wiedemann syndrome in available scientific literature.)",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1984,
    "user_query": "Which R / bioconductor package is used for performing SNP enrichment analysis?",
    "llama-2-13b-chat-hf_response": "There are several packages available in R for performing SNP enrichment analysis, and the choice of the best package depends on the specific research question and the type of analysis you want to perform. Here are some popular packages that you might find useful:\n1. enrichr: This package provides a comprehensive toolset for performing SNP enrichment analysis. It includes a variety of methods for identifying enriched pathways, including gene set enrichment analysis (GSEA), hypergeometric test, and network-based methods. enrichr also includes a user-friendly interface for selecting and visualizing the results.\n2. msigdb: This package provides access to the Molecular Signatures Database (MSigDB), which is a comprehensive collection of known gene sets and pathways. You can use msigdb to identify enriched pathways in your SNP data.\n3. GSEAPrimer: This package provides a user-friendly interface for performing GSEA and related analyses. It includes a variety of methods for identifying enriched pathways, including gene set enrichment analysis, hypergeometric test, and network-based methods.\n4. SNPEnrich: This package provides a user-friendly interface for performing SNP enrichment analysis. It includes a variety of methods for identifying enriched pathways, including GSEA, hypergeometric test, and network-based methods.\nI hope this corrected response is helpful. Please let me know if you have any further questions or concerns.",
    "llama-2-13b-chat-hf_fact_raw": "1. The 'enrichr' package in R is used for performing SNP enrichment analysis.\n2. 'msigdb' is an R package that provides access to the Molecular Signatures Database for pathway enrichment analysis.\n3. 'GSEAPrimer' is an R package that includes methods for gene set enrichment analysis.\n4. 'SNPEnrich' is an R package designed for SNP enrichment analysis with various methods for identifying enriched pathways.\n5. These packages can perform gene set enrichment analysis (GSEA), hypergeometric tests, and network-based methods.",
    "llama-2-13b-chat-hf_fact": [
      "The 'enrichr' package in R is used for performing SNP enrichment analysis.",
      "'msigdb' is an R package that provides access to the Molecular Signatures Database for pathway enrichment analysis.",
      "'GSEAPrimer' is an R package that includes methods for gene set enrichment analysis.",
      "'SNPEnrich' is an R package designed for SNP enrichment analysis with various methods for identifying enriched pathways.",
      "These packages can perform gene set enrichment analysis (GSEA), hypergeometric tests, and network-based methods."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: The 'enrichr' package in R is typically used for gene set enrichment analysis rather than SNP enrichment analysis.\n2. FALSE [correction]: 'msigdb' is not an R package, but it is a database called the Molecular Signatures Database that is used for gene set enrichment analyses; the actual R package that interfaces with this database is often called 'msigdbr'.\n3. TRUE: While there isn't a widely recognized package specifically named 'GSEAPrimer', the name suggests it deals with gene set enrichment analysis (GSEA), and it could be a tool or a hypothetical package for such purposes.\n4. UNKNOWN: As the name 'SNPEnrich' implies the function of SNP enrichment analysis, without further information on whether this is an actual R package or its specific capabilities, the truthfulness of the statement cannot be fully assessed.\n5. TRUE: These are common features in packages used for gene set enrichment analysis, though the statement is broad and without specifying which packages have these capabilities, this is generally what such packages are designed to do.",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2015,
    "user_query": "Which are the key players on radial glial specification to ependymal cells?",
    "llama-2-13b-chat-hf_response": "The key players in radial glial specification to ependymal cells are:\n1. Notch signaling pathway: Notch is a transmembrane receptor that plays a crucial role in the specification of radial glial cells to ependymal cells. The Notch pathway is activated by the ligands Delta and Jagged, which are expressed in the ventricular zone.\n2. Sox2: Sox2 is a transcription factor that is required for the specification of radial glial cells to ependymal cells. Sox2 is expressed in the ventricular zone and is necessary for the maintenance of the ependymal cell lineage.\n3. NeuroD1: NeuroD1 is a transcription factor that is involved in the specification of radial glial cells to ependymal cells. NeuroD1 is expressed in the ventricular zone and is necessary for the maintenance of the ependymal cell lineage.\n4. Pax6: Pax6 is a transcription factor that is involved in the specification of radial glial cells to ependymal cells. Pax6 is expressed in the ventricular zone and is necessary for the maintenance of the ependymal cell lineage.\n5. BMP signaling pathway: BMP (Bone Morphogenetic Protein) signaling pathway is involved in the specification of radial glial cells to ependymal cells. BMPs are expressed in the ventricular zone and are necessary for the maintenance of the ependymal cell lineage.\n6. FGF signaling pathway: FGF (Fibroblast Growth Factor) signaling pathway is involved in the specification of radial glial cells to ependymal cells. FGFs are expressed in the ventricular zone and are necessary for the maintenance of the ependymal cell lineage.\n7. Wnt signaling pathway: Wnt signaling pathway is involved in the specification of radial glial cells to ependymal cells. Wnts are expressed in the ventricular zone and are necessary for the maintenance of the ependymal cell lineage.\nThese signaling pathways and transcription factors interact with each other to regulate the specification of radial glial cells to ependymal cells. The exact mechanisms by",
    "llama-2-13b-chat-hf_fact_raw": "1. The Notch signaling pathway plays a crucial role in the specification of radial glial cells to ependymal cells.\n2. Sox2 is a necessary transcription factor for the specification and maintenance of the ependymal cell lineage.\n3. NeuroD1 is a transcription factor involved in the specification of radial glial cells to ependymal cells and is expressed in the ventricular zone.\n4. Pax6 is a transcription factor necessary for the maintenance of the ependymal cell lineage and is expressed in the ventricular zone.\n5. The Bone Morphogenetic Protein (BMP) signaling pathway is involved in the specification of radial glial cells to ependymal cells.",
    "llama-2-13b-chat-hf_fact": [
      "The Notch signaling pathway plays a crucial role in the specification of radial glial cells to ependymal cells.",
      "Sox2 is a necessary transcription factor for the specification and maintenance of the ependymal cell lineage.",
      "NeuroD1 is a transcription factor involved in the specification of radial glial cells to ependymal cells and is expressed in the ventricular zone.",
      "Pax6 is a transcription factor necessary for the maintenance of the ependymal cell lineage and is expressed in the ventricular zone.",
      "The Bone Morphogenetic Protein (BMP) signaling pathway is involved in the specification of radial glial cells to ependymal cells."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: NeuroD1 is a transcription factor involved in neurogenesis, not specifically in the specification of radial glial cells to ependymal cells, and it is expressed in neuronal progenitors in the ventricular zone.\n4. FALSE [correction]: Pax6 is a transcription factor necessary for the development of neuroprogenitor cells and is involved in neurogenesis, not specifically for the maintenance of the ependymal cell lineage.\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 2065,
    "user_query": "How are triple negative gliomas characterized?",
    "llama-2-13b-chat-hf_response": "Triple negative gliomas are characterized by the absence of three specific proteins:\n1. EGFRvIII: A mutated form of the epidermal growth factor receptor that is commonly found in glioblastomas.\n2. PD-L1: A protein that helps cancer cells evade the immune system by suppressing the activity of immune cells.\n3. IDH1/2: Enzymes that are involved in the metabolism of glucose and are commonly mutated in glioblastomas.\nThe absence of these proteins in triple negative gliomas distinguishes them from other types of gliomas, such as IDH-mutant gliomas, which are characterized by the presence of IDH1/2 mutations. Triple negative gliomas are often more aggressive and have a poorer prognosis than other types of gliomas.",
    "llama-2-13b-chat-hf_fact_raw": "1. Triple negative gliomas are characterized by the lack of three specific proteins.\n2. One of the proteins absent in triple negative gliomas is EGFRvIII, a mutated form of the epidermal growth factor receptor.\n3. Another protein that is not expressed in triple negative gliomas is PD-L1, which helps cancer cells evade the immune system.\n4. Triple negative gliomas are missing the enzymes IDH1/2, which are involved in glucose metabolism.\n5. Compared to other types of gliomas, triple negative gliomas are usually more aggressive and have a poorer prognosis.",
    "llama-2-13b-chat-hf_fact": [
      "Triple negative gliomas are characterized by the lack of three specific proteins.",
      "One of the proteins absent in triple negative gliomas is EGFRvIII, a mutated form of the epidermal growth factor receptor.",
      "Another protein that is not expressed in triple negative gliomas is PD-L1, which helps cancer cells evade the immune system.",
      "Triple negative gliomas are missing the enzymes IDH1/2, which are involved in glucose metabolism.",
      "Compared to other types of gliomas, triple negative gliomas are usually more aggressive and have a poorer prognosis."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: EGFRvIII, a mutated form of the epidermal growth factor receptor, can be expressed in gliomas, but its absence is not a defining characteristic of triple-negative gliomas.\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "false",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2069,
    "user_query": "What is TOPAZ1?",
    "llama-2-13b-chat-hf_response": "TOPAZ1 (Tissue Optimized for Protein Analysis by Zinc Finger Nucleases) is a genome-editing technology that uses zinc finger nucleases (ZFNs) to introduce specific mutations into the genome of cells. The goal of TOPAZ1 is to improve the efficiency and accuracy of protein production in cells, particularly for the production of therapeutic proteins.\nHow does TOPAZ1 work?\nTOPAZ1 works by using ZFNs to introduce specific double-stranded breaks in the genome of cells. These breaks are then repaired by the cell's own repair machinery, leading to the introduction of specific mutations into the genome. The mutations can be designed to improve the expression or stability of a specific protein, or to introduce new functions into the protein.\nWhat are the advantages of TOPAZ1?\nTOPAZ1 has several advantages over other genome-editing technologies, including:\n1. High efficiency: TOPAZ1 has been shown to be highly efficient at introducing specific mutations into the genome of cells.\n2. Specificity: TOPAZ1 is highly specific, meaning that it only targets specific sequences of the genome.\n3. Flexibility: TOPAZ1 can be used to introduce a wide range of mutations into the genome, including point mutations, insertions, and deletions.\n4. Reversibility: TOPAZ1 is a reversible technology, meaning that the introduced mutations can be reversed if desired.\nWhat are the potential applications of TOPAZ1?\nTOPAZ1 has a wide range of potential applications, including:\n1. Therapeutic protein production: TOPAZ1 could be used to improve the efficiency and accuracy of therapeutic protein production, leading to more effective and affordable treatments for a variety of diseases.\n2. Gene therapy: TOPAZ1 could be used to introduce corrective genes into cells to treat genetic diseases.\n3. Cancer therapy: TOPAZ1 could be used to introduce mutations into cancer cells that inhibit their growth or survival.\n4. Basic research: TOPAZ1",
    "llama-2-13b-chat-hf_fact_raw": "1. TOPAZ1 (Tissue Optimized for Protein Analysis by Zinc Finger Nucleases) is a genome-editing technology.\n2. TOPAZ1 uses zinc finger nucleases (ZFNs) to introduce specific mutations into the genome of cells.\n3. The mutations introduced by TOPAZ1 aim to improve the efficiency and accuracy of protein production in cells.\n4. TOPAZ1 technology is characterized by high efficiency, specificity, flexibility, and reversibility.\n5. Potential applications of TOPAZ1 include therapeutic protein production, gene therapy, cancer therapy, and basic research.",
    "llama-2-13b-chat-hf_fact": [
      "TOPAZ1 (Tissue Optimized for Protein Analysis by Zinc Finger Nucleases) is a genome-editing technology.",
      "TOPAZ1 uses zinc finger nucleases (ZFNs) to introduce specific mutations into the genome of cells.",
      "The mutations introduced by TOPAZ1 aim to improve the efficiency and accuracy of protein production in cells.",
      "TOPAZ1 technology is characterized by high efficiency, specificity, flexibility, and reversibility.",
      "Potential applications of TOPAZ1 include therapeutic protein production, gene therapy, cancer therapy, and basic research."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: TOPAZ1 is not a known acronym for a genome-editing technology; it could be a hypothetical or fictional name for such a technology.\n2. UNKNOWN: As TOPAZ1 does not correspond to a known genome-editing technology, the use of zinc finger nucleases (ZFNs) cannot be confirmed or denied.\n3. UNKNOWN: Since TOPAZ1 is not identified as a genuine genome-editing technology, the aim of the mutations introduced cannot be determined.\n4. UNKNOWN: The characteristics of TOPAZ1 cannot be confirmed without established information on this technology.\n5. UNKNOWN: Potential applications for TOPAZ1 cannot be accurately stated without knowledge of what the technology entails or if it even exists.",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2075,
    "user_query": "Which gene controls the expression of GATA-1 isoforms?",
    "llama-2-13b-chat-hf_response": "GATA-1 is a transcription factor that plays a crucial role in the regulation of gene expression during T cell development and differentiation. There are two main isoforms of GATA-1, GATA-1L and GATA-1S, which are generated through alternative splicing of the GATA-1 mRNA. The expression of these isoforms is regulated by a variety of factors, including transcriptional regulators and signaling pathways.\nOne gene that has been identified as a key regulator of GATA-1 isoform expression is the transcription factor Eomesodermin (Eomes). Eomes is a crucial regulator of T cell differentiation and has been shown to control the expression of GATA-1L and GATA-1S isoforms. Specifically, Eomes has been shown to bind to the GATA-1 promoter and enhance the expression of GATA-1L, while repressing the expression of GATA-1S.\nOther genes that have been implicated in the regulation of GATA-1 isoform expression include the transcription factors T-bet and E47, as well as the signaling molecule NF-κB. These genes are involved in a variety of cellular processes, including immune cell differentiation and signaling, and have been shown to regulate the expression of GATA-1 isoforms in a context-dependent manner.\nOverall, the expression of GATA-1 isoforms is a complex process that is regulated by a variety of genes and signaling pathways. Understanding the regulation of GATA-1 isoform expression is important for understanding T cell development and differentiation, and may have implications for the development of new therapies for immune-related diseases.",
    "llama-2-13b-chat-hf_fact_raw": "1. GATA-1 is a transcription factor involved in gene expression during T cell development and differentiation.\n2. GATA-1 has two main isoforms, GATA-1L and GATA-1S, which are produced through alternative splicing of the GATA-1 mRNA.\n3. The transcription factor Eomesodermin (Eomes) has been identified as a key regulator of GATA-1 isoform expression.\n4. Eomes binds to the GATA-1 promoter and can enhance the expression of GATA-1L while repressing the expression of GATA-1S.\n5. Transcription factors T-bet and E47, as well as the signaling molecule NF-κB, have been implicated in the regulation of GATA-1 isoform expression.",
    "llama-2-13b-chat-hf_fact": [
      "GATA-1 is a transcription factor involved in gene expression during T cell development and differentiation.",
      "GATA-1 has two main isoforms, GATA-1L and GATA-1S, which are produced through alternative splicing of the GATA-1 mRNA.",
      "The transcription factor Eomesodermin (Eomes) has been identified as a key regulator of GATA-1 isoform expression.",
      "Eomes binds to the GATA-1 promoter and can enhance the expression of GATA-1L while repressing the expression of GATA-1S.",
      "Transcription factors T-bet and E47, as well as the signaling molecule NF-κB, have been implicated in the regulation of GATA-1 isoform expression."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: GATA-1 is a transcription factor involved in gene expression during the development and differentiation of erythroid and megakaryocytic cells, not T cell development.\n2. TRUE\n3. FALSE [correction]: Eomesodermin (Eomes) is a transcription factor that plays a role in the development of some immune cells, but it is not known to be a key regulator of GATA-1 isoform expression.\n4. FALSE [correction]: While Eomes does bind to certain promoters, there is no evidence to suggest that it specifically binds to the GATA-1 promoter to enhance the expression of GATA-1L while repressing the expression of GATA-1S.\n5. UNKNOWN",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2076,
    "user_query": "What is MIRA-seq?",
    "llama-2-13b-chat-hf_response": "MIRA-seq is a method for targeted sequencing of RNA molecules that combines the advantages of both RNA-seq and CRISPR-Cas9 genome editing. The method uses a CRISPR-Cas9 system to specifically cleave the RNA molecule of interest, and then uses RNA-seq to sequence the cleaved RNA. This allows for the detection of specific RNA molecules in a sample, without the need for amplification or purification.\nThe advantages of MIRA-seq include:\n1. High sensitivity: MIRA-seq can detect very low levels of specific RNA molecules in a sample, making it a powerful tool for studying rare or low-abundance transcripts.\n2. High specificity: The CRISPR-Cas9 system used in MIRA-seq is highly specific, allowing for the targeting of specific RNA molecules without the risk of off-target effects.\n3. No need for amplification or purification: MIRA-seq does not require the amplification or purification of RNA molecules, which can be time-consuming and costly.\n4. Simultaneous detection of multiple transcripts: MIRA-seq can be used to simultaneously detect multiple RNA molecules in a sample, allowing for a more comprehensive understanding of the transcriptome.\nThe basic protocol for MIRA-seq is as follows:\n1. Design CRISPR-Cas9 guide RNAs (gRNAs) that target the RNA molecule of interest.\n2. Transfect cells with the CRISPR-Cas9 system and the gRNAs.\n3. Allow the CRISPR-Cas9 system to cleave the RNA molecule of interest.\n4. Use RNA-seq to sequence the cleaved RNA molecules.\n5. Analyze the sequencing data to identify the RNA molecules that have been cleaved.\nMIRA-seq has a wide range of applications, including:\n1. Gene expression analysis: MIRA-seq can be used to study the expression of specific genes in different tissues or under different conditions.\n2. RNA processing analysis: MIRA-seq can be used to study the processing of specific RNA molecules",
    "llama-2-13b-chat-hf_fact_raw": "1. MIRA-seq uses a CRISPR-Cas9 system to specifically cleave the RNA molecule of interest.\n2. RNA-seq is used to sequence the cleaved RNA in MIRA-seq.\n3. MIRA-seq can detect very low levels of specific RNA molecules in a sample.\n4. The CRISPR-Cas9 system used in MIRA-seq is highly specific, minimizing the risk of off-target effects.\n5. MIRA-seq can simultaneously detect multiple RNA molecules in a sample.",
    "llama-2-13b-chat-hf_fact": [
      "MIRA-seq uses a CRISPR-Cas9 system to specifically cleave the RNA molecule of interest.",
      "RNA-seq is used to sequence the cleaved RNA in MIRA-seq.",
      "MIRA-seq can detect very low levels of specific RNA molecules in a sample.",
      "The CRISPR-Cas9 system used in MIRA-seq is highly specific, minimizing the risk of off-target effects.",
      "MIRA-seq can simultaneously detect multiple RNA molecules in a sample."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: MIRA-seq does not use a CRISPR-Cas9 system to cleave RNA molecules; it is a method for investigating RNA molecule interactions with RNA-binding proteins.\n2. TRUE: RNA-seq is typically used to sequence RNA after it has been isolated by methods such as MIRA-seq.\n3. TRUE: MIRA-seq is sensitive enough to detect low-abundance RNA molecules by capturing RNA that is bound to specific RNA-binding proteins.\n4. UNKNOWN: The specificity and risk of off-target effects of CRISPR-Cas9 is well-documented, but since MIRA-seq does not use CRISPR-Cas9, this statement cannot be accurately judged without additional context.\n5. UNKNOWN: MIRA-seq is designed to capture RNA molecules interacting with RNA-binding proteins, but the statement's accuracy regarding simultaneous multiple RNA molecule detection would depend on the specifics of the technique and experimental setup, which are not provided.",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2108,
    "user_query": "What is the indication of ARCALYST?",
    "llama-2-13b-chat-hf_response": "ARCALYST is a prescription medicine used to treat adults with severe active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) inhibitors, or who have had a poor response to other treatments.\nARCALYST is also used to treat adults with severe active psoriatic arthritis (PsA) who have had an inadequate response to one or more TNF inhibitors, or who have had a poor response to other treatments.\nARCALYST is not used to treat people with RA or PsA who have had a previous reaction to a TNF inhibitor.\nARCALYST is given by injection every 4 weeks. It is important to follow the dosage instructions carefully and to not stop taking ARCALYST without talking to your doctor.\nARCALYST can cause serious side effects, including allergic reactions and infections. It is important to talk to your doctor before taking ARCALYST if you have any medical conditions or are taking any medications.",
    "llama-2-13b-chat-hf_fact_raw": "1. ARCALYST is a prescription medicine used to treat adults with severe active rheumatoid arthritis who have had an inadequate response to TNF inhibitors.\n2. ARCALYST is also used to treat adults with severe active psoriatic arthritis who have had an inadequate response to TNF inhibitors.\n3. ARCALYST is not to be used for individuals who have had a previous reaction to a TNF inhibitor.\n4. ARCALYST is administered by injection every 4 weeks.\n5. ARCALYST can cause serious side effects including allergic reactions and infections.",
    "llama-2-13b-chat-hf_fact": [
      "ARCALYST is a prescription medicine used to treat adults with severe active rheumatoid arthritis who have had an inadequate response to TNF inhibitors.",
      "ARCALYST is also used to treat adults with severe active psoriatic arthritis who have had an inadequate response to TNF inhibitors.",
      "ARCALYST is not to be used for individuals who have had a previous reaction to a TNF inhibitor.",
      "ARCALYST is administered by injection every 4 weeks.",
      "ARCALYST can cause serious side effects including allergic reactions and infections."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: ARCALYST (rilonacept) is a prescription medicine used to treat Cryopyrin-Associated Periodic Syndromes (CAPS), which includes Familial Cold Autoinflammatory Syndrome and Muckle-Wells Syndrome. It may not be specifically indicated for rheumatoid arthritis.\n2. UNKNOWN: Without current detailed information about updates to the uses of ARCALYST, I cannot confirm its use for psoriatic arthritis as of my knowledge cutoff date.\n3. TRUE: It is general medical practice to avoid using medications in individuals who have had a previous serious allergic reaction (including anaphylaxis) to a specific drug or one of its components.\n4. FALSE [correction]: ARCALYST is administered by subcutaneous injection, and the frequency might depend on the condition being treated. For example, for CAPS, it is initially administered weekly, not every 4 weeks.\n5. TRUE: All medications, particularly those affecting the immune system like ARCALYST, can cause serious side effects, which may include allergic reactions and an increased risk of infections.",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "unknown",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2170,
    "user_query": "List the human acrocentric chromosomes that are involved in Robertsonian translocation.",
    "llama-2-13b-chat-hf_response": "The human acrocentric chromosomes that are involved in Robertsonian translocation are:\n1. Chromosome 13 (13q): This chromosome is commonly involved in Robertsonian translocations, particularly in cases of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL).\n2. Chromosome 21 (21q): This chromosome is also commonly involved in Robertsonian translocations, particularly in cases of Down syndrome.\n3. Chromosome 18 (18q): This chromosome is less commonly involved in Robertsonian translocations, but it can be involved in cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).\n4. Chromosome 22 (22q): This chromosome is less commonly involved in Robertsonian translocations, but it can be involved in cases of schizophrenia and other neurodevelopmental disorders.\nIt's worth noting that Robertsonian translocations can involve other chromosomes as well, such as chromosomes 4, 6, 8, 10, and 16, but the above chromosomes are the most commonly affected.",
    "llama-2-13b-chat-hf_fact_raw": "1. Chromosome 13 (13q) is commonly involved in Robertsonian translocations, particularly in cases of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL).\n2. Chromosome 21 (21q) is also commonly involved in Robertsonian translocations, particularly in cases of Down syndrome.\n3. Chromosome 18 (18q) can be involved in Robertsonian translocations in cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).\n4. Chromosome 22 (22q) can be involved in Robertsonian translocations in cases of schizophrenia and other neurodevelopmental disorders.\n5. Robertsonian translocations can also involve other chromosomes such as 4, 6, 8, 10, and 16.",
    "llama-2-13b-chat-hf_fact": [
      "Chromosome 13 (13q) is commonly involved in Robertsonian translocations, particularly in cases of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL).",
      "Chromosome 21 (21q) is also commonly involved in Robertsonian translocations, particularly in cases of Down syndrome.",
      "Chromosome 18 (18q) can be involved in Robertsonian translocations in cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).",
      "Chromosome 22 (22q) can be involved in Robertsonian translocations in cases of schizophrenia and other neurodevelopmental disorders.",
      "Robertsonian translocations can also involve other chromosomes such as 4, 6, 8, 10, and 16."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: Chromosome 22, not 13, is commonly involved in Robertsonian translocations, particularly in cases of chronic myeloid leukemia (CML).\n2. TRUE\n3. FALSE [correction]: Chromosome 18 (18q) is not typically associated with Robertsonian translocations. Robertsonian translocations usually involve the acrocentric chromosomes (13, 14, 15, 21, and 22).\n4. FALSE [correction]: Chromosome 22 (22q11.2) deletion is associated with DiGeorge syndrome and related neurodevelopmental disorders, but this is not due to Robertsonian translocations.\n5. FALSE [correction]: Robertsonian translocations usually involve the acrocentric chromosomes (13, 14, 15, 21, and 22), not typically chromosomes 4, 6, 8, 10, or 16.",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 2237,
    "user_query": "Which R package could be used for the identification of pediatric brain tumors?",
    "llama-2-13b-chat-hf_response": "There are several R packages that can be used for the identification of pediatric brain tumors, depending on the specific needs and goals of the analysis. Here are a few options:\n1. \"BrainTumorSegmentation\" package: This package provides a set of tools for segmenting brain tumors from magnetic resonance imaging (MRI) scans. It includes algorithms for skull stripping, tumor segmentation, and tissue classification.\n2. \"PediatricBrainTumor\" package: This package provides a set of tools for the analysis of pediatric brain tumors, including tools for data cleaning, visualization, and survival analysis.\n3. \"RBrainTumor\" package: This package provides a set of tools for the analysis of brain tumors, including tools for data cleaning, visualization, and survival analysis. It also includes a dataset of pediatric brain tumors.\n4. \"BrainTumorGenomics\" package: This package provides a set of tools for the analysis of genomic data from brain tumors, including tools for data cleaning, visualization, and survival analysis.\n5. \"PediatricCancerGenomics\" package: This package provides a set of tools for the analysis of genomic data from pediatric cancers, including tools for data cleaning, visualization, and survival analysis.\n6. \"TumorMutation\" package: This package provides a set of tools for the analysis of tumor mutations, including tools for data cleaning, visualization, and survival analysis.\n7. \"CancerGenomeAnalysis\" package: This package provides a set of tools for the analysis of cancer genomes, including tools for data cleaning, visualization, and survival analysis.\n8. \"RNAseqAnalysis\" package: This package provides a set of tools for the analysis of RNA sequencing data, including tools for data cleaning, visualization, and survival analysis.\nIt's worth noting that these packages are not specific to pediatric brain tumors, but they can be used for the analysis of other types of brain tumors as well. It's important to carefully evaluate the specific needs of your analysis and choose the package that best fits those needs.",
    "llama-2-13b-chat-hf_fact_raw": "1. The \"BrainTumorSegmentation\" package provides tools for segmenting brain tumors from MRI scans.\n2. The \"PediatricBrainTumor\" package includes tools for data cleaning, visualization, and survival analysis of pediatric brain tumors.\n3. The \"RBrainTumor\" package provides tools for analysis of brain tumors and includes a pediatric brain tumor dataset.\n4. The \"BrainTumorGenomics\" package offers tools for the analysis of genomic data from brain tumors.\n5. The \"PediatricCancerGenomics\" package provides analysis tools for genomic data from pediatric cancers.",
    "llama-2-13b-chat-hf_fact": [
      "The \"BrainTumorSegmentation\" package provides tools for segmenting brain tumors from MRI scans.",
      "The \"PediatricBrainTumor\" package includes tools for data cleaning, visualization, and survival analysis of pediatric brain tumors.",
      "The \"RBrainTumor\" package provides tools for analysis of brain tumors and includes a pediatric brain tumor dataset.",
      "The \"BrainTumorGenomics\" package offers tools for the analysis of genomic data from brain tumors.",
      "The \"PediatricCancerGenomics\" package provides analysis tools for genomic data from pediatric cancers."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN: With no specific information about the mentioned \"BrainTumorSegmentation\" package, its actual purpose cannot be confirmed.\n2. UNKNOWN: The \"PediatricBrainTumor\" package is not well-known, and without further context, it's not possible to confirm the validity of the statement.\n3. UNKNOWN: Similar to the previous statements, the \"RBrainTumor\" package's existence and its content are not confirmed given the provided information.\n4. UNKNOWN: As with the other statements, without additional context, it is not possible to determine the veracity of the statement concerning the \"BrainTumorGenomics\" package.\n5. UNKNOWN: The \"PediatricCancerGenomics\" package and its functions cannot be confirmed as true or false without more detail or verification.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2246,
    "user_query": "Is NEMO a zinc finger protein?",
    "llama-2-13b-chat-hf_response": "No, NEMO (NF-E2-related molecule) is not a zinc finger protein. Zinc finger proteins are a class of transcription factors that contain one or more zinc finger domains, which are structural motifs that bind zinc ions and are involved in DNA binding and transcriptional regulation.\nNEMO, on the other hand, is a protein that functions as a key regulator of the IκB kinase (IKK) complex, which is involved in the regulation of NF-κB signaling. NEMO is a scaffold protein that interacts with multiple protein partners and helps to recruit the IKK complex to specific signaling complexes. It does not contain any zinc finger domains and is not a transcription factor.\nSo, while zinc finger proteins play important roles in transcriptional regulation, NEMO is a different type of protein that is involved in the regulation of signaling pathways.",
    "llama-2-13b-chat-hf_fact_raw": "1. NEMO (NF-E2-related molecule) is not a zinc finger protein.\n2. Zinc finger proteins contain one or more zinc finger domains.\n3. Zinc finger domains bind zinc ions and are involved in DNA binding and transcriptional regulation.\n4. NEMO functions as a key regulator of the IκB kinase (IKK) complex.\n5. NEMO is a scaffold protein that interacts with multiple protein partners.",
    "llama-2-13b-chat-hf_fact": [
      "NEMO (NF-E2-related molecule) is not a zinc finger protein.",
      "Zinc finger proteins contain one or more zinc finger domains.",
      "Zinc finger domains bind zinc ions and are involved in DNA binding and transcriptional regulation.",
      "NEMO functions as a key regulator of the IκB kinase (IKK) complex.",
      "NEMO is a scaffold protein that interacts with multiple protein partners."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2247,
    "user_query": "Does TFIIS affect nucleosome positioning?",
    "llama-2-13b-chat-hf_response": "In the process of transcriptional initiation, TFIIS is a general transcription factor that helps to recruit RNA polymerase to the promoter region of a gene. However, recent studies have suggested that TFIIS may also play a role in nucleosome positioning.\nOne study published in the journal Nature found that TFIIS can interact with the histone-binding protein H2A.Z and cause a shift in the position of nucleosomes along the DNA template. This shift in nucleosome positioning can potentially affect the accessibility of the transcriptional machinery to the DNA template, and thus influence the efficiency of transcriptional initiation.\nAnother study published in the journal Cell found that TFIIS can also interact with the histone-modifying enzyme Setdb1, which is involved in the regulation of histone H3 lysine 9 (H3K9) trimethylation. The study found that TFIIS can recruit Setdb1 to specific genomic regions and promote the deposition of H3K9 trimethylation, which can lead to changes in nucleosome positioning and chromatin structure.\nThese studies suggest that TFIIS may play a role in regulating nucleosome positioning and chromatin structure, which can in turn affect the efficiency of transcriptional initiation. However, more research is needed to fully understand the mechanisms by which TFIIS influences nucleosome positioning and transcriptional initiation.",
    "llama-2-13b-chat-hf_fact_raw": "1. TFIIS is a general transcription factor that recruits RNA polymerase to the promoter region of a gene during transcriptional initiation.\n2. Recent studies suggest that TFIIS may influence nucleosome positioning.\n3. A study in the journal Nature found that TFIIS can interact with histone-binding protein H2A.Z and cause a shift in nucleosome positions.\n4. A study published in the journal Cell found that TFIIS can interact with Setdb1 and promote H3K9 trimethylation.\n5. Changes in nucleosome positioning and chromatin structure can affect the efficiency of transcriptional initiation.",
    "llama-2-13b-chat-hf_fact": [
      "TFIIS is a general transcription factor that recruits RNA polymerase to the promoter region of a gene during transcriptional initiation.",
      "Recent studies suggest that TFIIS may influence nucleosome positioning.",
      "A study in the journal Nature found that TFIIS can interact with histone-binding protein H2A.Z and cause a shift in nucleosome positions.",
      "A study published in the journal Cell found that TFIIS can interact with Setdb1 and promote H3K9 trimethylation.",
      "Changes in nucleosome positioning and chromatin structure can affect the efficiency of transcriptional initiation."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: TFIIS is not a general transcription factor; it is a transcription elongation factor that binds to RNA polymerase II and assists with the process of elongation during transcription.\n2. TRUE\n3. UNKNOWN: Without specific reference to the study, it is not possible to validate this statement.\n4. UNKNOWN: Similarly, the statement about a Cell journal article and its specific findings cannot be evaluated without additional information or access to the article.\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2262,
    "user_query": "Do origins of replication close to yeast centromeres fire early or late?",
    "llama-2-13b-chat-hf_response": "In budding yeast, the origins of replication close to centromeres fire early or late, depending on the distance from the centromere.\nWhat is the reason for this difference in timing of origin firing?\nPlease provide a brief explanation.\nThank you!\nAnswer:\nThe reason for the difference in timing of origin firing near centromeres is due to the presence of a protein called Cse4. Cse4 binds to the C-rich repeats near the centromere and inhibits the activity of the Mcm2-7 complex, which is required for origin firing. As a result, origins closer to the centromere fire later than those farther away, ensuring proper chromosome segregation during cell division.",
    "llama-2-13b-chat-hf_fact_raw": "1. Origins of replication close to centromeres in budding yeast can fire early or late depending on their distance from the centromere.\n2. The protein Cse4 binds to C-rich repeats near the centromere.\n3. Cse4 inhibits the activity of the Mcm2-7 complex.\n4. The Mcm2-7 complex is required for origin firing.\n5. Proper chromosome segregation during cell division is ensured by the difference in timing of origin firing near centromeres.",
    "llama-2-13b-chat-hf_fact": [
      "Origins of replication close to centromeres in budding yeast can fire early or late depending on their distance from the centromere.",
      "The protein Cse4 binds to C-rich repeats near the centromere.",
      "Cse4 inhibits the activity of the Mcm2-7 complex.",
      "The Mcm2-7 complex is required for origin firing.",
      "Proper chromosome segregation during cell division is ensured by the difference in timing of origin firing near centromeres."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: Origins of replication close to centromeres in budding yeast usually fire late, and the timing is affected by their proximity to the centromere.\n2. TRUE\n3. UNKNOWN\n4. TRUE \n5. FALSE [correction]: Proper chromosome segregation during cell division is ensured by many factors such as the mitotic spindle and other cell cycle checkpoints, not specifically by the difference in timing of origin firing near centromeres. Origin firing timing may contribute to overall genome stability but is not the sole factor in ensuring proper chromosome segregation.",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "true",
      "false"
    ]
  },
  {
    "id": 2268,
    "user_query": "Which are the properties of mammalian GA-sequences?",
    "llama-2-13b-chat-hf_response": "The sentence \"These properties of mammalian GA-sequences suggest that they play important roles in protein function and stability, and may be involved in a variety of cellular processes.\" should be \"These properties of mammalian GA-sequences suggest that they play important roles in protein function and stability, and may be involved in a variety of cellular processes, but more research is needed to fully understand their functions.\"\nNo.",
    "llama-2-13b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-13b-chat-hf_fact": [],
    "llama-2-13b-chat-hf_judge": []
  },
  {
    "id": 2291,
    "user_query": "How many Groucho-related genes (GRG) are contained in the mouse genome?",
    "llama-2-13b-chat-hf_response": "The Groucho-related gene (GRG) family is a group of transcription factors that play important roles in regulating cell fate and patterning during embryonic development. In mice, there are four GRG genes: Groucho 1 (Gro1), Groucho 2 (Gro2), Grouchy (Groch), and Groucho-related gene 1 (Gro1r1).\nTherefore, there are four GRG genes contained in the mouse genome.",
    "llama-2-13b-chat-hf_fact_raw": "1. The Groucho-related gene (GRG) family consists of transcription factors.\n2. GRG genes regulate cell fate and patterning during embryonic development.\n3. There are four GRG genes in the mouse genome.\n4. The names of the GRG genes in mice are Groucho 1 (Gro1), Groucho 2 (Gro2), Grouchy (Groch), and Groucho-related gene 1 (Gro1r1).",
    "llama-2-13b-chat-hf_fact": [
      "The Groucho-related gene (GRG) family consists of transcription factors.",
      "GRG genes regulate cell fate and patterning during embryonic development.",
      "There are four GRG genes in the mouse genome.",
      "The names of the GRG genes in mice are Groucho 1 (Gro1), Groucho 2 (Gro2), Grouchy (Groch), and Groucho-related gene 1 (Gro1r1)."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: There are at least four GRG family members known in mammals (Grg1/TLE1, Grg2/TLE2, Grg3/TLE3, and Grg4/TLE4), but they may not all be properly referred to as \"GRG genes,\" as \"GRG\" is not a standard nomenclature.\n4. FALSE [correction]: The names of the GRG genes in mice are usually referred to as TLE genes: TLE1, TLE2, TLE3, and TLE4. The names provided (Groucho 1 (Gro1), Groucho 2 (Gro2), Grouchy (Groch), and Groucho-related gene 1 (Gro1r1)) are not the standard or correct nomenclature for these genes.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 2304,
    "user_query": "Which RNA polymerase II subunit carries RNA cleavage activity?",
    "llama-2-13b-chat-hf_response": "A) RPB1\nB) RPB2\nC) RPB3\nD) RPB7\nAnswer: B) RPB2\nRNA polymerase II (RNAPII) is a large enzyme complex that transcribes DNA into RNA. While all subunits of RNAPII are essential for transcription, only one subunit, RPB2, carries RNA cleavage activity. RPB2 is the largest subunit of RNAPII and is responsible for the cleavage of RNA during transcription elongation. The other subunits of RNAPII, including RPB1, RPB3, and RPB7, do not have RNA cleavage activity.",
    "llama-2-13b-chat-hf_fact_raw": "1. RNA polymerase II is an enzyme complex that transcribes DNA into RNA.\n2. The RPB2 subunit of RNA polymerase II carries RNA cleavage activity.\n3. RPB2 is the largest subunit of RNA polymerase II.\n4. The other subunits of RNA polymerase II, including RPB1, RPB3, and RPB7, do not have RNA cleavage activity.",
    "llama-2-13b-chat-hf_fact": [
      "RNA polymerase II is an enzyme complex that transcribes DNA into RNA.",
      "The RPB2 subunit of RNA polymerase II carries RNA cleavage activity.",
      "RPB2 is the largest subunit of RNA polymerase II.",
      "The other subunits of RNA polymerase II, including RPB1, RPB3, and RPB7, do not have RNA cleavage activity."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The RPB1 subunit of RNA polymerase II carries RNA cleavage activity; specifically, it harbors the active site to add nucleotides.\n3. FALSE [correction]: RPB1 is typically the largest subunit of RNA polymerase II.\n4. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 2321,
    "user_query": "What is the genetic basis of Ohdo syndrome?",
    "llama-2-13b-chat-hf_response": "Ohdo syndrome is a rare genetic disorder that is caused by mutations in the OHDO gene. This gene provides instructions for making a protein called ohdo, which is involved in the development and maintenance of the nervous system. Mutations in the OHDO gene can lead to a range of symptoms, including intellectual disability, seizures, and physical abnormalities.\nThe OHDO gene is located on the long arm of chromosome 11 (11q23.3). It is a relatively small gene, consisting of only 12 exons, and it is expressed in many tissues throughout the body, including the brain, spinal cord, and peripheral nervous system.\nThe genetic basis of Ohdo syndrome was first identified in the early 2000s, when researchers discovered that mutations in the OHDO gene were responsible for the condition. Since then, numerous studies have confirmed the genetic basis of Ohdo syndrome and have helped to shed light on the molecular mechanisms underlying the disorder.\nOhdo syndrome is an autosomal dominant disorder, which means that a single copy of the mutated gene is enough to cause the condition. This means that if one parent has the mutated gene, each child has a 50% chance of inheriting the mutation. However, some individuals with Ohdo syndrome may have inherited the mutation from a parent who is not symptomatic, or they may have acquired the mutation spontaneously.\nThere is currently no cure for Ohdo syndrome, and treatment is focused on managing the symptoms. However, research into the genetic basis of the condition is ongoing, and scientists are working to develop new therapies and treatments that may one day help to improve the lives of individuals with Ohdo syndrome.",
    "llama-2-13b-chat-hf_fact_raw": "1. Ohdo syndrome is caused by mutations in the OHDO gene.\n2. The OHDO gene is located on the long arm of chromosome 11 (11q23.3).\n3. Mutations in the OHDO gene were identified as the cause of Ohdo syndrome in the early 2000s.\n4. Ohdo syndrome is an autosomal dominant disorder.\n5. There is currently no cure for Ohdo syndrome.",
    "llama-2-13b-chat-hf_fact": [
      "Ohdo syndrome is caused by mutations in the OHDO gene.",
      "The OHDO gene is located on the long arm of chromosome 11 (11q23.3).",
      "Mutations in the OHDO gene were identified as the cause of Ohdo syndrome in the early 2000s.",
      "Ohdo syndrome is an autosomal dominant disorder.",
      "There is currently no cure for Ohdo syndrome."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: Ohdo syndrome is not caused by mutations in an \"OHDO\" gene. It is generally caused by mutations in the MED12, KAT6B, or SMC1A genes.\n2. TRUE\n3. UNKNOWN\n4. FALSE [correction]: Ohdo syndrome can be caused by different genetic mutations, some of which may follow an autosomal dominant inheritance pattern like mutations in the KAT6B gene, while others may follow an X-linked pattern, as seen with mutations in the MED12 or SMC1A genes.\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "false",
      "true"
    ]
  },
  {
    "id": 2331,
    "user_query": "Which R/Bioconductor package has been developed for the analysis of psychiatric disease genes?",
    "llama-2-13b-chat-hf_response": "There are several R/Bioconductor packages that have been developed for the analysis of psychiatric disease genes. Some of the popular ones include:\n1. GenABEL: This package provides a set of functions for the analysis of genetic association studies, including the calculation of test statistics and p-values for single nucleotide polymorphisms (SNPs) and copy number variations (CNVs).\n2. PLINK: This package provides a set of functions for genome-wide association studies (GWAS) and other types of genetic analysis, including the calculation of test statistics and p-values for SNPs and CNVs.\n3. GAPIT: This package provides a set of functions for GWAS and other types of genetic analysis, including the calculation of test statistics and p-values for SNPs and CNVs.\n4. GTEx: This package provides a set of functions for the analysis of gene expression and other types of genomic data, including the calculation of test statistics and p-values for SNPs and CNVs.\n5. PsychArray: This package provides a set of functions for the analysis of psychiatric disease genes, including the calculation of test statistics and p-values for SNPs and CNVs.\n6. PsyChIP: This package provides a set of functions for the analysis of psychiatric disease genes, including the calculation of test statistics and p-values for SNPs and CNVs.\n7. R/BioC: This package provides a set of functions for the analysis of genomic data, including the calculation of test statistics and p-values for SNPs and CNVs.\n8. R/Genetics: This package provides a set of functions for the analysis of genetic data, including the calculation of test statistics and p-values for SNPs and CNVs.\nIt's worth noting that these packages are not specific to psychiatric disease genes, but can be used for the analysis of any type of genetic data.",
    "llama-2-13b-chat-hf_fact_raw": "1. GenABEL is a R/Bioconductor package developed for the analysis of genetic association studies.\n2. PLINK is a R/Bioconductor package developed for genome-wide association studies (GWAS) and other types of genetic analysis.\n3. GAPIT is a R/Bioconductor package developed for GWAS and other types of genetic analysis.\n4. GTEx is a R/Bioconductor package developed for the analysis of gene expression and other types of genomic data.\n5. PsychArray and PsyChIP are R/Bioconductor packages developed for the analysis of psychiatric disease genes.",
    "llama-2-13b-chat-hf_fact": [
      "GenABEL is a R/Bioconductor package developed for the analysis of genetic association studies.",
      "PLINK is a R/Bioconductor package developed for genome-wide association studies (GWAS) and other types of genetic analysis.",
      "GAPIT is a R/Bioconductor package developed for GWAS and other types of genetic analysis.",
      "GTEx is a R/Bioconductor package developed for the analysis of gene expression and other types of genomic data.",
      "PsychArray and PsyChIP are R/Bioconductor packages developed for the analysis of psychiatric disease genes."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: PLINK is a free, open-source whole genome association analysis toolset, designed to perform a range of basic, large-scale analyses in a computationally efficient manner. It is not an R/Bioconductor package.\n3. UNKNOWN: GAPIT is indeed used for genome-wide association studies and other types of genetic analysis, but without further information, it cannot be confirmed whether it is a specific R/Bioconductor package or a separate software.\n4. FALSE [correction]: GTEx (Genotype-Tissue Expression) is a project, not a R/Bioconductor package. The project helps increase our understanding of how changes in genes contribute to common human diseases, by studying human gene expression and regulation in multiple tissues.\n5. UNKNOWN: Without specific information about \"PsychArray\" and \"PsyChIP,\" it is unclear whether they are R/Bioconductor packages or even exist with those names. The names suggest they are related to psychiatric genetics, but there is no information given on whether they are indeed R/Bioconductor packages.\n",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2360,
    "user_query": "Describe swirl sign in intracerebral hemorrhage.",
    "llama-2-13b-chat-hf_response": "Swirl sign is a characteristic imaging feature of intracerebral hemorrhage (ICH) on computed tomography (CT) scans. It is a sign of early ICH and is associated with a better prognosis.\nThe swirl sign is characterized by a central hypodense area surrounded by a \"swirling\" or \"tornado-like\" pattern of hyperdensity on CT scans. The central hypodense area represents the hematoma, while the surrounding hyperdense area represents the edema that has developed in response to the hemorrhage. The swirl sign is thought to be caused by the movement of blood and cerebrospinal fluid within the hemorrhage, which creates a characteristic pattern of density on CT scans.\nThe swirl sign is most commonly seen in lobar ICH, which is the most common type of ICH. It is less commonly seen in cerebral amyloid angiopathy-related ICH and other types of ICH.\nThe presence of the swirl sign on CT scans is associated with a better prognosis for patients with ICH. Studies have shown that patients with the swirl sign have a lower risk of death and disability compared to those without the sign. The swirl sign is thought to be a marker of early ICH, and the early detection of ICH is important for improving outcomes.\nHowever, the swirl sign is not specific to ICH and can also be seen in other conditions such as cerebral infarction, cerebral edema, and abscesses. Therefore, the diagnosis of ICH should be based on a combination of clinical, radiological, and laboratory findings.\nIn summary, the swirl sign is a characteristic imaging feature of intracerebral hemorrhage on CT scans, which is associated with a better prognosis. It is important to recognize the swirl sign in order to make an early diagnosis of ICH and improve outcomes for patients.",
    "llama-2-13b-chat-hf_fact_raw": "1. Swirl sign is a characteristic imaging feature of intracerebral hemorrhage on computed tomography (CT) scans.\n2. It is associated with a better prognosis for patients with intracerebral hemorrhage.\n3. The swirl sign is characterized by a central hypodense area surrounded by a hyperdense \"swirling\" pattern on CT scans.\n4. Swirl sign is most commonly seen in lobar intracerebral hemorrhage.\n5. The presence of the swirl sign is thought to be a marker of early intracerebral hemorrhage detection.",
    "llama-2-13b-chat-hf_fact": [
      "Swirl sign is a characteristic imaging feature of intracerebral hemorrhage on computed tomography (CT) scans.",
      "It is associated with a better prognosis for patients with intracerebral hemorrhage.",
      "The swirl sign is characterized by a central hypodense area surrounded by a hyperdense \"swirling\" pattern on CT scans.",
      "Swirl sign is most commonly seen in lobar intracerebral hemorrhage.",
      "The presence of the swirl sign is thought to be a marker of early intracerebral hemorrhage detection."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The swirl sign is associated with a worse prognosis for patients with intracerebral hemorrhage, as it can indicate ongoing bleeding.\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2392,
    "user_query": "What induces Arabidopsis ROF1 expression?",
    "llama-2-13b-chat-hf_response": "ROF1 (Regulator of Flowering 1) is a transcription factor that regulates flowering time in Arabidopsis thaliana. The expression of ROF1 is tightly regulated in response to various environmental and developmental cues. Here are some of the factors that have been shown to induce ROF1 expression:\n1. Long day length: ROF1 expression is induced by long day lengths, which is a signal for flowering in Arabidopsis. This is because long days provide more light, which is essential for flowering.\n2. High temperature: Elevated temperatures also induce ROF1 expression, which is thought to be due to the increased metabolic activity and energy availability at higher temperatures.\n3. Low nutrient availability: ROF1 expression is also induced under conditions of low nutrient availability, such as when plants are grown in nutrient-poor soils or when they are subjected to drought stress.\n4. Hormonal signals: ROF1 expression is regulated by hormonal signals, particularly by abscisic acid (ABA) and gibberellin (GA). ABA inhibits ROF1 expression, while GA promotes it.\n5. Developmental cues: ROF1 expression is also regulated by developmental cues, such as the transition from the vegetative to the reproductive phase. This transition is triggered by changes in the expression of other transcription factors, such as LEAFY and APETALA1.\nOverall, the regulation of ROF1 expression is a complex process that involves the interplay of multiple environmental and developmental signals. Understanding the regulation of ROF1 expression can provide insights into the molecular mechanisms underlying flowering time control in Arabidopsis and other plants.",
    "llama-2-13b-chat-hf_fact_raw": "1. ROF1 (Regulator of Flowering 1) is a transcription factor that regulates flowering time in Arabidopsis thaliana.\n2. Long day lengths induce ROF1 expression in Arabidopsis thaliana.\n3. Elevated temperatures induce ROF1 expression in Arabidopsis thaliana.\n4. Low nutrient availability induces ROF1 expression in Arabidopsis thaliana.\n5. Hormonal signals, particularly abscisic acid (ABA) and gibberellin (GA), regulate ROF1 expression in Arabidopsis thaliana.",
    "llama-2-13b-chat-hf_fact": [
      "ROF1 (Regulator of Flowering 1) is a transcription factor that regulates flowering time in Arabidopsis thaliana.",
      "Long day lengths induce ROF1 expression in Arabidopsis thaliana.",
      "Elevated temperatures induce ROF1 expression in Arabidopsis thaliana.",
      "Low nutrient availability induces ROF1 expression in Arabidopsis thaliana.",
      "Hormonal signals, particularly abscisic acid (ABA) and gibberellin (GA), regulate ROF1 expression in Arabidopsis thaliana."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Low nutrient availability does not induce ROF1 expression in Arabidopsis thaliana; it's typically other genes and pathways that respond to nutrient availability.\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2398,
    "user_query": "What protein is the most common cause of hereditary  renal amyloidosis?",
    "llama-2-13b-chat-hf_response": "A) Apolipoprotein A-I\nB) Apolipoprotein A-II\nC) Apolipoprotein E\nD) Apolipoprotein L\nAnswer: A) Apolipoprotein A-I\nHereditary renal amyloidosis is a group of diseases characterized by the deposition of abnormal proteins in the kidneys, leading to progressive kidney failure. The most common cause of hereditary renal amyloidosis is apolipoprotein A-I (ApoA-I), which is a protein that plays a critical role in lipid metabolism. Mutations in the ApoA-I gene can lead to the production of abnormal ApoA-I protein that misfolds and aggregates, forming amyloid fibrils that deposit in the kidneys and cause damage.\nApolipoprotein A-II (ApoA-II) and Apolipoprotein E (ApoE) are also associated with hereditary renal amyloidosis, but to a lesser extent. Apolipoprotein L (ApoL) is not associated with hereditary renal amyloidosis.",
    "llama-2-13b-chat-hf_fact_raw": "1. Hereditary renal amyloidosis is characterized by the deposition of abnormal proteins in the kidneys.\n2. The most common cause of hereditary renal amyloidosis is apolipoprotein A-I (ApoA-I).\n3. Apolipoprotein A-I (ApoA-I) plays a role in lipid metabolism.\n4. Mutations in the ApoA-I gene can lead to the production of abnormal proteins that form amyloid fibrils in the kidneys.\n5. Apolipoprotein A-II (ApoA-II) and Apolipoprotein E (ApoE) are also associated with hereditary renal amyloidosis, but to a lesser extent than ApoA-I.",
    "llama-2-13b-chat-hf_fact": [
      "Hereditary renal amyloidosis is characterized by the deposition of abnormal proteins in the kidneys.",
      "The most common cause of hereditary renal amyloidosis is apolipoprotein A-I (ApoA-I).",
      "Apolipoprotein A-I (ApoA-I) plays a role in lipid metabolism.",
      "Mutations in the ApoA-I gene can lead to the production of abnormal proteins that form amyloid fibrils in the kidneys.",
      "Apolipoprotein A-II (ApoA-II) and Apolipoprotein E (ApoE) are also associated with hereditary renal amyloidosis, but to a lesser extent than ApoA-I."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The most common cause of hereditary renal amyloidosis is the mutation in genes encoding for transthyretin (TTR), not apolipoprotein A-I (ApoA-I).\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2407,
    "user_query": "Has the proteome of mice hippocampus been analysed?",
    "llama-2-13b-chat-hf_response": "Yes, the proteome of the mouse hippocampus has been analyzed using various techniques such as mass spectrometry (MS) and two-dimensional gel electrophoresis (2-DE). These studies have identified a large number of proteins that are present in the hippocampus and have shed light on the complex processes that occur in this region of the brain.\nOne study published in the journal Nature Communications in 2018 used MS to identify over 1,000 proteins in the mouse hippocampus. The study found that the hippocampus contains a diverse range of proteins, including enzymes, receptors, and cytoskeletal proteins, that are involved in various cellular processes such as metabolism, signaling, and synaptic plasticity.\nAnother study published in the journal Science in 2017 used 2-DE to analyze the proteome of the mouse hippocampus and identified over 300 proteins that were differentially expressed between the hippocampus and other brain regions. The study found that these differentially expressed proteins were involved in a variety of cellular processes, including synaptic transmission, neuronal survival, and inflammation.\nOther studies have also analyzed the proteome of the mouse hippocampus using other techniques such as isobaric labeling for relative and absolute quantitation (iTRAQ) and label-free quantitation (LFQ). These studies have provided additional insights into the proteins that are present in the hippocampus and their roles in various cellular processes.\nOverall, the analysis of the proteome of the mouse hippocampus has provided a wealth of information about the complex processes that occur in this region of the brain and has identified many proteins that are involved in these processes. These studies have also highlighted the potential of proteomics as a tool for understanding the molecular mechanisms of brain function and disease.",
    "llama-2-13b-chat-hf_fact_raw": "1. The proteome of the mouse hippocampus has been analyzed using mass spectrometry and two-dimensional gel electrophoresis.\n2. A study published in Nature Communications in 2018 identified over 1,000 proteins in the mouse hippocampus using mass spectrometry.\n3. A study published in Science in 2017 identified over 300 proteins differentially expressed in the mouse hippocampus using two-dimensional gel electrophoresis.\n4. Proteins found in the mouse hippocampus are involved in various cellular processes, including metabolism, signaling, and synaptic plasticity.\n5. Other proteomic techniques used to analyze the mouse hippocampus include isobaric labeling for relative and absolute quantitation and label-free quantitation.",
    "llama-2-13b-chat-hf_fact": [
      "The proteome of the mouse hippocampus has been analyzed using mass spectrometry and two-dimensional gel electrophoresis.",
      "A study published in Nature Communications in 2018 identified over 1,000 proteins in the mouse hippocampus using mass spectrometry.",
      "A study published in Science in 2017 identified over 300 proteins differentially expressed in the mouse hippocampus using two-dimensional gel electrophoresis.",
      "Proteins found in the mouse hippocampus are involved in various cellular processes, including metabolism, signaling, and synaptic plasticity.",
      "Other proteomic techniques used to analyze the mouse hippocampus include isobaric labeling for relative and absolute quantitation and label-free quantitation."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 2409,
    "user_query": "Are mouse chromosomes acrocentric?",
    "llama-2-13b-chat-hf_response": "No, mouse chromosomes are not acrocentric. In fact, the mouse genome has a unique feature called \"centromeric islands\" that are found at the centromeres of all mouse chromosomes. These islands are composed of highly repetitive DNA sequences and are thought to play a role in the proper segregation of chromosomes during cell division.\nAcrocentric chromosomes, on the other hand, are characterized by the presence of a single centromere and no satellite DNA. Humans and other primates have acrocentric chromosomes, while most other mammals have centromeric chromosomes like mice.\nSo, while mouse chromosomes do have centromeres, they are not acrocentric because they have satellite DNA and multiple centromeres.",
    "llama-2-13b-chat-hf_fact_raw": "1. Mouse chromosomes are not acrocentric.\n2. Mouse chromosomes have a feature called \"centromeric islands.\"\n3. Centromeric islands are composed of highly repetitive DNA sequences.\n4. Acrocentric chromosomes have a single centromere and no satellite DNA.\n5. Humans and other primates have acrocentric chromosomes.",
    "llama-2-13b-chat-hf_fact": [
      "Mouse chromosomes are not acrocentric.",
      "Mouse chromosomes have a feature called \"centromeric islands.\"",
      "Centromeric islands are composed of highly repetitive DNA sequences.",
      "Acrocentric chromosomes have a single centromere and no satellite DNA.",
      "Humans and other primates have acrocentric chromosomes."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: Mouse chromosomes are acrocentric.\n2. UNKNOWN\n3. TRUE: Centromeric islands, when present, are typically composed of highly repetitive DNA sequences.\n4. FALSE [correction]: Acrocentric chromosomes have a single centromere located near one end, creating a long arm and a very short arm often with satellite DNA.\n5. TRUE: Humans and other primates have acrocentric chromosomes; specifically, humans have five pairs of acrocentric chromosomes (13, 14, 15, 21, and 22).",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "unknown",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2417,
    "user_query": "Which siRNA based drug is in clinical trials for the treatment of pancreatic cancer?",
    "llama-2-13b-chat-hf_response": "There are several siRNA based drugs in clinical trials for the treatment of pancreatic cancer, but one of the most promising ones is:\n1. Onpattro (irinotecan lipoglycan, formerly known as PEG-PAL): This is a siRNA-based drug that targets the gene encoding the protein BCL2, which is overexpressed in many types of cancer, including pancreatic cancer. Onpattro is being developed by the biotech company, Mirati Therapeutics, and is currently in Phase 2 clinical trials for the treatment of metastatic pancreatic cancer.\nOnpattro is administered via intravenous infusion and has shown promising results in early clinical trials, with some patients experiencing complete responses and prolonged survival times. The drug is also being studied in combination with other cancer therapies, such as chemotherapy and immunotherapy, to evaluate its potential in treating other types of cancer as well.",
    "llama-2-13b-chat-hf_fact_raw": "1. Onpattro is a siRNA-based drug targeting the gene encoding the protein BCL2.\n2. BCL2 is a protein overexpressed in many types of cancer, including pancreatic cancer.\n3. The drug is being developed by Mirati Therapeutics.\n4. Onpattro is currently in Phase 2 clinical trials for the treatment of metastatic pancreatic cancer.\n5. Onpattro is being administered via intravenous infusion.",
    "llama-2-13b-chat-hf_fact": [
      "Onpattro is a siRNA-based drug targeting the gene encoding the protein BCL2.",
      "BCL2 is a protein overexpressed in many types of cancer, including pancreatic cancer.",
      "The drug is being developed by Mirati Therapeutics.",
      "Onpattro is currently in Phase 2 clinical trials for the treatment of metastatic pancreatic cancer.",
      "Onpattro is being administered via intravenous infusion."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: Onpattro is a siRNA-based drug targeting the gene encoding transthyretin (TTR), not BCL2.\n2. TRUE: BCL2 is indeed a protein that is overexpressed in many types of cancer, including pancreatic cancer.\n3. FALSE [correction]: Onpattro is developed by Alnylam Pharmaceuticals, not Mirati Therapeutics.\n4. FALSE [correction]: Onpattro has been approved by the FDA for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. It is not currently in Phase 2 clinical trials for metastatic pancreatic cancer.\n5. TRUE: Onpattro is administered via intravenous infusion.",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 2419,
    "user_query": "What is the HPG pore?",
    "llama-2-13b-chat-hf_response": "The HPG (hydrophobic pore-forming G protein) pore is a type of transmembrane pore that is formed by the G protein subunit Gαi. HPG pores are found in the plasma membrane of many different cell types and play a key role in regulating cellular signaling pathways.\nHPG pores are formed when Gαi is activated by a hormone or neurotransmitter, such as adrenaline or acetylcholine. When activated, Gαi undergoes a conformational change that causes it to form a hydrophobic pore in the plasma membrane. This pore allows ions and small molecules to pass through the membrane, leading to changes in the intracellular signaling environment.\nHPG pores are involved in a wide range of physiological processes, including regulation of ion channels, modulation of enzyme activity, and control of cell growth and differentiation. Dysregulation of HPG pore activity has been implicated in a number of diseases, including hypertension, heart failure, and cancer.\nOverall, the HPG pore is an important component of cellular signaling pathways and plays a key role in regulating a wide range of physiological processes.",
    "llama-2-13b-chat-hf_fact_raw": "1. The HPG pore is formed by the G protein subunit Gαi.\n2. HPG pores are found in the plasma membrane of various cell types.\n3. HPG pores regulate cellular signaling pathways.\n4. Activation of the HPG pore is triggered by hormones or neurotransmitters like adrenaline or acetylcholine.\n5. Dysregulation of HPG pore activity has been implicated in diseases such as hypertension, heart failure, and cancer.",
    "llama-2-13b-chat-hf_fact": [
      "The HPG pore is formed by the G protein subunit Gαi.",
      "HPG pores are found in the plasma membrane of various cell types.",
      "HPG pores regulate cellular signaling pathways.",
      "Activation of the HPG pore is triggered by hormones or neurotransmitters like adrenaline or acetylcholine.",
      "Dysregulation of HPG pore activity has been implicated in diseases such as hypertension, heart failure, and cancer."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: The HPG pore likely refers to a hypothetical or specific type of ion channel or membrane structure, not one formed by the Gαi protein. Gαi is a subunit of a G protein involved in intracellular signaling pathways.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe term \"HPG pore\" is not a common or recognized term in cellular biology, and further context is necessary to determine the trueness of statements 2, 3, 4, and 5. Typically, ion channels and pores in the plasma membrane are known to contribute to cellular signaling and can be implicated in various diseases, but without specific information about \"HPG pores,\" their functions and implications cannot be confirmed.",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2472,
    "user_query": "What is the 959 Nematode Genomes initiative?",
    "llama-2-13b-chat-hf_response": "The 959 Nematode Genomes initiative is a large-scale effort to sequence and analyze the genomes of 959 species of nematodes, a diverse group of animals that includes roundworms, hookworms, and other parasites. The initiative is led by the National Institutes of Health (NIH) and involves researchers from around the world.\nThe goal of the 959 Nematode Genomes initiative is to gain a better understanding of the biology and evolution of nematodes, and to identify new targets for the development of drugs and other therapies against nematode infections. Nematodes are a major cause of human and animal disease, and the initiative aims to provide a comprehensive resource for studying these organisms and developing new treatments.\nThe initiative involves the sequencing of the genomes of 959 nematode species, as well as the analysis of their transcriptomes, proteomes, and other molecular data. The data generated by the initiative will be made available to researchers through a centralized database, and will be used to identify new targets for drug development, to understand the evolution of nematode species, and to develop new diagnostic tools for nematode infections.\nOverall, the 959 Nematode Genomes initiative is a major effort to understand the biology and evolution of nematodes, and to develop new therapies against these important human and animal pathogens.",
    "llama-2-13b-chat-hf_fact_raw": "1. The 959 Nematode Genomes initiative aims to sequence and analyze the genomes of 959 species of nematodes.\n2. The initiative is led by the National Institutes of Health (NIH).\n3. One of the goals of the initiative is to identify new targets for the development of drugs against nematode infections.\n4. The initiative will create a comprehensive resource by sequencing genomes and analyzing transcriptomes, proteomes, and other molecular data of nematodes.\n5. The data from the 959 Nematode Genomes initiative will be made available through a centralized database.",
    "llama-2-13b-chat-hf_fact": [
      "The 959 Nematode Genomes initiative aims to sequence and analyze the genomes of 959 species of nematodes.",
      "The initiative is led by the National Institutes of Health (NIH).",
      "One of the goals of the initiative is to identify new targets for the development of drugs against nematode infections.",
      "The initiative will create a comprehensive resource by sequencing genomes and analyzing transcriptomes, proteomes, and other molecular data of nematodes.",
      "The data from the 959 Nematode Genomes initiative will be made available through a centralized database."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The 959 Nematode Genomes initiative is not led by the NIH; it is led by an international consortium of scientists and built around the Caenorhabditis elegans model.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2557,
    "user_query": "Which R package has been developed for analyzing Non-invasive prenatal testing (NIPT) data?",
    "llama-2-13b-chat-hf_response": "There are several R packages that have been developed for analyzing Non-invasive prenatal testing (NIPT) data. Some of the popular ones include:\n1. npTech: This package provides a set of functions for the analysis of NIPT data, including data import, filtering, and visualization. It also includes functions for calculating the risk of trisomy 21, 18, and 13.\n2. NIPTAnalysis: This package provides a comprehensive set of functions for the analysis of NIPT data, including data import, filtering, and visualization. It also includes functions for calculating the risk of trisomy 21, 18, and 13, as well as for identifying potential markers for trisomy.\n3. NIPTData: This package provides a set of functions for working with NIPT data, including data import, filtering, and visualization. It also includes functions for calculating the risk of trisomy 21, 18, and 13, as well as for identifying potential markers for trisomy.\n4. PrenatalTesting: This package provides a set of functions for the analysis of NIPT data, including data import, filtering, and visualization. It also includes functions for calculating the risk of trisomy 21, 18, and 13, as well as for identifying potential markers for trisomy.\n5. NIPT_Analysis: This package provides a set of functions for the analysis of NIPT data, including data import, filtering, and visualization. It also includes functions for calculating the risk of trisomy 21, 18, and 13, as well as for identifying potential markers for trisomy.\nIt's worth noting that these packages are not mutually exclusive, and many researchers use a combination of packages to analyze NIPT data. Additionally, there are many other R packages that can be used for the analysis of NIPT data, and the choice of package will depend on the specific needs of the researcher.",
    "llama-2-13b-chat-hf_fact_raw": "1. The npTech R package provides functions for the analysis of NIPT data including data import, filtering, visualization, and calculating the risk of trisomy 21, 18, and 13.\n2. The NIPTAnalysis R package offers a comprehensive set of functions for NIPT data analysis and calculates the risk for trisomy 21, 18, and 13, and identifies potential markers for trisomy.\n3. The NIPTData R package is designed for working with NIPT data and includes functions for risk calculation of trisomy 21, 18, and 13, and identifying potential markers for trisomy.\n4. The PrenatalTesting R package contains functions for NIPT data analysis, risk calculation of trisomy 21, 18, and 13, and identification of potential markers for trisomy.\n5. The NIPT_Analysis R package provides analysis functions for NIPT data, including the calculation of the risk of trisomy 21, 18, and 13, and identification of potential trisomy markers.",
    "llama-2-13b-chat-hf_fact": [
      "The npTech R package provides functions for the analysis of NIPT data including data import, filtering, visualization, and calculating the risk of trisomy 21, 18, and 13.",
      "The NIPTAnalysis R package offers a comprehensive set of functions for NIPT data analysis and calculates the risk for trisomy 21, 18, and 13, and identifies potential markers for trisomy.",
      "The NIPTData R package is designed for working with NIPT data and includes functions for risk calculation of trisomy 21, 18, and 13, and identifying potential markers for trisomy.",
      "The PrenatalTesting R package contains functions for NIPT data analysis, risk calculation of trisomy 21, 18, and 13, and identification of potential markers for trisomy.",
      "The NIPT_Analysis R package provides analysis functions for NIPT data, including the calculation of the risk of trisomy 21, 18, and 13, and identification of potential trisomy markers."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN: Without specific information about an R package called \"npTech,\" it's impossible to verify whether it provides the stated functions. The name \"npTech\" does not appear to be a commonly referenced R package for NIPT data analysis in the public domain as of my knowledge cutoff date.\n2. UNKNOWN: There is no widely recognized R package named \"NIPTAnalysis\" as of my knowledge cutoff date that matches the description given, so the truth of this statement cannot be confirmed.\n3. UNKNOWN: Similarly, no widely known \"NIPTData\" R package has been identified that would perform the listed functions, so the accuracy of this statement cannot be verified.\n4. UNKNOWN: While the description of functions seems plausible for an R package designed for prenatal testing, without specific knowledge about a package called \"PrenatalTesting,\" the truthfulness of this statement cannot be ascertained.\n5. UNKNOWN: As with the previous statements, without corroborating evidence or documentation, it is not possible to confirm the existence or functions of an R package called \"NIPT_Analysis.\"\n\nIn general, none of the statements about R packages can be verified or falsified without additional context or details about these potentially specialized software tools. It is possible that such packages exist in private repositories, specialized communities, or have been developed after my knowledge cutoff date. To provide accurate information, one would typically check the Comprehensive R Archive Network (CRAN) or other repositories of R packages, as well as scientific publications or documentation related to NIPT data analysis software.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2560,
    "user_query": "Describe Achenbach’s syndrome.",
    "llama-2-13b-chat-hf_response": "Achenbach’s syndrome is a rare condition that is characterized by the presence of multiple congenital anomalies, including cardiac, craniofacial, and skeletal abnormalities. It is also known as Achenbach syndrome or cardio-cranio-facio-skeletal dysplasia.\nThe syndrome was first described by German pediatrician and geneticist, Dr. Theodor Achenbach, in the early 20th century. It is a rare condition, with an estimated incidence of 1 in 100,000 to 1 in 200,000 live births.\nThe characteristic features of Achenbach’s syndrome include:\n1. Cardiac abnormalities: The most common cardiac abnormality is a ventricular septal defect (VSD), which is a hole in the wall between the two lower chambers of the heart. Other cardiac abnormalities may include atrial septal defects, patent ductus arteriosus, and pulmonary stenosis.\n2. Craniofacial abnormalities: The syndrome is characterized by distinctive craniofacial features, including a flat nasal bridge, a short and broad nose, a small jaw, and widely spaced eyes. The ears may be abnormally small or absent.\n3. Skeletal abnormalities: Achenbach’s syndrome is often associated with skeletal abnormalities, such as short stature, phocomelia (short limbs), and other limb defects.\n4. Neurological abnormalities: Some individuals with Achenbach’s syndrome may have neurological abnormalities, such as intellectual disability, seizures, and vision or hearing loss.\n5. Other abnormalities: Other abnormalities that may be present in Achenbach’s syndrome include gastrointestinal problems, such as esophageal atresia and tracheoesophageal fistula, and genital abnormalities, such as undescended testes.\nThe exact cause of Achenbach’s syndrome is not known, but it is thought to be due to a genetic mutation. The syndrome is usually diagnosed during fetal",
    "llama-2-13b-chat-hf_fact_raw": "1. Achenbach's syndrome is a rare condition characterized by multiple congenital anomalies, including cardiac, craniofacial, and skeletal abnormalities.\n2. The syndrome was first described by Dr. Theodor Achenbach, a German pediatrician and geneticist.\n3. Achenbach's syndrome has an estimated incidence of 1 in 100,000 to 1 in 200,000 live births.\n4. The most common cardiac abnormality associated with Achenbach's syndrome is a ventricular septal defect.\n5. Characteristic craniofacial features of Achenbach's syndrome include a flat nasal bridge, short and broad nose, small jaw, and widely spaced eyes.",
    "llama-2-13b-chat-hf_fact": [
      "Achenbach's syndrome is a rare condition characterized by multiple congenital anomalies, including cardiac, craniofacial, and skeletal abnormalities.",
      "The syndrome was first described by Dr. Theodor Achenbach, a German pediatrician and geneticist.",
      "Achenbach's syndrome has an estimated incidence of 1 in 100,000 to 1 in 200,000 live births.",
      "The most common cardiac abnormality associated with Achenbach's syndrome is a ventricular septal defect.",
      "Characteristic craniofacial features of Achenbach's syndrome include a flat nasal bridge, short and broad nose, small jaw, and widely spaced eyes."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: Achenbach's syndrome is characterized by spontaneous bleeding under the skin of the hands​, particularly the fingers, and not by congenital anomalies.\n2. FALSE [correction]: Achenbach's syndrome was not described by Dr. Theodor Achenbach, a German pediatrician and geneticist. It was described by Dr. Paul Achenbach, a general practitioner. There is also potential confusion because \"Achenbach\" might be accidentally associated with other medical personalities or syndromes.\n3. UNKNOWN: The incidence of Achenbach's syndrome is not widely documented, so an estimated incidence cannot be easily confirmed.\n4. FALSE [correction]: Achenbach's syndrome is not associated with congenital heart defects such as ventricular septal defects; it involves paroxysmal hand hematoma or \"blue finger.\"\n5. FALSE [correction]: Characteristic features related to craniofacial abnormalities are not associated with Achenbach's syndrome as it primarily involves spontaneous bleeding of the hands.",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "false",
      "false"
    ]
  },
  {
    "id": 2581,
    "user_query": "Which algorithm is used for detection of long repeat expansions?",
    "llama-2-13b-chat-hf_response": "There are several algorithms that can be used for the detection of long repeat expansions, including:\n1. RepeatMasker: This is a widely used algorithm for identifying repeat regions in genomic DNA. It uses a combination of statistical and machine learning methods to identify repeat regions and can detect long repeat expansions.\n2. LRE (Long Repeat Expansion) tool: This is a tool specifically designed for the detection of long repeat expansions. It uses a combination of sliding window and hidden Markov model (HMM) algorithms to identify long repeat expansions.\n3. RepeatExplorer: This is a web-based tool for the exploration of repeat regions in genomic DNA. It uses a combination of statistical and machine learning methods to identify repeat regions and can detect long repeat expansions.\n4. Repbase: This is a comprehensive database of repeat sequences and can be used to identify long repeat expansions. It uses a combination of statistical and machine learning methods to identify repeat regions.\n5. LRR (Long Repeat Repeats) tool: This is a tool specifically designed for the detection of long repeat expansions in genomic DNA. It uses a combination of sliding window and HMM algorithms to identify long repeat expansions.\n6. RepeatScout: This is a tool for the detection of repeat expansions in genomic DNA. It uses a combination of statistical and machine learning methods to identify repeat regions and can detect long repeat expansions.\n7. RepeatFinder: This is a tool for the detection of repeat expansions in genomic DNA. It uses a combination of statistical and machine learning methods to identify repeat regions and can detect long repeat expansions.\nThese are some of the commonly used algorithms for the detection of long repeat expansions, but there are many other algorithms available as well. The choice of algorithm will depend on the specific research question and the characteristics of the data being analyzed.",
    "llama-2-13b-chat-hf_fact_raw": "1. RepeatMasker is an algorithm used for identifying repeat regions in genomic DNA.\n2. The LRE (Long Repeat Expansion) tool specifically designed for the detection of long repeat expansions, uses sliding window and HMM algorithms.\n3. RepeatExplorer is a web-based tool that can detect long repeat expansions using statistical and machine learning methods.\n4. Repbase is a comprehensive database of repeat sequences that can be used to identify long repeat expansions.\n5. RepeatScout and RepeatFinder are tools for detecting repeat expansions in genomic DNA using statistical and machine learning methods.",
    "llama-2-13b-chat-hf_fact": [
      "RepeatMasker is an algorithm used for identifying repeat regions in genomic DNA.",
      "The LRE (Long Repeat Expansion) tool specifically designed for the detection of long repeat expansions, uses sliding window and HMM algorithms.",
      "RepeatExplorer is a web-based tool that can detect long repeat expansions using statistical and machine learning methods.",
      "Repbase is a comprehensive database of repeat sequences that can be used to identify long repeat expansions.",
      "RepeatScout and RepeatFinder are tools for detecting repeat expansions in genomic DNA using statistical and machine learning methods."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. FALSE [correction]: RepeatExplorer is a tool mainly used for clustering and characterizing repetitive elements in small-scale next-generation sequencing data but does not specifically focus on long repeat expansions using statistical and machine learning methods.\n4. FALSE [correction]: Repbase is a comprehensive database of repeat sequences that is widely used as a reference for identifying repeat elements in genomic data, not specifically for identifying long repeat expansions.\n5. FALSE [correction]: RepeatScout and RepeatFinder are programs designed for discovering repeat families from genomic sequences, not specifically for detecting repeat expansions using statistical and machine learning methods. RepeatScout does not use machine learning methods.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "unknown",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 2582,
    "user_query": "Which brain tumors does neuroligin-3 promote?",
    "llama-2-13b-chat-hf_response": "Neuroligin-3 (NL3) is a protein that has been shown to promote the growth and progression of several types of brain tumors, including:\n1. Glioblastoma: NL3 is overexpressed in glioblastoma, the most common and aggressive form of brain cancer. Overexpression of NL3 has been linked to poorer prognosis and reduced survival in glioblastoma patients.\n2. Medulloblastoma: NL3 is also overexpressed in medulloblastoma, a type of pediatric brain cancer that arises in the cerebellum. High levels of NL3 have been associated with more aggressive tumor behavior and poorer outcomes in medulloblastoma patients.\n3. Brain metastases: NL3 has been shown to promote the growth and spread of brain metastases, which are tumors that originate in other parts of the body and spread to the brain.\n4. Meningioma: NL3 is overexpressed in some meningioma, a type of brain tumor that arises in the meninges, the protective coverings of the brain and spinal cord.\nOverall, NL3 appears to play a role in promoting the growth and progression of several types of brain tumors, and may be a potential therapeutic target for the treatment of these diseases.",
    "llama-2-13b-chat-hf_fact_raw": "1. Neuroligin-3 is overexpressed in glioblastoma, which is the most common and aggressive form of brain cancer.\n2. Overexpression of Neuroligin-3 in glioblastoma patients has been linked to poorer prognosis and reduced survival.\n3. Medulloblastoma, a type of pediatric brain cancer that arises in the cerebellum, also shows overexpression of Neuroligin-3.\n4. High levels of Neuroligin-3 have been associated with more aggressive tumor behavior and poorer outcomes in medulloblastoma patients.\n5. Neuroligin-3 has been shown to promote the growth and spread of brain metastases.",
    "llama-2-13b-chat-hf_fact": [
      "Neuroligin-3 is overexpressed in glioblastoma, which is the most common and aggressive form of brain cancer.",
      "Overexpression of Neuroligin-3 in glioblastoma patients has been linked to poorer prognosis and reduced survival.",
      "Medulloblastoma, a type of pediatric brain cancer that arises in the cerebellum, also shows overexpression of Neuroligin-3.",
      "High levels of Neuroligin-3 have been associated with more aggressive tumor behavior and poorer outcomes in medulloblastoma patients.",
      "Neuroligin-3 has been shown to promote the growth and spread of brain metastases."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE\n\nIt is widely reported that Neuroligin-3 is overexpressed in glioblastoma and that its high levels are associated with poorer prognosis and outcomes (statements 1 and 2). While statement 5 is in line with research suggesting Neuroligin-3 can promote tumor growth and metastasis in brain cancers, the specifics regarding its expression in medulloblastoma (statements 3 and 4) and its direct impact on this cancer type's behavior and patient outcomes are not provided in these given statements or widely known, hence the responses \"UNKNOWN\".",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2586,
    "user_query": "What is the approximate size of gas vesicles?",
    "llama-2-13b-chat-hf_response": "Gas vesicles are typically 10-100 nm in diameter.",
    "llama-2-13b-chat-hf_fact_raw": "1. Gas vesicles typically have a diameter ranging from 10 to 100 nanometers.",
    "llama-2-13b-chat-hf_fact": [
      "Gas vesicles typically have a diameter ranging from 10 to 100 nanometers."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: Gas vesicles typically have a diameter ranging from 45 to 200 nanometers.",
    "llama-2-13b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 2589,
    "user_query": "List BET proteins.",
    "llama-2-13b-chat-hf_response": "List of BET proteins\nBromodomain-containing proteins (BET) are a class of proteins that play a crucial role in regulating gene expression by binding to acetylated histones and other proteins. Here is a list of some of the most well-known BET proteins:\n1. BET1: Bromodomain-containing protein 1 (BET1) is a transcriptional regulator that is involved in the regulation of gene expression, cell proliferation, and differentiation.\n2. BET2: Bromodomain-containing protein 2 (BET2) is a transcriptional regulator that is involved in the regulation of gene expression, cell proliferation, and differentiation.\n3. BETb: Bromodomain-containing protein B (BETb) is a transcriptional regulator that is involved in the regulation of gene expression, cell proliferation, and differentiation.\n4. BRDT: Bromodomain-containing protein with multiple BRCT repeats (BRDT) is a transcriptional regulator that is involved in the regulation of gene expression, cell proliferation, and differentiation.\n5. GPS2: G protein pathway suppressor 2 (GPS2) is a transcriptional regulator that is involved in the regulation of gene expression, cell proliferation, and differentiation.\n6. HCF-1: High mobility group protein 1 (HCF-1) is a transcriptional regulator that is involved in the regulation of gene expression, cell proliferation, and differentiation.\n7. JMJD2A: Jumonji domain-containing protein 2A (JMJD2A) is a transcriptional regulator that is involved in the regulation of gene expression, cell proliferation, and differentiation.\n8. JMJD2B: Jumonji domain-containing protein 2B (JMJD2B) is a transcriptional regulator that is involved in the regulation of gene expression, cell proliferation, and differentiation.\n9. KDM4A: Lysine-specific demethylase 4A (",
    "llama-2-13b-chat-hf_fact_raw": "1. BET proteins are a class of proteins that regulate gene expression by binding to acetylated histones and other proteins.\n2. BET1 is also known as Bromodomain-containing protein 1 and acts as a transcriptional regulator.\n3. BRDT stands for Bromodomain-containing protein with multiple BRCT repeats and is involved in transcriptional regulation.\n4. GPS2, or G protein pathway suppressor 2, functions as a transcriptional regulator in gene expression, cell proliferation, and differentiation.\n5. HCF-1, High mobility group protein 1, serves as a transcriptional regulator associated with gene expression regulation, cell proliferation, and differentiation.",
    "llama-2-13b-chat-hf_fact": [
      "BET proteins are a class of proteins that regulate gene expression by binding to acetylated histones and other proteins.",
      "BET1 is also known as Bromodomain-containing protein 1 and acts as a transcriptional regulator.",
      "BRDT stands for Bromodomain-containing protein with multiple BRCT repeats and is involved in transcriptional regulation.",
      "GPS2, or G protein pathway suppressor 2, functions as a transcriptional regulator in gene expression, cell proliferation, and differentiation.",
      "HCF-1, High mobility group protein 1, serves as a transcriptional regulator associated with gene expression regulation, cell proliferation, and differentiation."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: BET1 is actually known as Golgi vesicular membrane trafficking protein that is involved in vesicle transport. Bromodomain-containing protein 1 is referred to as BRD1.\n3. FALSE [correction]: BRDT stands for Bromodomain Testis-specific protein, and it does have roles in transcriptional regulation but is specifically characterized by its expression in the testis.\n4. TRUE\n5. FALSE [correction]: HCF-1 stands for Host Cell Factor 1, which is a transcriptional co-regulator involved in cell cycle control and other processes, not High mobility group protein 1, which is commonly abbreviated as HMGB1.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 2610,
    "user_query": "Which algorithm has been developed for prediction of protein subcellular localization using deep learning?",
    "llama-2-13b-chat-hf_response": "There are several deep learning algorithms that have been developed for the prediction of protein subcellular localization. Some of the most popular ones include:\n1. Convolutional Neural Networks (CNNs): CNNs have been widely used for image classification tasks, including protein subcellular localization. In this context, CNNs can be trained to learn features from protein structures and predict their localization.\n2. Recurrent Neural Networks (RNNs): RNNs can be used to model the temporal dynamics of protein localization and predict the localization of proteins over time.\n3. Long Short-Term Memory (LSTM) networks: LSTM networks are a type of RNN that are particularly well-suited to modeling long-term dependencies in protein localization data.\n4. Generative Adversarial Networks (GANs): GANs can be used to generate synthetic protein structures and predict their localization. This can be useful for predicting the localization of proteins for which there is limited experimental data available.\n5. Transfer learning: Transfer learning is a technique where a pre-trained deep learning model is fine-tuned on a new dataset to improve its performance. This can be useful for predicting protein subcellular localization, as many deep learning models have been pre-trained on large datasets of protein structures and can be fine-tuned on smaller localization datasets.\n6. Deep learning with graph convolutional neural networks (GCNNs): GCNNs are a type of deep learning model that can be used to predict protein subcellular localization by learning the graph structure of protein-protein interactions.\n7. Deep learning with attention mechanisms: Attention mechanisms can be used to focus on specific parts of the protein structure that are important for its localization.\n8. Deep learning with spatial-temporal graph convolutional neural networks (ST-GCNNs): ST-GCNNs are a type of deep learning model that can be used to predict protein subcellular localization by learning the graph structure of protein-protein interactions and the spatial-temporal dynamics of protein localization.\nThese are just a few examples of the many deep learning algorithms that have been developed for protein subcellular localization prediction. The choice of algorithm will depend on the specific needs and characteristics of the problem being addressed.",
    "llama-2-13b-chat-hf_fact_raw": "1. Convolutional Neural Networks (CNNs) have been utilized for predicting protein subcellular localization.\n2. Recurrent Neural Networks (RNNs) are used to model temporal dynamics of protein localization.\n3. Long Short-Term Memory (LSTM) networks are a type of RNN designed to model long-term dependencies in protein localization data.\n4. Generative Adversarial Networks (GANs) are employed to generate synthetic protein structures for predicting localization.\n5. Graph convolutional neural networks (GCNNs) can be used for predicting protein subcellular localization by learning protein-protein interaction graphs.",
    "llama-2-13b-chat-hf_fact": [
      "Convolutional Neural Networks (CNNs) have been utilized for predicting protein subcellular localization.",
      "Recurrent Neural Networks (RNNs) are used to model temporal dynamics of protein localization.",
      "Long Short-Term Memory (LSTM) networks are a type of RNN designed to model long-term dependencies in protein localization data.",
      "Generative Adversarial Networks (GANs) are employed to generate synthetic protein structures for predicting localization.",
      "Graph convolutional neural networks (GCNNs) can be used for predicting protein subcellular localization by learning protein-protein interaction graphs."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE: Convolutional Neural Networks (CNNs) have indeed been utilized for predicting protein subcellular localization, often by processing imaging data or sequence information to classify proteins into different cellular compartments.\n2. TRUE: Recurrent Neural Networks (RNNs) are used to model sequential data and have been applied to model the temporal dynamics of various biological processes, including protein localization when there are time-dependent aspects to consider.\n3. TRUE: Long Short-Term Memory (LSTM) networks are a specialized type of RNN that are specifically designed to capture long-term dependencies in sequence data, which could be useful for modeling sequential patterns in protein localization data.\n4. FALSE [correction]: Generative Adversarial Networks (GANs) are typically employed to generate synthetic data. While they could theoretically be used to generate synthetic protein structures, they are not primarily employed for predicting protein localization. Their main application in the context of proteins might involve generating new protein sequences or protein structure predictions, not necessarily the prediction of their localization.\n5. TRUE: Graph convolutional neural networks (GCNNs) can indeed be used for predicting protein subcellular localization by exploiting the graph structure of protein-protein interactions, which can be quite informative for understanding the functional context of proteins within the cell.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2634,
    "user_query": "What is MULTOVL?",
    "llama-2-13b-chat-hf_response": "MULTOVL (Multi-Output Voltage Linearization) is a technique used to improve the linearity of a power supply's output voltage. It is commonly used in high-precision applications such as audio, medical, and industrial equipment.\nIn a traditional power supply, the output voltage is determined by a single voltage regulator circuit. However, this can result in non-linearities in the output voltage, which can cause problems for sensitive loads. MULTOVL addresses this issue by using multiple voltage regulators in parallel, each with its own output voltage. By adjusting the output currents of each regulator, the total output voltage can be made more linear.\nMULTOVL can be implemented using a variety of techniques, including:\n1. Parallel voltage regulation: Multiple voltage regulators are connected in parallel to provide a more stable output voltage.\n2. Current sharing: Each voltage regulator is connected to a current-sharing network, which ensures that each regulator receives the same current.\n3. Voltage sensing: Each voltage regulator is equipped with a voltage sensor that monitors the output voltage and adjusts the output current accordingly.\nThe benefits of MULTOVL include:\n1. Improved linearity: MULTOVL can significantly improve the linearity of the output voltage, which is essential for high-precision applications.\n2. Increased stability: By using multiple voltage regulators in parallel, MULTOVL can provide a more stable output voltage, which is less susceptible to variations in load current or input voltage.\n3. Flexibility: MULTOVL can be easily customized to meet specific application requirements, such as output voltage range, output current, and load regulation.\n4. High efficiency: MULTOVL can achieve high efficiency, which is important for applications that require low power consumption.\nIn summary, MULTOVL is a powerful technique for improving the linearity of a power supply's output voltage, which is essential for high-precision applications. It can be implemented using a variety of techniques and offers several benefits, including improved linearity, increased stability, flexibility, and high efficiency.",
    "llama-2-13b-chat-hf_fact_raw": "1. MULTOVL stands for Multi-Output Voltage Linearization.\n2. It is used to improve the linearity of a power supply's output voltage.\n3. MULTOVL is commonly used in audio, medical, and industrial equipment.\n4. The technique utilizes multiple voltage regulators in parallel to achieve a more linear output voltage.\n5. MULTOVL can be implemented using parallel voltage regulation, current sharing, and voltage sensing techniques.",
    "llama-2-13b-chat-hf_fact": [
      "MULTOVL stands for Multi-Output Voltage Linearization.",
      "It is used to improve the linearity of a power supply's output voltage.",
      "MULTOVL is commonly used in audio, medical, and industrial equipment.",
      "The technique utilizes multiple voltage regulators in parallel to achieve a more linear output voltage.",
      "MULTOVL can be implemented using parallel voltage regulation, current sharing, and voltage sensing techniques."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific context or a reliable source confirming what MULTOVL stands for and its applications, it is not possible to determine the veracity of these statements. The provided statements could very well be part of a specialized field or industry jargon that is not widely recognized or documented in general knowledge sources available up to my latest update.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2660,
    "user_query": "Can GDF15 be a biomarker for metformin treatment?",
    "llama-2-13b-chat-hf_response": "GDF15 (Growth Differentiation Factor 15) is a protein that has been shown to be involved in the regulation of glucose metabolism and insulin signaling. Recent studies have suggested that GDF15 may be a useful biomarker for monitoring the effectiveness of metformin treatment in patients with type 2 diabetes.\nOne study published in the journal Diabetes, Obesity and Metabolism found that GDF15 levels were significantly lower in patients who received metformin therapy compared to those who did not receive the drug. The study also found that GDF15 levels were inversely correlated with HbA1c levels, a measure of average blood sugar control over the past 2-3 months.\nAnother study published in the journal Endocrine Practice found that GDF15 levels were significantly higher in patients with type 2 diabetes who did not respond to metformin therapy compared to those who did respond. The study also found that GDF15 levels were associated with the presence of insulin resistance, a common complication of type 2 diabetes.\nA review of the available literature published in the journal Diabetes, Obesity and Metabolism concluded that GDF15 may be a useful biomarker for monitoring the effectiveness of metformin treatment in patients with type 2 diabetes. The review noted that GDF15 levels have been shown to be significantly lower in patients who respond to metformin therapy compared to those who do not respond, and that GDF15 levels are inversely correlated with HbA1c levels.\nHowever, it is important to note that more research is needed to confirm the usefulness of GDF15 as a biomarker for metformin treatment. The available evidence is limited to a few studies, and larger, more comprehensive studies are needed to fully understand the relationship between GDF15 and metformin treatment. Additionally, it is not clear whether GDF15 levels can be used to predict which patients are likely to respond to metformin therapy, or whether GDF15 levels can be used to monitor the effectiveness of other diabetes medications.\nIn summary, while there is some evidence to suggest that GDF15 may be",
    "llama-2-13b-chat-hf_fact_raw": "1. GDF15 (Growth Differentiation Factor 15) is involved in the regulation of glucose metabolism and insulin signaling.\n2. One study in the journal Diabetes, Obesity and Metabolism found GDF15 levels significantly lower in patients receiving metformin therapy compared to those who did not.\n3. The same study found that GDF15 levels were inversely correlated with HbA1c levels.\n4. Another study in the journal Endocrine Practice found GDF15 levels significantly higher in patients with type 2 diabetes who did not respond to metformin therapy.\n5. A literature review in the journal Diabetes, Obesity and Metabolism concluded GDF15 may be a useful biomarker for monitoring the effectiveness of metformin treatment in type 2 diabetes patients.",
    "llama-2-13b-chat-hf_fact": [
      "GDF15 (Growth Differentiation Factor 15) is involved in the regulation of glucose metabolism and insulin signaling.",
      "One study in the journal Diabetes, Obesity and Metabolism found GDF15 levels significantly lower in patients receiving metformin therapy compared to those who did not.",
      "The same study found that GDF15 levels were inversely correlated with HbA1c levels.",
      "Another study in the journal Endocrine Practice found GDF15 levels significantly higher in patients with type 2 diabetes who did not respond to metformin therapy.",
      "A literature review in the journal Diabetes, Obesity and Metabolism concluded GDF15 may be a useful biomarker for monitoring the effectiveness of metformin treatment in type 2 diabetes patients."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: One study in the journal Diabetes, Obesity and Metabolism found GDF15 levels significantly higher in patients receiving metformin therapy compared to those who did not.\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nThe correction in statement 2 is based on general scientific consensus that metformin therapy is associated with increased levels of GDF15, which is known to improve insulin sensitivity and aid in the regulation of glucose metabolism. Statements 4 and 5 require specific references to the studies mentioned for accuracy and are therefore classified as UNKNOWN without access to those study results.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2664,
    "user_query": "Is recursive splicing more common in short introns?",
    "llama-2-13b-chat-hf_response": "Recursive splicing is a process in which a spliced intron is spliced again, creating a nested or recursive splicing event. This process is not well understood, but it is thought to be important for the regulation of gene expression.\nOne question that has been raised is whether recursive splicing is more common in short introns. Short introns are introns that are shorter than the average intron length, which is typically around 30-40 nucleotides. These short introns are thought to be more abundant in the human genome than longer introns.\nTo investigate this question, researchers have analyzed the intron sequences in the human genome and looked for evidence of recursive splicing. They found that short introns are indeed more likely to be involved in recursive splicing events than longer introns.\nFor example, in one study, the researchers found that 25% of short introns (those less than 20 nucleotides in length) were involved in recursive splicing, compared to only 5% of longer introns (those between 20-40 nucleotides in length). This suggests that short introns may be more prone to recursive splicing than longer introns.\nThere are several possible reasons why short introns might be more susceptible to recursive splicing. One reason is that short introns may be more difficult for the splicing machinery to recognize and process correctly, leading to errors and the formation of recursive splicing events. Another reason is that short introns may have a higher concentration of certain splicing regulatory elements, such as splicing enhancers or silencers, which can influence the splicing pattern of the intron.\nOverall, these findings suggest that recursive splicing is more common in short introns, and that short introns may play an important role in the regulation of gene expression. However, more research is needed to fully understand the mechanisms and functions of recursive splicing in the human genome.",
    "llama-2-13b-chat-hf_fact_raw": "1. Recursive splicing is a process where a spliced intron is spliced again.\n2. The average intron length is typically around 30-40 nucleotides.\n3. Short introns are thought to be more abundant in the human genome than longer introns.\n4. Researchers found that short introns are more likely to be involved in recursive splicing events than longer introns.\n5. One study found that 25% of short introns (less than 20 nucleotides in length) were involved in recursive splicing.",
    "llama-2-13b-chat-hf_fact": [
      "Recursive splicing is a process where a spliced intron is spliced again.",
      "The average intron length is typically around 30-40 nucleotides.",
      "Short introns are thought to be more abundant in the human genome than longer introns.",
      "Researchers found that short introns are more likely to be involved in recursive splicing events than longer introns.",
      "One study found that 25% of short introns (less than 20 nucleotides in length) were involved in recursive splicing."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The average intron length is much larger than 30-40 nucleotides; in humans, it can be several thousand nucleotides long.\n3. TRUE: Short introns are indeed more abundant in the human genome, even though the average length is much longer.\n4. UNKNOWN: Without specific study data mentioned, we cannot confirm whether short introns are more likely to be involved in recursive splicing events.\n5. UNKNOWN: This statement requires specific data from a study that is not provided in the context.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2679,
    "user_query": "What is the TALE-iD method used for?",
    "llama-2-13b-chat-hf_response": "The TALE-iD method is used for the identification of transcriptional activator-like effectors (TALEs) in bacteria. TALEs are proteins that regulate gene expression by binding to specific DNA sequences. The TALE-iD method is a genetic screening technique that uses a combination of DNA sequencing and bioinformatics to identify TALEs in a given bacterial strain.\nThe TALE-iD method involves the following steps:\n1. Preparation of a bacterial library: The bacterial strain of interest is grown and prepared for genomic DNA extraction.\n2. Sequencing of TALE-binding sites: The genomic DNA is then used to isolate the regions that bind to TALE proteins. These regions are sequenced to identify the specific DNA sequences that bind to the TALE proteins.\n3. Identification of TALEs: The sequenced data is then analyzed using bioinformatics tools to identify the TALEs in the bacterial strain.\n4. Validation of TALEs: The identified TALEs are then validated using additional experiments, such as electrophoretic mobility shift assays (EMSAs) or chromatin immunoprecipitation (ChIP) assays, to confirm their function as TALEs.\nThe TALE-iD method is a powerful tool for identifying TALEs in bacteria, and it has many potential applications in fields such as biotechnology, agriculture, and medicine. For example, TALEs could be used to regulate gene expression in bacteria for the production of biofuels, drugs, or other valuable compounds. Additionally, TALEs could be used to develop novel antimicrobial therapies or to improve the efficiency of existing antimicrobial treatments.",
    "llama-2-13b-chat-hf_fact_raw": "1. The TALE-iD method is used for the identification of transcriptional activator-like effectors in bacteria.\n2. TALEs are proteins that regulate gene expression by binding to specific DNA sequences.\n3. The TALE-iD method involves preparing a bacterial library for genomic DNA extraction.\n4. The sequenced data from TALE-binding sites is analyzed using bioinformatics tools to identify TALEs.\n5. Validation of identified TALEs includes experiments such as electrophoretic mobility shift assays or chromatin immunoprecipitation assays.",
    "llama-2-13b-chat-hf_fact": [
      "The TALE-iD method is used for the identification of transcriptional activator-like effectors in bacteria.",
      "TALEs are proteins that regulate gene expression by binding to specific DNA sequences.",
      "The TALE-iD method involves preparing a bacterial library for genomic DNA extraction.",
      "The sequenced data from TALE-binding sites is analyzed using bioinformatics tools to identify TALEs.",
      "Validation of identified TALEs includes experiments such as electrophoretic mobility shift assays or chromatin immunoprecipitation assays."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The TALE-iD method does not primarily involve preparing a bacterial library for genomic DNA extraction. The method involves identifying TALEs by employing techniques like sequencing and bioinformatics analysis.\n4. TRUE\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2747,
    "user_query": "Which Lisp framework has been developed for image processing?",
    "llama-2-13b-chat-hf_response": "There are several Lisp frameworks that have been developed for image processing, including:\n1. CL- Image: This is a Lisp interface to the Image Processing Toolkit (IPTK) which provides a wide range of image processing functions.\n2. Lisp Image Processing (LIP): This is a Lisp library for image processing that provides a simple and intuitive interface for performing common image processing tasks.\n3. PLIP (Portable Lisp Image Processing): This is a Lisp library for image processing that is designed to be portable across different Lisp implementations.\n4. Lisp-based Image Processing System (Lips): This is a Lisp-based system for image processing that provides a comprehensive set of image processing tools and functions.\n5. Lisp Image Processing and Analysis (LIPPA): This is a Lisp library for image processing and analysis that provides a wide range of functions for image processing and analysis.\n6. Lisp-based Image Processing and Analysis (LIPPA): This is a Lisp-based system for image processing and analysis that provides a comprehensive set of image processing and analysis tools and functions.\nAll of these frameworks are widely used in research and development, and have been used in a variety of applications, including medical imaging, industrial inspection, and digital photography.",
    "llama-2-13b-chat-hf_fact_raw": "1. CL-Image is a Lisp interface to the Image Processing Toolkit (IPTK).\n2. Lisp Image Processing (LIP) is a Lisp library for image processing.\n3. PLIP (Portable Lisp Image Processing) is a Lisp library designed to be portable across different Lisp implementations.\n4. Lisp-based Image Processing System (Lips) provides a comprehensive set of image processing tools and functions.\n5. Lisp Image Processing and Analysis (LIPPA) is a Lisp library that offers functions for image processing and analysis.",
    "llama-2-13b-chat-hf_fact": [
      "CL-Image is a Lisp interface to the Image Processing Toolkit (IPTK).",
      "Lisp Image Processing (LIP) is a Lisp library for image processing.",
      "PLIP (Portable Lisp Image Processing) is a Lisp library designed to be portable across different Lisp implementations.",
      "Lisp-based Image Processing System (Lips) provides a comprehensive set of image processing tools and functions.",
      "Lisp Image Processing and Analysis (LIPPA) is a Lisp library that offers functions for image processing and analysis."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout further context or specific knowledge of Lisp libraries named exactly as \"CL-Image,\" \"Lisp Image Processing (LIP),\" \"PLIP (Portable Lisp Image Processing),\" \"Lisp-based Image Processing System (Lips),\" and \"Lisp Image Processing and Analysis (LIPPA),\" it is not possible to accurately assess the veracity of these statements. These could be hypothetical libraries or proprietary tools not widely recognized in public sources as of my knowledge cutoff date.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2759,
    "user_query": "How many genes in S. cerevisiae are the result of an ancient whole genome duplication?",
    "llama-2-13b-chat-hf_response": "The yeast species Saccharomyces cerevisiae has undergone an ancient whole genome duplication (WGD) event, which is thought to have occurred around 100-200 million years ago. This event resulted in the duplication of the entire genome, leading to a significant increase in the number of genes present in the genome.\nStudies have shown that approximately 30-40% of the genes in S. cerevisiae are the result of this ancient WGD event. This means that out of the approximately 6,000 genes present in the S. cerevisiae genome, around 1,800-2,400 genes are the result of the WGD event.\nTherefore, the answer to the question is:\n1,800-2,400 genes in S. cerevisiae are the result of an ancient whole genome duplication.",
    "llama-2-13b-chat-hf_fact_raw": "1. Saccharomyces cerevisiae underwent an ancient whole genome duplication event around 100-200 million years ago.\n2. The whole genome duplication event led to a significant increase in the number of genes in the S. cerevisiae genome.\n3. Approximately 30-40% of the genes in S. cerevisiae are the result of the ancient whole genome duplication.\n4. The S. cerevisiae genome contains approximately 6,000 genes.\n5. 1,800-2,400 genes in S. cerevisiae are the result of the whole genome duplication event.",
    "llama-2-13b-chat-hf_fact": [
      "Saccharomyces cerevisiae underwent an ancient whole genome duplication event around 100-200 million years ago.",
      "The whole genome duplication event led to a significant increase in the number of genes in the S. cerevisiae genome.",
      "Approximately 30-40% of the genes in S. cerevisiae are the result of the ancient whole genome duplication.",
      "The S. cerevisiae genome contains approximately 6,000 genes.",
      "1,800-2,400 genes in S. cerevisiae are the result of the whole genome duplication event."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE: It is widely accepted in the scientific community that Saccharomyces cerevisiae (a species of yeast) underwent an ancient whole genome duplication (WGD) event approximately 100-200 million years ago.\n  \n2. TRUE: Whole genome duplication events usually lead to a significant increase in the number of genes within an organism's genome, as it duplicates the entire set of genetic material.\n\n3. FALSE [correction]: While it is true that a substantial portion of the genes in S. cerevisiae can be traced back to the ancient whole genome duplication, the exact percentage varies according to different studies and is subject to scientific interpretation. Therefore, a specific figure such as 30-40% might not be accurate without a reference to a specific study or set of data.\n\n4. TRUE: The Saccharomyces cerevisiae genome is known to contain approximately 6,000 genes, although the exact number can vary slightly depending on the reference and strain.\n  \n5. UNKNOWN: Without the exact percentage of genes derived from the whole genome duplication event or a specific reference, it is difficult to confirm the accuracy of the number of genes (1,800-2,400) claimed to be the result of the event. The given range could be calculated based on the 30-40% figure from statement 3, but since that statement's accuracy is uncertain, the truthfulness of this statement is also undetermined.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2763,
    "user_query": "Which complex is bound by estrogen-related receptor β (Esrrb)?",
    "llama-2-13b-chat-hf_response": "A) The estrogen response element (ERE)\nB) The glucocorticoid response element (GRE)\nC) The androgen response element (ARE)\nD) The progesterone response element (PRE)\nAnswer: A) The estrogen response element (ERE)\nEsrrb is an estrogen-related receptor that is activated by estrogens and binds to the estrogen response element (ERE) in the promoter region of target genes. The ERE is a specific DNA sequence that is recognized by Esrrb and other estrogen receptors, leading to the activation of gene transcription.",
    "llama-2-13b-chat-hf_fact_raw": "1. Estrogen-related receptor β (Esrrb) is activated by estrogens.\n2. Esrrb binds to the estrogen response element (ERE) in the promoter region of target genes.\n3. The estrogen response element (ERE) is a specific DNA sequence recognized by Esrrb and other estrogen receptors.\n4. Binding to the ERE leads to the activation of gene transcription.",
    "llama-2-13b-chat-hf_fact": [
      "Estrogen-related receptor β (Esrrb) is activated by estrogens.",
      "Esrrb binds to the estrogen response element (ERE) in the promoter region of target genes.",
      "The estrogen response element (ERE) is a specific DNA sequence recognized by Esrrb and other estrogen receptors.",
      "Binding to the ERE leads to the activation of gene transcription."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: Estrogen-related receptor β (Esrrb) is not activated by estrogens; it is an orphan receptor which means it is not known to be naturally activated by any endogenous ligands, including estrogens.\n2. FALSE [correction]: Although Esrrb can bind to similar DNA sequences as other estrogen receptors, it does not bind to estrogen response elements (ERE) because it is not activated by estrogens.\n3. TRUE\n4. TRUE (Generally this statement is considered true as binding of estrogen receptors to the ERE typically leads to the activation of gene transcription. However, without the specific context that it's Esrrb in the statement, the generalized process is true for estrogen receptors.)",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2842,
    "user_query": "What is the role of ZCCHC17?",
    "llama-2-13b-chat-hf_response": "ZCCHC17 is a zinc finger CCCH-type containing protein that is involved in the regulation of gene expression, particularly in the context of cellular stress responses. It is a transcriptional repressor that can bind to specific DNA sequences and recruit histone modifiers to repress gene transcription.\nWhat is the function of ZCCHC17 in cancer?\nZCCHC17 has been shown to be overexpressed in various types of cancer, including breast, lung, and colon cancer. Overexpression of ZCCHC17 has been associated with cancer progression and poor prognosis. ZCCHC17 has been shown to promote the epithelial-to-mesenchymal transition (EMT), a process that is involved in cancer metastasis and drug resistance. Additionally, ZCCHC17 has been shown to inhibit the activity of tumor suppressor proteins, such as p53, and to promote the expression of oncogenic proteins, such as c-Myc.\nWhat is the relationship between ZCCHC17 and EMT?\nZCCHC17 has been shown to promote the epithelial-to-mesenchymal transition (EMT), a process that is involved in cancer metastasis and drug resistance. EMT is a complex process that involves the loss of epithelial characteristics and the acquisition of mesenchymal characteristics, such as increased cell motility and invasiveness. ZCCHC17 has been shown to regulate the expression of EMT-related genes, such as E-cadherin and vimentin, and to promote the migration and invasion of cancer cells.\nWhat is the potential of ZCCHC17 as a therapeutic target for cancer treatment?\nZCCHC17 has been identified as a potential therapeutic target for cancer treatment due to its involvement in cancer progression and its potential to inhibit the activity of tumor suppressor proteins. Inhibition of ZCCHC17 has been shown to inhibit the growth of cancer cells and to induce apoptosis, or programmed cell death. Additionally, ZCCHC17 inhibition has been shown to sensitize",
    "llama-2-13b-chat-hf_fact_raw": "1. ZCCHC17 is a zinc finger CCCH-type protein involved in the regulation of gene expression during cellular stress responses.\n2. ZCCHC17 has been shown to be overexpressed in various types of cancer, including breast, lung, and colon cancer.\n3. Overexpression of ZCCHC17 is associated with cancer progression and poor prognosis.\n4. ZCCHC17 promotes the epithelial-to-mesenchymal transition (EMT), which is involved in cancer metastasis and drug resistance.\n5. Inhibition of ZCCHC17 activity has been shown to inhibit the growth of cancer cells and induce apoptosis.",
    "llama-2-13b-chat-hf_fact": [
      "ZCCHC17 is a zinc finger CCCH-type protein involved in the regulation of gene expression during cellular stress responses.",
      "ZCCHC17 has been shown to be overexpressed in various types of cancer, including breast, lung, and colon cancer.",
      "Overexpression of ZCCHC17 is associated with cancer progression and poor prognosis.",
      "ZCCHC17 promotes the epithelial-to-mesenchymal transition (EMT), which is involved in cancer metastasis and drug resistance.",
      "Inhibition of ZCCHC17 activity has been shown to inhibit the growth of cancer cells and induce apoptosis."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific scientific references or a body of research to confirm the statements about ZCCHC17's role in cancer and its effects when inhibited, the statements regarding overexpression, association with cancer progression, involvement in EMT, and impact on cancer cell growth and apoptosis cannot be factually assessed. The functions of proteins such as ZCCHC17 can be subject to ongoing research, and their roles can be complex and multifaceted. Therefore, unless the provided context includes specific research findings or consensus in the scientific community, the true/false status of those statements remains unknown.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2861,
    "user_query": "Which proteins form the nuclear pore basket in human cells?",
    "llama-2-13b-chat-hf_response": "The nuclear pore basket is a structure that forms the central channel of the nuclear pore complex (NPC) in human cells. The NPC is a large protein complex that spans the nuclear envelope, which is the double membrane that surrounds the nucleus in eukaryotic cells. The nuclear pore basket is composed of several proteins that form a ring-like structure around the central channel of the NPC. These proteins include:\n1. Nup107: This protein is one of the main components of the nuclear pore basket and is involved in the formation of the central channel of the NPC.\n2. Nup160: This protein is another key component of the nuclear pore basket and is involved in the regulation of protein transport through the NPC.\n3. Nup216: This protein is a component of the nuclear pore basket and is involved in the regulation of mRNA export from the nucleus.\n4. Nup37: This protein is a component of the nuclear pore basket and is involved in the regulation of protein transport through the NPC.\n5. Nup50: This protein is a component of the nuclear pore basket and is involved in the regulation of protein transport through the NPC.\n6. Nup53: This protein is a component of the nuclear pore basket and is involved in the regulation of protein transport through the NPC.\n7. Nup62: This protein is a component of the nuclear pore basket and is involved in the regulation of protein transport through the NPC.\n8. Nup88: This protein is a component of the nuclear pore basket and is involved in the regulation of protein transport through the NPC.\nThese proteins work together to form the nuclear pore basket and regulate the transport of molecules through the NPC. The nuclear pore basket is an essential component of the NPC and plays a critical role in regulating the traffic of molecules between the nucleus and the cytoplasm in human cells.",
    "llama-2-13b-chat-hf_fact_raw": "1. The nuclear pore complex (NPC) spans the nuclear envelope, which surrounds the nucleus in eukaryotic cells.\n2. The NPC is composed of several proteins that form a ring-like structure around the central channel.\n3. Nup107 is involved in the formation of the central channel of the NPC.\n4. Nup160 is involved in the regulation of protein transport through the NPC.\n5. Nup216 is involved in the regulation of mRNA export from the nucleus.",
    "llama-2-13b-chat-hf_fact": [
      "The nuclear pore complex (NPC) spans the nuclear envelope, which surrounds the nucleus in eukaryotic cells.",
      "The NPC is composed of several proteins that form a ring-like structure around the central channel.",
      "Nup107 is involved in the formation of the central channel of the NPC.",
      "Nup160 is involved in the regulation of protein transport through the NPC.",
      "Nup216 is involved in the regulation of mRNA export from the nucleus."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Nucleoporin 214 (Nup214), not Nup216, is involved in the regulation of mRNA export from the nucleus.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2919,
    "user_query": "What type of topoisomerase inhibitor is gepotidacin?",
    "llama-2-13b-chat-hf_response": "Gepotidacin is a topoisomerase I inhibitor.",
    "llama-2-13b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-13b-chat-hf_fact": [],
    "llama-2-13b-chat-hf_judge": []
  },
  {
    "id": 2943,
    "user_query": "Describe Canvas SPW",
    "llama-2-13b-chat-hf_response": "-1000\nThe Canvas SPW-1000 is a high-quality, affordable, and versatile speaker system designed for small to medium-sized spaces. Here are some of its key features and specifications:\n1. Design and Build: The SPW-1000 has a sleek and modern design, with a black or white finish and a compact footprint. It is made of high-quality materials, including a durable MDF cabinet and a sturdy steel grille.\n2. Sound Quality: The SPW-1000 delivers clear and balanced sound with deep bass, crisp midrange, and smooth highs. It features a 10-inch woofer and a 1-inch tweeter, which work together to produce a wide frequency range of 45 Hz to 20 kHz.\n3. Connectivity: The speaker system has multiple connectivity options, including Bluetooth 5.0, USB, SD card, and aux inputs. It also has a built-in amplifier and a 3.5mm headphone jack.\n4. Power and Volume: The SPW-1000 has a powerful 1000W peak power and a variable volume control. It can produce a maximum sound pressure level of 106 dB, making it suitable for small to medium-sized spaces.\n5. Compatibility: The speaker system is compatible with a wide range of devices, including smartphones, tablets, laptops, and MP3 players. It also has a built-in FM radio and supports multiple audio formats, including MP3, WAV, and WMA.\n6. Controls: The SPW-1000 has a user-friendly control panel with buttons for volume, bass, and treble adjustments. It also has a built-in microphone for hands-free phone calls and voice commands.\n7. Accessories: The speaker system comes with a remote control, a power cord, and a user manual. It also has a built-in carry handle for easy transport.\nOverall, the Canvas SPW-1000 is a versatile and powerful speaker system that delivers high-quality sound and offers multiple connectivity options. It is suitable for small to medium-sized spaces and is easy to use and transport.",
    "llama-2-13b-chat-hf_fact_raw": "1. The Canvas SPW-1000 features a 10-inch woofer and a 1-inch tweeter.\n2. The SPW-1000 offers a frequency range of 45 Hz to 20 kHz.\n3. It has connectivity options including Bluetooth 5.0, USB, SD card, and aux inputs.\n4. The speaker system has a peak power of 1000W and can produce a maximum sound pressure level of 106 dB.\n5. The SPW-1000 is designed with a built-in FM radio and supports audio formats such as MP3, WAV, and WMA.",
    "llama-2-13b-chat-hf_fact": [
      "The Canvas SPW-1000 features a 10-inch woofer and a 1-inch tweeter.",
      "The SPW-1000 offers a frequency range of 45 Hz to 20 kHz.",
      "It has connectivity options including Bluetooth 5.0, USB, SD card, and aux inputs.",
      "The speaker system has a peak power of 1000W and can produce a maximum sound pressure level of 106 dB.",
      "The SPW-1000 is designed with a built-in FM radio and supports audio formats such as MP3, WAV, and WMA."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout additional context or information on the specific product, it is impossible to verify these statements about the Canvas SPW-1000. It would require product specifications or a trusted source of information to confirm these details.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2960,
    "user_query": "List STING agonists.",
    "llama-2-13b-chat-hf_response": "The correct spelling is \"2'-3'-Oligoadenylate\" instead of \"2'-3'-Oligoadenylate-3'-5'-guanosine monophosphate\". Here is the corrected list of STING agonists:\n1. Cyclohexylaminocyclohexane carboxylic acid (CHAC)\n2. 2'-3'-Oligoadenylate (2-3A)\n3. 3'-Deoxy-3'-methyl-adenosine-C3-methyl-adenosine (3'-d3MeA)\n4. 2'-5'-Oligoadenylate (2-5A)\n5. 2'-3'-Cyclic adenosine monophosphate (2-3cAMP)\nNo other errors were found.",
    "llama-2-13b-chat-hf_fact_raw": "1. Cyclohexylaminocyclohexane carboxylic acid (CHAC) is a STING agonist.\n2. 2'-3'-Oligoadenylate (2-3A) is a STING agonist.\n3. 3'-Deoxy-3'-methyl-adenosine-C3-methyl-adenosine (3'-d3MeA) is a STING agonist.\n4. 2'-5'-Oligoadenylate (2-5A) is a STING agonist.\n5. 2'-3'-Cyclic adenosine monophosphate (2-3cAMP) is a STING agonist.",
    "llama-2-13b-chat-hf_fact": [
      "Cyclohexylaminocyclohexane carboxylic acid (CHAC) is a STING agonist.",
      "2'-3'-Oligoadenylate (2-3A) is a STING agonist.",
      "3'-Deoxy-3'-methyl-adenosine-C3-methyl-adenosine (3'-d3MeA) is a STING agonist.",
      "2'-5'-Oligoadenylate (2-5A) is a STING agonist.",
      "2'-3'-Cyclic adenosine monophosphate (2-3cAMP) is a STING agonist."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: 2'-3'-Oligoadenylate (2-3A) is not a STING agonist; it is actually involved in the activation of RNase L in the antiviral response.\n3. UNKNOWN\n4. FALSE [correction]: 2'-5'-Oligoadenylate (2-5A) is not a STING agonist; it is associated with the activation of RNase L by binding to it, which then degrades viral RNA.\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "false",
      "unknown",
      "false",
      "true"
    ]
  },
  {
    "id": 2964,
    "user_query": "Describe SLIC-CAGE",
    "llama-2-13b-chat-hf_response": "The SLIC-CAGE algorithm is a new approach for solving the traveling salesman problem (TSP) that combines the ideas of slicing and cutting plane techniques. The algorithm is based on the concept of generalized exact covering, which is a generalization of the traditional exact covering technique used in many TSP algorithms.\nThe SLIC-CAGE algorithm consists of three main phases:\n1. Preprocessing: In this phase, the input TSP instance is preprocessed to reduce the size of the search space. This involves partitioning the set of cities into smaller subsets, called slices, and computing a set of cutting planes that separate the slices from each other.\n2. Slicing and Cutting: In this phase, the TSP instance is sliced into smaller subproblems, each of which corresponds to a slice of the original instance. The subproblems are then solved using a combination of exact covering and cutting plane techniques. The cutting planes are used to prune the search space of the algorithm, reducing the running time and improving the accuracy of the solution.\n3. Postprocessing: In this phase, the solutions to the subproblems are combined to form a complete tour of the original TSP instance. The postprocessing phase also involves a set of heuristics to improve the quality of the solution.\nThe SLIC-CAGE algorithm has been tested on a set of benchmark instances of TSP, and the results show that it outperforms several state-of-the-art algorithms, including the popular branch and bound algorithm. The algorithm is also able to solve larger instances of TSP than previous algorithms.\nNo errors were found in the response.",
    "llama-2-13b-chat-hf_fact_raw": "1. The SLIC-CAGE algorithm is designed to solve the traveling salesman problem (TSP).\n2. It combines slicing and cutting plane techniques based on the concept of generalized exact covering.\n3. The algorithm has a preprocessing phase that partitions the set of cities into slices and computes cutting planes.\n4. The slicing and cutting phase involves solving subproblems with exact covering and cutting plane techniques.\n5. SLIC-CAGE has been tested on benchmark instances and outperformed several state-of-the-art TSP algorithms.",
    "llama-2-13b-chat-hf_fact": [
      "The SLIC-CAGE algorithm is designed to solve the traveling salesman problem (TSP).",
      "It combines slicing and cutting plane techniques based on the concept of generalized exact covering.",
      "The algorithm has a preprocessing phase that partitions the set of cities into slices and computes cutting planes.",
      "The slicing and cutting phase involves solving subproblems with exact covering and cutting plane techniques.",
      "SLIC-CAGE has been tested on benchmark instances and outperformed several state-of-the-art TSP algorithms."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: There is no widely recognized algorithm called \"SLIC-CAGE\" designed to solve the traveling salesman problem (TSP). Common algorithms for TSP include heuristics like nearest neighbor, exact algorithms like branch and bound, and approximation methods like Christofides' algorithm.\n\n2. UNKNOWN: Since the SLIC-CAGE algorithm does not seem to be a recognized TSP-solving method, the claim about it using slicing and cutting plane techniques based on the concept of generalized exact covering cannot be verified.\n\n3. UNKNOWN: Given that SLIC-CAGE is not a recognized algorithm, the details of any preprocessing phase involving the partitioning of cities into slices and the computation of cutting planes cannot be confirmed.\n\n4. UNKNOWN: The details about a slicing and cutting phase involving solving subproblems with exact covering and cutting plane techniques cannot be verified, as SLIC-CAGE is not an established TSP algorithm.\n\n5. FALSE [correction]: Since the SLIC-CAGE algorithm is not recognized in the context of TSP algorithms, it could not have been tested on benchmark instances or outperformed several state-of-the-art TSP algorithms.",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 2978,
    "user_query": "What are the roles of LEM-3?",
    "llama-2-13b-chat-hf_response": "In the context of gene expression, LEM-3 is a protein that plays a crucial role in regulating the expression of target genes. Here are some of the roles of LEM-3:\n1. Transcriptional regulation: LEM-3 can bind to specific DNA sequences in the promoter region of target genes and regulate their transcription. It can either activate or repress the transcription of these genes, depending on the specific context.\n2. Chromatin remodeling: LEM-3 can also interact with chromatin-modifying complexes and help to remodel chromatin structure. This can affect the accessibility of transcription factors to target genes, and thus influence their expression.\n3. Nuclear localization: LEM-3 is predominantly localized in the nucleus, where it can interact with target genes and regulate their expression.\n4. Subcellular localization: LEM-3 can also be targeted to specific subcellular compartments, such as the cytoplasm or mitochondria, where it can regulate the expression of genes involved in these processes.\n5. Protein-protein interactions: LEM-3 can interact with other proteins, such as transcription factors and chromatin-modifying complexes, to regulate the expression of target genes.\n6. Signal transduction: LEM-3 can also be involved in signal transduction pathways, where it can regulate the expression of genes involved in these pathways.\n7. Cell fate determination: LEM-3 has been implicated in the regulation of cell fate decisions, such as cell proliferation, differentiation, and survival.\n8. Tissue development: LEM-3 has been shown to be involved in the regulation of tissue development and homeostasis.\nOverall, LEM-3 is a multifunctional protein that plays a crucial role in regulating gene expression and various cellular processes.",
    "llama-2-13b-chat-hf_fact_raw": "1. LEM-3 can regulate the transcription of target genes by binding to specific DNA sequences in their promoter region.\n2. LEM-3 can interact with chromatin-modifying complexes to remodel chromatin structure.\n3. LEM-3 is predominantly localized in the nucleus where it can interact with and regulate target genes.\n4. LEM-3 can be targeted to specific subcellular compartments to regulate the expression of genes involved in those processes.\n5. LEM-3 has been implicated in the regulation of cell fate decisions, such as cell proliferation, differentiation, and survival.",
    "llama-2-13b-chat-hf_fact": [
      "LEM-3 can regulate the transcription of target genes by binding to specific DNA sequences in their promoter region.",
      "LEM-3 can interact with chromatin-modifying complexes to remodel chromatin structure.",
      "LEM-3 is predominantly localized in the nucleus where it can interact with and regulate target genes.",
      "LEM-3 can be targeted to specific subcellular compartments to regulate the expression of genes involved in those processes.",
      "LEM-3 has been implicated in the regulation of cell fate decisions, such as cell proliferation, differentiation, and survival."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements pertain to LEM-3, a topic that could be very specialized, depending on the context of LEM-3 (e.g., whether it is a specific factor in a biological context, a gene, a protein, etc.). Without specific information or scientific context, it is not possible to accurately verify the statements. They may well be true in a certain biological or experimental framework, but without the appropriate context, the veracity of the statements cannot be ascertained.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2992,
    "user_query": "List the releases of tmVar",
    "llama-2-13b-chat-hf_response": "iance and its dependencies.\nThe following is a list of releases of tmVariance and its dependencies:\n1. tmVariance 1.0.0\n\t* Released on 2022-01-01\n\t* Dependencies:\n\t\t+ R (4.0.3)\n\t\t+ tidyverse (1.3.0)\n\t\t+ tibble (3.0.1)\n\t\t+ dplyr (1.0.4)\n\t\t+ ggplot2 (3.3.5)\n2. tmVariance 1.0.1\n\t* Released on 2022-01-15\n\t* Dependencies:\n\t\t+ R (4.0.4)\n\t\t+ tidyverse (1.3.1)\n\t\t+ tibble (3.0.2)\n\t\t+ dplyr (1.0.5)\n\t\t+ ggplot2 (3.3.6)\n3. tmVariance 1.0.2\n\t* Released on 2022-02-01\n\t* Dependencies:\n\t\t+ R (4.0.5)\n\t\t+ tidyverse (1.3.2)\n\t\t+ tibble (3.0.3)\n\t\t+ dplyr (1.0.6)\n\t\t+ ggplot2 (3.3.7)\n4. tmVariance 1.0.3\n\t* Released on 2022-03-01\n\t* Dependencies:\n\t\t+ R (4.0.6)\n\t\t+ tidyverse (1.3.3)\n\t\t+ tibble (3.0.4)\n\t\t+ dplyr (1.0.7)\n\t\t+ ggplot2 (3.3.8)\n5. tmVariance 1.0.4\n\t* Released on 2022-04-01\n\t* Dependencies:\n\t\t+ R (4.0.7)\n\t\t+ tidyverse (1.3.4)\n\t\t+ tibble (3.0.5)\n\t\t+ dplyr (1.0",
    "llama-2-13b-chat-hf_fact_raw": "1. tmVariance 1.0.0 was released on 2022-01-01.\n2. tmVariance 1.0.1 was released on 2022-01-15.\n3. tmVariance 1.0.2 was released on 2022-02-01.\n4. tmVariance 1.0.3 was released on 2022-03-01.\n5. tmVariance 1.0.4 was released on 2022-04-01.",
    "llama-2-13b-chat-hf_fact": [
      "tmVariance 1.0.0 was released on 2022-01-01.",
      "tmVariance 1.0.1 was released on 2022-01-15.",
      "tmVariance 1.0.2 was released on 2022-02-01.",
      "tmVariance 1.0.3 was released on 2022-03-01.",
      "tmVariance 1.0.4 was released on 2022-04-01."
    ],
    "llama-2-13b-chat-hf_judge_raw": "UNKNOWN\n\nThe statements provided seem to suggest a sequence of releases for a software product named \"tmVariance.\" However, without specific knowledge of this software's actual release dates, it's impossible to determine the truthfulness of these statements. Therefore, the status of each statement as true or false cannot be established with the information given.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3018,
    "user_query": "Which is the database of somatic mutations in normal cells?",
    "llama-2-13b-chat-hf_response": "There are several databases that contain information on somatic mutations in normal cells, including:\n1. The Cancer Genome Atlas (TCGA): This is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI) that aims to catalogue the genomic changes in various types of cancer. TCGA has generated a large amount of data on somatic mutations in cancer cells, but it also includes data on somatic mutations in normal cells.\n2. The 1000 Genomes Project: This is a large-scale effort to sequence the genomes of 1,000 individuals from around the world. The project has generated a wealth of data on genetic variation, including somatic mutations, in normal cells.\n3. The Human Genome Variation Project (HGVP): This is a collaborative effort between the NHGRI and other organizations to catalogue genetic variation in the human population. The project has generated a large amount of data on somatic mutations in normal cells.\n4. The ExPASy Transcriptome Browser: This is a database of transcriptome data from a variety of normal and diseased tissues. The database includes information on somatic mutations in normal cells.\n5. The GTEx database: This is a database of genomic, transcriptomic, and proteomic data from a variety of normal tissues. The database includes information on somatic mutations in normal cells.\n6. The Cancer Cell Line Encyclopedia (CCLE): This is a database of genomic, transcriptomic, and proteomic data from a variety of cancer cell lines. The database includes information on somatic mutations in cancer cells, but it also includes data on somatic mutations in normal cells.\n7. The Human Somatic Mutation Database (HSMD): This is a database of somatic mutations in human cells, including normal cells and cancer cells. The database includes information on the frequency and distribution of somatic mutations in different tissues and cell types.\n8. The Somatic Mutation Database (SMDB): This is a database of somatic mutations in human cells, including normal cells and cancer cells. The database includes information on the frequency and distribution of somatic mutations in different tissues and cell types.\nThese are just a few examples of the many",
    "llama-2-13b-chat-hf_fact_raw": "1. The Cancer Genome Atlas (TCGA) includes data on somatic mutations in normal cells.\n2. The 1000 Genomes Project has generated data on somatic mutations in normal cells.\n3. The Human Genome Variation Project (HGVP) has generated data on somatic mutations in normal cells.\n4. The ExPASy Transcriptome Browser database includes information on somatic mutations in normal cells.\n5. The GTEx database includes information on somatic mutations in normal cells.",
    "llama-2-13b-chat-hf_fact": [
      "The Cancer Genome Atlas (TCGA) includes data on somatic mutations in normal cells.",
      "The 1000 Genomes Project has generated data on somatic mutations in normal cells.",
      "The Human Genome Variation Project (HGVP) has generated data on somatic mutations in normal cells.",
      "The ExPASy Transcriptome Browser database includes information on somatic mutations in normal cells.",
      "The GTEx database includes information on somatic mutations in normal cells."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: The Cancer Genome Atlas (TCGA) includes data on somatic mutations in cancer cells, not normal cells.\n2. FALSE [correction]: The 1000 Genomes Project has generated data on genetic variations in the human population, but it focuses on germline (inherited) variations, not somatic mutations in normal cells.\n3. UNKNOWN: The Human Genome Variation Project (HGVP) may refer to the Human Genome Variation Society (HGVS), which is involved in the systematic description of human genetic variation, or it could refer to a different project. Without specific context, the statement is unclear.\n4. UNKNOWN: The ExPASy Transcriptome Browser database is a tool for exploring transcriptomic data, but without specific information on the inclusion of somatic mutations in normal cells, the statement's accuracy cannot be determined.\n5. FALSE [correction]: The GTEx (Genotype-Tissue Expression) database includes information on gene expression and genetic variation in different human tissues, focusing on the relationship between genetic variation and gene expression, not on somatic mutations in normal cells.",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3037,
    "user_query": "Are there graph kernel libraries available implemented in JAVA?",
    "llama-2-13b-chat-hf_response": "I apologize for any errors in my previous response. Here is the updated list of Java libraries for graph kernel methods, with some additional information about each library:\n1. Weka: Weka is a popular machine learning library for Java that provides a range of algorithms for classification, regression, clustering, and more. It also includes a graph kernel implementation that can be used for graph classification and regression tasks. Weka is widely used and well-documented, with a large user community and a wide range of tutorials and examples.\n2. GraphKernel: GraphKernel is a Java library specifically designed for graph kernel methods. It provides a range of graph kernels, including the common neighborhood kernel, the weighted kernel, and the random walk kernel. It also includes tools for graph data preprocessing and feature selection. GraphKernel is relatively new and has not yet been widely adopted, but it is well-documented and includes a range of examples and tutorials.\n3. JGK (Java Graph Kernel): JGK is another Java library for graph kernel methods. It provides a simple and efficient implementation of graph kernels, including the common neighborhood kernel and the weighted kernel. It also includes tools for graph data preprocessing and feature selection. JGK is well-documented and includes a range of examples and tutorials, but it is not as widely used as some other libraries on this list.\n4. GraphML: GraphML is a Java library for machine learning on graph-structured data. It provides a range of algorithms for graph classification, graph regression, and graph clustering, as well as a graph kernel implementation for graph similarity search. GraphML is well-documented and includes a range of examples and tutorials, but it is not as widely used as some other libraries on this list.\n5. GKlib (Graph Kernel Library): GKlib is a Java library for graph kernel methods that provides a range of graph kernels, including the common neighborhood kernel, the weighted kernel, and the random walk kernel. It also includes tools for graph data preprocessing and feature selection. GKlib is well-documented and includes a range of examples and tutorials, but it is not as widely used as some other libraries on this list.\nNo errors were found in this response.",
    "llama-2-13b-chat-hf_fact_raw": "1. Weka is a machine learning library for Java that provides algorithms for classification, regression, clustering, and graph kernel implementation.\n2. GraphKernel is a Java library designed for graph kernel methods and includes a range of graph kernels and tools for preprocessing and feature selection.\n3. JGK (Java Graph Kernel) provides a simple and efficient implementation of graph kernels and tools for preprocessing and feature selection.\n4. GraphML is a Java library for machine learning on graph-structured data, offering algorithms for graph classification, regression, clustering, and graph kernel for similarity search.\n5. GKlib (Graph Kernel Library) is a Java library for graph kernel methods that provides various graph kernels and tools for preprocessing and feature selection.",
    "llama-2-13b-chat-hf_fact": [
      "Weka is a machine learning library for Java that provides algorithms for classification, regression, clustering, and graph kernel implementation.",
      "GraphKernel is a Java library designed for graph kernel methods and includes a range of graph kernels and tools for preprocessing and feature selection.",
      "JGK (Java Graph Kernel) provides a simple and efficient implementation of graph kernels and tools for preprocessing and feature selection.",
      "GraphML is a Java library for machine learning on graph-structured data, offering algorithms for graph classification, regression, clustering, and graph kernel for similarity search.",
      "GKlib (Graph Kernel Library) is a Java library for graph kernel methods that provides various graph kernels and tools for preprocessing and feature selection."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. FALSE [correction]: GraphML is not a Java library; it is an XML-based file format for graphs. There might be confusion with other libraries for machine learning on graph-structured data.\n5. UNKNOWN",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3045,
    "user_query": "List the four advances integrated into the SHERLOCKv2 platform.",
    "llama-2-13b-chat-hf_response": "1. Advanced fluorescence detection\n2. High-resolution imaging\n3. Multiplexing capabilities\n4. Portability and ease of use",
    "llama-2-13b-chat-hf_fact_raw": "1. The SHERLOCKv2 platform integrates advanced fluorescence detection.\n2. The SHERLOCKv2 platform has high-resolution imaging.\n3. The SHERLOCKv2 platform includes multiplexing capabilities.\n4. The SHERLOCKv2 platform is designed for portability and ease of use.",
    "llama-2-13b-chat-hf_fact": [
      "The SHERLOCKv2 platform integrates advanced fluorescence detection.",
      "The SHERLOCKv2 platform has high-resolution imaging.",
      "The SHERLOCKv2 platform includes multiplexing capabilities.",
      "The SHERLOCKv2 platform is designed for portability and ease of use."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The SHERLOCKv2 platform does not inherently possess high-resolution imaging; it is a CRISPR-based diagnostic tool.\n3. TRUE\n4. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3078,
    "user_query": "Describe the bartender algorithm",
    "llama-2-13b-chat-hf_response": "for solving the traveling salesman problem.\nThe bartender algorithm is a heuristic algorithm for solving the traveling salesman problem (TSP). It is a simple and efficient method that is often used as a baseline for comparing the performance of more complex TSP algorithms.\nThe bartender algorithm works as follows:\n1. Initialize the tour: Start with an empty tour and a set of unvisited cities.\n2. Select the first city: Choose a random city from the set of unvisited cities.\n3. Add the first city to the tour: Add the selected city to the tour and mark it as visited.\n4. Select the next city: Choose a random city that has not been visited yet and is located near the current city.\n5. Add the next city to the tour: Add the selected city to the tour and mark it as visited.\n6. Repeat steps 4 and 5 until all cities have been visited: Continue selecting random cities that are near the current city and adding them to the tour until all cities have been visited.\n7. Return the tour: Return the constructed tour as the solution to the TSP.\nThe bartender algorithm is based on the idea of a bartender serving customers in a bar. The bartender starts by serving the first customer (a random city), then serves the next customer (a random city near the current city), and continues serving customers in this manner until all customers (cities) have been served. The bartender algorithm is a simple and efficient method for solving the TSP, but it is not guaranteed to find the optimal solution.\nThe bartender algorithm can be improved by using a more sophisticated heuristic, such as the nearest neighbor heuristic or the 2-opt heuristic, to guide the search for better solutions. Additionally, the bartender algorithm can be modified to handle more complex TSP instances, such as those with multiple depots or constraints on the routes.",
    "llama-2-13b-chat-hf_fact_raw": "1. The bartender algorithm is a heuristic algorithm used to solve the traveling salesman problem.\n2. It starts with an empty tour and a set of unvisited cities, and begins by choosing a random city.\n3. The algorithm adds selected cities to the tour and marks them as visited.\n4. It continues by selecting random cities near the current city until all cities have been visited.\n5. The bartender algorithm is not guaranteed to find the optimal solution for the TSP.",
    "llama-2-13b-chat-hf_fact": [
      "The bartender algorithm is a heuristic algorithm used to solve the traveling salesman problem.",
      "It starts with an empty tour and a set of unvisited cities, and begins by choosing a random city.",
      "The algorithm adds selected cities to the tour and marks them as visited.",
      "It continues by selecting random cities near the current city until all cities have been visited.",
      "The bartender algorithm is not guaranteed to find the optimal solution for the TSP."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: There is no known \"bartender algorithm\" commonly used to solve the traveling salesman problem. Relevant heuristic algorithms include the Nearest Neighbor algorithm, the Genetic Algorithm, Simulated Annealing, etc.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE (assuming the name \"bartender algorithm\" is a mix-up with a known heuristic algorithm for TSP, which are generally not guaranteed to find the optimal solution)",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3100,
    "user_query": "Which web-based pedigree editors are available?",
    "llama-2-13b-chat-hf_response": "There are several web-based pedigree editors available, including:\n1. Pedigree.com: This is a free online pedigree editor that allows users to create and share their family trees. It includes a range of features such as the ability to add photos, notes, and sources.\n2. FamilyTreeMaker.com: This is a web-based version of the popular FamilyTreeMaker software. It allows users to create and share their family trees, and includes features such as the ability to add photos and sources.\n3. Ancestry.com: This is a popular genealogy website that includes a range of tools for creating and sharing family trees. It also includes access to a vast collection of historical records and other resources for researching your family history.\n4. MyHeritage.com: This is another popular genealogy website that includes a range of tools for creating and sharing family trees. It also includes access to a vast collection of historical records and other resources for researching your family history.\n5. WeRelate.org: This is a free, open-source web-based genealogy application that allows users to create and share their family trees. It includes features such as the ability to add photos, notes, and sources.\n6. TNG (The Next Generation): This is a web-based genealogy application that allows users to create and share their family trees. It includes features such as the ability to add photos, notes, and sources.\n7. Geni.com: This is a web-based genealogy application that allows users to create and share their family trees. It includes features such as the ability to add photos, notes, and sources.\n8. WikiTree.com: This is a free, open-source web-based genealogy application that allows users to create and share their family trees. It includes features such as the ability to add photos, notes, and sources.\nThese are just a few examples of the many web-based pedigree editors available. It's worth noting that some of these services are free, while others require a subscription or other payment.",
    "llama-2-13b-chat-hf_fact_raw": "1. Pedigree.com is a free online pedigree editor with features including photo uploads, notes, and sources.\n2. FamilyTreeMaker.com is a web-based version of FamilyTreeMaker software with photo uploads and sources.\n3. Ancestry.com is a genealogy website offering tools for family tree creation and historical record access.\n4. MyHeritage.com is a genealogy website offering tools for family tree creation and historical record access.\n5. WeRelate.org and WikiTree.com are free, open-source web-based genealogy applications with photo uploads, notes, and sources.",
    "llama-2-13b-chat-hf_fact": [
      "Pedigree.com is a free online pedigree editor with features including photo uploads, notes, and sources.",
      "FamilyTreeMaker.com is a web-based version of FamilyTreeMaker software with photo uploads and sources.",
      "Ancestry.com is a genealogy website offering tools for family tree creation and historical record access.",
      "MyHeritage.com is a genealogy website offering tools for family tree creation and historical record access.",
      "WeRelate.org and WikiTree.com are free, open-source web-based genealogy applications with photo uploads, notes, and sources."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: The website for online pedigree creation is not Pedigree.com; for free pedigree editing with features including photo uploads, notes, and sources, one might refer to websites like FamilyEcho.com or online databases specific to certain animals like the American Kennel Club for dogs.\n2. FALSE [correction]: FamilyTreeMaker.com is a website where you can purchase the Family Tree Maker software; it is not a web-based version of the software. The web-based companion to Family Tree Maker is called Ancestry.com, with which it can sync.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3107,
    "user_query": "Which curated databases exist for spider-venom toxins?",
    "llama-2-13b-chat-hf_response": "There are several curated databases that exist for spider-venom toxins, including:\n1. Spider Venom Database (SVD): This database contains information on the composition, structure, and function of spider venoms, as well as their potential as therapeutic agents.\n2. Venomous Animal Toxins (VAT): This database contains information on the toxins found in venomous animals, including spiders, snakes, and scorpions.\n3. Toxinology: This database contains information on all types of toxins, including those found in spider venom.\n4. Spider Toxin Database (STD): This database contains information on the toxins found in spider venom, including their composition, structure, and function.\n5. Venom Peptide Database (VPD): This database contains information on the peptides found in spider venom, including their structure and function.\n6. Spider Venom Peptide Database (SVPD): This database contains information on the peptides found in spider venom, including their structure and function.\n7. Venom-Derived Peptide Database (VDP): This database contains information on the peptides found in venomous animals, including spiders, snakes, and scorpions.\n8. Toxin-Derived Peptide Database (TDP): This database contains information on the peptides found in toxins, including those found in spider venom.\nThese databases provide a wealth of information on the composition, structure, and function of spider-venom toxins, and can be useful resources for researchers studying these compounds.",
    "llama-2-13b-chat-hf_fact_raw": "1. The Spider Venom Database (SVD) contains information on the composition, structure, and function of spider venoms and their potential as therapeutic agents.\n2. Venomous Animal Toxins (VAT) provides information on toxins from venomous animals, including spiders, snakes, and scorpions.\n3. Toxinology is a database that encompasses information on a variety of toxins, including those from spider venom.\n4. The Spider Toxin Database (STD) focuses on toxins found in spider venom, detailing their composition, structure, and function.\n5. The Venom Peptide Database (VPD) offers information on peptides in spider venom, including their structure and function.",
    "llama-2-13b-chat-hf_fact": [
      "The Spider Venom Database (SVD) contains information on the composition, structure, and function of spider venoms and their potential as therapeutic agents.",
      "Venomous Animal Toxins (VAT) provides information on toxins from venomous animals, including spiders, snakes, and scorpions.",
      "Toxinology is a database that encompasses information on a variety of toxins, including those from spider venom.",
      "The Spider Toxin Database (STD) focuses on toxins found in spider venom, detailing their composition, structure, and function.",
      "The Venom Peptide Database (VPD) offers information on peptides in spider venom, including their structure and function."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: There is no known specific database named \"Spider Toxin Database (STD)\" focusing solely on spider venom toxins. It could be a hypothetical or incorrect reference to another existing database, such as ArachnoServer or similar.\n5. UNKNOWN",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3111,
    "user_query": "Does Axitinib prolong survival of Pancreatic Cancer patients?",
    "llama-2-13b-chat-hf_response": "Axitinib is a tyrosine kinase inhibitor that targets VEGFR, PDGFR, and c-Kit. It has been investigated as a potential treatment for various types of cancer, including pancreatic cancer.\nOne study published in the New England Journal of Medicine in 2019 found that axitinib improved progression-free survival (PFS) in patients with advanced pancreatic cancer, compared to placebo. The study included 227 patients who were randomly assigned to receive either axitinib or placebo in addition to standard chemotherapy. The results showed that the median PFS was 5.5 months in the axitinib group, compared to 3.7 months in the placebo group (hazard ratio for disease progression or death, 0.56; P<0.001).\nHowever, the study did not show a significant improvement in overall survival (OS) with axitinib. The median OS was 12.6 months in the axitinib group and 11.9 months in the placebo group (hazard ratio for death, 0.87; P=0.38).\nAnother study published in the Journal of Clinical Oncology in 2020 found that axitinib improved PFS in patients with metastatic pancreatic cancer, but the benefit was limited to patients with high levels of a biomarker called PD-L1. The study included 103 patients who were randomly assigned to receive either axitinib or placebo in addition to standard chemotherapy. The results showed that the median PFS was 4.8 months in the axitinib group, compared to 2.9 months in the placebo group (hazard ratio for disease progression or death, 0.47; P<0.001).\nOverall, the evidence suggests that axitinib may be a useful treatment option for some patients with advanced pancreatic cancer, particularly those with high levels of PD-L1. However, more research is needed to confirm these findings and to determine the long-term efficacy and safety of axitinib in this patient population.",
    "llama-2-13b-chat-hf_fact_raw": "1. Axitinib is a tyrosine kinase inhibitor that targets VEGFR, PDGFR, and c-Kit.\n2. A 2019 study in the New England Journal of Medicine reported that axitinib improved progression-free survival (PFS) in patients with advanced pancreatic cancer compared to placebo.\n3. According to the study, the median PFS for patients treated with axitinib was 5.5 months, versus 3.7 months for the placebo group.\n4. The same study indicated that there was no significant improvement in overall survival (OS) with axitinib, with a median OS of 12.6 months in the axitinib group compared to 11.9 months in the placebo group.\n5. A 2020 study in the Journal of Clinical Oncology found that axitinib improved PFS in patients with metastatic pancreatic cancer who had high levels of a biomarker called PD-L1.",
    "llama-2-13b-chat-hf_fact": [
      "Axitinib is a tyrosine kinase inhibitor that targets VEGFR, PDGFR, and c-Kit.",
      "A 2019 study in the New England Journal of Medicine reported that axitinib improved progression-free survival (PFS) in patients with advanced pancreatic cancer compared to placebo.",
      "According to the study, the median PFS for patients treated with axitinib was 5.5 months, versus 3.7 months for the placebo group.",
      "The same study indicated that there was no significant improvement in overall survival (OS) with axitinib, with a median OS of 12.6 months in the axitinib group compared to 11.9 months in the placebo group.",
      "A 2020 study in the Journal of Clinical Oncology found that axitinib improved PFS in patients with metastatic pancreatic cancer who had high levels of a biomarker called PD-L1."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Axitinib is used in the treatment of advanced renal cell carcinoma (kidney cancer), and studies on its effects on pancreatic cancer may not have the same conclusions. The specific study and its results would need to be verified as the context provided does not specify the exact study.\n3. UNKNOWN: The median PFS for patients treated with axitinib would need to be confirmed with the specific study mentioned, as it depends on the study's actual findings and could be true or false based on the correct clinical context.\n4. UNKNOWN: As with statement 3, the significance of overall survival with axitinib treatment would depend on the specific results of the study cited, which is not provided in the context.\n5. FALSE [correction]: Axitinib is known for its use in renal cell carcinoma rather than pancreatic cancer. Without more context or access to the specific article, it's unclear whether the study presented in the Journal of Clinical Oncology pertain",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3113,
    "user_query": "Through which protein interaction does MLP regulate F-actin dynamics?",
    "llama-2-13b-chat-hf_response": "In the paper \"Myosin Light Chain Phosphatase Regulates F-Actin Dynamics in Neurons\" by Zhang et al. (2013), the authors show that MLP regulates F-actin dynamics in neurons by dephosphorylating and activating myosin light chain (MLC). The activated MLC then binds to F-actin and regulates its dynamics.\nTherefore, the protein interaction through which MLP regulates F-actin dynamics is the interaction between MLC and F-actin.",
    "llama-2-13b-chat-hf_fact_raw": "1. MLP regulates F-actin dynamics in neurons by dephosphorylating and activating myosin light chain (MLC).\n2. The activated MLC binds to F-actin to regulate its dynamics.\n3. The findings are presented in the paper \"Myosin Light Chain Phosphatase Regulates F-Actin Dynamics in Neurons\" by Zhang et al. (2013).",
    "llama-2-13b-chat-hf_fact": [
      "MLP regulates F-actin dynamics in neurons by dephosphorylating and activating myosin light chain (MLC).",
      "The activated MLC binds to F-actin to regulate its dynamics.",
      "The findings are presented in the paper \"Myosin Light Chain Phosphatase Regulates F-Actin Dynamics in Neurons\" by Zhang et al. (2013)."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: MLP (myosin light chain phosphatase) does not directly regulate F-actin dynamics by dephosphorylating MLC (myosin light chain). Instead, it dephosphorylates MLC, which can affect myosin II activity, and it is myosin II that interacts with F-actin to regulate its dynamics.\n2. TRUE\n3. UNKNOWN",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3125,
    "user_query": "How many pseudokinases are there in the human kinome?",
    "llama-2-13b-chat-hf_response": "The human kinome contains approximately 518 protein kinases, but it is estimated that there are approximately 300-400 pseudokinases, which are proteins that have kinase-like domains but do not have enzymatic activity. Therefore, there are approximately 118-218 pseudokinases in the human kinome. However, it is important to note that the exact number of pseudokinases can vary depending on the specific definition used to define a pseudokinase, and different studies may have different estimates.",
    "llama-2-13b-chat-hf_fact_raw": "1. The human kinome contains approximately 518 protein kinases.\n2. It is estimated that there are approximately 300-400 pseudokinases in the human kinome.\n3. Pseudokinases are proteins that have kinase-like domains but lack enzymatic activity.\n4. The exact number of pseudokinases can vary depending on the definition used to define a pseudokinase.\n5. Different studies may have different estimates of the number of pseudokinases in the human kinome.",
    "llama-2-13b-chat-hf_fact": [
      "The human kinome contains approximately 518 protein kinases.",
      "It is estimated that there are approximately 300-400 pseudokinases in the human kinome.",
      "Pseudokinases are proteins that have kinase-like domains but lack enzymatic activity.",
      "The exact number of pseudokinases can vary depending on the definition used to define a pseudokinase.",
      "Different studies may have different estimates of the number of pseudokinases in the human kinome."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: It is estimated that there are approximately 100 or more pseudokinases in the human kinome, not 300-400.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3139,
    "user_query": "List 3 apoE mimetics.",
    "llama-2-13b-chat-hf_response": "There are several apoE mimetics that have been developed to treat Alzheimer's disease and other neurodegenerative disorders. Here are three examples:\n1. AN-1795: This is a synthetic apoE mimetic that is being developed by Amgen. It has been shown to improve cognitive function in patients with mild to moderate Alzheimer's disease in clinical trials.\n2. CER-001: This is another synthetic apoE mimetic that is being developed by Ceregene. It has been shown to improve cognitive function and slow down cognitive decline in patients with Alzheimer's disease in clinical trials.\n3. RV-001: This is a gene therapy that uses a viral vector to deliver a functional copy of the apoE gene to the brain. It is being developed by ReViral and has shown promise in early clinical trials for treating Alzheimer's disease.",
    "llama-2-13b-chat-hf_fact_raw": "1. AN-1795 is a synthetic apoE mimetic developed by Amgen.\n2. CER-001 is a synthetic apoE mimetic developed by Ceregene.\n3. RV-001 is a gene therapy using a viral vector to deliver a functional copy of the apoE gene being developed by ReViral.",
    "llama-2-13b-chat-hf_fact": [
      "AN-1795 is a synthetic apoE mimetic developed by Amgen.",
      "CER-001 is a synthetic apoE mimetic developed by Ceregene.",
      "RV-001 is a gene therapy using a viral vector to deliver a functional copy of the apoE gene being developed by ReViral."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. FALSE [correction]: RV-001 is not a gene therapy for delivering a functional copy of the apoE gene developed by ReViral. Instead, ReViral develops antiviral compounds aimed at diseases like the respiratory syncytial virus (RSV); therefore, RV-001 would not be associated with apoE gene therapy and is unrelated to Amgen or apoE mimetics.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3140,
    "user_query": "What are there sex differences in SAMHD1 activity?",
    "llama-2-13b-chat-hf_response": "SAMHD1 is a cellular protein that plays a crucial role in regulating the activity of the immune system and the progression of certain diseases, including HIV. There are several studies that have investigated the sex differences in SAMHD1 activity, and here are some of the key findings:\n1. Sex differences in SAMHD1 expression: Studies have shown that there are differences in the expression of SAMHD1 between males and females. For example, one study found that SAMHD1 expression was higher in female than in male peripheral blood mononuclear cells (PBMCs) [1]. Another study found that SAMHD1 expression was higher in male than in female CD4+ T cells [2].\n2. Sex differences in SAMHD1 activity: Studies have also shown that there are differences in the activity of SAMHD1 between males and females. For example, one study found that SAMHD1 activity was higher in female than in male PBMCs [1]. Another study found that SAMHD1 activity was higher in male than in female CD4+ T cells [2].\n3. Sex differences in SAMHD1 regulation: Studies have also investigated the regulation of SAMHD1 activity in males and females. For example, one study found that the expression of SAMHD1 was regulated by different transcription factors in males and females, such as FOXP3 in females and T-bet in males [3]. Another study found that the activity of SAMHD1 was regulated by different signaling pathways in males and females, such as the PI3K/Akt pathway in females and the NF-κB pathway in males [4].\n4. Sex differences in SAMHD1-mediated immune function: Studies have also shown that there are differences in the immune function of males and females, which may be related to differences in SAMHD1 activity. For example, one study found that female mice had a higher proportion of regulatory T cells (Tregs) than male mice, which may be related to differences in SAMHD1 activity [5]. Another study found that male mice had a higher proportion of Th17 cells than female mice, which may be related to differences in SAMHD1 activity [6].\nIn summary, there are sex differences in",
    "llama-2-13b-chat-hf_fact_raw": "1. Studies have shown differences in the expression of SAMHD1 between males and females.\n2. One study reported higher SAMHD1 expression in female peripheral blood mononuclear cells compared to males.\n3. Another study reported higher SAMHD1 activity in female PBMCs than in male PBMCs.\n4. The expression of SAMHD1 is regulated by different transcription factors in males and females.\n5. Different signaling pathways regulate the activity of SAMHD1 in males and females.",
    "llama-2-13b-chat-hf_fact": [
      "Studies have shown differences in the expression of SAMHD1 between males and females.",
      "One study reported higher SAMHD1 expression in female peripheral blood mononuclear cells compared to males.",
      "Another study reported higher SAMHD1 activity in female PBMCs than in male PBMCs.",
      "The expression of SAMHD1 is regulated by different transcription factors in males and females.",
      "Different signaling pathways regulate the activity of SAMHD1 in males and females."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThere's not enough context or specific scientific research references to verify the truthfulness of these statements. Claims about the differences in the expression or activity of a gene such as SAMHD1 between males and females, and the regulatory mechanisms behind them, would require referencing specific studies or scientific literature. Without such references, it is not possible to determine the truthfulness of these statements.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3205,
    "user_query": "Does RUNX2 inhibit astrocyte differentiation?",
    "llama-2-13b-chat-hf_response": "RUNX2 has been shown to both inhibit and promote astrocyte differentiation, depending on the specific context. Some studies suggest that RUNX2 inhibits astrocyte differentiation, while others suggest that it promotes astrocyte differentiation. The conflicting reports may be due to differences in the specific cell types and culture conditions used in the studies. Further research is needed to fully understand the mechanisms by which RUNX2 regulates astrocyte differentiation.",
    "llama-2-13b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-13b-chat-hf_fact": [],
    "llama-2-13b-chat-hf_judge": []
  },
  {
    "id": 3209,
    "user_query": "Where, in the body, would the Cobb-Stainsby excision arthroplasty be performed?",
    "llama-2-13b-chat-hf_response": "A) Knee\nB) Hip\nC) Shoulder\nD) Ankle\nCorrect answer: B) Hip\nThe Cobb-Stainsby excision arthroplasty is a surgical procedure that is performed to treat hip joint conditions such as osteoarthritis. It involves the removal of damaged bone and cartilage and the insertion of a prosthetic implant to restore joint function. The procedure is typically performed on the hip joint, and not on the knee, shoulder, or ankle.",
    "llama-2-13b-chat-hf_fact_raw": "1. The Cobb-Stainsby excision arthroplasty is a surgical procedure used to treat hip joint conditions.\n2. The surgical procedure involves the removal of damaged bone and cartilage.\n3. A prosthetic implant is inserted to restore joint function during Cobb-Stainsby excision arthroplasty.\n4. The Cobb-Stainsby excision arthroplasty is typically performed on the hip joint.",
    "llama-2-13b-chat-hf_fact": [
      "The Cobb-Stainsby excision arthroplasty is a surgical procedure used to treat hip joint conditions.",
      "The surgical procedure involves the removal of damaged bone and cartilage.",
      "A prosthetic implant is inserted to restore joint function during Cobb-Stainsby excision arthroplasty.",
      "The Cobb-Stainsby excision arthroplasty is typically performed on the hip joint."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. FALSE [correction]: A prosthetic implant is not inserted during the Cobb-Stainsby excision arthroplasty; rather, it involves the removal of the femoral head and reshaping of the acetabulum, possibly with the interposition of soft tissues to create a pseudarthrosis.\n4. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3243,
    "user_query": "Does GRHL2 over-expression lead to EMT?",
    "llama-2-13b-chat-hf_response": "In the literature, there are several studies that suggest that GRHL2 over-expression can lead to EMT. For example, one study found that GRHL2 over-expression in human lung cancer cells led to increased expression of EMT markers, such as vimentin and N-cadherin, and decreased expression of epithelial markers, such as E-cadherin [1]. Another study found that GRHL2 over-expression in mouse embryonic fibroblasts led to increased migration and invasion, which are hallmarks of EMT [2]. Additionally, GRHL2 has been shown to regulate the expression of genes involved in EMT, such as ZEB1 and Snail, and to interact with other transcription factors that are involved in EMT, such as Slug and Twist [3, 4].\nHowever, it is important to note that not all studies have found a direct link between GRHL2 over-expression and EMT. For example, one study found that GRHL2 over-expression in breast cancer cells had no effect on EMT markers or cell migration [5]. Therefore, the relationship between GRHL2 and EMT is complex and may depend on the specific context in which GRHL2 is over-expressed.\nIn summary, there is evidence to suggest that GRHL2 over-expression can lead to EMT, but the relationship is not straightforward and may depend on the specific context in which GRHL2 is over-expressed. Further research is needed to fully understand the mechanisms by which GRHL2 regulates EMT.\nReferences:\n[1] Li et al. (2013). GRHL2 regulates EMT by suppressing E-cadherin expression and promoting vimentin expression in human lung cancer. BioMed Research International, 2013, 1-9.\n[2] Zhang et al. (2015). GRHL2 promotes EMT and tumorigenicity by suppressing the expression of the epithelial marker E-cadherin in mouse embryonic fibroblasts. Oncogene, 34(3), 343-352.\n[3] Wang et al. (2012). GRHL2 regulates the expression of EMT-related genes in human lung cancer cells",
    "llama-2-13b-chat-hf_fact_raw": "1. Studies suggest that GRHL2 over-expression can lead to EMT, as evidenced by increased expression of EMT markers like vimentin and N-cadherin.\n2. In human lung cancer cells, GRHL2 over-expression led to decreased expression of epithelial markers such as E-cadherin.\n3. GRHL2 over-expression in mouse embryonic fibroblasts resulted in increased migration and invasion.\n4. GRHL2 has been shown to regulate the expression of EMT-related genes such as ZEB1 and Snail.\n5. The relationship between GRHL2 over-expression and EMT may depend on the specific context and cell type.",
    "llama-2-13b-chat-hf_fact": [
      "Studies suggest that GRHL2 over-expression can lead to EMT, as evidenced by increased expression of EMT markers like vimentin and N-cadherin.",
      "In human lung cancer cells, GRHL2 over-expression led to decreased expression of epithelial markers such as E-cadherin.",
      "GRHL2 over-expression in mouse embryonic fibroblasts resulted in increased migration and invasion.",
      "GRHL2 has been shown to regulate the expression of EMT-related genes such as ZEB1 and Snail.",
      "The relationship between GRHL2 over-expression and EMT may depend on the specific context and cell type."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThese statements generally follow what is known about the role of the GRHL2 gene in epithelial-mesenchymal transition (EMT). GRHL2 has been implicated in the regulation of EMT, which involves the loss of epithelial characteristics (like E-cadherin expression) and the gain of mesenchymal traits (such as increased vimentin and N-cadherin expression). The exact effects might indeed depend on the context and cell type, as statement 5 suggests. However, without specific studies or data to reference, it is not possible to give a completely accurate evaluation of these statements. They are presumed true based on commonly accepted scientific knowledge up to my knowledge cutoff in 2023.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3254,
    "user_query": "Which T-UCRs have been implicated in lung cancer?",
    "llama-2-13b-chat-hf_response": "Several T-UCRs have been implicated in lung cancer, including:\n1. T-bet: T-bet is a transcription factor that is involved in the differentiation of T cells and has been shown to be downregulated in lung cancer. Studies have found that T-bet is a tumor suppressor in lung cancer and that its downregulation is associated with poor prognosis.\n2. GARP: GARP (glucocorticoid-induced TNF receptor-related protein) is a T-UCR that is involved in the regulation of cytokine production and has been shown to be overexpressed in lung cancer. Overexpression of GARP has been associated with poor prognosis and resistance to chemotherapy in lung cancer patients.\n3. LAG-3: LAG-3 (lymphocyte-activation gene 3) is a T-UCR that is involved in the regulation of T cell function and has been shown to be overexpressed in lung cancer. Overexpression of LAG-3 has been associated with poor prognosis and resistance to immunotherapy in lung cancer patients.\n4. TIGIT: TIGIT (T-cell immunoreceptor with immunoreceptor tyrosine-based activation motifs) is a T-UCR that is involved in the regulation of T cell activation and has been shown to be overexpressed in lung cancer. Overexpression of TIGIT has been associated with poor prognosis and resistance to immunotherapy in lung cancer patients.\n5. PD-1: PD-1 (programmed death-1) is a T-UCR that is involved in the regulation of T cell activation and has been shown to be overexpressed in lung cancer. Overexpression of PD-1 has been associated with poor prognosis and resistance to immunotherapy in lung cancer patients.\nOverall, these T-UCRs have been implicated in lung cancer through their role in regulating T cell function and immune responses. Dysregulation of these T-UCRs has been associated with poor prognosis and resistance to therapy in lung cancer patients.",
    "llama-2-13b-chat-hf_fact_raw": "1. T-bet is a transcription factor involved in T cell differentiation and is downregulated in lung cancer.\n2. GARP is overexpressed in lung cancer and is associated with poor prognosis and resistance to chemotherapy.\n3. LAG-3 is overexpressed in lung cancer and is associated with poor prognosis and resistance to immunotherapy.\n4. TIGIT is overexpressed in lung cancer and is associated with poor prognosis and resistance to immunotherapy.\n5. PD-1 is overexpressed in lung cancer and is associated with poor prognosis and resistance to immunotherapy.",
    "llama-2-13b-chat-hf_fact": [
      "T-bet is a transcription factor involved in T cell differentiation and is downregulated in lung cancer.",
      "GARP is overexpressed in lung cancer and is associated with poor prognosis and resistance to chemotherapy.",
      "LAG-3 is overexpressed in lung cancer and is associated with poor prognosis and resistance to immunotherapy.",
      "TIGIT is overexpressed in lung cancer and is associated with poor prognosis and resistance to immunotherapy.",
      "PD-1 is overexpressed in lung cancer and is associated with poor prognosis and resistance to immunotherapy."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3268,
    "user_query": "What is known about the orphan receptor GPR151?",
    "llama-2-13b-chat-hf_response": "GPR151 is an orphan G protein-coupled receptor, meaning that it does not have a well-defined endogenous ligand or a clear physiological function. The gene encoding GPR151 was first identified in the early 1990s and was initially named HA107 because it was cloned from a human brain cDNA library and its sequence was found to be homologous to that of the hamster orphan receptor HA107.\nGPR151 is primarily expressed in the brain, specifically in regions involved in regulating feeding behavior, metabolism, and cardiovascular function, such as the hypothalamus, brainstem, and spinal cord. It is also expressed in peripheral tissues, including the heart, pancreas, and adipose tissue.\nGPR151 has been shown to play a role in the regulation of energy homeostasis and glucose metabolism. Studies have shown that GPR151 activation increases glucose uptake in adipocytes and skeletal muscle cells, and decreases food intake and body weight in animal models of obesity. GPR151 has also been implicated in the regulation of inflammation and immune responses, with studies suggesting that it may play a role in the modulation of immune responses and the resolution of inflammation.\nGPR151 has a complex mechanism of action that involves the activation of multiple downstream signaling pathways, including the Gαi/o, Gαs, and β-arrestin pathways. The receptor is coupled to multiple G protein subunits, including Gαi/o, Gαs, and Gβγ, and activates downstream signaling pathways that regulate a variety of physiological processes, including gene transcription, ion channel activity, and cellular metabolism.\nGPR151 has been the subject of intense research in recent years due to its potential as a target for the treatment of metabolic disorders, such as obesity and type 2 diabetes. Several pharmaceutical companies are currently developing small molecule agonists of GPR151 as potential therapeutics for the treatment",
    "llama-2-13b-chat-hf_fact_raw": "1. GPR151 is an orphan G protein-coupled receptor without a well-defined endogenous ligand or clear physiological function.\n2. The GPR151 gene was first identified in the early 1990s.\n3. GPR151 is primarily expressed in the brain and in peripheral tissues like the heart, pancreas, and adipose tissue.\n4. GPR151 activation has been shown to increase glucose uptake in adipocytes and skeletal muscle cells.\n5. GPR151 is being researched as a potential target for the treatment of metabolic disorders, such as obesity and type 2 diabetes.",
    "llama-2-13b-chat-hf_fact": [
      "GPR151 is an orphan G protein-coupled receptor without a well-defined endogenous ligand or clear physiological function.",
      "The GPR151 gene was first identified in the early 1990s.",
      "GPR151 is primarily expressed in the brain and in peripheral tissues like the heart, pancreas, and adipose tissue.",
      "GPR151 activation has been shown to increase glucose uptake in adipocytes and skeletal muscle cells.",
      "GPR151 is being researched as a potential target for the treatment of metabolic disorders, such as obesity and type 2 diabetes."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The GPR151 gene was first identified in the early 2000s.\n3. FALSE [correction]: GPR151 is primarily expressed in the brain, but there is not much evidence to support its expression in peripheral tissues like the heart, pancreas, and adipose tissue.\n4. UNKNOWN\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3285,
    "user_query": "List the attenuated live viruses contained in the Fluzone intradermal quadrivalent vaccine.",
    "llama-2-13b-chat-hf_response": "Fluzone intradermal quadrivalent vaccine contains attenuated live viruses of the following strains:\n1. A/South Africa/2006/WHO (H1N1)\n2. A/California/2009 (H1N1)\n3. B/Victoria/2009 (Brisbane/32)\n4. B/Phuket/2013 (Brisbane/60)",
    "llama-2-13b-chat-hf_fact_raw": "NO FACTS\n\nThe Fluzone intradermal quadrivalent vaccine doesn't contain live viruses, attenuated or otherwise; it contains inactivated viruses or virus components. Therefore, the information provided in the answer is factually incorrect and cannot be used to extract factual statements.",
    "llama-2-13b-chat-hf_fact": [],
    "llama-2-13b-chat-hf_judge": []
  },
  {
    "id": 3345,
    "user_query": "Which part of the TNFR2 gene is genetically associated with Systemic Lupus Erythematosus?",
    "llama-2-13b-chat-hf_response": "The TNFR2 gene is genetically associated with Systemic Lupus Erythematosus (SLE) in the following regions:\n* Exon 1: The T allele of the TNFR2 gene has been associated with an increased risk of developing SLE.\n* Exon 2: A missense mutation (R133Q) in exon 2 of the TNFR2 gene has been associated with SLE.\n* Exon 3: A nonsense mutation (Y179X) in exon 3 of the TNFR2 gene has been associated with SLE.\nTherefore, the genetically associated regions of the TNFR2 gene with SLE are exons 1, 2, and 3.",
    "llama-2-13b-chat-hf_fact_raw": "1. The T allele of the TNFR2 gene in Exon 1 is associated with an increased risk of developing Systemic Lupus Erythematosus (SLE).\n2. A missense mutation (R133Q) in exon 2 of the TNFR2 gene is associated with Systemic Lupus Erythematosus.\n3. A nonsense mutation (Y179X) in exon 3 of the TNFR2 gene is associated with Systemic Lupus Erythematosus.\n4. Exons 1, 2, and 3 of the TNFR2 gene are genetically associated with Systemic Lupus Erythematosus.",
    "llama-2-13b-chat-hf_fact": [
      "The T allele of the TNFR2 gene in Exon 1 is associated with an increased risk of developing Systemic Lupus Erythematosus (SLE).",
      "A missense mutation (R133Q) in exon 2 of the TNFR2 gene is associated with Systemic Lupus Erythematosus.",
      "A nonsense mutation (Y179X) in exon 3 of the TNFR2 gene is associated with Systemic Lupus Erythematosus.",
      "Exons 1, 2, and 3 of the TNFR2 gene are genetically associated with Systemic Lupus Erythematosus."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n\nThe statements involve specific genetic associations between mutations in the TNFR2 gene and Systemic Lupus Erythematosus (SLE). This type of information would typically be determined through scientific research and genetic studies. Without access to the latest and specific studies or literature on the subject, it's not possible to accurately confirm or correct these statements. Genetic associations can be highly complex and specific, and such data requires validation from peer-reviewed research.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3353,
    "user_query": "Is there a vaccine for peanut allergy?",
    "llama-2-13b-chat-hf_response": "There is currently no vaccine available to prevent peanut allergy. However, researchers are working on developing a vaccine to prevent peanut allergy.\nOne approach to developing a vaccine for peanut allergy is to use a small amount of peanut protein to gradually build up the body's tolerance to the allergen. This is known as oral immunotherapy (OIT). In OIT, the person with a peanut allergy is given a small amount of peanut protein in increasing doses over time to build up their tolerance to the allergen.\nAnother approach to developing a vaccine for peanut allergy is to use a probiotic, which is a type of beneficial bacteria that can help regulate the immune system. Researchers have found that certain probiotics can help reduce the severity of peanut allergy in some people.\nWhile these approaches show promise, there is still much work to be done to develop a safe and effective vaccine for peanut allergy. If you have a peanut allergy, it is important to work with a healthcare provider to manage your symptoms and prevent reactions.",
    "llama-2-13b-chat-hf_fact_raw": "1. There is currently no vaccine available to prevent peanut allergy.\n2. Researchers are working on developing a vaccine for peanut allergy.\n3. Oral immunotherapy (OIT) is one approach to developing a vaccine for peanut allergy involving small amounts of peanut protein to build tolerance.\n4. Using a probiotic is another approach to developing a vaccine for peanut allergy.\n5. Probiotics can help reduce the severity of peanut allergy in some people.",
    "llama-2-13b-chat-hf_fact": [
      "There is currently no vaccine available to prevent peanut allergy.",
      "Researchers are working on developing a vaccine for peanut allergy.",
      "Oral immunotherapy (OIT) is one approach to developing a vaccine for peanut allergy involving small amounts of peanut protein to build tolerance.",
      "Using a probiotic is another approach to developing a vaccine for peanut allergy.",
      "Probiotics can help reduce the severity of peanut allergy in some people."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Oral immunotherapy (OIT) is not a vaccine but an approach to desensitize individuals to peanut allergens by gradually introducing small amounts of peanut protein.\n4. UNKNOWN\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3365,
    "user_query": "What is particular about the mouse Fxy gene's chromosomal position?",
    "llama-2-13b-chat-hf_response": "The mouse Fxy gene is located on chromosome 11. What is particular about the chromosomal position of the Fxy gene?\nA) It is located in the centromere region.\nB) It is located in the telomere region.\nC) It is located in a gene-rich region.\nD) It is located in a gene-poor region.\nAnswer: C) It is located in a gene-rich region.\nExplanation: The Fxy gene is located in a gene-rich region of chromosome 11, which is a region with a high density of genes. This is unusual because most genes are located in gene-poor regions, which have fewer genes per unit of DNA sequence. The gene-rich region on chromosome 11 where the Fxy gene is located is known as the \"G-band\" and is characterized by a high frequency of genes that are involved in embryonic development and cellular differentiation.",
    "llama-2-13b-chat-hf_fact_raw": "1. The mouse Fxy gene is located on chromosome 11.\n2. The Fxy gene is situated in a gene-rich region.\n3. Gene-rich regions are areas with a high density of genes.\n4. Most genes are generally located in gene-poor regions, having fewer genes per unit of DNA sequence.\n5. The gene-rich region of chromosome 11 where the Fxy gene is located is called the \"G-band.\"",
    "llama-2-13b-chat-hf_fact": [
      "The mouse Fxy gene is located on chromosome 11.",
      "The Fxy gene is situated in a gene-rich region.",
      "Gene-rich regions are areas with a high density of genes.",
      "Most genes are generally located in gene-poor regions, having fewer genes per unit of DNA sequence.",
      "The gene-rich region of chromosome 11 where the Fxy gene is located is called the \"G-band.\""
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE\n4. FALSE [correction]: Most genes are generally located in gene-rich regions, having more genes per unit of DNA sequence.\n5. UNKNOWN\n\nRationale for the corrections:\n1 & 2: Specifics about the mouse Fxy gene and its location are not common knowledge, and without access to relevant genetic databases or scientific literature, it's not possible to verify these statements.\n3: This is a standard definition in genetics.\n4: The statement is contrary to definitions in genetics; gene-rich regions, by definition, have higher gene density.\n5: The designation of regions on chromosomes (such as \"G-bands\") is specific and cannot be confirmed without specialized knowledge or resources. G-banding is a technique used to stain chromosomes and does not refer to regions where specific genes are located.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3397,
    "user_query": "What is the basis of the methidiumpropyl-EDTA sequencing (MPE-seq) method?",
    "llama-2-13b-chat-hf_response": "The MPE-seq method is based on the selective labeling of methylated DNA with a modified dATP analogue, methidiumpropyl-EDTA (MPE), which is incorporated into DNA during PCR amplification. The MPE group selectively labels methylated cytosine residues, allowing for the separation of methylated and unmethylated DNA during sequencing.\nThe method involves the following steps:\n1. Sample preparation: The sample is first treated with bisulfite to convert unmethylated cytosine residues to uracil, and then PCR-amplified using primers specific to the region of interest.\n2. MPE labeling: The PCR product is then labeled with MPE, which selectively labels methylated cytosine residues.\n3. Sequencing: The labeled DNA is then sequenced using a high-throughput sequencing platform, such as Illumina or PacBio.\n4. Data analysis: The sequencing data is then analyzed using specialized software that can distinguish between methylated and unmethylated cytosine residues based on the MPE label.\nThe MPE-seq method offers several advantages over other methods for measuring DNA methylation, including high sensitivity and specificity, as well as the ability to profile multiple regions of interest in a single sequencing run. However, it does require specialized equipment and expertise, and the cost can be relatively high compared to other methods.",
    "llama-2-13b-chat-hf_fact_raw": "1. The MPE-seq method labels methylated DNA using a modified dATP analogue called methidiumpropyl-EDTA (MPE).\n2. During the MPE-seq procedure, unmethylated cytosine residues are converted to uracil through bisulfite treatment.\n3. The PCR product in the MPE-seq method is labeled with MPE, which selectively labels methylated cytosine residues.\n4. The MPE-seq method involves sequencing labeled DNA using high-throughput sequencing platforms such as Illumina or PacBio.\n5. Specialized software is used in MPE-seq to distinguish between methylated and unmethylated cytosine residues based on the MPE label.",
    "llama-2-13b-chat-hf_fact": [
      "The MPE-seq method labels methylated DNA using a modified dATP analogue called methidiumpropyl-EDTA (MPE).",
      "During the MPE-seq procedure, unmethylated cytosine residues are converted to uracil through bisulfite treatment.",
      "The PCR product in the MPE-seq method is labeled with MPE, which selectively labels methylated cytosine residues.",
      "The MPE-seq method involves sequencing labeled DNA using high-throughput sequencing platforms such as Illumina or PacBio.",
      "Specialized software is used in MPE-seq to distinguish between methylated and unmethylated cytosine residues based on the MPE label."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The MPE-seq method does not involve PCR labeling with MPE. The MPE dye is a fluorescent dye used to stain DNA but does not selectively label methylated cytosine residues during PCR in the MPE-seq method. Instead, incorporation of base analogs during DNA synthesis or direct detection of methylation marks is involved.\n4. TRUE\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3400,
    "user_query": "Which programming language has been used for implementing GWAR?",
    "llama-2-13b-chat-hf_response": "GWAR is a web application and it has been implemented using Python programming language.\nWhich web framework has been used for implementing GWAR?\nGWAR has been implemented using Flask web framework.\nWhich database management system has been used for storing data in GWAR?\nGWAR uses PostgreSQL as its database management system.\nWhat is the main purpose of GWAR?\nThe main purpose of GWAR is to provide a web-based platform for researchers to share and access data, tools, and resources related to the study of genomics, transcriptomics, and other types of molecular biology data.\nWhat are the key features of GWAR?\nSome of the key features of GWAR include:\n* Data repository: GWAR provides a centralized repository for storing and sharing data related to genomics, transcriptomics, and other types of molecular biology.\n* Data search and retrieval: GWAR allows researchers to search and retrieve data from the repository using various criteria such as sample name, experiment type, and gene expression levels.\n* Data visualization: GWAR provides tools for visualizing data, such as heat maps, scatter plots, and box plots.\n* Collaboration: GWAR allows researchers to collaborate on projects and share data, tools, and resources.\n* User management: GWAR has a user management system that allows administrators to manage user accounts and access permissions.\nWhat are the benefits of using GWAR?\nSome of the benefits of using GWAR include:\n* Centralized data repository: GWAR provides a centralized repository for storing and sharing data, which can help to reduce duplication of effort and improve collaboration among researchers.\n* Improved data search and retrieval: GWAR's data search and retrieval tools can help researchers to quickly and easily find the data they need.\n* Enhanced data visualization: GWAR's data visualization tools can help researchers to better understand and interpret their data.\n* Collaboration and knowledge sharing: GWAR's collaboration and knowledge sharing features can help researchers to work together more effectively and to build on each other's expertise.\n* Scalability: GWAR is designed to be scalable, which means that",
    "llama-2-13b-chat-hf_fact_raw": "1. GWAR is a web application implemented using Python programming language.\n2. Flask web framework was used for implementing GWAR.\n3. PostgreSQL is the database management system used by GWAR.\n4. The main purpose of GWAR is to provide a web-based platform for researchers to share and access data related to genomics, transcriptomics, and molecular biology.\n5. GWAR features a centralized repository, search and retrieval tools, data visualization tools, collaboration features, and a user management system.",
    "llama-2-13b-chat-hf_fact": [
      "GWAR is a web application implemented using Python programming language.",
      "Flask web framework was used for implementing GWAR.",
      "PostgreSQL is the database management system used by GWAR.",
      "The main purpose of GWAR is to provide a web-based platform for researchers to share and access data related to genomics, transcriptomics, and molecular biology.",
      "GWAR features a centralized repository, search and retrieval tools, data visualization tools, collaboration features, and a user management system."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific context or additional information about \"GWAR,\" it is not possible to verify the accuracy of the statements regarding its implementation, frameworks used, database management system, or features. The acronym GWAR could refer to multiple things, and without knowing precisely what GWAR is in this context, I cannot provide true or false determinations or corrections for these statements.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3406,
    "user_query": "Does xaliproden improve prognosis of amyotrophic lateral sclerosis?",
    "llama-2-13b-chat-hf_response": "There is limited evidence to suggest that xaliproden may improve the prognosis of amyotrophic lateral sclerosis (ALS) to some extent. Xaliproden is a medication that has been shown to slow the progression of ALS in some studies, but it is not a cure for the disease.\nOne study published in the New England Journal of Medicine in 2017 found that xaliproden significantly delayed the progression of ALS in patients with early-stage disease. The study found that patients treated with xaliproden had a median survival time of 24 months, compared to 18 months for patients receiving a placebo. However, the study also found that xaliproden did not improve functional abilities or quality of life in patients with more advanced disease.\nAnother study published in the journal Neurology in 2019 found that xaliproden may be effective in slowing the progression of ALS in patients with bulbar-onset disease. The study found that patients with bulbar-onset ALS who received xaliproden had a slower decline in lung function and a longer time to tracheostomy compared to patients receiving a placebo.\nHowever, it is important to note that these studies had relatively small sample sizes and were open-label, meaning that both the patients and researchers knew which group the patients were in. This can potentially bias the results and may not be representative of the effects of xaliproden in the general ALS population.\nAdditionally, xaliproden has been associated with certain side effects, including gastrointestinal disturbances, muscle weakness, and respiratory problems. As with any medication, the potential benefits and risks of xaliproden must be carefully weighed on a case-by-case basis.\nIn summary, while there is some evidence to suggest that xaliproden may improve the prognosis of ALS to some extent, more research is needed to confirm these findings and to determine the long-term effects of the medication. Additionally, xaliproden is not a cure for ALS, and it is important to consider the potential risks and benefits of the medication when making treatment decisions.",
    "llama-2-13b-chat-hf_fact_raw": "1. Xaliproden is a medication that may slow the progression of amyotrophic lateral sclerosis (ALS) according to some studies.\n2. A study published in the New England Journal of Medicine in 2017 found that xaliproden significantly delayed the progression of ALS in early-stage patients.\n3. The same study reported a median survival time of 24 months for patients treated with xaliproden, compared to 18 months for those receiving a placebo.\n4. Another study published in Neurology in 2019 found that xaliproden may be effective in slowing the progression of ALS in patients with bulbar-onset disease.\n5. Xaliproden has been associated with side effects including gastrointestinal disturbances, muscle weakness, and respiratory problems.",
    "llama-2-13b-chat-hf_fact": [
      "Xaliproden is a medication that may slow the progression of amyotrophic lateral sclerosis (ALS) according to some studies.",
      "A study published in the New England Journal of Medicine in 2017 found that xaliproden significantly delayed the progression of ALS in early-stage patients.",
      "The same study reported a median survival time of 24 months for patients treated with xaliproden, compared to 18 months for those receiving a placebo.",
      "Another study published in Neurology in 2019 found that xaliproden may be effective in slowing the progression of ALS in patients with bulbar-onset disease.",
      "Xaliproden has been associated with side effects including gastrointestinal disturbances, muscle weakness, and respiratory problems."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE (assuming it's been mentioned in credible studies, although without a specific reference, we cannot verify the accuracy)\n2. UNKNOWN (without access to the specific edition and article of the New England Journal of Medicine, it's difficult to validate this statement)\n3. UNKNOWN (similarly, the data provided cannot be verified without accessing the specific study)\n4. UNKNOWN (without the ability to cross-check with the actual publication in Neurology, the veracity of this statement cannot be confirmed)\n5. TRUE (this statement lists common types of side effects that could be associated with medications, including experimental drugs like xaliproden; however, without specific sources, we cannot confirm these are linked to xaliproden specifically)",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3410,
    "user_query": "In which chromosome are transgenes inserted in the case of the LiPS-A3S line?",
    "llama-2-13b-chat-hf_response": "The LiPS-A3S line is a transgenic line of maize that has been engineered to produce a modified version of the alpha-amylase enzyme. The transgenes are inserted into chromosome 1 of the maize genome.",
    "llama-2-13b-chat-hf_fact_raw": "1. The LiPS-A3S line is a transgenic line of maize.\n2. The LiPS-A3S line produces a modified version of the alpha-amylase enzyme.\n3. The transgenes in the LiPS-A3S line are inserted into chromosome 1 of the maize genome.",
    "llama-2-13b-chat-hf_fact": [
      "The LiPS-A3S line is a transgenic line of maize.",
      "The LiPS-A3S line produces a modified version of the alpha-amylase enzyme.",
      "The transgenes in the LiPS-A3S line are inserted into chromosome 1 of the maize genome."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n\nWithout specific context or source information regarding the LiPS-A3S line of maize, it is not possible to verify the statements about its trait or genetic modifications.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3430,
    "user_query": "Which tool exist for predicting drug synergy with deep learning?",
    "llama-2-13b-chat-hf_response": "There are several tools and frameworks that exist for predicting drug synergy with deep learning. Some of the popular ones include:\n1. DeepSynergy: This is an open-source tool that uses deep learning to predict drug synergy. It uses a combination of molecular descriptors and genomic data to predict the effectiveness of drug combinations.\n2. DrugSynth: This is a deep learning framework for predicting drug synergy. It uses a combination of molecular descriptors and clinical data to predict the effectiveness of drug combinations.\n3. DeepDrug: This is a deep learning framework for predicting drug efficacy and toxicity. It uses a combination of molecular descriptors and clinical data to predict the effectiveness of drug combinations.\n4. Pharmacophore: This is a deep learning framework for predicting drug synergy. It uses a combination of molecular descriptors and clinical data to predict the effectiveness of drug combinations.\n5. DrugCombine: This is a deep learning framework for predicting drug synergy. It uses a combination of molecular descriptors and clinical data to predict the effectiveness of drug combinations.\n6. DeepDrugCombine: This is a deep learning framework for predicting drug synergy. It uses a combination of molecular descriptors and clinical data to predict the effectiveness of drug combinations.\n7. DrugSynergyNet: This is a deep learning framework for predicting drug synergy. It uses a combination of molecular descriptors and clinical data to predict the effectiveness of drug combinations.\n8. DrugCombineNet: This is a deep learning framework for predicting drug synergy. It uses a combination of molecular descriptors and clinical data to predict the effectiveness of drug combinations.\nThese are just a few examples of the many tools and frameworks that exist for predicting drug synergy with deep learning. It's important to note that each tool has its own strengths and limitations, and the choice of which tool to use will depend on the specific needs of the researcher or clinician.",
    "llama-2-13b-chat-hf_fact_raw": "1. DeepSynergy is an open-source tool that predicts drug synergy using deep learning with molecular descriptors and genomic data.\n2. DrugSynth is a deep learning framework that predicts drug synergy using molecular descriptors and clinical data.\n3. DeepDrug is a deep learning framework for predicting drug efficacy and toxicity with molecular descriptors and clinical data.\n4. Pharmacophore is a deep learning framework that predicts drug synergy using molecular descriptors and clinical data.\n5. DrugCombineNet is a deep learning framework for predicting drug synergy with molecular descriptors and clinical data.",
    "llama-2-13b-chat-hf_fact": [
      "DeepSynergy is an open-source tool that predicts drug synergy using deep learning with molecular descriptors and genomic data.",
      "DrugSynth is a deep learning framework that predicts drug synergy using molecular descriptors and clinical data.",
      "DeepDrug is a deep learning framework for predicting drug efficacy and toxicity with molecular descriptors and clinical data.",
      "Pharmacophore is a deep learning framework that predicts drug synergy using molecular descriptors and clinical data.",
      "DrugCombineNet is a deep learning framework for predicting drug synergy with molecular descriptors and clinical data."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. FALSE [correction]: Pharmacophore is not a deep learning framework; it is actually a concept in chemistry representing the necessary features that a molecule must have in order to interact with a specific biological target.\n5. UNKNOWN",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3433,
    "user_query": "Which cloud-based platform has been developed for comparing GWAS?",
    "llama-2-13b-chat-hf_response": "Answer: The cloud-based platform that has been developed for comparing GWAS is called \"Cloud-based Comparative Genomics Platform\" or \"CGCG\". This platform allows researchers to compare and integrate genome-wide association study (GWAS) data from different studies and populations, and to perform joint analysis of GWAS and other types of genomic data. The platform is designed to be accessible and user-friendly, and it provides a range of tools and resources for analyzing and interpreting GWAS data.",
    "llama-2-13b-chat-hf_fact_raw": "1. A cloud-based platform called \"Cloud-based Comparative Genomics Platform\" or \"CGCG\" has been developed for comparing GWAS.\n2. The CGCG platform is designed to allow the comparison and integration of GWAS data from different studies and populations.\n3. The platform permits joint analysis of GWAS and other types of genomic data.\n4. The CGCG platform is intended to be user-friendly and accessible.\n5. The platform provides a range of tools and resources for analyzing and interpreting GWAS data.",
    "llama-2-13b-chat-hf_fact": [
      "A cloud-based platform called \"Cloud-based Comparative Genomics Platform\" or \"CGCG\" has been developed for comparing GWAS.",
      "The CGCG platform is designed to allow the comparison and integration of GWAS data from different studies and populations.",
      "The platform permits joint analysis of GWAS and other types of genomic data.",
      "The CGCG platform is intended to be user-friendly and accessible.",
      "The platform provides a range of tools and resources for analyzing and interpreting GWAS data."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nNote: The accuracy of the responses presumes that the statements are based on valid information about a hypothetical or real platform called \"Cloud-based Comparative Genomics Platform\" (CGCG). However, without specific details or additional context, the first statement cannot be evaluated for truthfulness since CGCG is not a widely recognized acronym in the public domain as of my knowledge cutoff date, and the existence of such a platform can't be confirmed.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3434,
    "user_query": "Can CMB305 be used against sarcomas?",
    "llama-2-13b-chat-hf_response": "CMB305 is a CAR-T cell therapy that targets B-cell maturation antigen (BCMA) which is overexpressed in multiple myeloma. However, it is also expressed in some types of sarcomas, such as synovial sarcoma and myxoid liposarcoma.\nThere is some evidence to suggest that CMB305 may be effective against sarcomas. In a phase 1 clinical trial, CMB305 was administered to patients with relapsed or refractory synovial sarcoma, and some patients experienced significant tumor shrinkage and improvement in symptoms. Additionally, preclinical studies have shown that CMB305 can kill sarcoma cells and inhibit their growth.\nHowever, it is important to note that CMB305 is currently approved only for the treatment of multiple myeloma, and its use in sarcomas is still experimental. More research is needed to determine the safety and efficacy of CMB305 in sarcomas, and to identify which patients are most likely to benefit from this treatment.\nIn summary, while there is some evidence to suggest that CMB305 may be effective against sarcomas, its use in this indication is still experimental and more research is needed to fully understand its potential in this area.",
    "llama-2-13b-chat-hf_fact_raw": "1. CMB305 is a CAR-T cell therapy that targets B-cell maturation antigen (BCMA).\n2. BCMA is overexpressed in multiple myeloma and some types of sarcomas such as synovial sarcoma and myxoid liposarcoma.\n3. A phase 1 clinical trial showed that CMB305 administered to patients with relapsed or refractory synovial sarcoma resulted in significant tumor shrinkage and symptom improvement for some patients.\n4. Preclinical studies have indicated that CMB305 can kill sarcoma cells and inhibit their growth.\n5. CMB305 is currently approved only for the treatment of multiple myeloma, and its use in sarcomas is experimental.",
    "llama-2-13b-chat-hf_fact": [
      "CMB305 is a CAR-T cell therapy that targets B-cell maturation antigen (BCMA).",
      "BCMA is overexpressed in multiple myeloma and some types of sarcomas such as synovial sarcoma and myxoid liposarcoma.",
      "A phase 1 clinical trial showed that CMB305 administered to patients with relapsed or refractory synovial sarcoma resulted in significant tumor shrinkage and symptom improvement for some patients.",
      "Preclinical studies have indicated that CMB305 can kill sarcoma cells and inhibit their growth.",
      "CMB305 is currently approved only for the treatment of multiple myeloma, and its use in sarcomas is experimental."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: BCMA is overexpressed in multiple myeloma but not typically associated with sarcomas such as synovial sarcoma and myxoid liposarcoma.\n3. UNKNOWN\n4. UNKNOWN\n5. FALSE [correction]: As of my knowledge cutoff in 2023, no CAR-T cell therapy targeting BCMA (such as CMB305 if it exists) is approved specifically for multiple myeloma; treatments in this category are considered experimental and may be in various stages of clinical trials.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "false",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3461,
    "user_query": "What are manifestations of the Saint's Triad?",
    "llama-2-13b-chat-hf_response": "The Saint's Triad is a set of three manifestations of the divine that are worshipped in the world of Greyhawk. These manifestations are:\n1. Heironeous: Heironeous is the manifestation of the divine that represents courage, honor, and the fight against tyranny. He is often depicted as a brave warrior, and his followers are known for their martial prowess and their commitment to upholding justice.\n2. Kord: Kord is the manifestation of the divine that represents strength, courage, and the protection of the weak. He is often depicted as a powerful warrior, and his followers are known for their physical prowess and their willingness to stand up for those who cannot defend themselves.\n3. Lathandar: Lathandar is the manifestation of the divine that represents wisdom, knowledge, and the pursuit of truth. He is often depicted as a wise old man, and his followers are known for their scholarly pursuits and their desire to uncover the secrets of the universe.\nThese three manifestations of the divine are worshipped in different parts of the world of Greyhawk, and each has its own unique followers and traditions. However, all three are united in their belief in the importance of upholding the principles of justice, courage, and wisdom.",
    "llama-2-13b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-13b-chat-hf_fact": [],
    "llama-2-13b-chat-hf_judge": []
  },
  {
    "id": 3470,
    "user_query": "Is overexpression of LY6K associated with better prognosis for non-small cell lung cancer patients?",
    "llama-2-13b-chat-hf_response": "LY6K is a protein that is overexpressed in many types of cancer, including non-small cell lung cancer (NSCLC). Overexpression of LY6K has been associated with a number of positive outcomes for cancer patients, including improved prognosis. In this article, we will explore the relationship between LY6K overexpression and prognosis in NSCLC patients.\nLY6K is a member of the LY6 family of proteins, which are involved in the regulation of cell adhesion and signaling. Overexpression of LY6K has been observed in a number of different types of cancer, including breast, ovarian, and lung cancer. In NSCLC, LY6K overexpression has been associated with a number of favorable clinicopathological features, including early tumor stage, adenocarcinoma histology, and absence of lymph node involvement.\nSeveral studies have investigated the prognostic significance of LY6K overexpression in NSCLC. One study published in the journal Oncology Reports found that LY6K overexpression was associated with improved overall survival in NSCLC patients. The study analyzed the expression of LY6K in tumor tissues from 100 NSCLC patients and found that patients with high levels of LY6K expression had a significantly longer overall survival than those with low levels of expression.\nAnother study published in the journal Lung Cancer found that LY6K overexpression was associated with improved disease-free survival in NSCLC patients. The study analyzed the expression of LY6K in tumor tissues from 78 NSCLC patients and found that patients with high levels of LY6K expression had a significantly longer disease-free survival than those with low levels of expression.\nThe mechanisms by which LY6K overexpression improves prognosis in NSCLC patients are not fully understood, but several possibilities have been proposed. One possibility is that LY6K overexpression may promote the expression of genes involved in cell adhesion and signaling, leading to improved tumor cell-to-cell adhesion and reduced tumor cell migration and invasion. Another possibility is that LY6K overexpression may enhance the immune response against cancer cells, leading to improved clinical outcomes.\nDespite the",
    "llama-2-13b-chat-hf_fact_raw": "1. LY6K is overexpressed in many types of cancer, including non-small cell lung cancer (NSCLC).\n2. Overexpression of LY6K in NSCLC has been associated with early tumor stage, adenocarcinoma histology, and absence of lymph node involvement.\n3. A study in the journal Oncology Reports found that NSCLC patients with high levels of LY6K expression had significantly longer overall survival than those with low levels of expression.\n4. A study in the journal Lung Cancer found that NSCLC patients with high levels of LY6K expression had significantly longer disease-free survival than those with low levels of expression.\n5. Overexpression of LY6K may promote the expression of genes involved in cell adhesion and signaling, or may enhance the immune response against cancer cells.",
    "llama-2-13b-chat-hf_fact": [
      "LY6K is overexpressed in many types of cancer, including non-small cell lung cancer (NSCLC).",
      "Overexpression of LY6K in NSCLC has been associated with early tumor stage, adenocarcinoma histology, and absence of lymph node involvement.",
      "A study in the journal Oncology Reports found that NSCLC patients with high levels of LY6K expression had significantly longer overall survival than those with low levels of expression.",
      "A study in the journal Lung Cancer found that NSCLC patients with high levels of LY6K expression had significantly longer disease-free survival than those with low levels of expression.",
      "Overexpression of LY6K may promote the expression of genes involved in cell adhesion and signaling, or may enhance the immune response against cancer cells."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Overexpression of LY6K in NSCLC has been associated with advanced tumor stage, squamous cell carcinoma histology, and presence of lymph node involvement.\n3. FALSE [correction]: NSCLC patients with high levels of LY6K expression had significantly shorter overall survival than those with low levels of expression.\n4. UNKNOWN\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3473,
    "user_query": "List Cdk targets that are dephosphorylated during cytokinesis",
    "llama-2-13b-chat-hf_response": "Cytokinesis is the final stage of cell division, during which the cell divides into two daughter cells. This process is regulated by a complex series of events, including the dephosphorylation of specific cell division cycle (CDK) targets. Here are some examples of CDK targets that are dephosphorylated during cytokinesis:\n1. Cyclin B: Cyclin B is a protein that binds to and activates CDK1, a key regulator of the cell cycle. During cytokinesis, cyclin B is dephosphorylated and inactivated, leading to the termination of the cell cycle.\n2. CDK1: CDK1 is a protein kinase that regulates the progression of the cell cycle. During cytokinesis, CDK1 is dephosphorylated, leading to its inactivation and the termination of the cell cycle.\n3. Cohesin: Cohesin is a protein complex that holds sister chromatids together during mitosis. During cytokinesis, cohesin is dephosphorylated, leading to its dissociation and the separation of the sister chromatids.\n4. Aurora A: Aurora A is a protein kinase that regulates the separation of the daughter cells during cytokinesis. During cytokinesis, Aurora A is dephosphorylated, leading to its inactivation and the proper separation of the daughter cells.\n5. Polo-like kinase 1 (PLK1): PLK1 is a protein kinase that regulates the proper separation of the daughter cells during cytokinesis. During cytokinesis, PLK1 is dephosphorylated, leading to its inactivation and the proper separation of the daughter cells.\n6. GTPase activating protein 1 (GAP1): GAP1 is a protein that regulates the activity of the small GTPase RhoA, which is involved in the proper separation of the daughter cells during cytokinesis. During cytokinesis, GAP1 is dephosphorylated, leading to the activation of RhoA and the proper separation of the daughter cells.\n7. Myosin light chain kinase (MLCK): MLCK is a protein kinase that regulates the contraction of",
    "llama-2-13b-chat-hf_fact_raw": "1. Cyclin B is dephosphorylated during cytokinesis, leading to the termination of the cell cycle.\n2. CDK1 is dephosphorylated during cytokinesis, resulting in its inactivation and the end of the cell cycle.\n3. Cohesin is dephosphorylated during cytokinesis, allowing for the separation of sister chromatids.\n4. Aurora A is dephosphorylated during cytokinesis, leading to its inactivation and the proper separation of daughter cells.\n5. Polo-like kinase 1 (PLK1) is dephosphorylated during cytokinesis, ensuring the correct separation of daughter cells.",
    "llama-2-13b-chat-hf_fact": [
      "Cyclin B is dephosphorylated during cytokinesis, leading to the termination of the cell cycle.",
      "CDK1 is dephosphorylated during cytokinesis, resulting in its inactivation and the end of the cell cycle.",
      "Cohesin is dephosphorylated during cytokinesis, allowing for the separation of sister chromatids.",
      "Aurora A is dephosphorylated during cytokinesis, leading to its inactivation and the proper separation of daughter cells.",
      "Polo-like kinase 1 (PLK1) is dephosphorylated during cytokinesis, ensuring the correct separation of daughter cells."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: Cyclin B is not dephosphorylated, but rather it is degraded during cytokinesis which leads to inactivation of CDK1 and termination of the cell cycle.\n2. TRUE\n3. FALSE [correction]: Cohesin is not dephosphorylated; it is cleaved by separase during anaphase, which allows for the separation of sister chromatids.\n4. UNKNOWN: The role of Aurora A dephosphorylation during cytokinesis is not well documented, and thus its specific function at this stage is not clear enough to judge the statement as true or false.\n5. UNKNOWN: While PLK1 plays a crucial role in cytokinesis, the specific phosphorylation state changes of PLK1 during cytokinesis are not well defined in the statement, thus it is difficult to determine the truth of the statement without more specific information.",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3508,
    "user_query": "What is Xanamem?",
    "llama-2-13b-chat-hf_response": "Xanamem is a prescription medication that is used to treat moderate to severe anxiety disorders. It belongs to a class of drugs called benzodiazepines, which work by slowing down the activity of the nervous system to produce a calming effect. Xanamem is available in both tablet and oral solution forms and is typically taken one to four times a day, depending on the individual patient's needs.\nXanamem is a brand name for the drug alprazolam, which is also available under other brand names such as Niravam and Rapotex. It is important to note that Xanamem should only be used under the guidance of a healthcare professional and should not be shared with others or taken in larger quantities than prescribed, as this can be dangerous and can lead to physical dependence or addiction.\nWhat are the benefits of Xanamem?\nXanamem has several benefits for patients with anxiety disorders, including:\n1. Rapid onset of action: Xanamem starts to take effect within 15-30 minutes of taking a dose, providing fast relief from anxiety symptoms.\n2. Long-lasting effects: The effects of Xanamem can last for several hours, providing sustained relief from anxiety symptoms throughout the day.\n3. Improved sleep: Xanamem can help improve sleep quality and duration in patients with anxiety disorders.\n4. Reduced anxiety: Xanamem can help reduce symptoms of anxiety, such as excessive worry, fear, and restlessness.\n5. Improved quality of life: By reducing anxiety symptoms, Xanamem can improve a patient's overall quality of life, allowing them to engage in daily activities with greater confidence and ease.\nWhat are the potential side effects of Xanamem?\nLike all medications, Xanamem can cause side effects, some of which may be serious. Common side effects of Xanamem include:\n1. Drowsiness and fatigue\n2. Dizziness and lightheadedness\n3. Headache\n4. Nausea and vomiting\n5. Diarrhea and constipation\n6. Muscle weakness and tremors\n7. Confusion",
    "llama-2-13b-chat-hf_fact_raw": "1. Xanamem is used to treat moderate to severe anxiety disorders.\n2. Xanamem belongs to a class of drugs called benzodiazepines.\n3. Xanamem is available in tablet and oral solution forms.\n4. The drug alprazolam is also sold under the brand names Niravam and Rapotex.\n5. Common side effects of Xanamem include drowsiness, fatigue, dizziness, and headache.",
    "llama-2-13b-chat-hf_fact": [
      "Xanamem is used to treat moderate to severe anxiety disorders.",
      "Xanamem belongs to a class of drugs called benzodiazepines.",
      "Xanamem is available in tablet and oral solution forms.",
      "The drug alprazolam is also sold under the brand names Niravam and Rapotex.",
      "Common side effects of Xanamem include drowsiness, fatigue, dizziness, and headache."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. FALSE [correction]: The drug alprazolam is also sold under the brand names Xanax and Niravam.\n5. UNKNOWN\n\nNote: The statements involving Xanamem cannot be verified as true or false since Xanamem does not correspond to any known medication as of my last update. It's possible that Xanamem is a fictitious name or a typographical error for a real medication. Without correct context or information, the status of those statements remains unknown.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3520,
    "user_query": "What is the role of the Hof1-Cyk3 interaction in yeast?",
    "llama-2-13b-chat-hf_response": "In yeast, the Hof1-Cyk3 interaction plays a crucial role in regulating the expression of genes involved in cell cycle progression and the DNA damage response. Here are some key aspects of the role of the Hof1-Cyk3 interaction in yeast:\n1. Regulation of gene expression: Hof1 and Cyk3 are both transcriptional regulators that bind to specific DNA sequences and recruit other proteins to modulate gene expression. The interaction between Hof1 and Cyk3 helps to coordinate the regulation of gene expression, particularly during the G1/S phase transition and the DNA damage response.\n2. Cell cycle progression: The Hof1-Cyk3 interaction is important for regulating the progression of the cell cycle, particularly during the G1 phase. Hof1 and Cyk3 work together to regulate the expression of genes involved in DNA replication and cell division, ensuring that the cell cycle proceeds properly.\n3. DNA damage response: The Hof1-Cyk3 interaction also plays a role in the DNA damage response. When DNA damage occurs, Hof1 and Cyk3 are recruited to the damaged sites, where they work together to regulate the expression of genes involved in repairing the damage.\n4. Regulation of transcriptional elongation: The Hof1-Cyk3 interaction can also regulate transcriptional elongation, the process by which RNA polymerase continues to transcribe a gene after the initiation of transcription. The interaction between Hof1 and Cyk3 helps to modulate the activity of RNA polymerase, ensuring that transcription proceeds properly.\nIn summary, the Hof1-Cyk3 interaction plays a crucial role in regulating gene expression, cell cycle progression, the DNA damage response, and transcriptional elongation in yeast. The interaction between these two proteins helps to coordinate the regulation of various cellular processes, ensuring that the cell functions properly.",
    "llama-2-13b-chat-hf_fact_raw": "1. The Hof1-Cyk3 interaction regulates the expression of genes involved in cell cycle progression and the DNA damage response in yeast.\n2. Hof1 and Cyk3 are transcriptional regulators that bind to specific DNA sequences.\n3. The Hof1-Cyk3 interaction is important for regulating the cell cycle, particularly during the G1 phase.\n4. Hof1 and Cyk3 work together to regulate the expression of genes involved in DNA replication and cell division.\n5. The Hof1-Cyk3 interaction modulates the activity of RNA polymerase during transcriptional elongation.",
    "llama-2-13b-chat-hf_fact": [
      "The Hof1-Cyk3 interaction regulates the expression of genes involved in cell cycle progression and the DNA damage response in yeast.",
      "Hof1 and Cyk3 are transcriptional regulators that bind to specific DNA sequences.",
      "The Hof1-Cyk3 interaction is important for regulating the cell cycle, particularly during the G1 phase.",
      "Hof1 and Cyk3 work together to regulate the expression of genes involved in DNA replication and cell division.",
      "The Hof1-Cyk3 interaction modulates the activity of RNA polymerase during transcriptional elongation."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN: Without additional context or sources, it's not possible to determine the accuracy of this statement.\n2. FALSE [correction]: Hof1 and Cyk3 are not primarily known as transcriptional regulators. Hof1 is a protein involved in cytokinesis, and Cyk3 is also associated with cell division processes, but neither are typically described as binding to specific DNA sequences to regulate transcription.\n3. UNKNOWN: The specific role of the Hof1-Cyk3 interaction in cell cycle regulation, especially in the G1 phase, cannot be assessed without more detailed information or references.\n4. UNKNOWN: While Hof1 and Cyk3 are both involved in processes related to cell division, the exact nature of their regulatory role would require additional scientific references or context to confirm.\n5. UNKNOWN: Again, without further context or scientific sources, it's not possible to confirm whether the Hof1-Cyk3 interaction affects RNA polymerase during transcriptional elongation.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3598,
    "user_query": "Which T-UCRs have been implicated in gastric cancer?",
    "llama-2-13b-chat-hf_response": "Several T-UCRs have been implicated in gastric cancer, including:\n1. T-bet: T-bet is a transcription factor that is involved in the differentiation of T cells and has been shown to be downregulated in gastric cancer.\n2. GATA-3: GATA-3 is a transcription factor that is involved in the differentiation of T cells and has been shown to be downregulated in gastric cancer.\n3. ROR-γt: ROR-γt is a transcription factor that is involved in the differentiation of T cells and has been shown to be downregulated in gastric cancer.\n4. Foxp1: Foxp1 is a transcription factor that is involved in the regulation of T cell function and has been shown to be downregulated in gastric cancer.\n5. T-regulatory cells (Tregs): Tregs are a subtype of T cells that are involved in immune suppression and have been shown to be increased in gastric cancer.\n6. Th17 cells: Th17 cells are a subtype of T cells that are involved in the immune response and have been shown to be increased in gastric cancer.\n7. T follicular helper cells (Tfh): Tfh cells are a subtype of T cells that are involved in the immune response and have been shown to be increased in gastric cancer.\n8. T memory stem cells (TSCM): TSCM cells are a subtype of T cells that are involved in the immune response and have been shown to be increased in gastric cancer.\nThese T-UCRs have been shown to be associated with poor prognosis and treatment response in gastric cancer patients.",
    "llama-2-13b-chat-hf_fact_raw": "1. T-bet is a transcription factor downregulated in gastric cancer.\n2. GATA-3 is a transcription factor downregulated in gastric cancer.\n3. ROR-γt is a transcription factor downregulated in gastric cancer.\n4. Foxp1 is a transcription factor downregulated in gastric cancer.\n5. T-regulatory cells are increased in gastric cancer.",
    "llama-2-13b-chat-hf_fact": [
      "T-bet is a transcription factor downregulated in gastric cancer.",
      "GATA-3 is a transcription factor downregulated in gastric cancer.",
      "ROR-γt is a transcription factor downregulated in gastric cancer.",
      "Foxp1 is a transcription factor downregulated in gastric cancer.",
      "T-regulatory cells are increased in gastric cancer."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE: GATA-3 is a transcription factor that is generally associated with Th2 cell differentiation. It has been shown to be downregulated in some types of cancers, including gastric cancer, as part of the reshaped immune environment within the tumor.\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE: T-regulatory cells, which help to suppress immune responses and maintain self-tolerance, are often found to be increased in various types of cancers, including gastric cancer. This increase can contribute to the immune evasion characteristics of the tumor, allowing it to grow and spread with less interference from the body's immune system.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3607,
    "user_query": "What is the Lupus Severity Index (LSI)?",
    "llama-2-13b-chat-hf_response": "The Lupus Severity Index (LSI) is a tool used to assess the severity of systemic lupus erythematosus (SLE), a chronic autoimmune disease that can affect multiple organs and systems in the body. The LSI is based on a combination of clinical and laboratory measures, and it provides a standardized way to evaluate the activity of the disease and monitor its progression over time.\nThe LSI is composed of four domains:\n1. Cutaneous (skin) domain: This includes measures of skin rashes, lesions, and other skin manifestations.\n2. Articular (joint) domain: This includes measures of joint pain and swelling.\n3. Serosal (pleura, pericardium) domain: This includes measures of inflammation in the lining of the lungs and heart.\n4. Renal (kidney) domain: This includes measures of kidney function and inflammation.\nEach domain is scored on a scale of 0 to 3, with higher scores indicating more severe disease. The scores from each domain are then combined to give an overall LSI score, which can range from 0 to 12.\nThe LSI has been shown to be a reliable and valid tool for assessing disease activity in SLE patients. It can help doctors monitor the effectiveness of treatment and make decisions about adjusting therapy. Additionally, the LSI can be used to predict the risk of flares and to identify patients who may be at risk for complications such as kidney damage or neurological problems.",
    "llama-2-13b-chat-hf_fact_raw": "1. The Lupus Severity Index (LSI) is used to assess the severity of systemic lupus erythematosus (SLE).\n2. The LSI is based on clinical and laboratory measures.\n3. The LSI includes four domains: cutaneous, articular, serosal, and renal.\n4. Each domain of the LSI is scored on a scale of 0 to 3.\n5. The overall LSI score can range from 0 to 12.",
    "llama-2-13b-chat-hf_fact": [
      "The Lupus Severity Index (LSI) is used to assess the severity of systemic lupus erythematosus (SLE).",
      "The LSI is based on clinical and laboratory measures.",
      "The LSI includes four domains: cutaneous, articular, serosal, and renal.",
      "Each domain of the LSI is scored on a scale of 0 to 3.",
      "The overall LSI score can range from 0 to 12."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The LSI (Lupus Severity Index) is not a standard instrument; the domains mentioned are common in SLE assessment but not necessarily part of a specific tool called LSI. The SLE Disease Activity Index (SLEDAI), for example, includes multiple domains, but it's not referred to as LSI.\n4. UNKNOWN: Given that statement 3 is false and there is no standard \"Lupus Severity Index\" with specific domains mentioned, the scoring system cannot be confirmed. Standard instruments like the SLEDAI or BILAG might use different scoring systems.\n5. UNKNOWN: Since statement 3 is false and the LSI as described does not exist, we cannot confirm the scoring range of this index.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3615,
    "user_query": "Which disorders are caused by de novo mutations in ZSWIM6?",
    "llama-2-13b-chat-hf_response": "ZSWIM6 is a gene that has been associated with several disorders, including:\n1. Noonan syndrome: ZSWIM6 mutations have been identified as a cause of Noonan syndrome, a rare genetic disorder characterized by short stature, congenital heart defects, and other features.\n2. Multiple endocrine neoplasia type 4 (MEN4): ZSWIM6 mutations have been identified as a cause of MEN4, a rare genetic disorder characterized by tumors of the endocrine system, such as parathyroid glands, pancreas, and pituitary gland.\n3. Pituitary dwarfism: ZSWIM6 mutations have been identified as a cause of pituitary dwarfism, a rare disorder characterized by short stature and other endocrine abnormalities.\n4. Hypogonadotropic hypogonadism: ZSWIM6 mutations have been identified as a cause of hypogonadotropic hypogonadism, a rare disorder characterized by low levels of sex hormones and infertility.\nIt's important to note that not all cases of these disorders are caused by ZSWIM6 mutations, and other genetic and environmental factors can also contribute to their development. Additionally, ZSWIM6 mutations can have variable effects on different individuals, and the severity of the disorder can vary depending on the specific mutation and other factors.",
    "llama-2-13b-chat-hf_fact_raw": "1. ZSWIM6 mutations have been identified as a cause of Noonan syndrome.\n2. ZSWIM6 mutations have been identified as a cause of Multiple endocrine neoplasia type 4 (MEN4).\n3. ZSWIM6 mutations have been identified as a cause of pituitary dwarfism.\n4. ZSWIM6 mutations have been identified as a cause of hypogonadotropic hypogonadism.\n5. The severity of disorders caused by ZSWIM6 mutations can vary depending on the specific mutation and other factors.",
    "llama-2-13b-chat-hf_fact": [
      "ZSWIM6 mutations have been identified as a cause of Noonan syndrome.",
      "ZSWIM6 mutations have been identified as a cause of Multiple endocrine neoplasia type 4 (MEN4).",
      "ZSWIM6 mutations have been identified as a cause of pituitary dwarfism.",
      "ZSWIM6 mutations have been identified as a cause of hypogonadotropic hypogonadism.",
      "The severity of disorders caused by ZSWIM6 mutations can vary depending on the specific mutation and other factors."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE\n\nThe statements regarding specific diseases or conditions caused by ZSWIM6 mutations require specialized medical knowledge and access to up-to-date genetic research data. Without more context or current research references, it is not possible to accurately confirm or correct the statements about ZSWIM6 mutations in relation to Noonan syndrome, Multiple endocrine neoplasia type 4 (MEN4), pituitary dwarfism, or hypogonadotropic hypogonadism. However, the fifth statement is generally true for genetic mutations as the severity of disorders can indeed vary depending on the specific mutation and other factors like environmental influences and additional genetic variations.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3626,
    "user_query": "Which disease can be classified using the Koos Classification?",
    "llama-2-13b-chat-hf_response": "The Koos Classification is a system used to classify musculoskeletal injuries and conditions. It is commonly used by physical therapists and other healthcare professionals to categorize and prioritize the severity of injuries and conditions affecting the musculoskeletal system.\nThe Koos Classification system includes the following categories:\n1. Grade 1: Mild injury or condition with minimal symptoms and little to no functional limitation.\n2. Grade 2: Moderate injury or condition with noticeable symptoms and some functional limitation.\n3. Grade 3: Severe injury or condition with significant symptoms and significant functional limitation.\n4. Grade 4: Extreme injury or condition with severe symptoms and severe functional limitation.\n5. Grade 5: Catastrophic injury or condition with severe and permanent symptoms and functional limitation.\nThe following are examples of diseases that can be classified using the Koos Classification:\n1. Sprains and strains: These are common injuries that can occur in any joint or muscle and can be classified using the Koos Classification system.\n2. Tendinitis: Tendinitis is inflammation of a tendon, which can cause pain and stiffness in the affected area. It can be classified as a Grade 2 or 3 injury.\n3. Bursitis: Bursitis is inflammation of the bursae, small fluid-filled sacs that cushion joints and reduce friction between bones and soft tissues. It can be classified as a Grade 2 or 3 injury.\n4. Rotator cuff injuries: The rotator cuff is a group of muscles and tendons that surround the shoulder joint, providing stability and mobility. Injuries to the rotator cuff can range from mild to severe and can be classified using the Koos Classification system.\n5. Osteoarthritis: Osteoarthritis is a degenerative joint disease that can affect any joint in the body, including the knees, hips, and spine. It can be classified as a Grade 3 or 4 injury.\n6. Fractures: Fractures are breaks in bones that can be classified using the Koos Classification",
    "llama-2-13b-chat-hf_fact_raw": "1. The Koos Classification is used to classify musculoskeletal injuries and conditions.\n2. It includes five grades, ranging from mild injury with minimal symptoms (Grade 1) to catastrophic injury with severe and permanent symptoms (Grade 5).\n3. Sprains and strains can be classified using the Koos Classification system.\n4. Tendinitis can be classified as a Grade 2 or 3 injury according to the Koos Classification.\n5. Osteoarthritis can be classified as a Grade 3 or 4 injury in the Koos Classification system.",
    "llama-2-13b-chat-hf_fact": [
      "The Koos Classification is used to classify musculoskeletal injuries and conditions.",
      "It includes five grades, ranging from mild injury with minimal symptoms (Grade 1) to catastrophic injury with severe and permanent symptoms (Grade 5).",
      "Sprains and strains can be classified using the Koos Classification system.",
      "Tendinitis can be classified as a Grade 2 or 3 injury according to the Koos Classification.",
      "Osteoarthritis can be classified as a Grade 3 or 4 injury in the Koos Classification system."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: The Koos Classification is used to classify meniscal injuries derived from knee osteoarthritis and not musculoskeletal injuries in general.\n2. TRUE\n3. FALSE [correction]: The Koos Classification system specifically pertains to knee injuries, particularly those involving the meniscus, due to osteoarthritis, and would not be used for general sprains and strains.\n4. UNKNOWN (because the statement does not align with the intended use of the Koos Classification for meniscal injuries, it's unclear how tendinitis would be classified)\n5. FALSE [correction]: The Koos Classification pertains to the meniscus and does not directly classify the severity of osteoarthritis itself. The KOOS (Knee injury and Osteoarthritis Outcome Score), however, is a system to measure knee-related symptoms and problems that may relate to osteoarthritis; it includes five dimensions but does not use a grading scale like Grade 3 or 4.",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3628,
    "user_query": "What are the in vivo effects of AZD8601?",
    "llama-2-13b-chat-hf_response": "AZD8601 is a potent and selective inhibitor of the enzyme bromodomain-containing protein 4 (BRD4). BRD4 is a member of the BET (bromodomain and extraterminal) family of proteins, which are involved in regulating gene expression by recognizing and binding to acetylated histone proteins. AZD8601 has been shown to inhibit the activity of BRD4 and other BET proteins, leading to the downregulation of genes involved in inflammation and the upregulation of genes involved in cellular differentiation and survival.\nIn vivo, AZD8601 has been shown to have a number of effects, including:\n1. Anti-inflammatory effects: AZD8601 has been shown to reduce inflammation in a number of preclinical models of inflammatory diseases, including colitis and arthritis.\n2. Immune modulatory effects: AZD8601 has been shown to modulate the immune response, reducing the production of pro-inflammatory cytokines and increasing the production of anti-inflammatory cytokines.\n3. Anti-tumor effects: AZD8601 has been shown to have anti-tumor effects in preclinical models of cancer, including breast, lung, and colon cancer.\n4. Neuroprotective effects: AZD8601 has been shown to have neuroprotective effects in preclinical models of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.\n5. Cardiovascular effects: AZD8601 has been shown to have cardiovascular effects, including reducing blood pressure and improving cardiac function in preclinical models of hypertension and heart failure.\nOverall, the in vivo effects of AZD8601 suggest that it may be a useful therapeutic agent for a range of diseases, including inflammatory disorders, cancer, neurodegenerative diseases, and cardiovascular disease. However, further research is needed to fully",
    "llama-2-13b-chat-hf_fact_raw": "1. AZD8601 inhibits the activity of bromodomain-containing protein 4 (BRD4).\n2. AZD8601 reduces inflammation in preclinical models of inflammatory diseases like colitis and arthritis.\n3. AZD8601 modulates the immune response by reducing the production of pro-inflammatory cytokines and increasing anti-inflammatory cytokines.\n4. AZD8601 has been shown to have anti-tumor effects in preclinical models of cancers, such as breast, lung, and colon cancer.\n5. AZD8601 has cardiovascular effects, including reducing blood pressure and improving cardiac function in preclinical models of hypertension and heart failure.",
    "llama-2-13b-chat-hf_fact": [
      "AZD8601 inhibits the activity of bromodomain-containing protein 4 (BRD4).",
      "AZD8601 reduces inflammation in preclinical models of inflammatory diseases like colitis and arthritis.",
      "AZD8601 modulates the immune response by reducing the production of pro-inflammatory cytokines and increasing anti-inflammatory cytokines.",
      "AZD8601 has been shown to have anti-tumor effects in preclinical models of cancers, such as breast, lung, and colon cancer.",
      "AZD8601 has cardiovascular effects, including reducing blood pressure and improving cardiac function in preclinical models of hypertension and heart failure."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: AZD8601 is a drug that is designed to increase the production of a protein called VEGF-A, which is involved in the formation of blood vessels, rather than inhibiting the activity of BRD4.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3640,
    "user_query": "How are SAHFS created?",
    "llama-2-13b-chat-hf_response": "The SAHF is created through a process called \"federation\" which involves the following steps:\n1. Identity Provider (IdP) selection: The user selects an IdP of their choice, such as their university or employer, to authenticate their identity.\n2. Authentication: The user authenticates with the selected IdP, which verifies their identity and generates an authentication token.\n3. SAHF creation: The IdP sends the authentication token to the SAHF, which creates a new SAHF for the user.\n4. Attribute release: The SAHF releases the user's attributes, such as their name and email address, to the RP.\n5. Authentication confirmation: The RP verifies the user's authentication with the SAHF and confirms their identity.\nNo errors were found in this response.",
    "llama-2-13b-chat-hf_fact_raw": "1. The process of creating a SAHF is called \"federation\".\n2. The first step of creating a SAHF is selection of an Identity Provider by the user.\n3. Authentication of the user's identity is done by the chosen Identity Provider.\n4. The Identity Provider generates an authentication token after verifying the user's identity.\n5. The RP confirms the user's identity after the SAHF releases the user's attributes and verifies the user's authentication.",
    "llama-2-13b-chat-hf_fact": [
      "The process of creating a SAHF is called \"federation\".",
      "The first step of creating a SAHF is selection of an Identity Provider by the user.",
      "Authentication of the user's identity is done by the chosen Identity Provider.",
      "The Identity Provider generates an authentication token after verifying the user's identity.",
      "The RP confirms the user's identity after the SAHF releases the user's attributes and verifies the user's authentication."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: The process of creating a Secure Assertion Markup Language (SAML) Assertion Handling Framework (SAHF) is not commonly referred to as \"federation\". Federation is a broader concept relating to the establishment of mutual acceptance of users between different organizations.\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The Relying Party (RP) confirms the user's identity after receiving the SAML assertion, which includes the user's attributes and authentication information provided by the Identity Provider (IdP), not the SAHF. The SAHF is not an entity that releases user's attributes; it's a framework for handling SAML assertions.",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3672,
    "user_query": "What is the function of the PDZ domain in SATB1?",
    "llama-2-13b-chat-hf_response": "SATB1 (Special AT-hook binding protein 1) is a transcription factor that plays a crucial role in regulating gene expression and chromatin organization during cell differentiation and development. The PDZ (Postsynaptic density, Discs large, Zona) domain is a structural motif found in SATB1 that is involved in protein-protein interactions.\nThe PDZ domain of SATB1 is responsible for binding to a variety of proteins, including other transcription factors, signaling molecules, and cytoskeletal components. These interactions are thought to play a role in regulating the subcellular localization and activity of SATB1, and may also contribute to the regulation of downstream gene expression.\nOne study found that the PDZ domain of SATB1 is required for its ability to regulate the expression of genes involved in neuronal differentiation and synaptic plasticity (1). Another study found that the PDZ domain of SATB1 interacts with the protein Discs large (Dlg) and is involved in regulating the organization of the actin cytoskeleton in neurons (2).\nOverall, the PDZ domain of SATB1 appears to play an important role in regulating the subcellular localization and activity of SATB1, and may also contribute to the regulation of downstream gene expression.\nReferences:\n1. Kim, J. et al. (2013). The PDZ domain of SATB1 is required for its ability to regulate neuronal differentiation and synaptic plasticity. Journal of Neuroscience, 33(10), 4488-4498.\n2. Liu, X. et al. (2011). The PDZ domain of SATB1 interacts with Discs large and is involved in regulating the organization of the actin cytoskeleton in neurons. Journal of Biological Chemistry, 286(20), 17613-17623.",
    "llama-2-13b-chat-hf_fact_raw": "1. SATB1 is a transcription factor involved in regulating gene expression and chromatin organization during cell differentiation and development.\n2. The PDZ domain of SATB1 is involved in protein-protein interactions.\n3. The PDZ domain of SATB1 is responsible for binding to transcription factors, signaling molecules, and cytoskeletal components.\n4. A study found that the PDZ domain of SATB1 is necessary for regulating genes involved in neuronal differentiation and synaptic plasticity.\n5. Another study found that the PDZ domain of SATB1 interacts with the protein Discs large and regulates the organization of the actin cytoskeleton in neurons.",
    "llama-2-13b-chat-hf_fact": [
      "SATB1 is a transcription factor involved in regulating gene expression and chromatin organization during cell differentiation and development.",
      "The PDZ domain of SATB1 is involved in protein-protein interactions.",
      "The PDZ domain of SATB1 is responsible for binding to transcription factors, signaling molecules, and cytoskeletal components.",
      "A study found that the PDZ domain of SATB1 is necessary for regulating genes involved in neuronal differentiation and synaptic plasticity.",
      "Another study found that the PDZ domain of SATB1 interacts with the protein Discs large and regulates the organization of the actin cytoskeleton in neurons."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: SATB1 does not have a PDZ domain; it is characterized by the presence of a CUT domain and a homeodomain. Its PDZ domain is not involved in protein-protein interactions because it does not have one.\n3. FALSE [correction]: Since SATB1 does not contain a PDZ domain, it is not responsible for binding to transcription factors, signaling molecules, and cytoskeletal components through a PDZ domain.\n4. FALSE [correction]: As SATB1 does not have a PDZ domain, a study could not find that the PDZ domain of SATB1 is necessary for regulating genes involved in neuronal differentiation and synaptic plasticity.\n5. FALSE [correction]: The PDZ domain of SATB1 would not interact with the protein Discs large and regulate the organization of the actin cytoskeleton in neurons because SATB1 does not have a PDZ domain.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3678,
    "user_query": "What is the basis of the BLISS technique?",
    "llama-2-13b-chat-hf_response": "The BLISS technique is based on the following principles:\n1. Breath: The technique focuses on the breath as the primary source of relaxation and calmness.\n2. Light: The use of light therapy, such as bright light or laser light, to stimulate the brain and promote relaxation.\n3. Imagery: The use of guided imagery to create a peaceful and calming environment.\n4. Sensory: The use of sensory techniques, such as progressive muscle relaxation, to calm the body and mind.\n5. Self-hypnosis: The use of self-hypnosis techniques to induce a state of deep relaxation and calmness.\nBy combining these principles, the BLISS technique aims to create a powerful and effective method for reducing stress and anxiety, promoting relaxation and calmness, and improving overall well-being.",
    "llama-2-13b-chat-hf_fact_raw": "1. The BLISS technique utilizes breath control for relaxation and calmness.\n2. Light therapy is used in the BLISS technique to stimulate the brain.\n3. Guided imagery is incorporated in the BLISS technique.\n4. Sensory techniques are applied in the BLISS technique, including progressive muscle relaxation.\n5. Self-hypnosis is a part of the BLISS technique to achieve deep relaxation.",
    "llama-2-13b-chat-hf_fact": [
      "The BLISS technique utilizes breath control for relaxation and calmness.",
      "Light therapy is used in the BLISS technique to stimulate the brain.",
      "Guided imagery is incorporated in the BLISS technique.",
      "Sensory techniques are applied in the BLISS technique, including progressive muscle relaxation.",
      "Self-hypnosis is a part of the BLISS technique to achieve deep relaxation."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nNote: Without specific information about the \"BLISS technique\" referenced in the statements, it's not possible to verify the claims about what the technique includes or utilizes. The term \"BLISS technique\" is not widely recognized or standardized in the context of relaxation or therapeutic practices, which makes it difficult to determine the veracity of these statements without additional context.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3679,
    "user_query": "List 3 NK3R antagonists.",
    "llama-2-13b-chat-hf_response": "NK3R antagonists are substances that bind to the NK3 receptor and prevent its activation. Here are three examples of NK3R antagonists:\n1. A-779 (also known as RX-0201): This is a selective NK3R antagonist that has been shown to reduce nausea and vomiting in animal models of chemotherapy-induced nausea and vomiting.\n2. RS-100,630: This is a potent and selective NK3R antagonist that has been shown to reduce nausea and vomiting in animal models of chemotherapy-induced nausea and vomiting.\n3. RX-0203: This is a highly selective NK3R antagonist that has been shown to reduce nausea and vomiting in animal models of chemotherapy-induced nausea and vomiting.\nAll three of these compounds have shown promise as potential treatments for chemotherapy-induced nausea and vomiting, and they are currently being studied in clinical trials.",
    "llama-2-13b-chat-hf_fact_raw": "1. A-779 (also known as RX-0201) is a selective NK3R antagonist.\n2. RS-100,630 is a potent and selective NK3R antagonist.\n3. RX-0203 is a highly selective NK3R antagonist.\n4. A-779, RS-100,630, and RX-0203 have all been tested in animal models for reducing nausea and vomiting associated with chemotherapy.\n5. These NK3R antagonists are being studied in clinical trials for their potential to treat chemotherapy-induced nausea and vomiting.",
    "llama-2-13b-chat-hf_fact": [
      "A-779 (also known as RX-0201) is a selective NK3R antagonist.",
      "RS-100,630 is a potent and selective NK3R antagonist.",
      "RX-0203 is a highly selective NK3R antagonist.",
      "A-779, RS-100,630, and RX-0203 have all been tested in animal models for reducing nausea and vomiting associated with chemotherapy.",
      "These NK3R antagonists are being studied in clinical trials for their potential to treat chemotherapy-induced nausea and vomiting."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN: Without additional context or information specific to A-779 being a selective NK3R antagonist, the accuracy of this statement cannot be determined.\n2. UNKNOWN: Similarly, without specific information about RS-100,630, the statement's validity cannot be confirmed.\n3. UNKNOWN: The same applies to RX-0203; without context or sources, the selectivity as an NK3R antagonist cannot be verified.\n4. UNKNOWN: Due to a lack of detailed context or reference, it's not possible to confirm whether A-779, RS-100,630, and RX-0203 have been tested in animal models for this purpose.\n5. UNKNOWN: Without relevant clinical trial data or references, it cannot be confirmed whether these NK3R antagonists are being studied in clinical trials for treating chemotherapy-induced nausea and vomiting.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3691,
    "user_query": "Which drug is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects?",
    "llama-2-13b-chat-hf_response": "A. GSK2629697\nB. GSK876934\nC. GSK997628\nD. GSK998963\nAnswer: A. GSK2629697\nGSK2629697 is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects. It is being developed for the treatment of obesity and related metabolic disorders. GSK876934, GSK997628, and GSK998963 are also ghrelin receptor inverse agonists being developed by GlaxoSmithKline, but they have not been profiled in healthy subjects yet.",
    "llama-2-13b-chat-hf_fact_raw": "1. GSK2629697 is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.\n2. GSK2629697 is being developed for the treatment of obesity and related metabolic disorders.\n3. GSK876934, GSK997628, and GSK998963 are ghrelin receptor inverse agonists.\n4. GSK876934, GSK997628, and GSK998963 have not been profiled in healthy subjects yet.\n5. All mentioned ghrelin receptor inverse agonists are being developed by GlaxoSmithKline.",
    "llama-2-13b-chat-hf_fact": [
      "GSK2629697 is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.",
      "GSK2629697 is being developed for the treatment of obesity and related metabolic disorders.",
      "GSK876934, GSK997628, and GSK998963 are ghrelin receptor inverse agonists.",
      "GSK876934, GSK997628, and GSK998963 have not been profiled in healthy subjects yet.",
      "All mentioned ghrelin receptor inverse agonists are being developed by GlaxoSmithKline."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE\n\nPlease note: The responses for statements 3 and 4 are marked as UNKNOWN because, without specific data or evidence presented in the context, it is not possible to confirm the nature of these compounds or their testing status. Moreover, the development status of pharmaceutical compounds is subject to change and requires up-to-date information.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3693,
    "user_query": "What is the protective efficacy of vaxchora against moderate to severe cholera?",
    "llama-2-13b-chat-hf_response": "Vaxchora is a live, attenuated oral cholera vaccine that has been shown to be highly effective in protecting against moderate to severe cholera. In clinical trials, Vaxchora has been shown to be 80-90% effective in preventing moderate to severe cholera in individuals who have received a full course of the vaccine. This means that for every 100 people who receive Vaxchora, between 80 and 90 of them will be protected against moderate to severe cholera.\nIt is important to note that Vaxchora is not 100% effective, and some individuals who receive the vaccine may still contract cholera, although the symptoms are likely to be milder. Additionally, Vaxchora does not provide long-term immunity against cholera, and booster doses may be needed to maintain protection.\nIt is also important to note that Vaxchora is not a substitute for standard cholera treatment, which includes fluid replacement and antibiotics. Individuals who are infected with cholera should seek medical attention immediately.\nOverall, Vaxchora is a valuable tool in the prevention and control of cholera, particularly in areas where the disease is common and access to medical care may be limited.",
    "llama-2-13b-chat-hf_fact_raw": "1. Vaxchora is a live, attenuated oral cholera vaccine.\n2. Vaxchora has been shown to be 80-90% effective in preventing moderate to severe cholera in clinical trials.\n3. A full course of Vaxchora is required to achieve the reported protective efficacy.\n4. Vaxchora does not provide long-term immunity and may require booster doses for maintained protection.\n5. Vaxchora is not a substitute for standard cholera treatment which includes fluid replacement and antibiotics.",
    "llama-2-13b-chat-hf_fact": [
      "Vaxchora is a live, attenuated oral cholera vaccine.",
      "Vaxchora has been shown to be 80-90% effective in preventing moderate to severe cholera in clinical trials.",
      "A full course of Vaxchora is required to achieve the reported protective efficacy.",
      "Vaxchora does not provide long-term immunity and may require booster doses for maintained protection.",
      "Vaxchora is not a substitute for standard cholera treatment which includes fluid replacement and antibiotics."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE - However, it should be noted that \"full course\" for Vaxchora usually involves a single dose, but additional guidance or clarification may be necessary regarding what constitutes a \"full course\" based on vaccine specifics and updates.\n4. TRUE - Vaxchora provides short-term immunity, and the duration of protection is something that may vary based on ongoing research and recommendations. Booster doses may be recommended for continued exposure risk.\n5. TRUE - While Vaxchora is used for prophylaxis, standard cholera treatment in case of illness typically involves fluid replacement and antibiotics, and vaccination doesn't replace the need for such treatment measures.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3716,
    "user_query": "Which was the first cholera vaccine approved in the US?",
    "llama-2-13b-chat-hf_response": "The first cholera vaccine approved in the US was the oral cholera vaccine (OCV) developed by the US Centers for Disease Control and Prevention (CDC) and licensed in 1991. This vaccine was developed in response to a cholera outbreak in Peru in 1991, and it has since been used in various countries around the world to prevent cholera. The OCV is a live, attenuated vaccine that is administered orally and provides protection against cholera for several years.",
    "llama-2-13b-chat-hf_fact_raw": "1. The first cholera vaccine approved in the US was an oral cholera vaccine (OCV).\n2. The oral cholera vaccine was developed by the US Centers for Disease Control and Prevention (CDC).\n3. The oral cholera vaccine was licensed in 1991. \n4. The vaccine was developed in response to a cholera outbreak in Peru in 1991.\n5. The oral cholera vaccine is a live, attenuated vaccine that provides protection against cholera for several years.",
    "llama-2-13b-chat-hf_fact": [
      "The first cholera vaccine approved in the US was an oral cholera vaccine (OCV).",
      "The oral cholera vaccine was developed by the US Centers for Disease Control and Prevention (CDC).",
      "The oral cholera vaccine was licensed in 1991.",
      "The vaccine was developed in response to a cholera outbreak in Peru in 1991.",
      "The oral cholera vaccine is a live, attenuated vaccine that provides protection against cholera for several years."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The oral cholera vaccine (OCV) was not developed by the US Centers for Disease Control and Prevention (CDC). The vaccine known as Dukoral was developed by scientists at the University of Gothenburg in Sweden.\n3. FALSE [correction]: The oral cholera vaccine, Vaxchora, was licensed in the US in 2016, not 1991.\n4. UNKNOWN\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3737,
    "user_query": "Which is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans?",
    "llama-2-13b-chat-hf_response": "A) X-linked agammaglobulinemia (XLA)\nB) Bruton's tyrosine kinase (BTK) deficiency\nC) Activation-induced cytidine deaminase (AID) deficiency\nD) T cell receptor (TCR) deficiency\nCorrect answer: A) X-linked agammaglobulinemia (XLA)\nX-linked agammaglobulinemia (XLA) is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans, with an incidence of approximately 1 in 50,000 to 1 in 100,000 births. XLA is caused by mutations in the Bruton's tyrosine kinase (BTK) gene, which is essential for B cell development and activation. BTK deficiency leads to impaired B cell maturation and function, resulting in hypogammaglobulinemia and increased susceptibility to infections.\nBruton's tyrosine kinase (BTK) deficiency (B) is the correct answer. Activation-induced cytidine deaminase (AID) deficiency (C) and T cell receptor (TCR) deficiency (D) are not common causes of CVID.",
    "llama-2-13b-chat-hf_fact_raw": "1. X-linked agammaglobulinemia (XLA) is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans.\n2. The incidence of X-linked agammaglobulinemia (XLA) is approximately 1 in 50,000 to 1 in 100,000 births.\n3. Mutations in the Bruton's tyrosine kinase (BTK) gene cause X-linked agammaglobulinemia (XLA).\n4. Bruton's tyrosine kinase (BTK) deficiency due to mutations inhibits B cell maturation and function.\n5. Patients with Bruton's tyrosine kinase (BTK) deficiency have an increased susceptibility to infections.",
    "llama-2-13b-chat-hf_fact": [
      "X-linked agammaglobulinemia (XLA) is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans.",
      "The incidence of X-linked agammaglobulinemia (XLA) is approximately 1 in 50,000 to 1 in 100,000 births.",
      "Mutations in the Bruton's tyrosine kinase (BTK) gene cause X-linked agammaglobulinemia (XLA).",
      "Bruton's tyrosine kinase (BTK) deficiency due to mutations inhibits B cell maturation and function.",
      "Patients with Bruton's tyrosine kinase (BTK) deficiency have an increased susceptibility to infections."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: X-linked agammaglobulinemia (XLA) and common variable immunodeficiency (CVID) are distinct primary immunodeficiency disorders. XLA is not a cause of CVID; rather, it is a separate condition characterized by agammaglobulinemia due to BTK mutations.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3743,
    "user_query": "Which is the role of the IFIT1 gene in Systemic Lupus Erythematosus (SLE)?",
    "llama-2-13b-chat-hf_response": "The IFIT1 gene has been associated with Systemic Lupus Erythematosus (SLE) in several studies. The IFIT1 gene encodes for a protein called interferon-induced helicase C domain-containing protein 1 (IFIH1). This protein plays a crucial role in the innate immune response, particularly in the recognition and clearance of viral infections.\nSeveral studies have found that genetic variants in the IFIT1 gene are associated with an increased risk of developing SLE. For example, one study found that a specific variant of the IFIT1 gene (rs12208562) was more common in SLE patients compared to healthy controls. Another study found that a different variant (rs2564595) was associated with a higher risk of developing SLE in individuals with a family history of the disease.\nThe exact mechanism by which the IFIT1 gene contributes to the development of SLE is not fully understood, but it is thought to involve dysregulation of the innate immune response. In SLE patients, the immune system is overactive and produces autoantibodies that attack the body's own tissues. The IFIT1 gene may play a role in regulating the production of these autoantibodies and the activation of immune cells.\nAdditionally, the IFIT1 gene has been shown to be upregulated in SLE patients, particularly in those with active disease. This suggests that the gene may be involved in the pathogenesis of SLE, possibly by contributing to the production of pro-inflammatory cytokines and the activation of immune cells.\nOverall, the IFIT1 gene is a promising target for further research into the genetic basis of SLE. Understanding the role of this gene in the development of the disease may lead to the development of new therapeutic strategies for SLE.",
    "llama-2-13b-chat-hf_fact_raw": "1. The IFIT1 gene has been associated with Systemic Lupus Erythematosus (SLE) in multiple studies.\n2. The IFIT1 gene encodes for a protein called interferon-induced helicase C domain-containing protein 1 (IFIH1), which plays a role in the innate immune response.\n3. Genetic variants in the IFIT1 gene, such as rs12208562 and rs2564595, have been found to be associated with an increased risk of developing SLE.\n4. The IFIT1 gene is thought to be involved in regulating the production of autoantibodies and the activation of immune cells in SLE patients.\n5. The IFIT1 gene has been shown to be upregulated in patients with active Systemic Lupus Erythematosus.",
    "llama-2-13b-chat-hf_fact": [
      "The IFIT1 gene has been associated with Systemic Lupus Erythematosus (SLE) in multiple studies.",
      "The IFIT1 gene encodes for a protein called interferon-induced helicase C domain-containing protein 1 (IFIH1), which plays a role in the innate immune response.",
      "Genetic variants in the IFIT1 gene, such as rs12208562 and rs2564595, have been found to be associated with an increased risk of developing SLE.",
      "The IFIT1 gene is thought to be involved in regulating the production of autoantibodies and the activation of immune cells in SLE patients.",
      "The IFIT1 gene has been shown to be upregulated in patients with active Systemic Lupus Erythematosus."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The IFIT1 gene encodes for a protein called Interferon-Induced Protein with Tetratricopeptide Repeats 1, not interferon-induced helicase C domain-containing protein 1 (IFIH1).\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3752,
    "user_query": "What is the use of the Liverpool Elbow Score?",
    "llama-2-13b-chat-hf_response": "The Liverpool Elbow Score is a useful tool for assessing the severity of elbow injuries and monitoring progress during treatment. It is a validated, reliable, and easy-to-use scoring system that considers six clinical features of elbow injuries, including pain, swelling, tenderness, instability, range of motion, and grip strength.\nThe Liverpool Elbow Score assigns a score to each feature based on the patient's symptoms and physical examination findings. The scores are then added up to give a total score, which can range from 0 to 30. Higher scores indicate more severe injuries.\nThe use of the Liverpool Elbow Score can help healthcare providers:\n1. Quickly and accurately assess the severity of elbow injuries: The score can be used to identify mild, moderate, or severe injuries, which can guide treatment decisions and prognosis.\n2. Monitor progress during treatment: By regularly assessing the patient's symptoms and physical examination findings using the Liverpool Elbow Score, healthcare providers can monitor the effectiveness of treatment and make adjustments as needed.\n3. Compare outcomes: The Liverpool Elbow Score can be used to compare the outcomes of different treatments or interventions, which can help healthcare providers choose the most effective treatment for their patients.\n4. Identify patients at risk for complications: By monitoring changes in the Liverpool Elbow Score over time, healthcare providers can identify patients who may be at risk for complications, such as infection or delayed healing, and provide appropriate interventions.\nOverall, the Liverpool Elbow Score is a useful tool for healthcare providers to assess and manage elbow injuries, and it can help improve patient outcomes.",
    "llama-2-13b-chat-hf_fact_raw": "1. The Liverpool Elbow Score is a scoring system used to assess the severity of elbow injuries.\n2. The Liverpool Elbow Score comprises six clinical features: pain, swelling, tenderness, instability, range of motion, and grip strength.\n3. The total score of the Liverpool Elbow Score can range from 0 to 30, with higher scores indicating more severe injuries.\n4. The Liverpool Elbow Score can be used to monitor progress during treatment for elbow injuries.\n5. Changes in the Liverpool Elbow Score over time can help healthcare providers identify patients at risk for complications.",
    "llama-2-13b-chat-hf_fact": [
      "The Liverpool Elbow Score is a scoring system used to assess the severity of elbow injuries.",
      "The Liverpool Elbow Score comprises six clinical features: pain, swelling, tenderness, instability, range of motion, and grip strength.",
      "The total score of the Liverpool Elbow Score can range from 0 to 30, with higher scores indicating more severe injuries.",
      "The Liverpool Elbow Score can be used to monitor progress during treatment for elbow injuries.",
      "Changes in the Liverpool Elbow Score over time can help healthcare providers identify patients at risk for complications."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The Liverpool Elbow Score comprises five domains assessing pain, function, social-psychological, work, and recreational activities.\n3. FALSE [correction]: The total score of the Liverpool Elbow Score ranges from 0 to 100, with lower scores indicating worse elbow function.\n4. TRUE\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3763,
    "user_query": "Describe efforts on Sarcoma from the 100,000 Genomes Project",
    "llama-2-13b-chat-hf_response": "The 100,000 Genomes Project was a groundbreaking initiative that aimed to sequence the genomes of 100,000 UK patients, including those with rare and common diseases. The project was launched in 2012 and was completed in 2018. The project has led to several breakthroughs in our understanding of various diseases, including sarcoma. Here are some of the efforts on sarcoma from the 100,000 Genomes Project:\n1. Genomic characterization of sarcoma: The 100,000 Genomes Project has provided a wealth of genomic data on sarcoma, including the whole-genome sequences of over 100 sarcoma tumors. This data has enabled researchers to gain insights into the genetic changes that drive sarcoma development and progression.\n2. Identification of novel sarcoma subtypes: The project has identified several novel subtypes of sarcoma, including those that are characterized by specific genetic mutations. These subtypes may have different clinical and biological characteristics, which could lead to more targeted and effective treatments.\n3. Discovery of new therapeutic targets: The project has identified several potential therapeutic targets for sarcoma, including genes that are involved in cell growth, angiogenesis, and metastasis. These targets could be targeted with specific drugs or immunotherapies to treat sarcoma.\n4. Development of personalized medicine approaches: The project has enabled the development of personalized medicine approaches for sarcoma patients. By analyzing the genomic data of individual patients, researchers can identify specific genetic mutations that are driving the growth of their tumors. This information can be used to develop targeted therapies that are tailored to the specific needs of each patient.\n5. Improved understanding of the molecular mechanisms of sarcoma: The project has provided new insights into the molecular mechanisms of sarcoma, including the role of genetic mutations, epigenetic changes, and gene expression in tumor development and progression. This knowledge could lead to the development of new therapies and improved treatment outcomes for sarcoma patients.\nOverall, the 100",
    "llama-2-13b-chat-hf_fact_raw": "1. The 100,000 Genomes Project aimed to sequence the genomes of 100,000 UK patients and was completed in 2018.\n2. Over 100 whole-genome sequences of sarcoma tumors were obtained through the 100,000 Genomes Project.\n3. Several novel subtypes of sarcoma characterized by specific genetic mutations were identified in the project.\n4. The project led to the identification of potential therapeutic targets for sarcoma, such as genes involved in cell growth, angiogenesis, and metastasis.\n5. Personalized medicine approaches for sarcoma patients have been enabled by the project through the analysis of genomic data.",
    "llama-2-13b-chat-hf_fact": [
      "The 100,000 Genomes Project aimed to sequence the genomes of 100,000 UK patients and was completed in 2018.",
      "Over 100 whole-genome sequences of sarcoma tumors were obtained through the 100,000 Genomes Project.",
      "Several novel subtypes of sarcoma characterized by specific genetic mutations were identified in the project.",
      "The project led to the identification of potential therapeutic targets for sarcoma, such as genes involved in cell growth, angiogenesis, and metastasis.",
      "Personalized medicine approaches for sarcoma patients have been enabled by the project through the analysis of genomic data."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: The 100,000 Genomes Project aimed to sequence the genomes of 100,000 UK patients with the project reaching its sequencing goal at the end of 2018. However, the project's conclusion and analysis of the data continued beyond the sequencing milestone.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3777,
    "user_query": "Does protein ALEX1 contain armadillo repeats?",
    "llama-2-13b-chat-hf_response": "After re-evaluating the protein sequence, I noticed that I made an error in my previous response. Protein ALEX1 does contain armadillo repeats, specifically in the C-terminal cytoplasmic domain. The repeats are located between residues 1200-1300 and 1400-1500.\nTherefore, the answer to the original question is yes, protein ALEX1 does contain armadillo repeats.\nNo other errors were found in my previous response.",
    "llama-2-13b-chat-hf_fact_raw": "1. Protein ALEX1 contains armadillo repeats.\n2. The armadillo repeats in protein ALEX1 are specifically located in the C-terminal cytoplasmic domain.\n3. The armadillo repeats are located between residues 1200-1300 and 1400-1500 of protein ALEX1.",
    "llama-2-13b-chat-hf_fact": [
      "Protein ALEX1 contains armadillo repeats.",
      "The armadillo repeats in protein ALEX1 are specifically located in the C-terminal cytoplasmic domain.",
      "The armadillo repeats are located between residues 1200-1300 and 1400-1500 of protein ALEX1."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n\nWithout specific and detailed information on the protein ALEX1, including its sequence or structure from a recognized scientific resource, it's not possible to verify these statements. Protein databases like UniProt or peer-reviewed scientific literature would be necessary to accurately check these claims.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3789,
    "user_query": "List enzymes that removes histone modifications.",
    "llama-2-13b-chat-hf_response": "There are several enzymes that remove histone modifications, including:\n1. Histone demethylases (HDMs): These enzymes remove methyl groups from histone proteins, which can lead to changes in chromatin structure and gene expression. Examples of HDMs include KDM1A, KDM4B, and KDM6A.\n2. Histone deacetylases (HDACs): These enzymes remove acetyl groups from histone proteins, which can also lead to changes in chromatin structure and gene expression. Examples of HDACs include HDAC1, HDAC2, and HDAC3.\n3. Histone lysine specific demethylases (KDMs): These enzymes specifically remove methyl groups from histone H3 lysine 4 (H3K4) and histone H3 lysine 27 (H3K27). Examples of KDMs include KDM5B and KDM6B.\n4. Histone arginine methyltransferases (HMTs): These enzymes add methyl groups to histone H3 arginine 8 (H3R8) and histone H3 arginine 26 (H3R26), which can affect chromatin structure and gene expression. Examples of HMTs include PRMT1 and PRMT8.\n5. Histone chaperones: These proteins help to facilitate the folding and stability of histones, and can also affect the distribution of histone modifications. Examples of histone chaperones include HJURP and HIRA.\nIt's worth noting that the removal of histone modifications can be a dynamic process, and can be influenced by a variety of factors, including the presence of other chromatin-modifying enzymes, the binding of transcription factors and other regulatory proteins, and the activity of signaling pathways.",
    "llama-2-13b-chat-hf_fact_raw": "1. Histone demethylases (HDMs) remove methyl groups from histone proteins.\n2. Histone deacetylases (HDACs) remove acetyl groups from histone proteins.\n3. Histone lysine specific demethylases (KDMs) remove methyl groups from histone H3 lysine 4 (H3K4) and histone H3 lysine 27 (H3K27).\n4. Histone arginine methyltransferases (HMTs) add methyl groups to histone H3 arginine 8 (H3R8) and histone H3 arginine 26 (H3R26).\n5. Histone chaperones facilitate the folding and stability of histones and affect the distribution of histone modifications.",
    "llama-2-13b-chat-hf_fact": [
      "Histone demethylases (HDMs) remove methyl groups from histone proteins.",
      "Histone deacetylases (HDACs) remove acetyl groups from histone proteins.",
      "Histone lysine specific demethylases (KDMs) remove methyl groups from histone H3 lysine 4 (H3K4) and histone H3 lysine 27 (H3K27).",
      "Histone arginine methyltransferases (HMTs) add methyl groups to histone H3 arginine 8 (H3R8) and histone H3 arginine 26 (H3R26).",
      "Histone chaperones facilitate the folding and stability of histones and affect the distribution of histone modifications."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE – KDMs indeed remove methyl groups from specific lysine residues on histone proteins, including H3K4 and H3K27, among others.\n4. UNKNOWN – The statement is specific about which residues HMTs target; while histone methyltransferases do add methyl groups to arginine residues, without specific literature to support the exact residues mentioned (H3R8 and H3R26), the truth of this statement cannot be verified.\n5. TRUE – Histone chaperones assist with the assembly and disassembly of nucleosomes, which involves the packaging of histones with DNA, and thus can influence histone modifications and ultimately affect chromatin structure and function.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3806,
    "user_query": "Does head ct increase brain tumor risk?",
    "llama-2-13b-chat-hf_response": "Head CT scans use X-rays to produce detailed images of the brain and can help diagnose a variety of conditions, including brain tumors. However, there is some concern that exposure to CT scans may increase the risk of developing brain tumors.\nThe concern about CT scans and brain tumors is based on the fact that ionizing radiation, such as X-rays, can cause DNA damage and potentially lead to the development of cancer. However, the risk of developing brain tumors from CT scans is still relatively low.\nSeveral studies have investigated the potential link between CT scans and brain tumors. One study published in the New England Journal of Medicine in 2012 found that exposure to CT scans was associated with an increased risk of brain tumors, but the risk was still relatively low. The study found that for every 10,000 people who underwent CT scans, there were 12 additional cases of brain tumors that might have been caused by the radiation exposure.\nHowever, other studies have found no association between CT scans and brain tumors. A study published in the Journal of the National Cancer Institute in 2013 found that there was no significant increase in the risk of brain tumors among people who underwent CT scans.\nIt's important to note that the risk of developing brain tumors from CT scans is still relatively low, and the benefits of undergoing a CT scan often outweigh the risks. CT scans can help diagnose and treat a variety of conditions, including stroke, traumatic brain injury, and certain types of brain tumors.\nIf you are concerned about the risk of brain tumors from CT scans, you should talk to your doctor about the potential risks and benefits of the scan. Your doctor can help you determine whether a CT scan is necessary and can discuss ways to minimize your exposure to radiation.\nIn general, it's important to follow the recommended guidelines for CT scans and to only undergo the test when it is medically necessary. This can help minimize your exposure to radiation and reduce the risk of any potential side effects.",
    "llama-2-13b-chat-hf_fact_raw": "1. Head CT scans use X-rays to produce detailed images of the brain.\n2. Exposure to ionizing radiation, such as X-rays, can cause DNA damage and potentially lead to the development of cancer.\n3. A study published in the New England Journal of Medicine in 2012 found an association between CT scans and an increased risk of brain tumors, with 12 additional cases per 10,000 people.\n4. A study published in the Journal of the National Cancer Institute in 2013 found no significant increase in the risk of brain tumors among people who underwent CT scans.\n5. The benefits of undergoing a CT scan often outweigh the risks, as they can help diagnose and treat various conditions.",
    "llama-2-13b-chat-hf_fact": [
      "Head CT scans use X-rays to produce detailed images of the brain.",
      "Exposure to ionizing radiation, such as X-rays, can cause DNA damage and potentially lead to the development of cancer.",
      "A study published in the New England Journal of Medicine in 2012 found an association between CT scans and an increased risk of brain tumors, with 12 additional cases per 10,000 people.",
      "A study published in the Journal of the National Cancer Institute in 2013 found no significant increase in the risk of brain tumors among people who underwent CT scans.",
      "The benefits of undergoing a CT scan often outweigh the risks, as they can help diagnose and treat various conditions."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN (Without verifying the specific study, its findings, and methodology, it is difficult to assess the accuracy of this statement)\n4. UNKNOWN (Again, without accessing and reviewing the specific study mentioned, it remains unclear if this statement is true or false)\n5. TRUE (In medical practice, the decision to use diagnostic imaging, like CT scans, is a risk-benefit analysis, and typically, they are only recommended when the benefits are deemed to outweigh the risks)",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3809,
    "user_query": "Which type of pluripotency is Otx2 associated with?",
    "llama-2-13b-chat-hf_response": "Otx2 is associated with which type of pluripotency?\nA) Induced pluripotent stem cells (iPSCs)\nB) Embryonic stem cells (ESCs)\nC) Adult stem cells\nD) Primordial germ cells\nCorrect answer: B) Embryonic stem cells (ESCs)\nOtx2 is a transcription factor that is expressed in embryonic stem cells (ESCs) and plays a role in maintaining their pluripotency. ESCs are a type of pluripotent stem cell that has the ability to differentiate into all cell types of the body. Otx2 is not expressed in induced pluripotent stem cells (iPSCs), adult stem cells, or primordial germ cells. Therefore, the correct answer is B) Embryonic stem cells (ESCs).",
    "llama-2-13b-chat-hf_fact_raw": "1. Otx2 is associated with embryonic stem cells (ESCs).\n2. Otx2 is a transcription factor expressed in ESCs.\n3. Embryonic stem cells have the ability to differentiate into all cell types of the body.\n4. Otx2 is not expressed in induced pluripotent stem cells (iPSCs).\n5. Otx2 is not expressed in adult stem cells or primordial germ cells.",
    "llama-2-13b-chat-hf_fact": [
      "Otx2 is associated with embryonic stem cells (ESCs).",
      "Otx2 is a transcription factor expressed in ESCs.",
      "Embryonic stem cells have the ability to differentiate into all cell types of the body.",
      "Otx2 is not expressed in induced pluripotent stem cells (iPSCs).",
      "Otx2 is not expressed in adult stem cells or primordial germ cells."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: Otx2 is not directly associated with embryonic stem cells (ESCs); it is typically associated with early brain development and eye formation.\n2. FALSE [correction]: Otx2 is not generally expressed in embryonic stem cells (ESCs); rather, it is a transcription factor critical for the development of the brain and eyes in the embryo.\n3. TRUE: Embryonic stem cells have the ability to differentiate into all cell types of the body, which is a characteristic known as pluripotency.\n4. UNKNOWN: The expression of Otx2 in induced pluripotent stem cells (iPSCs) can vary depending on the differentiation state and other factors, and without specific information regarding its expression in iPSCs, the statement cannot be accurately determined as true or false.\n5. UNKNOWN: The expression of Otx2 in adult stem cells or primordial germ cells is not generally characteristic, as Otx2 is more closely linked to neuroectodermal tissues, but without specific data, it is difficult to conclusively say whether Otx2 is or is not expressed in these cell types.",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3815,
    "user_query": "How many DNaseI hypersensitive sites (DHS) mark the murine beta globin locus region?",
    "llama-2-13b-chat-hf_response": "The murine beta globin locus region is a region of the mouse genome that contains the genes encoding the beta globin proteins, which are important for the transport of oxygen in the blood. DNaseI hypersensitive sites (DHS) are regions of the genome that are more accessible to the enzyme DNaseI, which is used to map regions of open chromatin.\nTo determine the number of DHS marking the murine beta globin locus region, we can use the UCSC Genome Browser, which provides a comprehensive map of DHS in the mouse genome. Using the UCSC Genome Browser, we can see that there are several DHS located within the murine beta globin locus region.\nSpecifically, there are 10 DHS located within the region spanning from approximately 125 kb upstream of the Hbb-b1 gene (which encodes the beta-1 globin protein) to approximately 125 kb downstream of the Hbb-b2 gene (which encodes the beta-2 globin protein). These DHS are marked by the UCSC Genome Browser with the symbol \"DHS\" and are indicated by red bars on the genomic coordinate display.\nTherefore, there are 10 DHS marking the murine beta globin locus region. These DHS likely represent regions of open chromatin that are more accessible to the DNaseI enzyme, and may be important for the regulation of gene expression within the beta globin locus.",
    "llama-2-13b-chat-hf_fact_raw": "1. The murine beta globin locus region contains the genes encoding the beta globin proteins.\n2. DNaseI hypersensitive sites (DHS) are regions more accessible to the enzyme DNaseI.\n3. The UCSC Genome Browser provides a map of DHS in the mouse genome.\n4. There are 10 DHS located within the region spanning from approximately 125 kb upstream of the Hbb-b1 gene to approximately 125 kb downstream of the Hbb-b2 gene.\n5. These 10 DHS are marked by the UCSC Genome Browser with the symbol \"DHS\" and are indicated by red bars on the genomic coordinate display.",
    "llama-2-13b-chat-hf_fact": [
      "The murine beta globin locus region contains the genes encoding the beta globin proteins.",
      "DNaseI hypersensitive sites (DHS) are regions more accessible to the enzyme DNaseI.",
      "The UCSC Genome Browser provides a map of DHS in the mouse genome.",
      "There are 10 DHS located within the region spanning from approximately 125 kb upstream of the Hbb-b1 gene to approximately 125 kb downstream of the Hbb-b2 gene.",
      "These 10 DHS are marked by the UCSC Genome Browser with the symbol \"DHS\" and are indicated by red bars on the genomic coordinate display."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN (Without specific data or reference, the exact number of DNaseI hypersensitive sites cannot be confirmed.)\n5. UNKNOWN (Without specific data or a visual inspection of the UCSC Genome Browser, the marking system, and color coding cannot be confirmed.)",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3822,
    "user_query": "List as many European influenza vaccines as possible.",
    "llama-2-13b-chat-hf_response": "There are several European influenza vaccines available, including:\n1. Fluarix (GlaxoSmithKline): This vaccine is approved for use in adults and children aged 6 months and older.\n2. Fluvir (Novartis): This vaccine is approved for use in adults and children aged 6 months and older.\n3. FluMist (MedImmune): This vaccine is approved for use in children aged 6 months to 17 years.\n4. Influpozzi (Sanofi Pasteur): This vaccine is approved for use in adults and children aged 6 months and older.\n5. Vaxigrip (Sanofi Pasteur): This vaccine is approved for use in adults and children aged 6 months and older.\n6. Fluad (Seqirus): This vaccine is approved for use in adults aged 65 years and older.\n7. Fluarix Quadrivalent (GlaxoSmithKline): This vaccine is approved for use in adults and children aged 6 months and older, and protects against four strains of the flu virus.\n8. Fluvir Quadrivalent (Novartis): This vaccine is approved for use in adults and children aged 6 months and older, and protects against four strains of the flu virus.\n9. FluMist Quadrivalent (MedImmune): This vaccine is approved for use in children aged 6 months to 17 years, and protects against four strains of the flu virus.\n10. Influpozzi Quadrivalent (Sanofi Pasteur): This vaccine is approved for use in adults and children aged 6 months and older, and protects against four strains of the flu virus.\nIt's important to note that this list may not be exhaustive, and there may be other European influenza vaccines available as well. Additionally, the availability of these vaccines may vary by country and region.",
    "llama-2-13b-chat-hf_fact_raw": "1. Fluarix, manufactured by GlaxoSmithKline, is approved for use in adults and children aged 6 months and older.\n2. Fluvir, manufactured by Novartis, is approved for use in adults and children aged 6 months and older.\n3. FluMist, manufactured by MedImmune, is approved for use in children aged 6 months to 17 years.\n4. Influpozzi, manufactured by Sanofi Pasteur, is approved for use in adults and children aged 6 months and older.\n5. Fluad, manufactured by Seqirus, is approved for use in adults aged 65 years and older.",
    "llama-2-13b-chat-hf_fact": [
      "Fluarix, manufactured by GlaxoSmithKline, is approved for use in adults and children aged 6 months and older.",
      "Fluvir, manufactured by Novartis, is approved for use in adults and children aged 6 months and older.",
      "FluMist, manufactured by MedImmune, is approved for use in children aged 6 months to 17 years.",
      "Influpozzi, manufactured by Sanofi Pasteur, is approved for use in adults and children aged 6 months and older.",
      "Fluad, manufactured by Seqirus, is approved for use in adults aged 65 years and older."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Fluvir is not a known brand name for a flu vaccine by Novartis. A well-known flu vaccine manufactured by Novartis was previously called Fluvirin, which was approved for use in people aged 4 years and older before Novartis's flu vaccine business was acquired by CSL's Seqirus.\n3. FALSE [correction]: FluMist, manufactured by MedImmune, is approved for use in people aged 2 through 49 years according to the guidelines provided by U.S. CDC.\n4. TRUE\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3832,
    "user_query": "Is the Paramyxovirus geneome segmented, negative-sense RNA?",
    "llama-2-13b-chat-hf_response": "Yes, the paramyxovirus genome is segmented and consists of negative-sense RNA. Paramyxoviruses are a family of viruses that include measles, mumps, and respiratory syncytial virus (RSV). The genome of these viruses is made up of multiple segments of RNA, which are negative-sense, meaning that the RNA molecule has a negative charge.\nEach segment of the paramyxovirus genome is called an \"exon\" and is flanked by regions of non-coding RNA called \"introns.\" The exons encode the viral proteins, while the introns do not. During the process of transcription, the viral RNA polymerase reads the exons and ignores the introns, resulting in the production of mRNA that is complementary to the viral DNA. This complementary mRNA is then translated into protein.\nThe segmentation of the paramyxovirus genome is thought to be an adaptation that allows the virus to regulate the expression of its genes and to evade the host's immune system. By breaking up the genome into smaller segments, the virus can control the timing and location of gene expression, and it can also make it more difficult for the host to recognize and respond to the virus.\nOverall, the segmented, negative-sense RNA genome of paramyxoviruses is a unique feature of these viruses and plays an important role in their replication and pathogenesis.",
    "llama-2-13b-chat-hf_fact_raw": "1. The paramyxovirus genome is segmented.\n2. The paramyxovirus genome consists of negative-sense RNA.\n3. Paramyxovirus family includes viruses such as measles, mumps, and respiratory syncytial virus (RSV).\n4. Each segment of the paramyxovirus genome is called an \"exon.\"\n5. The exons in the paramyxovirus genome encode the viral proteins.",
    "llama-2-13b-chat-hf_fact": [
      "The paramyxovirus genome is segmented.",
      "The paramyxovirus genome consists of negative-sense RNA.",
      "Paramyxovirus family includes viruses such as measles, mumps, and respiratory syncytial virus (RSV).",
      "Each segment of the paramyxovirus genome is called an \"exon.\"",
      "The exons in the paramyxovirus genome encode the viral proteins."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: The paramyxovirus genome is not segmented; it is a single, non-segmented strand of negative-sense RNA.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The paramyxovirus genome does not have segments so it does not have exons. In viruses with non-segmented RNA genomes, the term \"exon\" is not applicable, as \"exon\" refers to segments of DNA or RNA that code for a portion of the final mature RNA product in eukaryotic cells after introns have been removed by RNA splicing.\n5. FALSE [correction]: Given that the term \"exon\" is not applicable to paramyxoviruses as corrected in statement 4, this statement is false. The correct term for the regions in the paramyxovirus genome that encode viral proteins would simply be \"genes\" or \"coding sequences.\"",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 3869,
    "user_query": "Roflumilast Cream is effective for which disease?",
    "llama-2-13b-chat-hf_response": "Roflumilast cream is used to treat moderate to severe plaque psoriasis. It works by reducing inflammation and slowing down the growth of skin cells.\nWhat is the recommended dosage of Roflumilast Cream?\nThe recommended dosage of Roflumilast cream is 0.5% to 2% applied topically once or twice daily, depending on the severity of the psoriasis.\nWhat are the side effects of Roflumilast Cream?\nCommon side effects of Roflumilast cream include:\n* Redness\n* Itching\n* Burning\n* Stinging\n* Dryness\n* Flaking\nSerious side effects of Roflumilast cream are rare, but can include:\n* Allergic reactions\n* Infections\n* Skin irritation\nIt is important to follow the dosage instructions carefully and to discontinue use if any side effects occur.\nWhat precautions should be taken while using Roflumilast Cream?\nHere are some precautions to be taken while using Roflumilast cream:\n* Avoid using Roflumilast cream on open wounds or sunburned skin.\n* Do not use Roflumilast cream if you have a history of allergic reactions to any of the ingredients.\n* Avoid exposing the treated area to direct sunlight or UV light.\n* Do not use Roflumilast cream if you have a history of skin cancer or are at risk of developing skin cancer.\n* Pregnant or breastfeeding women should consult their doctor before using Roflumilast cream.\n* Roflumilast cream may interact with other medications, so it is important to inform your doctor of all medications you are currently taking.\nIt is important to follow the precautions carefully to minimize the risk of side effects and to ensure the effectiveness of the treatment.",
    "llama-2-13b-chat-hf_fact_raw": "1. Roflumilast cream is used to treat moderate to severe plaque psoriasis.\n2. The recommended dosage of Roflumilast cream is 0.5% to 2% applied topically once or twice daily.\n3. Common side effects of Roflumilast cream include redness, itching, burning, stinging, dryness, and flaking.\n4. Serious side effects of Roflumilast cream can include allergic reactions and infections.\n5. Roflumilast cream should not be used on open wounds, sunburned skin, or by individuals with a history of skin cancer or at risk of developing skin cancer.",
    "llama-2-13b-chat-hf_fact": [
      "Roflumilast cream is used to treat moderate to severe plaque psoriasis.",
      "The recommended dosage of Roflumilast cream is 0.5% to 2% applied topically once or twice daily.",
      "Common side effects of Roflumilast cream include redness, itching, burning, stinging, dryness, and flaking.",
      "Serious side effects of Roflumilast cream can include allergic reactions and infections.",
      "Roflumilast cream should not be used on open wounds, sunburned skin, or by individuals with a history of skin cancer or at risk of developing skin cancer."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The recommended dosage of Roflumilast cream is not specified in this statement. The percentage used can vary, and specific dosage instructions, including the percentage of the cream and frequency of use, should be obtained from the prescribing information or a healthcare professional.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: While it would be prudent to avoid using Roflumilast cream on open wounds or sunburned skin due to potential irritation or adverse effects, there is no specific mention of contraindication in individuals with a history of skin cancer or those at risk of developing skin cancer in the provided statements. Such precautions should be discussed with a healthcare professional and could vary based on the specific medication formulation and patient history.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3885,
    "user_query": "Which tools have been developed for identifying and visualising ncRNA promoters?",
    "llama-2-13b-chat-hf_response": "There are several tools that have been developed for identifying and visualising non-coding RNA (ncRNA) promoters. Some of the commonly used tools include:\n1. StarBase: StarBase is a web-based tool that uses a combination of sequence and chromatin features to predict the promoters of ncRNAs. It can also be used to visualise the predicted promoters on a genomic scale.\n2. CRNAC: CRNAC is a tool that uses a combination of sequence and chromatin features to predict the promoters of long non-coding RNAs (lncRNAs). It can also be used to visualise the predicted promoters on a genomic scale.\n3. LncRNA-Predict: LncRNA-Predict is a tool that uses a combination of sequence and chromatin features to predict the promoters of lncRNAs. It can also be used to visualise the predicted promoters on a genomic scale.\n4. RNA-seq-based methods: RNA-seq can be used to identify the transcripts and their promoters by mapping the RNA-seq reads to the reference genome. Tools such as HISAT2, STAR, and TopHat can be used for this purpose.\n5. Chromatin conformation capture (3C) methods: 3C methods can be used to identify the interactions between different regions of the genome, including the promoters of ncRNAs. Tools such as 4C, 5C, and Hi-C can be used for this purpose.\n6. Assay for transposase-accessible chromatin (ATAC-seq): ATAC-seq is a method that uses the transposase enzyme to fragment the chromatin and then sequences the fragments to identify the accessible regions of the genome. This can be used to identify the promoters of ncRNAs.\n7. Chromatin immunoprecipitation sequencing (ChIP-seq): ChIP-seq is a method that uses antibodies to immunoprecipitate the DNA-binding proteins and then sequences the precipitated DNA to identify the regions of the genome that are bound by the proteins. This can be used to identify the promoters of nc",
    "llama-2-13b-chat-hf_fact_raw": "1. StarBase uses sequence and chromatin features to predict promoters of ncRNAs and visualize them on a genomic scale.\n2. CRNAC predicts and visualizes promoters of long non-coding RNAs (lncRNAs) using sequence and chromatin features.\n3. LncRNA-Predict is a tool for predicting and visualizing lncRNA promoters based on sequence and chromatin features.\n4. RNA-seq-based methods, using tools like HISAT2, STAR, and TopHat, can identify transcripts and their promoters by mapping RNA-seq reads to the reference genome.\n5. Chromatin conformation capture methods, including 4C, 5C, and Hi-C, can identify interactions between genome regions, including ncRNA promoters.",
    "llama-2-13b-chat-hf_fact": [
      "StarBase uses sequence and chromatin features to predict promoters of ncRNAs and visualize them on a genomic scale.",
      "CRNAC predicts and visualizes promoters of long non-coding RNAs (lncRNAs) using sequence and chromatin features.",
      "LncRNA-Predict is a tool for predicting and visualizing lncRNA promoters based on sequence and chromatin features.",
      "RNA-seq-based methods, using tools like HISAT2, STAR, and TopHat, can identify transcripts and their promoters by mapping RNA-seq reads to the reference genome.",
      "Chromatin conformation capture methods, including 4C, 5C, and Hi-C, can identify interactions between genome regions, including ncRNA promoters."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN: The statement about StarBase's functionality is specific and without additional context validating its accuracy, it cannot be confirmed as true or false.\n\n2. FALSE [correction]: It's not clear from the statement whether \"CRNAC\" is a real tool or has the described functionality. As the statement stands, there is no widely recognized tool called \"CRNAC\" with the described functionality, so the statement cannot be verified.\n\n3. UNKNOWN: The functionality of \"LncRNA-Predict\" cannot be established as true or false without additional information confirming the tool's existence and its capabilities.\n\n4. TRUE: RNA-seq-based methods like HISAT2, STAR, and TopHat are indeed used to identify transcripts by mapping RNA-seq reads to the reference genome. These tools can facilitate the identification of promoters, although they may not directly predict them.\n\n5. TRUE: Chromatin conformation capture methods, including 4C, 5C, and Hi-C, are used to identify physical interactions between different regions of the genome, which can be useful for identifying regulatory elements such as ncRNA promoters.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3918,
    "user_query": "List example genes that SWIM tool has identified and which are down-regulated in glioblastoma",
    "llama-2-13b-chat-hf_response": ".\nThe SWIM tool has identified several genes that are down-regulated in glioblastoma, including:\n1. TP53: A tumor suppressor gene that is frequently mutated in glioblastoma.\n2. PTEN: A phosphatase that regulates the PI3K/Akt signaling pathway and is down-regulated in many types of cancer, including glioblastoma.\n3. PD-1: A cell surface protein that is involved in immune checkpoint regulation and is down-regulated in many types of cancer, including glioblastoma.\n4. CDKN2A: A tumor suppressor gene that is down-regulated in many types of cancer, including glioblastoma.\n5. SLC25A38: A gene that is involved in the regulation of mitochondrial function and is down-regulated in glioblastoma.\n6. CAV1: A gene that is involved in the regulation of cell adhesion and is down-regulated in glioblastoma.\n7. KRAS: A gene that is involved in the regulation of cell signaling and is frequently mutated in glioblastoma.\n8. EGFR: A gene that is involved in the regulation of cell signaling and is down-regulated in glioblastoma.\n9. MGMT: A gene that is involved in the repair of DNA damage and is down-regulated in glioblastoma.\n10. BAX: A pro-apoptotic gene that is down-regulated in glioblastoma.\nThese genes are identified based on the analysis of RNA sequencing data from glioblastoma tumors and normal brain tissues. The SWIM tool uses a machine learning algorithm to identify genes that are differentially expressed between the two groups, and then uses a statistical test to determine which of these genes are most likely to be genuinely down-regulated in glioblastoma.",
    "llama-2-13b-chat-hf_fact_raw": "1. SWIM tool identified TP53 as a tumor suppressor gene that is frequently mutated in glioblastoma.\n2. PTEN, which regulates the PI3K/Akt signaling pathway, is down-regulated in glioblastoma.\n3. PD-1, a cell surface protein involved in immune checkpoint regulation, is down-regulated in glioblastoma.\n4. CDKN2A, a tumor suppressor gene, is down-regulated in glioblastoma.\n5. SLC25A38, which regulates mitochondrial function, is down-regulated in glioblastoma.",
    "llama-2-13b-chat-hf_fact": [
      "SWIM tool identified TP53 as a tumor suppressor gene that is frequently mutated in glioblastoma.",
      "PTEN, which regulates the PI3K/Akt signaling pathway, is down-regulated in glioblastoma.",
      "PD-1, a cell surface protein involved in immune checkpoint regulation, is down-regulated in glioblastoma.",
      "CDKN2A, a tumor suppressor gene, is down-regulated in glioblastoma.",
      "SLC25A38, which regulates mitochondrial function, is down-regulated in glioblastoma."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: PD-1 is an immune checkpoint protein that is typically upregulated in many forms of cancer, including glioblastoma, to help tumor cells evade the immune system.\n4. TRUE\n5. UNKNOWN",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3926,
    "user_query": "Which R packages have been developed for studying TADs?",
    "llama-2-13b-chat-hf_response": "There are several R packages that have been developed for studying TADs, including:\n1. `TADs`: This package provides a set of functions for working with TADs, including functions for calculating TAD boundaries, identifying TADs in genomic data, and visualizing TADs.\n2. `TADfinder`: This package provides a set of functions for identifying TADs in genomic data using a variety of methods, including peak calling, motif analysis, and sequence-based methods.\n3. `TADtools`: This package provides a set of functions for working with TADs, including functions for calculating TAD boundaries, identifying TADs in genomic data, and visualizing TADs.\n4. `ChromatinTADs`: This package provides a set of functions for working with chromatin TADs, including functions for identifying TADs in chromatin immunoprecipitation sequencing (ChIP-seq) data and visualizing TADs.\n5. `HiC-TADs`: This package provides a set of functions for working with high-throughput chromosome conformation capture (HiC) data and identifying TADs in that data.\n6. `TADmap`: This package provides a set of functions for visualizing TADs in genomic data and for identifying the boundaries of TADs.\n7. `TADcluster`: This package provides a set of functions for clustering TADs based on their genomic positions and other features.\n8. `TADnetwork`: This package provides a set of functions for constructing and analyzing networks of TADs and their interactions.\nThese packages can be installed and loaded into R using the standard package installation and loading procedures. Once loaded, they can be used to analyze and visualize TADs in genomic data.",
    "llama-2-13b-chat-hf_fact_raw": "1. The 'TADs' R package offers functions for calculating TAD boundaries and visualizing TADs.\n2. The 'TADfinder' R package can identify TADs using methods like peak calling and sequence-based analysis.\n3. The 'ChromatinTADs' R package works with chromatin TADs identified in ChIP-seq data.\n4. The 'HiC-TADs' R package provides functions for handling HiC data to identify TADs.\n5. The 'TADmap' R package includes functions for visualizing TADs and identifying their boundaries.",
    "llama-2-13b-chat-hf_fact": [
      "The 'TADs' R package offers functions for calculating TAD boundaries and visualizing TADs.",
      "The 'TADfinder' R package can identify TADs using methods like peak calling and sequence-based analysis.",
      "The 'ChromatinTADs' R package works with chromatin TADs identified in ChIP-seq data.",
      "The 'HiC-TADs' R package provides functions for handling HiC data to identify TADs.",
      "The 'TADmap' R package includes functions for visualizing TADs and identifying their boundaries."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. FALSE [correction]: The 'HiTC' R package provides functions for handling Hi-C data to identify TADs and not 'HiC-TADs'.\n5. UNKNOWN",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3927,
    "user_query": "Which bioconductor tool has been developed for accessing bacterial regulatory networks?",
    "llama-2-13b-chat-hf_response": "There are several bioconductor tools that have been developed for accessing bacterial regulatory networks. Some of the popular ones include:\n1. Cytoscape: Cytoscape is a widely used tool for visualizing and analyzing bacterial regulatory networks. It allows users to import data from various sources, including ChIP-seq, gene expression, and protein-protein interaction data, and then use a variety of algorithms to infer regulatory relationships between genes.\n2. ARACNe: ARACNe (Algorithm for the Reconstruction of Accurate Cellular Networks) is a tool for reconstructing regulatory networks from gene expression data. It uses a Bayesian approach to infer the presence of regulatory interactions between genes, and can be used to analyze both single-cell and bulk gene expression data.\n3. Inferelator: Inferelator is a tool for inferring regulatory relationships between genes from gene expression data. It uses a Bayesian approach to model the probability of a regulatory interaction between two genes, based on the expression profiles of the genes and the known regulatory interactions in the network.\n4. Regulatory Network Inference (RNI): RNI is a tool for inferring regulatory networks from gene expression data. It uses a Bayesian approach to model the probability of a regulatory interaction between two genes, based on the expression profiles of the genes and the known regulatory interactions in the network.\n5. NetworkAnalyst: NetworkAnalyst is a tool for analyzing and visualizing bacterial regulatory networks. It allows users to import data from various sources, including ChIP-seq, gene expression, and protein-protein interaction data, and then use a variety of algorithms to infer regulatory relationships between genes.\n6. Bacterial Regulatory Network (BRN): BRN is a tool for reconstructing regulatory networks from gene expression data. It uses a Bayesian approach to infer the presence of regulatory interactions between genes, and can be used to analyze both single-cell and bulk gene expression data.\n7. Regulatory Genome Engineering (RGE): RGE is a tool for engineering bacterial regulatory networks. It allows users to design and test new regulatory networks, and then use these networks to control gene expression in bacteria.\nThese are just a few examples",
    "llama-2-13b-chat-hf_fact_raw": "1. Cytoscape is used for visualizing and analyzing bacterial regulatory networks, and it can import data from various sources.\n2. ARACNe is a tool that reconstructs regulatory networks from gene expression data using a Bayesian approach.\n3. Inferelator infers regulatory relationships between genes from gene expression data, utilizing a Bayesian method.\n4. NetworkAnalyst analyzes and visualizes bacterial regulatory networks and allows data import from different sources.\n5. Bacterial Regulatory Network (BRN) reconstructs regulatory networks from gene expression data and can be applied to both single-cell and bulk data.",
    "llama-2-13b-chat-hf_fact": [
      "Cytoscape is used for visualizing and analyzing bacterial regulatory networks, and it can import data from various sources.",
      "ARACNe is a tool that reconstructs regulatory networks from gene expression data using a Bayesian approach.",
      "Inferelator infers regulatory relationships between genes from gene expression data, utilizing a Bayesian method.",
      "NetworkAnalyst analyzes and visualizes bacterial regulatory networks and allows data import from different sources.",
      "Bacterial Regulatory Network (BRN) reconstructs regulatory networks from gene expression data and can be applied to both single-cell and bulk data."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE: Cytoscape is often used for visualizing complex networks, including biological networks such as bacterial regulatory networks, and it indeed supports importing data from various sources.\n2. FALSE [correction]: ARACNe is a tool for reconstructing regulatory networks, but it does not use a Bayesian approach. It uses information theory to infer the networks from gene expression data, specifically the data processing inequality (DPI).\n3. FALSE [correction]: Inferelator does infer regulatory relationships between genes from gene expression data; however, it typically does not use a Bayesian method. It uses various statistical and machine learning approaches to achieve this.\n4. TRUE: NetworkAnalyst is a comprehensive visual analytics platform for network-based meta-analysis and visualization, and it does support analysis and visualization of various biological networks, including those relevant to bacteria, and allows for data import from different sources.\n5. UNKNOWN: The term \"Bacterial Regulatory Network (BRN)\" can refer to the networks themselves, not to a specific tool or algorithm. There are various tools designed to analyze gene regulatory networks and they can often be applied to various types of data, including single-cell and bulk data. However, without a specific reference to a software or algorithm named \"Bacterial Regulatory Network,\" the accuracy of the statement cannot be determined.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3933,
    "user_query": "What are the end products of the shikimate pathway?",
    "llama-2-13b-chat-hf_response": "The shikimate pathway is a metabolic route that produces several important aromatic compounds in plants, fungi, and bacteria. The end products of the shikimate pathway are:\n1. Quinates: These are the final products of the shikimate pathway and are used in the synthesis of important aromatic compounds such as flavonoids, alkaloids, and lignins.\n2. Aromatic amino acids: The shikimate pathway also produces aromatic amino acids such as phenylalanine, tyrosine, and tryptophan, which are important for protein synthesis.\n3. Nucleotides: The shikimate pathway produces nucleotides such as ATP, CTP, GTP, and UTP, which are essential for energy metabolism and protein synthesis.\n4. Flavonoids: The shikimate pathway is also involved in the synthesis of flavonoids, which are a class of plant secondary metabolites that have antioxidant and pigment properties.\n5. Alkaloids: The shikimate pathway can also produce alkaloids, which are a class of naturally occurring compounds that have a wide range of biological activities.\nOverall, the end products of the shikimate pathway play important roles in plant metabolism and are involved in the synthesis of a wide range of compounds that are essential for plant growth and development.",
    "llama-2-13b-chat-hf_fact_raw": "1. The shikimate pathway produces quinates which are used in the synthesis of flavonoids, alkaloids, and lignins.\n2. Aromatic amino acids such as phenylalanine, tyrosine, and tryptophan are end products of the shikimate pathway.\n3. The shikimate pathway results in the production of nucleotides including ATP, CTP, GTP, and UTP.\n4. Flavonoids, which have antioxidant and pigment properties, are synthesized from the shikimate pathway.\n5. Alkaloids, having a wide range of biological activities, are also produced by the shikimate pathway.",
    "llama-2-13b-chat-hf_fact": [
      "The shikimate pathway produces quinates which are used in the synthesis of flavonoids, alkaloids, and lignins.",
      "Aromatic amino acids such as phenylalanine, tyrosine, and tryptophan are end products of the shikimate pathway.",
      "The shikimate pathway results in the production of nucleotides including ATP, CTP, GTP, and UTP.",
      "Flavonoids, which have antioxidant and pigment properties, are synthesized from the shikimate pathway.",
      "Alkaloids, having a wide range of biological activities, are also produced by the shikimate pathway."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: The shikimate pathway does not produce quinates for the synthesis of flavonoids, alkaloids, and lignins. It is involved in the synthesis of aromatic amino acids.\n2. TRUE\n3. FALSE [correction]: The shikimate pathway does not result in the production of nucleotides including ATP, CTP, GTP, and UTP. It is involved in the synthesis of aromatic amino acids, which are building blocks for proteins and other important molecules, not nucleotides.\n4. TRUE\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3936,
    "user_query": "Is cabergoline used for treatment of the Nelson's syndrome ?",
    "llama-2-13b-chat-hf_response": "Yes, cabergoline is used for the treatment of Nelson's syndrome, which is a rare condition that occurs when a pituitary tumor compresses the optic chiasm and causes visual disturbances, headaches, and pituitary insufficiency. Cabergoline, a dopamine receptor agonist, is used to reduce the size of the tumor and relieve symptoms.\nNelson's syndrome is a rare condition that occurs in some cases of pituitary tumors, particularly those that produce excess growth hormone. The condition is named after Dr. Edward Nelson, who first described it in the medical literature in 1965.\nCabergoline is a medication that works by binding to dopamine receptors in the pituitary gland and inhibiting the production of growth hormone. It is commonly used to treat hypergrowth hormone secretion and acromegaly, a condition in which the body produces too much growth hormone, leading to abnormal growth and enlargement of body tissues.\nIn the treatment of Nelson's syndrome, cabergoline is used to reduce the size of the pituitary tumor and relieve symptoms such as visual disturbances, headaches, and pituitary insufficiency. The medication is usually given in doses ranging from 0.5 to 1.0 mg per week, and the dose may be adjusted based on the patient's response to the medication.\nWhile cabergoline is effective in reducing the size of pituitary tumors and relieving symptoms of Nelson's syndrome, it is not a cure for the condition. In some cases, surgery may be necessary to remove the tumor, and radiation therapy may be used to shrink the tumor before surgery.\nIt is important to note that cabergoline can have side effects, including nausea, vomiting, and headache. In rare cases, the medication can cause a condition called dopamine dysregulation syndrome, which can lead to impulsive behavior, confusion, and hallucinations. Therefore, it is important to use cabergoline under the close supervision of a healthcare provider.",
    "llama-2-13b-chat-hf_fact_raw": "1. Cabergoline is used for the treatment of Nelson's syndrome.\n2. Nelson's syndrome can cause visual disturbances, headaches, and pituitary insufficiency due to a pituitary tumor compressing the optic chiasm.\n3. Cabergoline is a dopamine receptor agonist that binds to dopamine receptors in the pituitary gland.\n4. Cabergoline can reduce the size of pituitary tumors and relieve symptoms of Nelson's syndrome.\n5. Side effects of cabergoline can include nausea, vomiting, headache, and dopamine dysregulation syndrome.",
    "llama-2-13b-chat-hf_fact": [
      "Cabergoline is used for the treatment of Nelson's syndrome.",
      "Nelson's syndrome can cause visual disturbances, headaches, and pituitary insufficiency due to a pituitary tumor compressing the optic chiasm.",
      "Cabergoline is a dopamine receptor agonist that binds to dopamine receptors in the pituitary gland.",
      "Cabergoline can reduce the size of pituitary tumors and relieve symptoms of Nelson's syndrome.",
      "Side effects of cabergoline can include nausea, vomiting, headache, and dopamine dysregulation syndrome."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: Cabergoline is not typically used for the treatment of Nelson's syndrome. It is used for the treatment of prolactinomas, which are pituitary tumors that secrete the hormone prolactin. Nelson's syndrome is characterized by the growth of a pituitary adenoma after the removal of the adrenal glands and is most commonly treated with surgery or radiotherapy.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: While cabergoline can reduce the size of prolactin-secreting pituitary tumors (prolactinomas) and relieve associated symptoms, it is not mainly used for the treatment of Nelson's syndrome. Cabergoline's effects on Nelson's syndrome are not well established.\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3939,
    "user_query": "What is the main manifestation of Liebenberg syndrome?",
    "llama-2-13b-chat-hf_response": "Liebenberg syndrome is a rare condition that is characterized by a combination of symptoms including:\n1. Difficulty with speech and language development: Children with Liebenberg syndrome may have difficulty articulating words, stuttering, or having a hard time understanding language.\n2. Intellectual disability: Children with Liebenberg syndrome may have below-average intelligence and may struggle with learning and academic tasks.\n3. Autism spectrum disorder: Many children with Liebenberg syndrome also have autism spectrum disorder, which can affect their social and emotional development.\n4. Seizures: Some children with Liebenberg syndrome may experience seizures, which can be a sign of the condition.\n5. Delayed physical development: Children with Liebenberg syndrome may have delayed physical development, including delayed walking, talking, and other milestones.\n6. Distinctive facial features: Children with Liebenberg syndrome may have distinctive facial features, such as a flat nasal bridge, a small jaw, and widely spaced eyes.\n7. Sleep disturbances: Children with Liebenberg syndrome may have difficulty sleeping or may experience sleep disturbances, such as insomnia or restlessness.\n8. Behavioral problems: Children with Liebenberg syndrome may have behavioral problems, such as anxiety, depression, or attention deficit hyperactivity disorder (ADHD).\nIt is important to note that every child with Liebenberg syndrome is unique and may experience a different combination of these symptoms. The severity of the condition can also vary widely between individuals.",
    "llama-2-13b-chat-hf_fact_raw": "1. Liebenberg syndrome is characterized by difficulty with speech and language development.\n2. Intellectual disability is a symptom of Liebenberg syndrome.\n3. Many children with Liebenberg syndrome also have autism spectrum disorder.\n4. Seizures can be a sign of Liebenberg syndrome.\n5. Children with Liebenberg syndrome may have distinctive facial features, such as a flat nasal bridge, a small jaw, and widely spaced eyes.",
    "llama-2-13b-chat-hf_fact": [
      "Liebenberg syndrome is characterized by difficulty with speech and language development.",
      "Intellectual disability is a symptom of Liebenberg syndrome.",
      "Many children with Liebenberg syndrome also have autism spectrum disorder.",
      "Seizures can be a sign of Liebenberg syndrome.",
      "Children with Liebenberg syndrome may have distinctive facial features, such as a flat nasal bridge, a small jaw, and widely spaced eyes."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN: The statement regarding Liebenberg syndrome is not a common medical condition, and there is no widely recognized syndrome by this name. Without additional context, it is not possible to determine the accuracy of this statement.\n2. UNKNOWN: Similar to the first statement, due to the lack of established medical information on Liebenberg syndrome, it's unclear whether intellectual disability is a symptom.\n3. UNKNOWN: As there is no clarity on what Liebenberg syndrome entails, it is unknown whether it is associated with autism spectrum disorder.\n4. UNKNOWN: With insufficient information on the syndrome, it is not possible to confirm if seizures are a sign of it.\n5. UNKNOWN: Without verified medical sources or information about Liebenberg syndrome, one cannot validate the claim about distinctive facial features. \n\n*Please note that Liebenberg syndrome is not a recognized medical condition in any standard references or medical literature as of my knowledge cutoff in 2023. It is possible that it could be a very rare condition, misnamed, or fictional. Always refer to up-to-date, reliable medical sources for information on medical conditions.",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3977,
    "user_query": "List orally bioavailable MPS1 kinase inhibitors",
    "llama-2-13b-chat-hf_response": "MPS1 (Mitosis-Associated Protein 1) is a serine/threonine kinase that plays a crucial role in regulating the G2/M checkpoint of the cell cycle. MPS1 is overexpressed in various types of cancer, and its overexpression is associated with poor prognosis. Therefore, MPS1 has been considered as a potential target for cancer therapy. Here are some orally bioavailable MPS1 kinase inhibitors that have been developed:\n1. Sotrastaurin (AEZS-108): Sotrastaurin is a potent and selective MPS1 inhibitor that has shown antitumor activity in preclinical studies. It is currently being evaluated in clinical trials for the treatment of various types of cancer, including non-small cell lung cancer and pancreatic cancer.\n2. RX-0201: RX-0201 is a highly selective MPS1 inhibitor that has shown potent antitumor activity in preclinical studies. It is currently being developed by Rexahn Pharmaceuticals for the treatment of various types of cancer, including breast cancer and ovarian cancer.\n3. BMS-986177: BMS-986177 is a potent and selective MPS1 inhibitor that has shown antitumor activity in preclinical studies. It is currently being developed by Bristol-Myers Squibb for the treatment of various types of cancer, including lung cancer and pancreatic cancer.\n4. GS-99739: GS-99739 is a highly selective MPS1 inhibitor that has shown potent antitumor activity in preclinical studies. It is currently being developed by Gilead Sciences for the treatment of various types of cancer, including breast cancer and ovarian cancer.\n5. HG-10-102-01: HG-10-102-01 is a highly selective MPS1 inhibitor that has shown potent antitumor activity in preclinical studies. It is currently being developed by Hengrui Therapeutics for the treatment of various types of cancer,",
    "llama-2-13b-chat-hf_fact_raw": "1. Sotrastaurin (AEZS-108) is an orally bioavailable MPS1 kinase inhibitor currently evaluated in clinical trials.\n2. RX-0201 is an orally bioavailable MPS1 kinase inhibitor being developed by Rexahn Pharmaceuticals.\n3. BMS-986177 is an orally bioavailable MPS1 kinase inhibitor being developed by Bristol-Myers Squibb.\n4. GS-99739 is an orally bioavailable MPS1 kinase inhibitor being developed by Gilead Sciences.\n5. HG-10-102-01 is an orally bioavailable MPS1 kinase inhibitor being developed by Hengrui Therapeutics.",
    "llama-2-13b-chat-hf_fact": [
      "Sotrastaurin (AEZS-108) is an orally bioavailable MPS1 kinase inhibitor currently evaluated in clinical trials.",
      "RX-0201 is an orally bioavailable MPS1 kinase inhibitor being developed by Rexahn Pharmaceuticals.",
      "BMS-986177 is an orally bioavailable MPS1 kinase inhibitor being developed by Bristol-Myers Squibb.",
      "GS-99739 is an orally bioavailable MPS1 kinase inhibitor being developed by Gilead Sciences.",
      "HG-10-102-01 is an orally bioavailable MPS1 kinase inhibitor being developed by Hengrui Therapeutics."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: Sotrastaurin (AEZS-108) is not an MPS1 kinase inhibitor; it is actually a protein kinase C inhibitor being evaluated in clinical trials.\n2. FALSE [correction]: RX-0201 (also known as Archexin) is not an MPS1 kinase inhibitor; it is an antisense oligonucleotide targeted against Akt1 mRNA being developed by Rexahn Pharmaceuticals.\n3. UNKNOWN: Without specific information about BMS-986177, it is difficult to determine the accuracy of this statement as MPS1 kinase inhibitors are an area of active research and development.\n4. UNKNOWN: Similar to statement 3, without specific information on GS-99739, it is not possible to confirm or deny the accuracy of this statement.\n5. UNKNOWN: Similarly, without specific information on HG-10-102-01, the accuracy of this statement cannot be determined.",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4031,
    "user_query": "Was golimumab tested for diabetes?",
    "llama-2-13b-chat-hf_response": "Golimumab, a TNF-alpha inhibitor, has been studied for its potential benefits in treating diabetes. However, the current evidence is limited and inconclusive.\nThere have been a few small studies and case series that have suggested that TNF-alpha inhibitors, including golimumab, may have beneficial effects on glycemic control and inflammatory markers in patients with type 2 diabetes. However, these studies have been largely observational and have not been powered to establish definitive conclusions.\nOne small randomized controlled trial (RCT) published in 2013 found that golimumab did not significantly improve glycemic control or inflammatory markers in patients with type 2 diabetes compared to placebo. Another RCT published in 2017 found that golimumab improved glycemic control and reduced inflammatory markers in patients with type 2 diabetes and cardiovascular disease, but the study was small and had limited follow-up.\nOverall, the current evidence is insufficient to support the use of golimumab for the treatment of diabetes. Larger, longer-term studies are needed to determine whether TNF-alpha inhibitors, including golimumab, have a role in the management of diabetes.",
    "llama-2-13b-chat-hf_fact_raw": "1. Golimumab has been studied for its potential benefits in treating diabetes.\n2. Small studies and case series have suggested TNF-alpha inhibitors may benefit glycemic control and inflammatory markers in type 2 diabetes patients.\n3. A randomized controlled trial published in 2013 found no significant improvement with golimumab in glycemic control or inflammatory markers compared to placebo in type 2 diabetes patients.\n4. A 2017 randomized controlled trial found that golimumab improved glycemic control and reduced inflammatory markers in patients with type 2 diabetes and cardiovascular disease.\n5. Current evidence is insufficient to support the use of golimumab for the treatment of diabetes.",
    "llama-2-13b-chat-hf_fact": [
      "Golimumab has been studied for its potential benefits in treating diabetes.",
      "Small studies and case series have suggested TNF-alpha inhibitors may benefit glycemic control and inflammatory markers in type 2 diabetes patients.",
      "A randomized controlled trial published in 2013 found no significant improvement with golimumab in glycemic control or inflammatory markers compared to placebo in type 2 diabetes patients.",
      "A 2017 randomized controlled trial found that golimumab improved glycemic control and reduced inflammatory markers in patients with type 2 diabetes and cardiovascular disease.",
      "Current evidence is insufficient to support the use of golimumab for the treatment of diabetes."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. FALSE [correction]: There is no readily available evidence or well-known study as of my knowledge cutoff in 2023 that a randomized controlled trial in 2013 found no significant improvement with golimumab in glycemic control or inflammatory markers compared to placebo in type 2 diabetes patients. Therefore, without specific details to the contrary, this statement cannot be confirmed as true or false.\n4. UNKNOWN\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "unknown",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 4055,
    "user_query": "Is progeria caused by an autosomal recessive gene?",
    "llama-2-13b-chat-hf_response": "Progeria, also known as Hutchinson-Gilford Progeria Syndrome (HGPS), is a rare genetic disorder that causes accelerated aging in children. It is characterized by rapid growth and development during the first two years of life, followed by a rapid decline and death in the teens or early twenties.\nThe genetic cause of progeria was first identified in 2003, when researchers discovered that the disorder is caused by mutations in the LMNA gene. This gene provides instructions for making a protein called lamin A, which is involved in the structure and maintenance of the nuclear lamina, a network of fibers that provides support and shape to the nucleus.\nThe LMNA gene is located on chromosome 1, and it is an autosomal dominant gene, meaning that a single copy of the mutated gene is enough to cause the disorder. However, some cases of progeria have been found to be caused by a different type of mutation, known as a triplication, where three copies of the LMNA gene are present instead of the usual two.\nSo, to answer your question, progeria is caused by an autosomal dominant mutation in the LMNA gene, but some cases may also be caused by a triplication of the gene.",
    "llama-2-13b-chat-hf_fact_raw": "1. Progeria is also known as Hutchinson-Gilford Progeria Syndrome (HGPS).\n2. The genetic cause of progeria was identified in 2003 as being due to mutations in the LMNA gene.\n3. The LMNA gene produces a protein called lamin A.\n4. Lamin A is involved in the structure and maintenance of the nuclear lamina.\n5. Progeria is caused by an autosomal dominant mutation, but some cases are due to a triplication of the LMNA gene.",
    "llama-2-13b-chat-hf_fact": [
      "Progeria is also known as Hutchinson-Gilford Progeria Syndrome (HGPS).",
      "The genetic cause of progeria was identified in 2003 as being due to mutations in the LMNA gene.",
      "The LMNA gene produces a protein called lamin A.",
      "Lamin A is involved in the structure and maintenance of the nuclear lamina.",
      "Progeria is caused by an autosomal dominant mutation, but some cases are due to a triplication of the LMNA gene."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Progeria is typically caused by a de novo autosomal dominant mutation in the LMNA gene, but it is not due to a triplication of the gene. The most common mutation is a point mutation that affects the gene's coding for lamin A, leading to the production of an abnormal version of the protein.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 4082,
    "user_query": "What are common variants at 12q14 and 12q24 associated with?",
    "llama-2-13b-chat-hf_response": "Common variants at 12q14 and 12q24 have been associated with various diseases and traits, including:\n12q14:\n* Breast cancer: Several studies have identified variants in this region as risk factors for breast cancer. For example, a study published in the journal Nature Genetics in 2012 found that women with a specific variant in the gene C124W had an increased risk of developing breast cancer.\n* Ovarian cancer: A study published in the journal Cancer Research in 2013 found that women with a variant in the gene RAD51C in 12q14 had an increased risk of developing ovarian cancer.\n* Prostate cancer: A study published in the journal Cancer Research in 2010 found that men with a variant in the gene EZH2 in 12q14 had an increased risk of developing prostate cancer.\n12q24:\n* Coronary artery disease: A study published in the journal Nature Genetics in 2009 found that variants in this region were associated with an increased risk of coronary artery disease.\n* Type 2 diabetes: A study published in the journal Nature Genetics in 2010 found that variants in this region were associated with an increased risk of type 2 diabetes.\n* Height: A study published in the journal Nature Genetics in 2010 found that variants in this region were associated with height.\nIt's important to note that these associations are based on observational studies and more research is needed to confirm these findings and understand the underlying biology. Additionally, the effects of these variants may be small and may interact with other factors to influence disease risk.",
    "llama-2-13b-chat-hf_fact_raw": "1. Variants in the 12q14 region have been identified as risk factors for breast cancer, according to a study published in Nature Genetics in 2012.\n2. A study published in Cancer Research in 2013 found an association between a variant in the gene RAD51C in 12q14 and an increased risk of ovarian cancer.\n3. Men with a variant in the gene EZH2 in 12q14 were found to have an increased risk of developing prostate cancer, as reported in a study in Cancer Research in 2010.\n4. Coronary artery disease has been linked to variants in the 12q24 region, based on a study published in Nature Genetics in 2009.\n5. A study published in Nature Genetics in 2010 reported that variants in the 12q24 region were associated with an increased risk of type 2 diabetes and height.",
    "llama-2-13b-chat-hf_fact": [
      "Variants in the 12q14 region have been identified as risk factors for breast cancer, according to a study published in Nature Genetics in 2012.",
      "A study published in Cancer Research in 2013 found an association between a variant in the gene RAD51C in 12q14 and an increased risk of ovarian cancer.",
      "Men with a variant in the gene EZH2 in 12q14 were found to have an increased risk of developing prostate cancer, as reported in a study in Cancer Research in 2010.",
      "Coronary artery disease has been linked to variants in the 12q24 region, based on a study published in Nature Genetics in 2009.",
      "A study published in Nature Genetics in 2010 reported that variants in the 12q24 region were associated with an increased risk of type 2 diabetes and height."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 4096,
    "user_query": "Which are the ligands of the Roundabout (Robo) receptors?",
    "llama-2-13b-chat-hf_response": "The Roundabout (Robo) receptors are a family of G protein-coupled receptors that play a crucial role in the regulation of various physiological processes, including development, tissue repair, and immune responses. The Robo receptors are activated by a variety of ligands, including:\n1. Gurken (Grk): Gurken is a ligand that is expressed in the Drosophila embryo and binds to the Robo receptor to regulate the migration and differentiation of cells during embryonic development.\n2. Slam (SLAM): Slam is a ligand that is expressed on the surface of immune cells and binds to the Robo receptor to regulate the activation of immune responses.\n3. Neurited (Nrt): Neurited is a ligand that is expressed in the nervous system and binds to the Robo receptor to regulate the development and maintenance of neurons.\n4. Draper (Dpr): Draper is a ligand that is expressed in the Drosophila embryo and binds to the Robo receptor to regulate the migration and differentiation of cells during embryonic development.\n5. Spitz (Spi): Spitz is a ligand that is expressed in the Drosophila embryo and binds to the Robo receptor to regulate the migration and differentiation of cells during embryonic development.\nThese ligands play a crucial role in regulating the activity of the Robo receptors and are involved in a variety of physiological processes, including the regulation of cell migration, differentiation, and immune responses.",
    "llama-2-13b-chat-hf_fact_raw": "1. Gurken (Grk) is a ligand expressed in the Drosophila embryo that binds to the Robo receptor.\n2. Slam (SLAM) is a ligand found on the surface of immune cells that binds to the Robo receptor.\n3. Neurited (Nrt) is a ligand expressed in the nervous system that binds to the Robo receptor.\n4. Draper (Dpr) is a ligand expressed in the Drosophila embryo that binds to the Robo receptor.\n5. Spitz (Spi) is a ligand expressed in the Drosophila embryo that binds to the Robo receptor.",
    "llama-2-13b-chat-hf_fact": [
      "Gurken (Grk) is a ligand expressed in the Drosophila embryo that binds to the Robo receptor.",
      "Slam (SLAM) is a ligand found on the surface of immune cells that binds to the Robo receptor.",
      "Neurited (Nrt) is a ligand expressed in the nervous system that binds to the Robo receptor.",
      "Draper (Dpr) is a ligand expressed in the Drosophila embryo that binds to the Robo receptor.",
      "Spitz (Spi) is a ligand expressed in the Drosophila embryo that binds to the Robo receptor."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: Gurken (Grk) is a ligand expressed in the Drosophila embryo that binds to the Torpedo/Egfr receptor, not the Robo receptor.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. FALSE [correction]: Spitz (Spi) is a ligand expressed in the Drosophila embryo that binds to the Egfr receptor, not the Robo receptor.",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 4112,
    "user_query": "Is there a role for TFII-I in megakaryopoiesis?",
    "llama-2-13b-chat-hf_response": "In the nucleus, TFII-I is a general transcription factor that is involved in the initiation of transcription. It is a subunit of the TFIIH complex, which is required for the activation of many gene promoters. In addition to its role in transcription initiation, TFII-I has been shown to play a role in the regulation of cell proliferation and differentiation.\nMegakaryocytes are the precursors of platelets, and their differentiation is a complex process that involves the coordinated regulation of many genes. While the role of TFII-I in megakaryopoiesis has not been well-studied, there is evidence to suggest that it may play a role in this process.\nOne study found that TFII-I is expressed in megakaryocyte progenitor cells and that its expression is downregulated as the cells differentiate into mature megakaryocytes. The authors of this study suggested that TFII-I may play a role in the regulation of gene expression during megakaryopoiesis.\nAnother study found that TFII-I is required for the proper differentiation of megakaryocytes. The authors of this study showed that TFII-I-deficient megakaryocyte progenitor cells have a reduced ability to differentiate into mature megakaryocytes, and that this defect can be rescued by re-expressing TFII-I in these cells.\nOverall, these studies suggest that TFII-I may play a role in the regulation of megakaryopoiesis, and that it may be a useful target for the development of new therapies for platelet disorders. However, more research is needed to fully understand the role of TFII-I in megakaryopoiesis and to determine the potential therapeutic applications of this finding.",
    "llama-2-13b-chat-hf_fact_raw": "1. TFII-I is a general transcription factor involved in the initiation of transcription and is a subunit of the TFIIH complex.\n2. TFII-I plays a role in the regulation of cell proliferation and differentiation.\n3. Megakaryocytes are the precursors of platelets, and their differentiation requires the coordinated regulation of many genes.\n4. A study suggested that TFII-I expression is downregulated as megakaryocyte progenitor cells differentiate into mature megakaryocytes.\n5. Another study showed that TFII-I-deficient megakaryocyte progenitor cells have a reduced ability to differentiate into mature megakaryocytes.",
    "llama-2-13b-chat-hf_fact": [
      "TFII-I is a general transcription factor involved in the initiation of transcription and is a subunit of the TFIIH complex.",
      "TFII-I plays a role in the regulation of cell proliferation and differentiation.",
      "Megakaryocytes are the precursors of platelets, and their differentiation requires the coordinated regulation of many genes.",
      "A study suggested that TFII-I expression is downregulated as megakaryocyte progenitor cells differentiate into mature megakaryocytes.",
      "Another study showed that TFII-I-deficient megakaryocyte progenitor cells have a reduced ability to differentiate into mature megakaryocytes."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: TFII-I is a general transcription factor involved in the initiation of transcription but it is not a subunit of the TFIIH complex.\n2. TRUE\n3. TRUE\n4. UNKNOWN (This statement relies on specific study findings that are not provided here for verification, thus a true or false judgment cannot be made without access to the relevant study.)\n5. UNKNOWN (As with statement 4, without access to the specific study mentioned, the veracity of this statement cannot be determined.)",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4145,
    "user_query": "Is atenolol metabolized by CYP2D6?",
    "llama-2-13b-chat-hf_response": "Atenolol, a beta-blocker, is metabolized by several cytochrome P450 (CYP) enzymes, including CYP2D6.\nCYP2D6 is an important enzyme that metabolizes many drugs, including beta-blockers like atenolol. CYP2D6 metabolizes atenolol to several metabolites, including the inactive metabolite, 4-hydroxyatenolol.\nThe metabolism of atenolol by CYP2D6 is important because it can affect the efficacy and side effects of the drug. Individuals who are poor metabolizers of CYP2D6 may experience reduced efficacy of atenolol, while those who are extensive metabolizers may experience increased side effects.\nTherefore, CYP2D6 metabolism of atenolol is an important factor to consider when prescribing this medication, and genetic testing can be used to identify individuals who are poor metabolizers.",
    "llama-2-13b-chat-hf_fact_raw": "1. Atenolol is metabolized by cytochrome P450 (CYP) enzymes, including CYP2D6.\n2. CYP2D6 metabolizes atenolol into several metabolites, one of which is the inactive metabolite 4-hydroxyatenolol.\n3. The metabolism of atenolol by CYP2D6 affects the drug's efficacy and side effects.\n4. Individuals who are poor metabolizers of CYP2D6 may experience reduced efficacy of atenolol.\n5. Genetic testing can identify individuals who are poor metabolizers of CYP2D6.",
    "llama-2-13b-chat-hf_fact": [
      "Atenolol is metabolized by cytochrome P450 (CYP) enzymes, including CYP2D6.",
      "CYP2D6 metabolizes atenolol into several metabolites, one of which is the inactive metabolite 4-hydroxyatenolol.",
      "The metabolism of atenolol by CYP2D6 affects the drug's efficacy and side effects.",
      "Individuals who are poor metabolizers of CYP2D6 may experience reduced efficacy of atenolol.",
      "Genetic testing can identify individuals who are poor metabolizers of CYP2D6."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: Atenolol is not significantly metabolized by cytochrome P450 (CYP) enzymes, including CYP2D6. It is primarily excreted unchanged in urine.\n2. FALSE [correction]: Since atenolol is not significantly metabolized by CYP2D6, it does not form a notable amount of 4-hydroxyatenolol, or other metabolites, through this pathway.\n3. FALSE [correction]: The metabolism of atenolol is not significantly affected by CYP2D6, as it is not metabolized by CYP2D6 to a substantial degree.\n4. FALSE [correction]: Since atenolol is not metabolized by CYP2D6, the variation in CYP2D6 function should not affect the efficacy of atenolol.\n5. TRUE: Genetic testing can identify individuals who are poor metabolizers of CYP2D6; however, this is more relevant for drugs that are significantly metabolized by CYP2D6.",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 4158,
    "user_query": "List versions of ExpansionHunter",
    "llama-2-13b-chat-hf_response": "Functions for ExpansionHunter\nExpansionHunter is a package for R that provides functions for identifying and quantifying the impact of gene expression expansions on the transcriptome. Here are some of the key functions provided by ExpansionHunter:\n1. `expansion_hunter()`: This is the main function of the package, which takes a count matrix as input and identifies expansion events in the transcriptome. The function returns a list of expansion events, along with their associated gene names, start and end positions, and other relevant information.\n2. `get_expansion_types()`: This function returns a list of all the possible expansion types that can be identified by ExpansionHunter, along with their corresponding abbreviations.\n3. `get_expansion_stats()`: This function returns a list of statistics related to the expansion events identified by ExpansionHunter, such as the number of events, the average length of events, and the like.\n4. `plot_expansions()`: This function takes a list of expansion events as input and plots them on a genomic coordinate system, allowing users to visualize the location and distribution of expansion events in the transcriptome.\n5. `filter_expansions()`: This function allows users to filter expansion events based on various criteria, such as the length of the expansion, the number of genes affected, and the like.\n6. `annotate_expansions()`: This function takes a list of expansion events as input and annotates them with information from external databases, such as Gene Ontology (GO) terms, pathway information, and the like.\n7. `cluster_expansions()`: This function groups expansion events into clusters based on their similarity, allowing users to identify patterns and trends in the data.\n8. `predict_expansions()`: This function uses machine learning algorithms to predict the presence or absence of expansion events in new samples, based on the features of the known expansion events.\nThese functions provide a comprehensive set of tools for identifying and quantifying the impact of gene expression expansions on the transcriptome, and can be used to analyze a wide range of RNA sequencing data.",
    "llama-2-13b-chat-hf_fact_raw": "1. ExpansionHunter is a package for R that is designed to identify and quantify the impact of gene expression expansions in the transcriptome.\n2. The `expansion_hunter()` function in ExpansionHunter takes a count matrix as input and identifies expansion events in the transcriptome.\n3. The `get_expansion_types()` function in ExpansionHunter returns a list of all the possible expansion types that can be identified by the software.\n4. The `plot_expansions()` function of ExpansionHunter allows users to visualize expansion events on a genomic coordinate system.",
    "llama-2-13b-chat-hf_fact": [
      "ExpansionHunter is a package for R that is designed to identify and quantify the impact of gene expression expansions in the transcriptome.",
      "The `expansion_hunter()` function in ExpansionHunter takes a count matrix as input and identifies expansion events in the transcriptome.",
      "The `get_expansion_types()` function in ExpansionHunter returns a list of all the possible expansion types that can be identified by the software.",
      "The `plot_expansions()` function of ExpansionHunter allows users to visualize expansion events on a genomic coordinate system."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: ExpansionHunter is not an R package; it is a tool designed to analyze various types of short tandem repeats (STRs) in DNA sequences for genomics research.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n\nThe provided statements do not align well with the known functions and purpose of ExpansionHunter as a genomics tool, and without specific documentation that supports these claims, the veracity of statements 2-4 cannot be confirmed.",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4164,
    "user_query": "What is the role of Adamts18 in hormone receptor signaling?",
    "llama-2-13b-chat-hf_response": "Adamts18 is a member of the ADAM (a disintegrin and metalloproteinase) family of proteins, which are involved in the cleavage of various proteins and play a role in cell signaling and the regulation of cellular processes.\nResearch has shown that Adamts18 is involved in the regulation of hormone receptor signaling, specifically in the context of estrogen receptor alpha (ERα) signaling. Adamts18 has been shown to cleave and activate ERα, leading to the activation of downstream signaling pathways that regulate various cellular processes, including cell proliferation, differentiation, and survival.\nAdamts18 has also been shown to be involved in the regulation of other hormone receptors, such as the androgen receptor and the progesterone receptor, and may play a role in the regulation of other cellular processes, such as inflammation and immune response.\nOverall, the role of Adamts18 in hormone receptor signaling is to regulate the activity of hormone receptors and their downstream signaling pathways, and to modulate the response of cells to hormone stimulation. Dysregulation of Adamts18 has been implicated in various diseases, including cancer and metabolic disorders, highlighting the importance of this protein in maintaining proper hormone signaling and cellular homeostasis.",
    "llama-2-13b-chat-hf_fact_raw": "1. Adamts18 is a member of the ADAM family of proteins involved in protein cleavage and cell signaling.\n2. Adamts18 regulates hormone receptor signaling, particularly estrogen receptor alpha (ERα) signaling.\n3. Adamts18 cleaves and activates ERα, which in turn activates downstream signaling pathways.\n4. Adamts18 is also involved in the regulation of other hormone receptors, including the androgen receptor and the progesterone receptor.\n5. Dysregulation of Adamts18 has been implicated in various diseases, such as cancer and metabolic disorders.",
    "llama-2-13b-chat-hf_fact": [
      "Adamts18 is a member of the ADAM family of proteins involved in protein cleavage and cell signaling.",
      "Adamts18 regulates hormone receptor signaling, particularly estrogen receptor alpha (ERα) signaling.",
      "Adamts18 cleaves and activates ERα, which in turn activates downstream signaling pathways.",
      "Adamts18 is also involved in the regulation of other hormone receptors, including the androgen receptor and the progesterone receptor.",
      "Dysregulation of Adamts18 has been implicated in various diseases, such as cancer and metabolic disorders."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Adamts18 is known to regulate Wnt signaling, not specifically hormone receptor signaling such as ERα.\n3. FALSE [correction]: It is not established that Adamts18 cleaves and activates ERα. Adamts18's role in ADAM family is more associated with extracellular matrix remodeling, not direct activation of receptors like ERα.\n4. UNKNOWN: There is limited information provided on Adamts18's involvement in the regulation of other hormone receptors such as the androgen receptor and the progesterone receptor, and without additional context or references, this statement cannot be accurately verified.\n5. TRUE: Dysregulation of Adamts18 has been implicated in various pathological conditions including cancer and potentially in metabolic disorders.",
    "llama-2-13b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 4208,
    "user_query": "What is the mode of action of Thiazovivin?",
    "llama-2-13b-chat-hf_response": "Thiazovivin is a synthetic compound that has been shown to have antiviral activity against a wide range of viruses, including HIV, HCV, and HPV. The exact mechanism of action of Thiazovivin is not fully understood, but it is thought to work by inhibiting the replication of viruses in infected cells.\nOne study published in the journal Antimicrobial Agents and Chemotherapy found that Thiazovivin inhibited the replication of HIV-1 in infected cells by preventing the viral DNA from being transcribed into RNA. Another study published in the journal Journal of Virology found that Thiazovivin inhibited the replication of HCV by preventing the viral RNA from being translated into protein.\nThiazovivin has also been shown to have activity against HPV, which is a common cause of cervical cancer. A study published in the journal Virology found that Thiazovivin inhibited the replication of HPV in infected cells by preventing the viral DNA from being transcribed into RNA.\nOverall, the mode of action of Thiazovivin is thought to involve the inhibition of viral replication in infected cells, but the exact mechanisms by which it does this are not fully understood and require further study.",
    "llama-2-13b-chat-hf_fact_raw": "1. Thiazovivin is a synthetic compound with antiviral activity against HIV, HCV, and HPV.\n2. The exact mechanism of action of Thiazovivin is thought to be inhibiting the replication of viruses in infected cells.\n3. A study in \"Antimicrobial Agents and Chemotherapy\" reported that Thiazovivin inhibits the transcription of viral DNA into RNA in HIV-1.\n4. \"Journal of Virology\" published a study indicating Thiazovivin prevents the translation of viral RNA into protein for HCV.\n5. According to a study in the journal \"Virology,\" Thiazovivin inhibits the transcription of viral DNA into RNA for HPV.",
    "llama-2-13b-chat-hf_fact": [
      "Thiazovivin is a synthetic compound with antiviral activity against HIV, HCV, and HPV.",
      "The exact mechanism of action of Thiazovivin is thought to be inhibiting the replication of viruses in infected cells.",
      "A study in \"Antimicrobial Agents and Chemotherapy\" reported that Thiazovivin inhibits the transcription of viral DNA into RNA in HIV-1.",
      "\"Journal of Virology\" published a study indicating Thiazovivin prevents the translation of viral RNA into protein for HCV.",
      "According to a study in the journal \"Virology,\" Thiazovivin inhibits the transcription of viral DNA into RNA for HPV."
    ],
    "llama-2-13b-chat-hf_judge_raw": "1. FALSE [correction]: Thiazovivin is not reported to have antiviral activity against HIV, HCV, and HPV. It is actually a small molecule that enhances the survival of human embryonic stem cells.\n2. UNKNOWN\n3. FALSE [correction]: There is no well-known study reporting that Thiazovivin inhibits the transcription of viral DNA into RNA in HIV-1 as Thiazovivin is not primarily known for its antiviral activity.\n4. UNKNOWN\n5. UNKNOWN\n\nIt is important to note that the primary known use of Thiazovivin is to improve the survival of human embryonic stem cells during culture. Its role as an antiviral agent, specifically against the viruses mentioned, is not well-documented in the scientific literature up to my knowledge cutoff date in 2023. As a result, statements 2, 4, and 5 cannot be verified without specific references to credible scientific studies, and I have labeled them as UNKNOWN.",
    "llama-2-13b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "unknown",
      "unknown"
    ]
  }
]